Surgery	O
1999	O
Jan;125(	O
1	O
)	O
:46	O
-	O
52	O
Oncogene	O
profile	O
of	O
papillary	B-malignancy-type
thyroid	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Sugg	O
SL	O
,	O
Ezzat	O
S,	O
Zheng	O
L,	O
Freeman	O
JL	O
,	O
Rosen	O
IB	O
,	O
Asa	O
SL.	O
Department	O
of	O
Surgery	O
,	O
Mount	O
Sinai	O
Hospital	O
,	O
Toronto	O
,	O
Ontario	O
,	O
Canada	O
.	O
BACKGROUND	O
:	O
Our	O
purpose	O
was	O
to	O
study	O
the	O
expression	O
of	O
multiple	O
oncogenes	O
in	O
papillary	B-malignancy-type
thyroid	I-malignancy-type
cancer	I-malignancy-type
for	O
possible	O
interactions	O
and	O
prognostic	O
significance	O
.	O
METHODS	O
:	O
Twenty	O
papillary	B-malignancy-type
thyroid	I-malignancy-type
carcinomas	I-malignancy-type
were	O
studied	O
for	O
expression	O
/	O
mutation	O
of	O
3	O
oncogenes	O
:	O
ras	O
,	O
ret	O
/	O
PTC	O
,	O
and	O
erbB-2	O
/	O
neu	O
.	O
H	O
,	O
N	O
,	O
and	O
K	O
ras	O
codons	O
were	O
examined	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
single	O
-	O
stranded	O
conformation	O
polymorphism	O
,	O
and	O
sequencing	O
.	O
The	O
thyroid	O
oncogene	O
ret	O
/	O
PTC	O
was	O
identified	O
by	O
reverse	O
transcription	O
(	O
RT	O
)	O
-	O
PCR	O
.	O
Gene	O
amplification	O
of	O
erbB-2	O
/	O
neu	O
was	O
analyzed	O
by	O
differential	O
PCR	O
.	O
The	O
transmembrane	O
domain	O
of	O
erbB-2	O
/	O
neu	O
was	O
sequenced	O
for	O
activating	O
mutations	O
.	O
Quantitation	O
of	O
erbB-2	O
/	O
neu	O
mRNA	O
was	O
evaluated	O
by	O
competitive	O
RT	O
-	O
PCR	O
,	O
and	O
protein	O
expression	O
was	O
determined	O
by	O
immunohistochemistry	O
.	O
RESULTS	O
:	O
Among	O
20	O
tumors	B-malignancy-type
,	O
3	O
had	O
insular	O
/	O
anaplastic	O
dedifferentiation	O
,	O
13	O
were	O
intrathyroidal	B-malignancy-type
,	O
and	O
7	O
were	O
metastatic	B-malignancy-type
to	I-malignancy-type
cervical	I-malignancy-type
lymph	I-malignancy-type
nodes	I-malignancy-type
(	O
6	O
)	O
or	O
lung	B-malignancy-type
(	O
1	O
)	O
.	O
An	O
H-ras	O
13	O
mutation	O
was	O
found	O
in	O
1	O
metastatic	B-malignancy-type
tumor	I-malignancy-type
and	O
an	O
N-ras	O
61	O
mutation	O
in	O
1	O
intrathyroidal	B-malignancy-type
tumor	I-malignancy-type
.	O
ret	O
/	O
PTC	O
was	O
identified	O
in	O
3	O
intrathyroidal	B-malignancy-type
and	O
5	O
metastatic	B-malignancy-type
tumors	B-malignancy-type
.	O
No	O
erbB-2	O
/	O
neu	O
DNA	O
amplification	O
or	O
mutations	O
were	O
identified	O
,	O
although	O
4	O
tumors	O
had	O
elevated	O
erbB-2	O
/	O
neu	O
mRNA	O
levels	O
.	O
Three	O
of	O
20	O
patients	O
had	O
abnormalities	O
detected	O
in	O
multiple	O
oncogenes	O
;	O
2	O
had	O
elevated	O
erbB-2	O
/	O
neu	O
mRNA	O
and	O
ret	O
/	O
PTC	O
rearrangements	O
,	O
and	O
1	O
of	O
these	O
had	O
pulmonary	B-malignancy-type
metastasis	I-malignancy-type
.	O
An	O
intrathyroidal	B-malignancy-type
papillary	I-malignancy-type
cancer	I-malignancy-type
had	O
an	O
N	O
61	O
ras	O
mutation	O
and	O
a	O
ret	O
/	O
PTC	O
gene	O
rearrangement	O
.	O
CONCLUSIONS	O
:	O
ret	O
/	O
PTC	O
rearrangements	O
are	O
present	O
in	O
40	O
%	O
of	O
papillary	B-malignancy-type
thyroid	I-malignancy-type
carcinomas	I-malignancy-type
and	O
may	O
play	O
a	O
role	O
in	O
metastatic	O
behavior	O
.	O
In	O
contrast	O
,	O
ras	O
mutations	O
are	O
rare	O
(	O
10	O
%	O
)	O
.	O
erbB-2	O
/	O
neu	O
gene	O
amplification	O
and	O
activating	O
mutations	O
are	O
not	O
detected	O
,	O
although	O
elevated	O
mRNA	O
levels	O
were	O
found	O
in	O
20	O
%	O
of	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
.	O
The	O
lack	O
of	O
correlation	O
among	O
the	O
3	O
oncogenes	O
in	O
17	O
of	O
20	O
(	O
85	O
%	O
)	O
papillary	B-malignancy-type
thyroid	I-malignancy-type
carcinomas	I-malignancy-type
suggests	O
that	O
they	O
were	O
not	O
cumulative	O
factors	O
in	O
the	O
pathogenesis	O
of	O
these	O
tumors	O
.	O
PMID	O
:	O
9889797	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Lab	O
Invest	O
1998	O
Dec;78(	O
12	O
)	O
:1633	O
-	O
6	O
KIT	O
mutation	O
portends	O
poor	O
prognosis	O
in	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
/	I-malignancy-type
smooth	I-malignancy-type
muscle	I-malignancy-type
tumors	I-malignancy-type
.	O
Ernst	O
SI	O
,	O
Hubbs	O
AE	O
,	O
Przygodzki	O
RM	O
,	O
Emory	O
TS	O
,	O
Sobin	O
LH	O
,	O
O'Leary	O
TJ.	O
Department	O
of	O
Cellular	O
Pathology	O
,	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
,	O
Washington	O
,	O
District	O
of	O
Columbia	O
20306	O
-	O
6000	O
,	O
USA	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
/	I-malignancy-type
smooth	I-malignancy-type
muscle	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
are	O
uncommon	O
neoplasms	B-malignancy-type
for	O
which	O
current	O
criteria	O
for	O
the	O
diagnosis	O
of	O
malignancy	O
(	O
location	O
,	O
size	O
,	O
and	O
mitotic	O
index	O
)	O
do	O
not	O
always	O
reliably	O
predict	O
patient	O
outcome	O
.	O
Recently	O
,	O
mutation	O
of	O
KIT	O
oncogene	O
exon	O
11	O
has	O
been	O
observed	O
in	O
some	O
of	O
these	O
tumors	O
,	O
but	O
the	O
relationship	O
between	O
mutation	O
and	O
clinical	O
outcome	O
has	O
not	O
yet	O
been	O
determined	O
.	O
DNA	O
was	O
obtained	O
from	O
the	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
of	O
35	O
gastric	B-malignancy-type
GISTs	I-malignancy-type
.	O
A	O
segment	O
of	O
exon	O
11	O
was	O
amplified	O
by	O
PCR	O
and	O
sequenced	O
on	O
an	O
ABI	O
377	O
sequencer	O
.	O
The	O
relationship	O
between	O
the	O
presence	O
or	O
absence	O
of	O
mutation	O
,	O
tumor	O
size	O
,	O
and	O
mitotic	O
index	O
was	O
investigated	O
using	O
correlation	O
analysis	O
,	O
and	O
the	O
relationship	O
between	O
mutation	O
and	O
outcome	O
was	O
investigated	O
using	O
Kaplan	O
-	O
Meier	O
plots	O
,	O
the	O
Cox	O
-	O
Mantel	O
statistic	O
,	O
and	O
the	O
Cox	O
regression	O
model	O
.	O
Exon	O
11	O
deletion	O
mutations	O
were	O
identified	O
in	O
10	O
cases	O
,	O
and	O
point	O
mutations	O
were	O
identified	O
in	O
an	O
additional	O
3	O
cases	O
;	O
22	O
cases	O
demonstrated	O
no	O
KIT	O
mutations	O
.	O
KIT	O
mutation	O
was	O
associated	O
with	O
decreased	O
survival	O
(	O
p	O
=	O
0.001	O
)	O
,	O
with	O
fewer	O
than	O
30	O
%	O
of	O
patients	O
surviving	O
more	O
than	O
3	O
years	O
,	O
compared	O
with	O
over	O
65	O
%	O
survival	O
for	O
patients	O
whose	O
tumors	O
did	O
not	O
bear	O
the	O
mutation	O
.	O
KIT	O
mutation	O
did	O
not	O
correlate	O
with	O
either	O
the	O
mitotic	O
index	O
or	O
the	O
tumor	O
size	O
.	O
In	O
conclusion	O
,	O
KIT	O
mutation	O
is	O
associated	O
with	O
poor	O
prognosis	O
in	O
patients	O
with	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
.	O
Whether	O
the	O
KIT	O
mutation	O
will	O
prove	O
to	O
be	O
an	O
independent	O
prognostic	O
factor	O
awaits	O
the	O
completion	O
of	O
larger	O
studies	O
.	O
PMID	O
:	O
9881963	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pathol	O
1998	O
Sep;186(	O
1	O
)	O
:41	O
-	O
50	O
Pancreatic	B-malignancy-type
endocrine	I-malignancy-type
tumours	I-malignancy-type
:	O
evidence	O
for	O
a	O
tumour	O
suppressor	O
pathogenesis	O
and	O
for	O
a	O
tumour	O
suppressor	O
gene	O
on	O
chromosome	O
17p	O
.	O
Beghelli	O
S,	O
Pelosi	O
G	O
,	O
Zamboni	O
G	O
,	O
Falconi	O
M,	O
Iacono	O
C	O
,	O
Bordi	O
C	O
,	O
Scarpa	O
A.	O
Istituto	O
di	O
Anatomia	O
Patologica	O
Universita	O
di	O
Verona	O
,	O
Italy	O
.	O
Two	O
molecular	O
pathways	O
leading	O
to	O
cancer	O
are	O
known	O
.	O
Common	O
-	O
type	O
cancers	O
arise	O
from	O
the	O
'	O
tumour	O
suppressor	O
'	O
pathway	O
,	O
characterized	O
by	O
gross	O
chromosomal	O
changes	O
and	O
allelic	O
losses	O
(	O
LOH	O
)	O
in	O
an	O
average	O
of	O
25	O
per	O
cent	O
or	O
more	O
of	O
randomly	O
chosen	O
chromosomal	O
loci	O
.	O
The	O
'	O
mutator	O
pathway	O
'	O
has	O
been	O
recognized	O
in	O
a	O
subset	O
of	O
cancers	O
,	O
characterized	O
by	O
widespread	O
microsatellite	O
DNA	O
instability	O
and	O
rarity	O
of	O
chromosomal	O
losses	O
.	O
The	O
present	O
study	O
has	O
investigated	O
20	O
pancreatic	B-malignancy-type
endocrine	I-malignancy-type
tumours	I-malignancy-type
(	O
PETs	B-malignancy-type
)	O
for	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
seven	O
chromosomal	O
loci	O
(	O
3p14	O
,	O
7q	O
31	O
-	O
32	O
,	O
11q13	O
,	O
13q14	O
,	O
18q21	O
,	O
17p13	O
,	O
and	O
17q21	O
)	O
;	O
microsatellite	O
instability	O
;	O
and	O
Ki-ras	O
,	O
N-ras	O
,	O
and	O
p53	O
gene	O
mutations	O
.	O
LOH	O
was	O
found	O
in	O
an	O
average	O
of	O
24	O
per	O
cent	O
of	O
the	O
chromosomal	O
loci	O
analysed	O
.	O
No	O
tumour	O
showed	O
microsatellite	O
instability	O
.	O
Ki-ras	O
and	O
p53	O
mutations	O
were	O
each	O
found	O
in	O
one	O
case	O
.	O
The	O
frequency	O
of	O
losses	O
was	O
higher	O
in	O
malignant	O
(	O
40	O
per	O
cent	O
)	O
than	O
in	O
benign	O
(	O
17	O
per	O
cent	O
)	O
tumours	O
(	O
p	O
=	O
0.009	O
)	O
,	O
and	O
the	O
specific	O
chromosome	O
17p13	O
LOH	O
was	O
associated	O
with	O
extrapancreatic	O
extension	O
of	O
disease	O
(	O
p	O
=	O
0.007	O
)	O
,	O
high	O
proliferative	O
activity	O
(	O
p	O
=	O
0.001	O
)	O
,	O
and	O
absence	O
of	O
progesterone	O
receptors	O
(	O
p	O
=	O
0.01	O
)	O
.	O
A	O
common	O
deleted	O
region	O
on	O
chromosome	O
17p13	O
and	O
the	O
rarity	O
of	O
p53	O
gene	O
mutations	O
suggest	O
the	O
existence	O
of	O
a	O
novel	O
tumour	O
suppressor	O
gene	O
involved	O
in	O
the	O
pathogenesis	O
of	O
PETs	B-malignancy-type
in	O
this	O
chromosomal	O
area	O
.	O
PMID	O
:	O
9875139	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Epidemiol	O
Biomarkers	O
Prev	O
1998	O
Dec;7(	O
12	O
)	O
:1127	O
-	O
31	O
Accuracy	O
of	O
DNA	O
amplification	O
from	O
archival	O
hematological	O
slides	O
for	O
use	O
in	O
genetic	O
biomarker	O
studies	O
.	O
Boyle	O
EB	O
,	O
Steinbuch	O
M,	O
Tekautz	O
T	O
,	O
Gutman	O
JR	O
,	O
Robison	O
LL	O
,	O
Perentesis	O
JP	O
.	O
Division	O
of	O
Pediatric	O
Hematology	O
,	O
University	O
of	O
Minnesota	O
Cancer	O
Center	O
,	O
Minneapolis	O
55455	O
,	O
USA	O
.	O
Archival	O
slides	O
are	O
a	O
potentially	O
useful	O
source	O
of	O
DNA	O
for	O
mutation	O
analyses	O
in	O
large	O
population	O
-	O
based	O
studies	O
.	O
However	O
,	O
it	O
is	O
unknown	O
whether	O
specimen	O
age	O
or	O
histological	O
stains	O
alter	O
the	O
accuracy	O
of	O
Taq	O
polymerase	O
or	O
induce	O
secondary	O
mutations	O
in	O
sample	O
DNA	O
.	O
To	O
address	O
this	O
question	O
,	O
we	O
evaluated	O
five	O
methods	O
for	O
extraction	O
of	O
genomic	O
DNA	O
from	O
archival	O
bone	O
marrow	O
slides	O
of	O
17	O
leukemia	B-malignancy-type
patients	O
and	O
analyzed	O
exons	O
1	O
and	O
2	O
of	O
the	O
N	O
-	O
and	O
K	O
-	O
ras	O
genes	O
for	O
the	O
presence	O
of	O
mutations	O
.	O
Of	O
the	O
five	O
methods	O
,	O
optimal	O
DNA	O
purification	O
was	O
achieved	O
by	O
boiling	O
and	O
phenol	O
:	O
chloroform	O
extraction	O
.	O
N	O
-	O
and	O
K	O
-	O
ras	O
exons	O
1	O
and	O
2	O
were	O
independently	O
amplified	O
using	O
35	O
cycles	O
of	O
PCR	O
,	O
and	O
6	O
-	O
12	O
clones	O
for	O
each	O
exon	O
were	O
isolated	O
and	O
individually	O
sequenced	O
for	O
each	O
patient	O
.	O
Mutations	O
were	O
confirmed	O
by	O
repeat	O
extraction	O
,	O
cloning	O
,	O
and	O
sequencing	O
.	O
Sixteen	O
of	O
17	O
patient	O
samples	O
were	O
successfully	O
amplified	O
(	O
94	O
%	O
)	O
,	O
including	O
slides	O
up	O
to	O
29	O
years	O
old	O
.	O
Twelve	O
slides	O
had	O
been	O
stained	O
with	O
Wright	O
-	O
Giemsa	O
,	O
I	O
stained	O
with	O
toluidine	O
blue	O
,	O
and	O
4	O
were	O
unstained	O
.	O
A	O
total	O
of	O
16	O
single	O
-	O
base	O
mutations	O
were	O
identified	O
of	O
33,840	O
nucleotides	O
sequenced	O
.	O
No	O
insertions	O
or	O
deletions	O
were	O
identified	O
.	O
Six	O
of	O
16	O
single	O
-	O
base	O
mutations	O
were	O
previously	O
described	O
activating	O
mutations	O
in	O
codon	O
13	O
of	O
N-ras	O
exon	O
1	O
.	O
The	O
10	O
other	O
mutations	O
were	O
in	O
other	O
regions	O
of	O
the	O
N	O
-	O
and	O
K	O
-	O
ras	O
genes	O
and	O
were	O
not	O
reproduced	O
after	O
repeat	O
extraction	O
,	O
cloning	O
,	O
and	O
sequencing	O
.	O
The	O
frequency	O
of	O
these	O
other	O
alterations	O
was	O
I	O
of	O
3384	O
bp	O
.	O
This	O
value	O
is	O
comparable	O
with	O
the	O
inherent	O
error	O
frequency	O
for	O
Taq	O
polymerase	O
.	O
Our	O
findings	O
suggest	O
that	O
high	O
fidelity	O
DNA	O
amplification	O
can	O
be	O
achieved	O
using	O
archival	O
hematological	O
slides	O
as	O
old	O
as	O
29	O
years	O
and	O
can	O
be	O
reliably	O
used	O
in	O
genetic	O
analyses	O
.	O
PMID	O
:	O
9865432	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Endocrinol	O
(	O
Oxf	O
)	O
1998	O
Sep;49(	O
3	O
)	O
:317	O
-	O
23	O
Prevalences	O
of	O
Gs	O
alpha	O
,	O
ras	O
,	O
p53	O
mutations	O
and	O
ret	O
/	O
PTC	O
rearrangement	O
in	O
differentiated	B-malignancy-type
thyroid	I-malignancy-type
tumours	I-malignancy-type
in	O
a	O
Korean	O
population	O
.	O
Park	O
KY	O
,	O
Koh	O
JM	O
,	O
Kim	O
YI	O
,	O
Park	O
HJ	O
,	O
Gong	O
G	O
,	O
Hong	O
SJ	O
,	O
Ahn	O
IM	O
.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Asan	O
Institute	O
for	O
Life	O
Sciences	O
and	O
Technology	O
,	O
Seoul	O
,	O
Korea	O
.	O
OBJECTIVE	O
:	O
In	O
thyroid	B-malignancy-type
tumours	I-malignancy-type
,	O
ras	O
,	O
Gs	O
alpha	O
,	O
p53	O
mutations	O
and	O
ret	O
/	O
PTC	O
rearrangement	O
have	O
been	O
reported	O
with	O
variable	O
prevalences	O
in	O
different	O
geographical	O
regions	O
.	O
We	O
studied	O
the	O
prevalence	O
of	O
these	O
mutations	O
and	O
rearrangement	O
in	O
thyroid	B-malignancy-type
tumours	I-malignancy-type
in	O
a	O
Korean	O
population	O
.	O
As	O
MDM2	O
and	O
Bcl-1	O
protein	O
expressions	O
have	O
been	O
suggested	O
to	O
be	O
associated	O
with	O
p53	O
protein	O
,	O
we	O
also	O
studied	O
possible	O
relationships	O
among	O
them	O
.	O
PATIENTS	O
AND	O
DESIGN	O
:	O
Eleven	O
cases	O
of	O
adenomatous	B-malignancy-type
goitre	I-malignancy-type
,	O
eight	O
cases	O
of	O
follicular	B-malignancy-type
adenoma	I-malignancy-type
,	O
five	O
cases	O
of	O
follicular	B-malignancy-type
carcinoma	I-malignancy-type
and	O
37	O
cases	O
of	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
were	O
included	O
in	O
this	O
study	O
.	O
To	O
find	O
mutations	O
and	O
rearrangement	O
,	O
RT	O
-	O
PCR	O
,	O
SSCP	O
and/or	O
direct	O
sequencing	O
,	O
after	O
subcloning	O
if	O
necessary	O
,	O
were	O
used	O
,	O
and	O
immunohistochemical	O
stainings	O
were	O
performed	O
for	O
p53	O
,	O
MDM2	O
and	O
Bcl-2	O
proteins	O
in	O
cases	O
of	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
.	O
RESULTS	O
:	O
We	O
could	O
not	O
find	O
any	O
rearrangement	O
for	O
ret	O
/	O
PTC	O
-	O
1	O
,	O
-	O
2	O
,	O
-	O
3	O
and	O
mutation	O
of	O
Gs	O
alpha	O
.	O
For	O
the	O
ras	O
oncogene	O
,	O
K	O
and	O
H	O
-	O
ras	O
mutations	O
were	O
not	O
found	O
,	O
but	O
N-ras	O
mutations	O
,	O
point	O
mutation	O
of	O
CAA	O
to	O
CGA	O
in	O
codon	O
61	O
,	O
were	O
detected	O
in	O
one	O
follicular	B-malignancy-type
adenoma	I-malignancy-type
(	O
12.5	O
%	O
,	O
1	O
/	O
8	O
)	O
and	O
one	O
follicular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
33	O
%	O
,	O
1	O
/	O
3	O
)	O
.	O
p53	O
mutations	O
were	O
detected	O
in	O
only	O
one	O
case	O
of	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
(	O
3	O
%	O
,	O
1	O
/	O
31	O
:	O
exon	O
8	O
,	O
codon	O
266	O
GGA	O
-->	O
GAA	O
)	O
.	O
In	O
30	O
cases	O
of	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
without	O
p53	O
mutation	O
,	O
the	O
prevalences	O
of	O
positive	O
immunohistochemical	O
staining	O
were	O
13.3	O
%	O
for	O
p53	O
protein	O
,	O
53.3	O
%	O
for	O
MDM2	O
protein	O
and	O
56.7	O
%	O
for	O
Bcl-2	O
protein	O
.	O
While	O
over	O
-	O
expression	O
of	O
p53	O
protein	O
was	O
not	O
significantly	O
related	O
to	O
that	O
of	O
MDM2	O
and	O
Bcl-2	O
proteins	O
,	O
over	O
-	O
expression	O
of	O
MDM2	O
and	O
Bcl-2	O
in	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
were	O
associated	O
.	O
CONCLUSION	O
:	O
ret	O
/	O
PTC	O
rearrangement	O
,	O
Gs	O
alpha	O
,	O
ras	O
and	O
p53	O
mutations	O
are	O
relatively	O
rare	O
in	O
differentiated	B-malignancy-type
thyroid	I-malignancy-type
neoplasms	I-malignancy-type
from	O
a	O
Korean	O
population	O
,	O
which	O
may	O
reflect	O
genetic	O
and	O
environmental	O
differences	O
from	O
patients	O
in	O
countries	O
with	O
high	O
prevalences	O
.	O
P53	O
protein	O
over	O
-	O
expression	O
was	O
noted	O
in	O
13.3	O
%	O
of	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
cases	O
without	O
p53	O
mutation	O
and	O
was	O
not	O
significantly	O
related	O
to	O
MDM2	O
and	O
Bcl-2	O
expression	O
.	O
PMID	O
:	O
9861322	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Anticancer	O
Res	O
1998	O
Sep	O
-	O
Oct;18(	O
5A	O
)	O
:3395	O
-	O
8	O
Second	O
primary	O
cancers	O
after	O
resection	O
of	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
with	O
ras	O
gene	O
mutation	O
.	O
Sugio	O
K	O
,	O
Fukuyama	O
Y	O
,	O
Sakada	O
T	O
,	O
Nishioka	O
K	O
,	O
Yamazaki	O
K	O
,	O
Ushijima	O
C	O
,	O
Tsukamoto	O
S,	O
Ishida	O
T	O
,	O
Sugimachi	O
K.	O
Department	O
of	O
Surgery	O
II	O
,	O
Faculty	O
of	O
Medicine	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
,	O
Japan	O
.	O
sugio@surg2.med	O
.kyushu	O
-	O
u.ac.	O
jp	O
BACKGROUND	O
:	O
Ras	O
gene	O
mutations	O
are	O
associated	O
with	O
a	O
poor	O
prognosis	O
in	O
patients	O
with	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
.	O
However	O
,	O
the	O
association	O
between	O
cases	O
with	O
ras	O
gene	O
mutation	O
and	O
an	O
occurrence	O
of	O
second	O
primary	O
cancer	O
is	O
unknown	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
We	O
examined	O
89	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
obtained	O
from	O
patients	O
treated	O
by	O
curative	O
resection	O
,	O
and	O
four	O
second	O
primary	O
cancers	O
,	O
for	O
mutation	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
three	O
ras	O
oncogenes	O
using	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
hybridization	O
techniques	O
.	O
RESULTS	O
:	O
Ras	O
gene	O
mutations	O
were	O
detected	O
in	O
13	O
cases	O
.	O
Six	O
patients	O
died	O
from	O
recurrent	O
disease	O
within	O
3	O
years	O
.	O
Of	O
the	O
seven	O
patients	O
who	O
survived	O
over	O
5	O
years	O
,	O
three	O
patients	O
demonstrated	O
a	O
metachronous	O
second	O
primary	O
cancer	O
after	O
the	O
operation	O
for	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
and	O
one	O
patient	O
had	O
synchronous	B-malignancy-type
laryngeal	I-malignancy-type
cancer	I-malignancy-type
.	O
Two	O
of	O
the	O
cases	O
with	O
second	O
primary	O
cancer	O
demonstrated	O
the	O
ras	O
gene	O
mutation	O
.	O
One	O
had	O
the	O
same	O
mutation	O
as	O
that	O
of	O
the	O
primary	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
and	O
the	O
other	O
had	O
a	O
different	O
mutation	O
from	O
the	O
first	O
lung	B-malignancy-type
cancer	I-malignancy-type
.	O
CONCLUSION	O
:	O
Ras	O
gene	O
mutations	O
play	O
an	O
important	O
role	O
in	O
tumor	O
progression	O
of	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
and	O
also	O
might	O
have	O
an	O
role	O
in	O
the	O
carcinogenesis	O
in	O
respiratory	B-malignancy-type
tract	I-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
9858914	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
1998	O
Dec;103(	O
3	O
)	O
:740	O
-	O
9	O
Systemic	O
mastocytosis	O
associated	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
:	O
report	O
of	O
two	O
cases	O
and	O
detection	O
of	O
the	O
c-kit	O
mutation	O
Asp	O
-	O
816	O
to	O
Val	O
.	O
Sperr	O
WR	O
,	O
Walchshofer	O
S,	O
Horny	O
HP	O
,	O
Fodinger	O
M,	O
Simonitsch	O
I	O
,	O
Fritsche	O
-	O
Polanz	O
R,	O
Schwarzinger	O
I	O
,	O
Tschachler	O
E	O
,	O
Sillaber	O
C	O
,	O
Hagen	O
W	O
,	O
Geissler	O
K	O
,	O
Chott	O
A	O
,	O
Lechner	O
K	O
,	O
Valent	O
P.	O
Department	O
of	O
Internal	O
Medicine	O
I	O
,	O
University	O
of	O
Vienna	O
,	O
Austria	O
.	O
A	O
subset	O
of	O
patients	O
with	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
(	O
SM	B-malignancy-type
)	O
develop	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
However	O
,	O
little	O
is	O
known	O
about	O
the	O
biology	O
of	O
such	O
leukaemias	B-malignancy-type
and	O
their	O
relationship	O
to	O
the	O
mast	O
cell	O
(	O
MC	O
)	O
lineage	O
.	O
We	O
report	O
on	O
two	O
female	O
patients	O
who	O
suffered	O
from	O
SM	B-malignancy-type
and	O
AML	B-malignancy-type
.	O
According	O
to	O
FAB	O
criteria	O
,	O
the	O
leukaemias	B-malignancy-type
were	O
classified	O
as	O
AML-M4	B-malignancy-type
(	O
patient	O
1	O
)	O
and	O
AML-MO	B-malignancy-type
(	O
patient	O
2	O
)	O
.	O
The	O
coexistence	O
of	O
the	O
two	O
distinct	O
neoplasms	B-malignancy-type
(	O
AML	B-malignancy-type
and	O
SM	B-malignancy-type
)	O
was	O
demonstrable	O
by	O
immunostaining	O
of	O
serial	O
bone	O
marrow	O
(	O
BM	O
)	O
sections	O
with	O
monoclonal	O
antibodies	O
(	O
mAb	O
)	O
.	O
In	O
particular	O
,	O
the	O
MC	O
infiltrates	O
were	O
found	O
to	O
react	O
with	O
mAb	O
against	O
MC	O
-	O
tryptase	O
and	O
MC	O
growth	O
factor	O
receptor	O
c-kit	O
(	O
CD117	O
)	O
,	O
but	O
not	O
with	O
mAb	O
to	O
CD15	O
or	O
CD34	O
.	O
In	O
contrast	O
,	O
the	O
AML	B-malignancy-type
blasts	O
were	O
immunoreactive	O
for	O
CD15	O
(	O
patient	O
1	O
)	O
or	O
CD34	O
(	O
patient	O
2	O
)	O
,	O
but	O
did	O
not	O
express	O
tryptase	O
.	O
The	O
c-kit	O
point	O
mutation	O
Asp	O
-->	O
Val	O
at	O
codon	O
816	O
,	O
considered	O
to	O
play	O
a	O
role	O
in	O
the	O
transformation	O
of	O
MC	O
progenitors	O
,	O
was	O
detected	O
in	O
patient	O
1	O
in	O
a	O
BM	O
cell	O
fraction	O
containing	O
4	O
%	O
MC	O
.	O
However	O
,	O
no	O
c-kit	O
mutation	O
was	O
found	O
in	O
pure	O
AML	B-malignancy-type
blasts	O
(	O
<	O
1	O
%	O
MC	O
)	O
.	O
These	O
findings	O
argue	O
against	O
an	O
evolution	O
of	O
the	O
AML	B-malignancy-type
clone	O
from	O
neoplastic	B-malignancy-type
MC	I-malignancy-type
or	O
MC	O
-	O
committed	O
progenitors	O
.	O
PMID	O
:	O
9858225	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Invest	O
Dermatol	O
1998	O
Dec;111(	O
6)	O
:1227	O
-	O
31	O
Identification	O
of	O
activating	O
c-kit	O
mutations	O
in	O
adult	O
-	O
,	O
but	O
not	O
in	O
childhood	O
-	O
onset	O
indolent	B-malignancy-type
mastocytosis	I-malignancy-type
:	O
a	O
possible	O
explanation	O
for	O
divergent	O
clinical	O
behavior	O
.	O
Buttner	O
C	O
,	O
Henz	O
BM	O
,	O
Welker	O
P	O
,	O
Sepp	O
NT	O
,	O
Grabbe	O
J.	O
Department	O
of	O
Dermatology	O
,	O
Charite	O
,	O
Humboldt	O
University	O
,	O
Berlin	O
,	O
Germany	O
.	O
Mastocytosis	B-malignancy-type
represents	O
a	O
mast	O
cell	O
proliferative	O
disease	O
that	O
generally	O
runs	O
a	O
benign	O
clinical	O
course	O
,	O
with	O
spontaneous	O
remissions	O
mostly	O
by	O
puberty	O
in	O
childhood	O
-	O
onset	O
disease	O
,	O
although	O
rare	O
forms	O
,	O
particularly	O
in	O
adult	O
-	O
onset	O
disease	O
,	O
can	O
be	O
associated	O
with	O
(pre)malignant	O
hematologic	O
disorders	O
and	O
very	O
rarely	O
present	O
as	O
mast	B-malignancy-type
cell	I-malignancy-type
leukemia	I-malignancy-type
or	O
malignant	B-malignancy-type
mastocytosis	I-malignancy-type
.	O
Reasons	O
for	O
this	O
divergent	O
clinical	O
behavior	O
of	O
childhood	O
-	O
versus	O
adult	O
-	O
onset	O
disease	O
are	O
unknown	O
.	O
Recently	O
,	O
two	O
activating	O
mutations	O
in	O
the	O
intracellular	O
domain	O
of	O
the	O
proto	O
-	O
oncogene	O
c-kit	O
,	O
which	O
encodes	O
a	O
tyrosine	O
kinase	O
receptor	O
for	O
the	O
mast	O
cell	O
growth	O
factor	O
stem	O
cell	O
factor	O
,	O
have	O
been	O
detected	O
in	O
the	O
human	O
leukemic	O
mast	O
cell	O
line	O
HMC-1	O
.	O
We	O
have	O
therefore	O
studied	O
lesional	O
skin	O
biopsies	O
from	O
patients	O
with	O
adult	O
-	O
and	O
childhood	O
-	O
onset	O
indolent	B-malignancy-type
mastocytosis	I-malignancy-type
for	O
the	O
presence	O
of	O
these	O
codon	O
560	O
and	O
816	O
mutations	O
.	O
C-kit	O
coding	O
DNA	O
sequences	O
were	O
amplified	O
and	O
analyzed	O
by	O
mutation	O
-	O
specific	O
restriction	O
analyses	O
,	O
and	O
mutated	O
polymerase	O
chain	O
reaction	O
products	O
were	O
additionally	O
cloned	O
and	O
sequenced	O
.	O
The	O
codon	O
816	O
mutation	O
was	O
found	O
in	O
all	O
six	O
samples	O
from	O
adult	O
patients	O
,	O
but	O
not	O
in	O
any	O
of	O
the	O
11	O
specimens	O
from	O
children	O
.	O
In	O
addition	O
,	O
the	O
codon	O
560	O
mutation	O
could	O
be	O
demonstrated	O
for	O
the	O
first	O
time	O
in	O
indolent	B-malignancy-type
mastocytosis	I-malignancy-type
,	O
namely	O
in	O
two	O
of	O
four	O
specimens	O
from	O
adult	O
patients	O
,	O
but	O
not	O
in	O
those	O
from	O
two	O
children	O
.	O
These	O
data	O
thus	O
provide	O
a	O
possible	O
explanation	O
for	O
the	O
divergent	O
clinical	O
behavior	O
of	O
adult	O
-	O
versus	O
childhood	O
-	O
onset	O
indolent	B-malignancy-type
mastocytosis	I-malignancy-type
,	O
with	O
the	O
first	O
being	O
associated	O
with	O
an	O
activating	O
mutation	O
,	O
possibly	O
as	O
part	O
of	O
a	O
neoplastic	O
process	O
,	O
and	O
the	O
latter	O
representing	O
most	O
likely	O
a	O
reactive	O
process	O
of	O
an	O
as	O
yet	O
unknown	O
pathogenesis	O
.	O
PMID	O
:	O
9856847	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Gastroenterol	O
1998	O
Dec;27(	O
4)	O
:357	O
-	O
60	O
Pancreatic	B-malignancy-type
cancer	I-malignancy-type
associated	O
with	O
granulocyte	O
-	O
colony	O
stimulating	O
factor	O
production	O
confirmed	O
by	O
immunohistochemistry	O
.	O
Ohtsubo	O
K	O
,	O
Mouri	O
H	O
,	O
Sakai	O
J,	O
Akasofu	O
M,	O
Yamaguchi	O
Y	O
,	O
Watanabe	O
H	O
,	O
Gabata	O
T	O
,	O
Motoo	O
Y	O
,	O
Okai	O
T	O
,	O
Sawabu	O
N.	O
Department	O
of	O
Internal	O
Medicine	O
and	O
Medical	O
Oncology	O
,	O
Kanazawa	O
University	O
,	O
Japan	O
.	O
We	O
report	O
an	O
83	O
-	O
year	O
-	O
old	O
man	O
with	O
pancreatic	B-malignancy-type
body	I-malignancy-type
cancer	I-malignancy-type
of	I-malignancy-type
4.5	I-malignancy-type
cm	I-malignancy-type
in	I-malignancy-type
diameter	I-malignancy-type
.	O
Peripheral	O
leukocyte	O
count	O
was	O
15,700	O
/	O
microl	O
and	O
the	O
serum	O
concentration	O
of	O
granulocyte	O
-	O
colony	O
stimulating	O
factor	O
(	O
G-CSF	O
)	O
was	O
123	O
pg	O
/	O
ml	O
(	O
normal	O
,	O
6.0	O
-	O
21.9	O
pg	O
/	O
ml	O
)	O
on	O
admission	O
.	O
Furthermore	O
,	O
not	O
only	O
K-ras	O
codon	O
12	O
(	O
GGT	O
-->	O
GAT	O
)	O
but	O
also	O
p53	O
at	O
codon	O
247	O
(	O
CGG	O
-->	O
CCG	O
)	O
mutations	O
were	O
identified	O
in	O
the	O
pancreatic	O
juice	O
aspirated	O
endoscopically	O
.	O
We	O
performed	O
chemotherapy	O
with	O
two	O
courses	O
of	O
5-fluorouracil	O
,	O
pirarubicin	O
hydrochloride	O
,	O
and	O
mitomycin-C	O
,	O
resulting	O
in	O
no	O
beneficial	O
effect	O
.	O
After	O
the	O
second	O
course	O
the	O
patient	O
developed	O
interstitial	O
pneumonia	O
,	O
probably	O
caused	O
by	O
anticancer	O
drugs	O
,	O
and	O
died	O
4	O
months	O
after	O
the	O
tumor	O
was	O
detected	O
.	O
In	O
the	O
autopsy	O
tissue	O
,	O
the	O
tumor	O
macroscopically	O
occupied	O
the	O
pancreas	O
body	O
and	O
was	O
7	O
x	O
6	O
x	O
5	O
cm	O
in	O
size	O
.	O
Histopathologic	O
diagnosis	O
of	O
the	O
tumor	O
was	O
poorly	B-malignancy-type
differentiated	I-malignancy-type
adenosquamous	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Immunohistochemical	O
staining	O
of	O
the	O
autopsy	O
tissue	O
showed	O
that	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
cells	O
were	O
positive	O
for	O
G-CSF	O
.	O
This	O
is	O
the	O
first	O
case	O
report	O
of	O
G-CSF	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
pancreatic	I-malignancy-type
cancer	I-malignancy-type
confirmed	O
by	O
immunohistochemistry	O
.	O
PMID	O
:	O
9855271	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cell	O
Prolif	O
1998	O
Jun	O
-	O
Aug;31(3	O
-	O
4)	O
:139	O
-	O
53	O
Prognostic	O
significance	O
of	O
proliferative	O
activity	O
,	O
DNA	O
-	O
ploidy	O
,	O
p53	O
and	O
Ki-ras	O
point	O
mutations	O
in	O
colorectal	B-malignancy-type
liver	I-malignancy-type
metastases	I-malignancy-type
.	O
Russo	O
A	O
,	O
Migliavacca	O
M,	O
Bazan	O
V	O
,	O
Maturi	O
N	O
,	O
Morello	O
V	O
,	O
Dardanoni	O
G	O
,	O
Modica	O
G	O
,	O
Bazan	O
P	O
,	O
Albanese	O
I	O
,	O
La	O
Farina	O
M,	O
Tomasino	O
RM	O
.	O
Department	O
of	O
Clinical	O
Oncology	O
Research	O
,	O
University	O
of	O
Palermo	O
,	O
Italy	O
.	O
Paired	O
colorectal	B-malignancy-type
liver	I-malignancy-type
metastases	I-malignancy-type
(	O
CLM	B-malignancy-type
)	O
and	O
normal	O
tissue	O
samples	O
from	O
a	O
consecutive	O
series	O
of	O
36	O
patients	O
were	O
studied	O
prospectively	O
.	O
MIB-1	O
expression	O
was	O
studied	O
by	O
immunohistochemistry	O
on	O
paraffin	O
-	O
embedded	O
sections	O
.	O
DNA	O
ploidy	O
and	O
S-phase	O
fraction	O
(	O
SPF	O
)	O
measurements	O
were	O
performed	O
by	O
flow	O
cytometry	O
on	O
frozen	O
tissues	O
.	O
Mutations	O
within	O
the	O
p53	O
(	O
exons	O
5	O
-	O
8	O
)	O
and	O
c-Ki-ras	O
(	O
codons	O
12	O
and	O
13	O
)	O
genes	O
were	O
detected	O
by	O
PCR	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
followed	O
by	O
sequencing	O
.	O
A	O
high	O
correlation	O
was	O
observed	O
between	O
the	O
MIB-1	O
LI	O
and	O
SPF	O
value	O
(	O
rho	O
=	O
0.81	O
;	O
P	O
<	O
0.01	O
)	O
.	O
Moreover	O
,	O
p53	O
gene	O
mutations	O
were	O
associated	O
with	O
either	O
high	O
MIB-1	O
LI	O
and	O
high	O
SPF	O
.	O
In	O
univariate	O
analysis	O
,	O
SPF	O
and	O
MIB-1	O
levels	O
were	O
related	O
to	O
risk	O
of	O
death	O
.	O
The	O
association	O
between	O
overall	O
survival	O
and	O
DNA	O
-	O
ploidy	O
or	O
p53	O
mutations	O
did	O
not	O
reach	O
statistical	O
significance	O
,	O
but	O
a	O
slightly	O
better	O
survival	O
was	O
observed	O
for	O
patients	O
either	O
with	O
DNA	O
-	O
diploid	O
tumours	O
or	O
without	O
mutations	O
(	O
P	O
=	O
0.05	O
and	O
P	O
=	O
0.06	O
,	O
respectively	O
)	O
.	O
SPF	O
was	O
shown	O
by	O
multivariate	O
Cox	O
model	O
analysis	O
to	O
be	O
an	O
independent	O
prognostic	O
variable	O
and	O
thus	O
it	O
might	O
be	O
a	O
useful	O
prognostic	O
factor	O
in	O
patients	O
with	O
CLM	B-malignancy-type
.	O
PMID	O
:	O
9853427	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
1998	O
Sep	O
25	O
;131(	O
2	O
)	O
:171	O
-	O
5	O
Different	O
ras	O
gene	O
mutational	O
frequencies	O
in	O
thyroid	B-malignancy-type
papillary	I-malignancy-type
carcinomas	I-malignancy-type
in	O
Japan	O
and	O
Thailand	O
.	O
Naito	O
H	O
,	O
Pairojkul	O
C	O
,	O
Kitahori	O
Y	O
,	O
Yane	O
K	O
,	O
Miyahara	O
H	O
,	O
Konishi	O
N	O
,	O
Matsunaga	O
T	O
,	O
Hiasa	O
Y.	O
The	O
Second	O
Department	O
of	O
Pathology	O
,	O
Nara	O
Medical	O
University	O
,	O
Kashihara	O
,	O
Japan	O
.	O
The	O
incidence	O
and	O
pattern	O
of	O
ras	O
oncogene	O
mutations	O
in	O
human	O
malignancies	O
demonstrate	O
geographic	O
and	O
racial	O
differences	O
.	O
For	O
example	O
,	O
specificity	O
of	O
alterations	O
is	O
found	O
in	O
cholangiocellular	B-malignancy-type
carcinomas	I-malignancy-type
in	O
Thai	O
patients	O
with	O
a	O
different	O
etiology	O
from	O
those	O
in	O
Japanese	O
patients	O
.	O
In	O
the	O
present	O
study	O
,	O
a	O
comparison	O
of	O
ras	O
gene	O
mutations	O
in	O
thyroid	B-malignancy-type
papillary	I-malignancy-type
carcinomas	I-malignancy-type
from	O
Japanese	O
and	O
Thai	O
patients	O
was	O
performed	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
and	O
direct	O
sequencing	O
analyses	O
.	O
The	O
incidence	O
of	O
ras	O
mutation	O
differed	O
markedly	O
in	O
Japanese	O
(	O
two	O
of	O
24	O
carcinomas	B-malignancy-type
,	O
8.3	O
%	O
)	O
and	O
Thai	O
(	O
five	O
of	O
10	O
carcinomas	B-malignancy-type
,	O
50	O
%	O
)	O
patients	O
.	O
In	O
addition	O
,	O
all	O
but	O
one	O
ras	O
mutation	O
occurred	O
at	O
codon	O
12	O
of	O
the	O
K-ras	O
gene	O
in	O
the	O
Thai	O
cases	O
.	O
These	O
results	O
suggest	O
that	O
thyroid	B-malignancy-type
cancers	I-malignancy-type
in	O
Thailand	O
may	O
be	O
due	O
to	O
specific	O
genetic	O
and/or	O
environmental	O
factors	O
.	O
PMID	O
:	O
9851250	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
1998	O
Nov	O
15	O
;83(	O
10	O
)	O
:2120	O
-	O
9	O
Clinical	O
correlates	O
of	O
the	O
presence	O
of	O
the	O
Asp	O
816	O
Val	O
c-kit	O
mutation	O
in	O
the	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
patients	O
with	O
mastocytosis	B-malignancy-type
.	O
Worobec	O
AS	O
,	O
Semere	O
T	O
,	O
Nagata	O
H	O
,	O
Metcalfe	O
DD.	O
Laboratory	O
of	O
Allergic	O
Diseases	O
,	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infectious	O
Diseases	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
-	O
1881	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
The	O
Asp	O
816	O
Val	O
mutation	O
in	O
the	O
catalytic	O
domain	O
of	O
the	O
c-kit	O
receptor	O
has	O
been	O
identified	O
in	O
patients	O
with	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
.	O
METHODS	O
:	O
To	O
determine	O
whether	O
this	O
mutation	O
is	O
associated	O
with	O
identifiable	O
clinical	O
patterns	O
of	O
disease	O
and	O
prognosis	O
,	O
a	O
total	O
of	O
65	O
patients	O
with	O
mastocytosis	B-malignancy-type
were	O
screened	O
for	O
the	O
presence	O
of	O
the	O
Asp	O
816	O
Val	O
mutation	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
.	O
RESULTS	O
:	O
By	O
analysis	O
of	O
HinfI	O
digestion	O
products	O
,	O
the	O
authors	O
found	O
that	O
the	O
overall	O
prevalence	O
of	O
this	O
mutation	O
in	O
the	O
current	O
patient	O
series	O
was	O
25	O
%	O
.	O
The	O
presence	O
of	O
the	O
Asp	O
816	O
Val	O
mutation	O
in	O
PBMCs	O
was	O
observed	O
in	O
15	O
adults	O
(	O
of	O
16	O
Asp	O
816	O
Val	O
mutation	O
positive	O
patients	O
)	O
and	O
1	O
infant	O
,	O
but	O
not	O
in	O
any	O
children	O
with	O
mastocytosis	B-malignancy-type
.	O
Patients	O
whose	O
PBMCs	O
were	O
positive	O
for	O
this	O
mutation	O
(	O
category	B-malignancy-type
II	I-malignancy-type
and	O
a	O
subset	O
of	O
category	B-malignancy-type
Ib	I-malignancy-type
mastocytosis	I-malignancy-type
patients	O
)	O
manifested	O
a	O
more	O
severe	O
disease	O
pattern	O
,	O
with	O
clinical	O
features	O
ranging	O
in	O
severity	O
from	O
early	O
to	O
advanced	O
myelodysplastic	B-malignancy-type
or	O
myeloproliferative	B-malignancy-type
syndromes	B-malignancy-type
.	O
These	O
patients	O
more	O
commonly	O
had	O
osteosclerotic	O
bone	O
involvement	O
(	O
a	O
clinical	O
feature	O
primarily	O
observed	O
in	O
mastocytosis	B-malignancy-type
patients	O
with	O
an	O
associated	O
hematologic	O
disorder	O
)	O
as	O
well	O
as	O
immunoglobulin	O
dysregulation	O
and	O
peripheral	O
blood	O
abnormalities	O
.	O
Furthermore	O
,	O
pedigree	O
analysis	O
of	O
three	O
families	O
provided	O
evidence	O
that	O
the	O
mutation	O
was	O
somatic	O
.	O
CONCLUSIONS	O
:	O
Twenty-five	O
percent	O
of	O
all	O
patients	O
with	O
mastocytosis	B-malignancy-type
had	O
the	O
Asp	O
816	O
Val	O
mutation	O
in	O
PBMCs	O
;	O
56	O
%	O
of	O
these	O
patients	O
had	O
evidence	O
of	O
a	O
myelodysplastic	B-malignancy-type
or	O
myeloproliferative	B-malignancy-type
syndrome	I-malignancy-type
,	O
and	O
44	O
%	O
had	O
been	O
clinically	O
placed	O
in	O
the	O
indolent	B-malignancy-type
mastocytosis	I-malignancy-type
category	O
,	O
suggesting	O
that	O
the	O
current	O
classification	O
scheme	O
used	O
to	O
assign	O
prognosis	O
may	O
be	O
inadequate	O
.	O
Therefore	O
,	O
determination	O
of	O
the	O
presence	O
or	O
absence	O
of	O
this	O
mutation	O
in	O
PBMCs	O
of	O
mastocytosis	B-malignancy-type
patients	O
offers	O
a	O
useful	O
adjunct	O
in	O
determining	O
the	O
extent	O
of	O
workup	O
and	O
assigning	O
prognosis	O
in	O
this	O
complex	O
and	O
heterogeneous	O
disease	O
.	O
PMID	O
:	O
9827716	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gastroenterol	O
Clin	O
Biol	O
1998	O
Aug-	O
Sep;22(8	O
-	O
9)	O
:679	O
-	O
87	O
[	O
Analysis	O
of	O
genetic	O
disorders	O
of	O
cancer	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
rectum	I-malignancy-type
:	O
differences	O
in	O
relation	O
to	O
cancer	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
colon	I-malignancy-type
]	O
[Article	O
in	O
French	O
]	O
Rebischung	O
C	O
,	O
Laurent	O
-	O
Puig	O
P	O
,	O
Gerard	O
JP	O
,	O
Thomas	O
G	O
,	O
Hamelin	O
R.	O
INSERM	O
U434	O
-	O
CEPH	O
,	O
Paris	O
.	O
AIMS	O
AND	O
METHODS	O
:	O
We	O
studied	O
the	O
mechanisms	O
of	O
colon	O
and	O
rectal	O
carcinogenesis	O
by	O
analysing	O
in	O
a	O
series	O
of	O
83	O
rectal	B-malignancy-type
tumors	I-malignancy-type
the	O
prevalence	O
of	O
the	O
two	O
tumor	O
types	O
characteristic	O
of	O
colon	B-malignancy-type
cancer	I-malignancy-type
,	O
i.e.	O
,	O
the	O
LOH	B-malignancy-type
+	I-malignancy-type
type	I-malignancy-type
,	O
defined	O
by	O
p53	O
and	O
APC	O
mutations	O
(	O
studied	O
by	O
DGGE	O
and	O
protein	O
truncation	O
assay	O
)	O
,	O
and	O
the	O
RER	B-malignancy-type
+	I-malignancy-type
type	I-malignancy-type
,	O
which	O
is	O
characterized	O
by	O
the	O
instability	O
of	O
some	O
mononucleotide	O
repeat	O
microsatellites	O
(	O
Bat	O
25	O
and	O
Bat	O
26	O
)	O
.	O
Additionally	O
,	O
we	O
analyzed	O
the	O
occurrence	O
of	O
Ki-Ras	O
mutations	O
(	O
direct	O
sequencing	O
)	O
.	O
RESULTS	O
:	O
Only	O
one	O
tumor	O
turned	O
out	O
to	O
be	O
RER	O
+	O
.	O
Moreover	O
,	O
in	O
59	O
%	O
of	O
the	O
tumor	O
cases	O
mutations	O
were	O
found	O
in	O
p53	O
,	O
essentially	O
affecting	O
codon	O
175	O
.	O
The	O
APC	O
and	O
Ki-Ras	O
genes	O
were	O
found	O
to	O
be	O
mutated	O
in	O
40	O
and	O
26	O
%	O
of	O
the	O
rectal	B-malignancy-type
tumors	I-malignancy-type
,	O
respectively	O
.	O
In	O
18	O
tumors	O
(	O
21	O
%	O
)	O
none	O
of	O
the	O
genes	O
studied	O
were	O
mutated	O
.	O
CONCLUSIONS	O
:	O
The	O
RER	O
+	O
phenotype	O
is	O
rare	O
among	O
rectal	B-malignancy-type
tumors	I-malignancy-type
,	O
which	O
are	O
essentially	O
LOH	O
+	O
.	O
In	O
these	O
LOH	O
+	O
tumors	O
the	O
p53	O
gene	O
is	O
more	O
frequently	O
mutated	O
than	O
in	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
with	O
the	O
same	O
phenotype	O
.	O
Mutations	O
in	O
the	O
APC	O
and	O
Ki-Ras	O
genes	O
,	O
on	O
the	O
other	O
hand	O
,	O
are	O
less	O
frequent	O
in	O
rectal	B-malignancy-type
tumors	I-malignancy-type
.	O
Tumors	O
with	O
the	O
RER	O
-	O
and	O
LOH	O
-	O
phenotype	O
may	O
develop	O
as	O
a	O
result	O
of	O
a	O
third	O
carcinogenesis	O
model	O
which	O
must	O
be	O
defined	O
.	O
PMID	O
:	O
9823556	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Cancer	O
Res	O
1996	O
Feb;2(	O
2	O
)	O
:411	O
-	O
8	O
Detection	O
of	O
K-ras	O
mutations	O
in	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
:	O
relationship	O
to	O
prognosis	O
.	O
Keohavong	O
P	O
,	O
DeMichele	O
MA	O
,	O
Melacrinos	O
AC	O
,	O
Landreneau	O
RJ	O
,	O
Weyant	O
RJ	O
,	O
Siegfried	O
JM	O
.	O
Department	O
of	O
Environmental	O
and	O
Occupational	O
Health	O
,	O
University	O
of	O
Pittsburgh	O
,	O
Pittsburgh	O
,	O
Pennsylvania	O
15238	O
,	O
USA	O
.	O
The	O
K-ras	O
mutation	O
is	O
one	O
of	O
the	O
most	O
common	O
genetic	O
alterations	O
found	O
in	O
human	O
lung	B-malignancy-type
cancer	I-malignancy-type
.	O
To	O
evaluate	O
the	O
prognostic	O
value	O
of	O
ras	O
gene	O
alterations	O
in	O
lung	B-malignancy-type
cancer	I-malignancy-type
in	O
a	O
U.S.	O
population	O
,	O
we	O
have	O
screened	O
173	O
human	O
lung	B-malignancy-type
tumors	I-malignancy-type
,	O
which	O
included	O
127	O
adenocarcinomas	B-malignancy-type
,	O
37	O
squamous	B-malignancy-type
carcinomas	I-malignancy-type
,	O
and	O
9	O
adenosquamous	B-malignancy-type
carcinomas	I-malignancy-type
,	O
for	O
mutations	O
in	O
the	O
K-ras	O
gene	O
using	O
the	O
combination	O
of	O
the	O
PCR	O
and	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O
Forty-three	O
tumors	O
contained	O
K-ras	O
mutations	O
.	O
Of	O
these	O
,	O
41	O
were	O
identified	O
among	O
the	O
adenocarcinomas	B-malignancy-type
(	O
32	O
%	O
)	O
,	O
1	O
among	O
the	O
squamous	B-malignancy-type
carcinomas	I-malignancy-type
(	O
2.7	O
%	O
)	O
,	O
and	O
1	O
among	O
the	O
adenosquamous	B-malignancy-type
carcinomas	I-malignancy-type
(	O
11	O
%	O
)	O
.	O
Forty	O
of	O
these	O
mutations	O
were	O
found	O
in	O
codon	O
12	O
and	O
consisted	O
of	O
24	O
G	O
to	O
T	O
transversions	O
,	O
12	O
G	O
to	O
A	O
transitions	O
,	O
2	O
G	O
to	O
C	O
transversions	O
,	O
and	O
1	O
double	O
GG	O
to	O
TT	O
mutation	O
.	O
Two	O
other	O
G	O
to	O
T	O
transversions	O
were	O
found	O
in	O
codon	O
13	O
,	O
and	O
1	O
A	O
to	O
C	O
transversion	O
was	O
found	O
in	O
codon	O
61	O
.	O
The	O
data	O
showed	O
that	O
gender	O
did	O
not	O
seem	O
to	O
affect	O
the	O
incidence	O
and	O
the	O
types	O
of	O
the	O
K-ras	O
mutations	O
or	O
amino	O
acid	O
changes	O
.	O
Examination	O
of	O
the	O
mutations	O
in	O
adenocarcinomas	B-malignancy-type
in	O
relation	O
to	O
overall	O
survival	O
showed	O
no	O
difference	O
in	O
adenocarcinomas	B-malignancy-type
with	O
K-ras	O
mutations	O
compared	O
with	O
K-ras	O
-	O
negative	O
adenocarcinomas	B-malignancy-type
.	O
However	O
,	O
the	O
substitution	O
of	O
the	O
wild	O
-	O
type	O
GGT	O
(	O
glycine	O
)	O
at	O
codon	O
12	O
with	O
a	O
GTT	O
(	O
valine	O
)	O
or	O
a	O
CGT	O
(	O
arginine	O
)	O
showed	O
a	O
strong	O
trend	O
(	O
P	O
=	O
0.07	O
)	O
toward	O
a	O
poorer	O
prognosis	O
compared	O
with	O
wild	O
-	O
type	O
or	O
other	O
amino	O
acid	O
substitutions	O
.	O
Substitution	O
of	O
the	O
wild	O
-	O
type	O
glycine	O
for	O
aspartate	O
(	O
GAT	O
)	O
showed	O
a	O
strong	O
trend	O
(	O
P	O
=	O
0.06	O
)	O
for	O
a	O
better	O
outcome	O
than	O
the	O
valine	O
or	O
arginine	O
substitution	O
.	O
Although	O
these	O
trends	O
will	O
require	O
larger	O
patient	O
populations	O
for	O
verification	O
,	O
these	O
data	O
suggest	O
that	O
the	O
prognostic	O
significance	O
of	O
K-ras	O
mutations	O
may	O
depend	O
on	O
the	O
amino	O
acid	O
substitution	O
in	O
the	O
p21(ras)	O
protein	O
.	O
PMID	O
:	O
9816185	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Cancer	O
Res	O
Clin	O
Oncol	O
1998;124(9	O
)	O
:517	O
-	O
22	O
Analysis	O
of	O
K-ras	O
gene	O
mutations	O
in	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
:	O
correlation	O
with	O
gender	O
,	O
histological	O
subtypes	O
,	O
and	O
clinical	O
outcome	O
.	O
Wang	O
YC	O
,	O
Lee	O
HS	O
,	O
Chen	O
SK	O
,	O
Yang	O
SC	O
,	O
Chen	O
CY	O
.	O
Institute	O
of	O
Toxicology	O
,	O
Chung	O
Shan	O
Medical	O
and	O
Dental	O
College	O
,	O
Taichung	O
,	O
Taiwan	O
,	O
Republic	O
of	O
China	O
.	O
PURPOSE	O
:	O
Lung	B-malignancy-type
cancer	I-malignancy-type
is	O
respectively	O
the	O
leading	O
and	O
second	O
-	O
leading	O
cause	O
of	O
cancer	O
deaths	O
among	O
women	O
and	O
men	O
in	O
Taiwan	O
.	O
The	O
commonest	O
pathological	O
type	O
of	O
lung	B-malignancy-type
carcinoma	I-malignancy-type
found	O
in	O
Taiwan	O
is	O
adenocarcinoma	B-malignancy-type
.	O
and	O
it	O
has	O
been	O
documented	O
that	O
K-ras	O
oncogene	O
mutation	O
occurs	O
in	O
a	O
subset	O
of	O
lung	O
adenocarcinoma	O
.	O
We	O
therefore	O
investigated	O
the	O
mutation	O
spectrum	O
and	O
clinicopathological	O
significance	O
of	O
K-ras	O
oncogene	O
mutations	O
in	O
lung	B-malignancy-type
cancer	I-malignancy-type
patients	O
in	O
Taiwan	O
.	O
METHODS	O
:	O
The	O
lung	B-malignancy-type
tumors	I-malignancy-type
were	O
surgically	O
resected	O
from	O
84	O
lung	B-malignancy-type
cancer	I-malignancy-type
patients	O
.	O
DNA	O
was	O
isolated	O
and	O
the	O
mutation	O
spectrum	O
was	O
examined	O
by	O
direct	O
sequencing	O
.	O
These	O
data	O
were	O
also	O
correlated	O
with	O
the	O
clinicopathological	O
characteristics	O
of	O
patients	O
.	O
RESULTS	O
:	O
K-ras	O
gene	O
mutations	O
were	O
detected	O
in	O
5	O
cases	O
among	O
the	O
84	O
patients	O
investigated	O
(	O
6.0	O
%	O
)	O
.	O
The	O
majority	O
of	O
mutations	O
occurred	O
in	O
exon	O
1	O
(	O
80	O
%	O
,	O
4	O
of	O
5	O
)	O
and	O
were	O
located	O
mainly	O
in	O
codons	O
12	O
and	O
13	O
.	O
Two	O
patients	O
had	O
G	O
x	O
C	O
-->	O
T	O
x	O
A	O
transversions	O
and	O
2	O
patients	O
had	O
G	O
x	O
C	O
-->	O
A	O
x	O
T	O
transitions	O
.	O
Notably	O
,	O
1	O
patient	O
had	O
a	O
G	O
x	O
C	O
base	O
-	O
pair	O
deletion	O
from	O
the	O
contiguous	O
G	O
x	O
C	O
base	O
pairs	O
located	O
between	O
codons	O
68	O
and	O
69	O
.	O
All	O
mutations	O
occurred	O
in	O
male	O
patients	O
who	O
were	O
smokers	O
.	O
The	O
incidences	O
of	O
K-ras	O
gene	O
mutation	O
among	O
male	O
and	O
female	O
patients	O
with	O
adenocarcinoma	B-malignancy-type
were	O
13	O
%	O
and	O
0	O
%	O
respectively	O
.	O
Patients	O
with	O
K-ras	O
gene	O
mutation	O
survived	O
for	O
shorter	O
periods	O
than	O
those	O
without	O
mutations	O
(	O
P	O
=	O
0.08	O
,	O
by	O
the	O
log	O
-	O
rank	O
test	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
incidence	O
of	O
K-ras	O
gene	O
mutations	O
for	O
male	O
and	O
female	O
patients	O
with	O
adenocarcinoma	B-malignancy-type
was	O
13	O
%	O
and	O
0	O
%	O
respectively	O
.	O
Thus	O
,	O
the	O
role	O
of	O
K-ras	O
in	O
the	O
development	O
of	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
among	O
Chinese	O
men	O
who	O
are	O
predominantly	O
smokers	O
is	O
not	O
significantly	O
different	O
from	O
that	O
in	O
other	O
populations	O
worldwide	O
.	O
However	O
,	O
K-ras	O
mutations	O
may	O
not	O
be	O
associated	O
with	O
adenocarcinoma	B-malignancy-type
among	O
women	O
in	O
Taiwan	O
,	O
who	O
are	O
virtually	O
all	O
nonsmokers	O
.	O
PMID	O
:	O
9808427	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Surg	O
Pathol	O
1998	O
Nov;22(	O
11	O
)	O
:1343	O
-	O
50	O
Bronchioloalveolar	B-malignancy-type
adenocarcinoma	I-malignancy-type
of	I-malignancy-type
lung	I-malignancy-type
:	O
monoclonal	O
origin	O
for	O
multifocal	B-malignancy-type
disease	I-malignancy-type
.	O
Holst	O
VA	O
,	O
Finkelstein	O
S,	O
Yousem	O
SA	O
.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Pittsburgh	O
School	O
of	O
Medicine	O
,	O
PA	O
,	O
USA	O
.	O
In	O
an	O
attempt	O
to	O
understand	O
the	O
histogenesis	O
and	O
molecular	O
pathogenesis	O
of	O
multifocal	B-malignancy-type
bronchioloalveolar	I-malignancy-type
lung	I-malignancy-type
carcinoma	I-malignancy-type
(	O
BAC	B-malignancy-type
)	O
we	O
studied	O
28	O
cases	O
of	O
BAC	B-malignancy-type
using	O
a	O
topographic	O
genotyping	O
approach	O
for	O
the	O
presence	O
of	O
K-ras	O
exon	O
1	O
mutations	O
and	O
p53	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
.	O
This	O
analytical	O
approach	O
demonstrated	O
K-ras	O
exon	O
1	O
mutations	O
in	O
12.5	O
%	O
of	O
solitary	B-malignancy-type
BACs	I-malignancy-type
,	O
40	O
%	O
of	O
BACs	B-malignancy-type
with	I-malignancy-type
microscopic	I-malignancy-type
or	I-malignancy-type
macroscopic	I-malignancy-type
satellite	I-malignancy-type
lesions	I-malignancy-type
,	O
and	O
60	O
%	O
of	O
BACs	B-malignancy-type
with	I-malignancy-type
intrathoracic	I-malignancy-type
metastases	I-malignancy-type
.	O
In	O
all	O
cases	O
with	O
K-ras	O
mutations	O
,	O
the	O
identical	O
point	O
mutation	O
was	O
present	O
in	O
the	O
primary	O
,	O
satellite	O
,	O
and	O
intrathoracic	B-malignancy-type
metastatic	I-malignancy-type
lesions	I-malignancy-type
.	O
When	O
p53	O
LOH	O
was	O
demonstrated	O
in	O
the	O
primary	O
lesion	O
,	O
it	O
was	O
also	O
detected	O
in	O
the	O
satellites	O
and	O
intrathoracic	B-malignancy-type
metastases	I-malignancy-type
.	O
No	O
significant	O
association	O
was	O
noted	O
between	O
the	O
presence	O
of	O
K-ras	O
mutations	O
and	O
p53	O
LOH	O
.	O
The	O
results	O
strongly	O
support	O
a	O
monoclonal	O
origin	O
of	O
multifocal	B-malignancy-type
BACs	I-malignancy-type
.	O
Furthermore	O
,	O
the	O
findings	O
support	O
the	O
theories	O
explaining	O
the	O
origin	O
of	O
multifocal	B-malignancy-type
BAC	I-malignancy-type
by	O
intraalveolar	O
route	O
of	O
spread	O
,	O
intrapulmonary	O
lymphatic	O
spread	O
,	O
or	O
aerosolization	O
leading	O
to	O
implantation	O
at	O
different	O
sites	O
.	O
A	O
trend	O
toward	O
an	O
increased	O
frequency	O
of	O
K-ras	O
mutations	O
and	O
p53	O
LOH	O
in	O
BACs	B-malignancy-type
with	O
satellites	O
or	O
metastases	O
compared	O
to	O
solitary	B-malignancy-type
BACs	I-malignancy-type
was	O
noted	O
.	O
PMID	O
:	O
9808126	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Invest	O
Dermatol	O
1998	O
Nov;111(	O
5	O
)	O
:757	O
-	O
61	O
N-ras	O
mutations	O
are	O
common	O
in	O
melanomas	B-malignancy-type
from	I-malignancy-type
sun	I-malignancy-type
-	I-malignancy-type
exposed	I-malignancy-type
skin	I-malignancy-type
of	O
humans	O
but	O
rare	O
in	B-malignancy-type
mucosal	I-malignancy-type
membranes	I-malignancy-type
or	O
unexposed	B-malignancy-type
skin	I-malignancy-type
.	O
Jiveskog	O
S,	O
Ragnarsson	O
-	O
Olding	O
B	O
,	O
Platz	O
A	O
,	O
Ringborg	O
U.	O
Department	O
of	O
Oncology	O
,	O
Radiumhemmet	O
,	O
Karolinska	O
Hospital	O
,	O
Stockholm	O
,	O
Sweden	O
.	O
Ras	O
mutations	O
,	O
preferentially	O
in	O
codon	O
61	O
of	O
the	O
N-ras	O
oncogene	O
,	O
are	O
common	O
in	O
human	O
cutaneous	B-malignancy-type
melanomas	I-malignancy-type
.	O
In	O
this	O
study	O
,	O
we	O
questioned	O
the	O
association	O
between	O
ras	O
mutations	O
in	O
primary	O
melanomas	B-malignancy-type
and	O
sun	O
exposure	O
.	O
DNA	O
was	O
extracted	O
from	O
formalin	O
-	O
fixed	O
primary	O
melanomas	B-malignancy-type
:	O
28	O
at	O
chronically	O
sun	O
-	O
exposed	O
head	O
and	O
neck	O
areas	O
,	O
18	O
at	O
sites	O
subject	O
to	O
intermittent	O
sun	O
exposure	O
,	O
and	O
28	O
from	O
unexposed	O
mucosal	O
membranes	O
(	O
vulva	O
/	O
vagina	O
,	O
anus	O
/	O
rectum	O
,	O
palate	O
)	O
.	O
Mutations	O
of	O
both	O
exons	O
of	O
H	O
-	O
,	O
K	O
-	O
,	O
and	O
N	O
-	O
ras	O
genes	O
were	O
examined	O
by	O
polymerase	O
chain	O
reaction	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
and	O
by	O
direct	O
nucleotide	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction	O
amplified	O
exons	O
.	O
Thirty-two	O
per	O
cent	O
of	O
the	O
head	B-malignancy-type
and	I-malignancy-type
neck	I-malignancy-type
melanomas	I-malignancy-type
and	O
11	O
%	O
of	O
the	O
melanomas	B-malignancy-type
from	I-malignancy-type
intermittently	I-malignancy-type
sun	I-malignancy-type
-	I-malignancy-type
exposed	I-malignancy-type
skin	I-malignancy-type
had	O
N-ras	O
codon	O
61	O
mutations	O
;	O
comparatively	O
only	O
7	O
%	O
of	O
the	O
tumors	B-malignancy-type
from	I-malignancy-type
the	I-malignancy-type
unexposed	I-malignancy-type
areas	I-malignancy-type
had	O
such	O
mutations	O
.	O
One	O
vulvar	B-malignancy-type
melanoma	I-malignancy-type
had	O
an	O
N-ras	O
codon	O
12	O
mutation	O
.	O
No	O
H-ras	O
or	O
K-ras	O
mutations	O
were	O
detected	O
in	O
any	O
sample	O
.	O
The	O
frequency	O
of	O
N-ras	O
exon	O
2	O
mutations	O
in	O
melanomas	B-malignancy-type
of	I-malignancy-type
typically	I-malignancy-type
sunbathed	I-malignancy-type
skin	I-malignancy-type
was	O
compared	O
for	O
the	O
first	O
time	O
with	O
that	O
in	O
melanomas	B-malignancy-type
of	I-malignancy-type
areas	I-malignancy-type
completely	I-malignancy-type
protected	I-malignancy-type
from	I-malignancy-type
sun	I-malignancy-type
exposure	I-malignancy-type
.	O
The	O
significantly	O
higher	O
frequency	O
(	O
p	O
=	O
0.04	O
,	O
chi	O
square	O
exact	O
test	O
)	O
of	O
these	O
N-ras	O
mutations	O
on	O
the	O
head	O
and	O
neck	O
demonstrates	O
their	O
UV	O
-	O
light	O
induction	O
in	O
a	O
subset	O
of	O
melanomas	B-malignancy-type
explaining	O
one	O
of	O
the	O
molecular	O
effects	O
of	O
UV	O
light	O
in	O
human	O
skin	O
.	O
PMID	O
:	O
9804334	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Chem	O
1998	O
Nov;44(	O
11	O
)	O
:2243	O
-	O
8	O
K-ras	O
gene	O
mutations	O
in	O
the	O
diagnosis	O
of	O
fine	O
-	O
needle	O
aspirates	O
of	O
pancreatic	B-malignancy-type
masses	I-malignancy-type
:	O
prospective	O
study	O
using	O
two	O
techniques	O
with	O
different	O
detection	O
limits	O
.	O
Mora	O
J,	O
Puig	O
P	O
,	O
Boadas	O
J,	O
Urgell	O
E	O
,	O
Montserrat	O
E	O
,	O
Lerma	O
E	O
,	O
Gonzalez	O
-	O
Sastre	O
F	O
,	O
Lluis	O
F	O
,	O
Farre	O
A	O
,	O
Capella	O
G.	O
Department	O
of	O
Clinical	O
Biochemistry	O
,	O
Hospital	O
de	O
la	O
Santa	O
Creu	O
i	O
Sant	O
Pau	O
,	O
Antoni	O
M.	O
Claret	O
,	O
Barcelona	O
,	O
Spain	O
.	O
lig@santpau.es	O
Detection	O
of	O
K-ras	O
mutations	O
may	O
be	O
useful	O
in	O
the	O
evaluation	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
,	O
in	O
a	O
prospective	O
design	O
,	O
the	O
diagnostic	O
utility	O
of	O
K-ras	O
mutation	O
analysis	O
in	O
62	O
consecutive	O
fine	O
-	O
needle	O
aspirates	O
of	O
pancreatic	B-malignancy-type
masses	I-malignancy-type
,	O
using	O
two	O
PCR	O
-	O
based	O
techniques	O
-	O
standard	O
and	O
enriched	O
-	O
with	O
detection	O
limits	O
of	O
a	O
mutant	O
allele	O
in	O
the	O
presence	O
of	O
10(2)	O
or	O
10(3)	O
wild	O
-	O
type	O
alleles	O
,	O
respectively	O
.	O
Cytology	O
alone	O
offered	O
a	O
diagnostic	O
sensitivity	O
of	O
75	O
%	O
.	O
The	O
enriched	O
higher	O
sensitivity	O
detection	O
technique	O
,	O
in	O
combination	O
with	O
cytology	O
,	O
offered	O
a	O
diagnostic	O
sensitivity	O
of	O
91	O
%	O
without	O
false	O
positives	O
.	O
The	O
molecular	O
analysis	O
would	O
have	O
contributed	O
to	O
diagnosis	O
in	O
an	O
additional	O
14	O
cases	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
The	O
standard	O
technique	O
contributed	O
to	O
diagnosis	O
in	O
an	O
additional	O
9	O
cases	O
.	O
These	O
results	O
strongly	O
support	O
the	O
use	O
of	O
the	O
enriched	O
method	O
of	O
detecting	O
K-ras	O
mutations	O
as	O
a	O
complement	O
to	O
cytology	O
in	O
the	O
evaluation	O
of	O
pancreatic	B-malignancy-type
masses	I-malignancy-type
.	O
PMID	O
:	O
9799749	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gastroenterology	O
1998	O
Nov;115(	O
5	O
)	O
:1144	O
-	O
53	O
Oncogenic	O
ras	O
induces	O
gastrin	O
gene	O
expression	O
in	O
colon	B-malignancy-type
cancer	I-malignancy-type
.	O
Nakata	O
H	O
,	O
Wang	O
SL	O
,	O
Chung	O
DC	O
,	O
Westwick	O
JK	O
,	O
Tillotson	O
LG.	O
Division	O
of	O
Digestive	O
Diseases	O
and	O
Nutrition	O
,	O
Department	O
of	O
Medicine	O
,	O
University	O
of	O
North	O
Carolina	O
,	O
Chapel	O
Hill	O
,	O
North	O
Carolina	O
,	O
USA	O
.	O
BACKGROUND	O
&	O
AIMS	O
:	O
The	O
expression	O
of	O
gastrin	O
,	O
as	O
a	O
tumor	O
growth	O
factor	O
,	O
is	O
significantly	O
increased	O
in	O
some	O
colon	B-malignancy-type
cancers	I-malignancy-type
compared	O
with	O
the	O
low	O
levels	O
found	O
in	O
normal	O
mucosa	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
the	O
transcriptional	O
mechanisms	O
of	O
gastrin	O
induction	O
in	O
colon	B-malignancy-type
cancer	I-malignancy-type
.	O
METHODS	O
:	O
Gastrin	O
messenger	O
(	O
mRNA	O
)	O
levels	O
and	O
K-ras	O
genotype	O
were	O
determined	O
in	O
colon	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
and	O
surgical	O
specimens	O
.	O
Colon	B-malignancy-type
cancer	I-malignancy-type
cells	O
were	O
transfected	O
with	O
oncogenic	O
ras	O
expression	O
vectors	O
,	O
and	O
transcriptional	O
activity	O
was	O
assayed	O
with	O
gastrin	O
-	O
luciferase	O
reporter	O
genes	O
.	O
RESULTS	O
:	O
Colon	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
and	O
tissues	O
with	O
K-ras	O
mutations	O
all	O
had	O
significantly	O
higher	O
gastrin	O
mRNA	O
levels	O
than	O
those	O
that	O
were	O
ras	O
wild	O
type	O
.	O
Treatment	O
of	O
several	O
ras	O
mutant	O
cell	O
lines	O
with	O
PD98059	O
,	O
an	O
inhibitor	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
kinase	O
,	O
resulted	O
in	O
a	O
decrease	O
in	O
endogenous	O
gastrin	O
mRNA	O
levels	O
.	O
The	O
effects	O
of	O
ras	O
on	O
gastrin	O
expression	O
appeared	O
to	O
be	O
mediated	O
through	O
the	O
gastrin	O
promoter	O
because	O
transfection	O
of	O
oncogenic	O
ras	O
and	O
activated	O
raf	O
expression	O
vectors	O
both	O
induced	O
gastrin	O
-	O
promoter	O
,	O
luciferase	O
-	O
reporter	O
genes	O
.	O
The	O
inductive	O
effects	O
of	O
oncogenic	O
ras	O
could	O
be	O
blocked	O
by	O
the	O
coexpression	O
of	O
dominant	O
negative	O
forms	O
of	O
raf	O
and	O
extracellular	O
regulated	O
kinase	O
.	O
CONCLUSIONS	O
:	O
Oncogenic	O
ras	O
induces	O
gastrin	O
gene	O
expression	O
through	O
activation	O
of	O
the	O
Raf	O
-	O
MEK	O
-	O
ERK	O
signal	O
transduction	O
pathway	O
.	O
PMID	O
:	O
9797369	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gastroenterology	O
1998	O
Nov;115(	O
5	O
)	O
:1090	O
-	O
5	O
A	O
novel	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
of	O
c-kit	O
gene	O
in	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
.	O
Nakahara	O
M,	O
Isozaki	O
K	O
,	O
Hirota	O
S,	O
Miyagawa	O
J,	O
Hase	O
-	O
Sawada	O
N	O
,	O
Taniguchi	O
M,	O
Nishida	O
T	O
,	O
Kanayama	O
S,	O
Kitamura	O
Y	O
,	O
Shinomura	O
Y	O
,	O
Matsuzawa	O
Y.	O
Second	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Osaka	O
,	O
Japan	O
.	O
BACKGROUND	O
&	O
AIMS	O
:	O
The	O
c-kit	O
gene	O
encodes	O
a	O
receptor	O
tyrosine	O
kinase	O
(	O
KIT	O
)	O
.	O
Recently	O
,	O
we	O
found	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
of	O
the	O
c-kit	O
gene	O
in	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
.	O
All	O
mutations	O
were	O
confined	O
within	O
the	O
11	O
amino	O
acids	O
(	O
Lys-550	O
to	O
Val-560	O
)	O
in	O
the	O
juxtamembrane	O
domain	O
,	O
but	O
one	O
GIST	O
showed	O
a	O
novel	O
deletion	O
-	O
type	O
mutation	O
at	O
codon	O
579	O
(	O
Asp	O
)	O
in	O
the	O
juxtamembrane	O
domain	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
clarify	O
whether	O
the	O
mutation	O
is	O
activating	O
.	O
METHODS	O
:	O
Mutant	O
c-kit	O
cDNA	O
was	O
transfected	O
into	O
an	O
interleukin	O
3	O
(	O
IL-3	O
)	O
-	O
dependent	O
Ba	O
/	O
F3	O
murine	O
lymphoid	O
cell	O
line	O
,	O
and	O
the	O
magnitude	O
of	O
autophosphorylation	O
of	O
the	O
mutant	O
KIT	O
was	O
examined	O
with	O
or	O
without	O
stem	O
cell	O
factor	O
(	O
SCF	O
)	O
,	O
a	O
ligand	O
of	O
KIT	O
.	O
An	O
in	O
vitro	O
kinase	O
assay	O
was	O
also	O
performed	O
.	O
The	O
biological	O
behavior	O
of	O
the	O
transfectant	O
was	O
estimated	O
by	O
both	O
an	O
in	O
vitro	O
proliferation	O
assay	O
and	O
in	O
vivo	O
transplantation	O
to	O
nude	O
mice	O
.	O
RESULTS	O
:	O
The	O
mutant	O
KIT	O
exhibited	O
constitutive	O
phosphorylation	O
and	O
strong	O
kinase	O
activity	O
without	O
SCF	O
.	O
The	O
transfectant	O
grew	O
autonomously	O
without	O
IL-3	O
and	O
SCF	O
,	O
and	O
it	O
formed	O
tumors	O
in	O
nude	O
mice	O
.	O
CONCLUSIONS	O
:	O
Deletion	O
at	O
codon	O
579	O
(	O
Asp	O
)	O
in	O
the	O
juxtamembrane	O
domain	O
of	O
the	O
c-kit	O
gene	O
is	O
a	O
novel	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
other	O
than	O
the	O
region	O
between	O
Lys-550	O
and	O
Val-560	O
.	O
PMID	O
:	O
9797363	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Ann	O
Hematol	O
1998	O
Sep;77(	O
3	O
)	O
:131	O
-	O
4	O
c-kit	O
mutation	O
and	O
osteopetrosis	O
-	O
like	O
osteopathy	O
in	O
a	O
patient	O
with	O
systemic	B-malignancy-type
mast	I-malignancy-type
cell	I-malignancy-type
disease	I-malignancy-type
.	O
Reinacher	O
-	O
Schick	O
A	O
,	O
Petrasch	O
S,	O
Longley	O
BJ	O
,	O
Teschendorf	O
C	O
,	O
Graeven	O
U	O
,	O
Schmiegel	O
W.	O
Department	O
of	O
Medicine	O
,	O
Knappschaftskrankenhaus	O
,	O
Ruhr	O
University	O
,	O
Bochum	O
,	O
Germany	O
.	O
Anke	O
.C.	O
Reinacher@ruhr	O
-	O
uni	O
-	O
bochum	O
.de	O
We	O
describe	O
the	O
case	O
of	O
a	O
69	O
-	O
year	O
-	O
old	O
man	O
with	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
and	O
severe	O
osteopetrosis	O
who	O
carries	O
a	O
somatic	O
activating	O
mutation	O
in	O
the	O
c-kit	O
proto	O
-	O
oncogene	O
.	O
The	O
patient	O
initially	O
presented	O
with	O
urticaria	B-malignancy-type
pigmentosa	I-malignancy-type
,	O
progressing	O
to	O
systemic	B-malignancy-type
mast	I-malignancy-type
cell	I-malignancy-type
disease	I-malignancy-type
with	O
severe	O
anemia	O
due	O
to	O
bone	O
marrow	O
involvement	O
,	O
chronic	O
diarrhea	O
,	O
and	O
hepatosplenomegaly	O
.	O
Direct	O
sequencing	O
using	O
amplimers	O
from	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reactions	O
(	O
RT	O
-	O
PCR	O
)	O
from	O
skin	O
mast	O
cell	O
-	O
derived	O
RNA	O
revealed	O
a	O
point	O
mutation	O
in	O
the	O
c-kit	O
proto	O
-	O
oncogene	O
at	O
position	O
2468	O
,	O
introducing	O
a	O
new	O
recognition	O
site	O
for	O
the	O
restriction	O
endonuclease	O
HinfI	O
.	O
Treatment	O
with	O
interferon-alpha	O
2a	O
,	O
prednisone	O
,	O
and	O
erythropoietin	O
was	O
initiated	O
.	O
Subsequently	O
,	O
clinical	O
symptoms	O
improved	O
significantly	O
and	O
hemoglobin	O
levels	O
are	O
now	O
stable	O
at	O
13	O
g	O
/	O
dl	O
.	O
PMID	O
:	O
9797083	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pathol	O
Int	O
1998	O
Sep;48(	O
9	O
)	O
:689	O
-	O
94	O
Alterations	O
of	O
p53	O
gene	O
and	O
Ha-ras	O
gene	O
are	O
independent	O
events	O
in	O
solar	B-malignancy-type
keratosis	I-malignancy-type
and	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Taguchi	O
M,	O
Tsuchida	O
T	O
,	O
Ikeda	O
S,	O
Sekiya	O
T.	O
Department	O
of	O
Dermatology	O
,	O
Saitama	O
Medical	O
School	O
,	O
Japan	O
.	O
mtaguchi@saitama	O
-	O
med	O
.ac.	O
jp	O
In	O
order	O
to	O
clarity	O
the	O
multiple	O
-	O
step	O
progression	O
from	O
solar	B-malignancy-type
keratosis	I-malignancy-type
to	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
,	O
aberrations	O
of	O
the	O
p53	O
gene	O
(	O
exons	O
2	O
-	O
11	O
)	O
and	O
ras	O
genes	O
(	O
exons	O
1	O
and	O
2	O
)	O
in	O
solar	B-malignancy-type
keratosis	I-malignancy-type
and	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
were	O
investigated	O
by	O
polymerase	O
chain	O
reaction	O
and	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O
In	O
a	O
series	O
of	O
Japanese	O
patients	O
,	O
eight	O
of	O
27	O
(	O
30	O
%	O
)	O
samples	O
of	O
solar	B-malignancy-type
keratosis	I-malignancy-type
and	O
three	O
of	O
six	O
(	O
50	O
%	O
)	O
samples	O
of	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
showed	O
structural	O
abnormalities	O
in	O
the	O
p53	O
gene	O
.	O
Only	O
one	O
solar	B-malignancy-type
keratosis	I-malignancy-type
(	O
4	O
%	O
)	O
showed	O
a	O
point	O
mutation	O
in	O
the	O
Ha-ras	O
gene	O
but	O
not	O
in	O
the	O
p53	O
gene	O
.	O
Among	O
these	O
cases	O
,	O
no	O
mutation	O
of	O
ras	O
genes	O
could	O
be	O
detected	O
in	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Simultaneous	O
mutation	O
of	O
ras	O
genes	O
and	O
the	O
p53	O
gene	O
was	O
not	O
detected	O
in	O
any	O
cases	O
of	O
either	O
solar	B-malignancy-type
keratosis	I-malignancy-type
or	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
It	O
is	O
concluded	O
that	O
aberrations	O
of	O
the	O
p53	O
gene	O
and	O
ras	O
genes	O
are	O
induced	O
through	O
independent	O
processes	O
of	O
ultraviolet	O
irradiation	O
in	O
the	O
course	O
of	O
carcinogenic	O
change	O
from	O
solar	B-malignancy-type
keratosis	I-malignancy-type
to	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
9778107	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1998	O
Oct;153(	O
4)	O
:1201	O
-	O
9	O
Specific	O
K-ras2	O
mutations	O
in	O
human	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
are	O
associated	O
with	O
DNA	O
near	O
-	O
diploid	O
aneuploidy	O
and	O
inhibition	O
of	O
proliferation	O
.	O
Giaretti	O
W	O
,	O
Rapallo	O
A	O
,	O
Geido	O
E	O
,	O
Sciutto	O
A	O
,	O
Merlo	O
F	O
,	O
Risio	O
M,	O
Rossini	O
FP	O
.	O
Laboratory	O
of	O
Biophysics	O
-	O
Cytometry	O
,	O
National	O
Institute	O
for	O
Cancer	O
Research	O
and	O
Treatment	O
,	O
Candiolo	O
,	O
Genoa	O
,	O
Italy	O
.	O
giaretti@hp380.ist	O
.unige	O
.it	O
Recent	O
studies	O
indicate	O
that	O
p21ras	O
proteins	O
mediate	O
their	O
multiple	O
cell	O
functions	O
through	O
interactions	O
with	O
multiple	O
effectors	O
and	O
that	O
the	O
number	O
of	O
new	O
effectors	O
is	O
growing	O
.	O
We	O
recently	O
reported	O
that	O
K-ras2	O
mutations	O
in	O
human	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
were	O
associated	O
with	O
chromosome	O
instability	O
and	O
proliferation	O
changes	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
extend	O
these	O
previous	O
observations	O
.	O
Hereditary	B-malignancy-type
and	O
multiple	B-malignancy-type
(	I-malignancy-type
n	I-malignancy-type
>	I-malignancy-type
or	I-malignancy-type
=	I-malignancy-type
5	I-malignancy-type
)	I-malignancy-type
adenomas	I-malignancy-type
and	O
adenomas	B-malignancy-type
with	O
early	O
cancer	O
were	O
excluded	O
.	O
Dysplasia	B-malignancy-type
was	O
moderate	O
in	O
91	O
cases	O
and	O
high	O
in	O
25	O
,	O
and	O
the	O
median	O
adenoma	B-malignancy-type
size	O
was	O
1.5	O
cm	O
.	O
K-ras2	O
spectrum	O
analysis	O
was	O
done	O
by	O
sequence	O
-	O
specific	O
oligonucleotide	O
hybridization	O
using	O
nuclear	O
suspensions	O
provided	O
by	O
analysis	O
and	O
sorting	O
of	O
multiparameter	O
flow	O
cytometry	O
.	O
In	O
particular	O
,	O
tissue	O
inflammatory	O
cells	O
were	O
separated	O
for	O
DNA	O
diploid	O
tumors	O
,	O
whereas	O
DNA	O
aneuploid	O
epithelial	B-malignancy-type
subclones	I-malignancy-type
were	O
analyzed	O
separately	O
.	O
K-ras2	O
mutations	O
and	O
DNA	O
aneuploidy	O
were	O
both	O
detected	O
in	O
29	O
of	O
116	O
(	O
25	O
%	O
)	O
cases	O
.	O
DNA	O
aneuploid	O
index	O
was	O
in	O
the	O
near	O
-	O
diploid	O
region	O
in	O
the	O
majority	O
of	O
cases	O
.	O
DNA	O
aneuploidy	O
was	O
strongly	O
associated	O
with	O
G	O
-->	O
C	O
/	O
T	O
transversions	O
.	O
An	O
association	O
was	O
also	O
found	O
between	O
low	O
S-phase	O
values	O
and	O
G	O
-->	O
A	O
transitions	O
.	O
These	O
findings	O
were	O
confirmed	O
using	O
multivariate	O
logistic	O
regression	O
analysis	O
to	O
account	O
for	O
the	O
effects	O
of	O
size	O
,	O
dysplasia	B-malignancy-type
,	O
site	O
,	O
type	O
,	O
age	O
,	O
and	O
sex	O
.	O
These	O
data	O
suggest	O
that	O
specific	O
K-ras2	O
mutations	O
in	O
a	O
subgroup	O
of	O
human	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
play	O
a	O
role	O
in	O
chromosome	O
instability	O
and	O
,	O
contrary	O
to	O
expectations	O
,	O
are	O
associated	O
with	O
inhibition	O
of	O
proliferation	O
.	O
PMID	O
:	O
9777951	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1998	O
Oct;153(	O
4)	O
:1063	O
-	O
78	O
Accumulated	O
clonal	O
genetic	O
alterations	O
in	O
familial	B-malignancy-type
and	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
carcinomas	I-malignancy-type
with	O
widespread	O
instability	O
in	O
microsatellite	O
sequences	O
.	O
Fujiwara	O
T	O
,	O
Stolker	O
JM	O
,	O
Watanabe	O
T	O
,	O
Rashid	O
A	O
,	O
Longo	O
P	O
,	O
Eshleman	O
JR	O
,	O
Booker	O
S,	O
Lynch	O
HT	O
,	O
Jass	O
JR	O
,	O
Green	O
JS	O
,	O
Kim	O
H	O
,	O
Jen	O
J,	O
Vogelstein	O
B	O
,	O
Hamilton	O
SR	O
.	O
Department	O
of	O
Pathology	O
,	O
The	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
Baltimore	O
,	O
Maryland	O
,	O
USA	O
.	O
A	O
subset	O
of	O
hereditary	B-malignancy-type
and	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
carcinomas	I-malignancy-type
is	O
defined	O
by	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
,	O
but	O
the	O
spectra	O
of	O
gene	O
mutations	O
have	O
not	O
been	O
characterized	O
extensively	O
.	O
Thirty-nine	O
hereditary	B-malignancy-type
nonpolyposis	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
syndrome	I-malignancy-type
carcinomas	I-malignancy-type
(	O
HNPCCa	B-malignancy-type
)	O
and	O
57	O
sporadic	B-malignancy-type
right	I-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
colonic	I-malignancy-type
carcinomas	I-malignancy-type
(	O
SRSCCa	B-malignancy-type
)	O
were	O
evaluated	O
.	O
Of	O
HNPCCa	B-malignancy-type
,	O
95	O
%	O
(	O
37	O
/	O
39	O
)	O
were	O
MSI	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
as	O
contrasted	O
with	O
31	O
%	O
(	O
18	O
/	O
57	O
)	O
of	O
SRSCCa	B-malignancy-type
(	O
P	O
<	O
0.000001	O
)	O
,	O
but	O
instability	O
tended	O
to	O
be	O
more	O
widespread	O
in	O
SRSCCa	B-malignancy-type
(	O
P	O
=	O
0.08	O
)	O
.	O
Absence	O
of	O
nuclear	O
hMSH2	O
mismatch	O
repair	O
gene	O
product	O
by	O
immunohistochemistry	O
was	O
associated	O
with	O
germline	O
hMSH2	O
mutation	O
(	O
P	O
=	O
0.0007	O
)	O
.	O
The	O
prevalence	O
of	O
K-ras	O
proto	O
-	O
oncogene	O
mutations	O
was	O
similar	O
in	O
HNPCCa	B-malignancy-type
and	O
SRSCCa	B-malignancy-type
(	O
30	O
%	O
(	O
11	O
/	O
37	O
)	O
and	O
30	O
%	O
(	O
16	O
/	O
54	O
)	O
)	O
,	O
but	O
no	O
HNPCCa	B-malignancy-type
from	O
patients	O
with	O
germline	O
hMSH2	O
mutation	O
had	O
codon	O
13	O
mutation	O
(	O
P	O
=	O
0.02	O
)	O
,	O
and	O
two	O
other	O
HNPCCa	B-malignancy-type
had	O
multiple	O
K-ras	O
mutations	O
attributable	O
to	O
subclones	O
.	O
18q	O
allelic	O
deletion	O
and	O
p53	O
gene	O
product	O
overexpression	O
were	O
inversely	O
related	O
to	O
MSI	O
(	O
P	O
=	O
0.0004	O
and	O
P	O
=	O
0.0001	O
,	O
respectively	O
)	O
.	O
Frameshift	O
mutation	O
of	O
the	O
transforming	O
growth	O
factor	O
beta	O
type	O
II	O
receptor	O
gene	O
was	O
frequent	O
in	O
all	O
MSI	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
cancers	I-malignancy-type
(	O
85	O
%	O
,	O
46	O
/	O
54	O
)	O
,	O
but	O
mutation	O
of	O
the	O
E2F-4	O
transcription	O
factor	O
gene	O
was	O
more	O
common	O
in	O
HNPCCa	B-malignancy-type
of	O
patients	O
with	O
germline	O
hMSH2	O
mutation	O
than	O
in	O
those	O
with	O
germline	O
bMLH1	O
mutation	O
(	O
100	O
%	O
(	O
8	O
/	O
8	O
)	O
versus	O
40	O
%	O
(	O
2	O
/	O
5	O
)	O
,	O
P	O
=	O
0.04	O
)	O
,	O
and	O
mutation	O
of	O
the	O
Bax	O
proapoptotic	O
gene	O
was	O
more	O
frequent	O
in	O
HNPCCa	B-malignancy-type
than	O
in	O
MSI	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
SRSCCa	I-malignancy-type
(	O
55	O
%	O
(	O
17	O
/	O
31	O
)	O
versus	O
13	O
%	O
(	O
2	O
/	O
15	O
)	O
,	O
P	O
=	O
0.01	O
)	O
.	O
The	O
most	O
common	O
combination	O
of	O
mutations	O
occurred	O
in	O
only	O
23	O
%	O
(	O
8	O
/	O
35	O
)	O
of	O
evaluable	O
MSI	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
cancers	I-malignancy-type
.	O
Our	O
findings	O
suggest	O
that	O
the	O
accumulation	O
of	O
specific	O
genetic	O
alterations	O
in	O
MSI	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
colorectal	I-malignancy-type
cancers	I-malignancy-type
is	O
markedly	O
heterogeneous	O
,	O
because	O
the	O
occurrence	O
of	O
some	O
mutations	O
(	O
eg	O
,	O
ras	O
,	O
E2F-4	O
,	O
and	O
Bax	O
genes	O
)	O
,	O
but	O
not	O
others	O
(	O
eg	O
,	O
transforming	O
growth	O
factor	O
beta	O
type	O
II	O
receptor	O
gene	O
)	O
,	O
depends	O
on	O
the	O
underlying	O
basis	O
of	O
the	O
mismatch	O
repair	O
deficiency	O
.	O
This	O
genetic	O
heterogeneity	O
may	O
contribute	O
to	O
the	O
heterogeneous	O
clinical	O
and	O
pathological	O
features	O
of	O
MSI	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
cancers	I-malignancy-type
.	O
PMID	O
:	O
9777938	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Oncol	O
1998	O
Nov;13(	O
5	O
)	O
:971	O
-	O
4	O
Detection	O
of	O
a	O
rare	O
point	O
mutation	O
at	O
codon	O
59	O
and	O
relatively	O
high	O
incidence	O
of	O
H-ras	O
mutation	O
in	O
Indian	O
oral	B-malignancy-type
cancer	I-malignancy-type
.	O
Munirajan	O
AK	O
,	O
Mohanprasad	O
BK	O
,	O
Shanmugam	O
G	O
,	O
Tsuchida	O
N.	O
Department	O
of	O
Molecular	O
Cellular	O
Oncology	O
and	O
Microbiology	O
,	O
Tokyo	O
Medical	O
and	O
Dental	O
University	O
,	O
Bunkyo	O
-	O
ku	O
,	O
Tokyo	O
113	O
-	O
8549	O
,	O
Japan	O
.	O
Analysis	O
of	O
H	O
-	O
,	O
K	O
-	O
and	O
N	O
-	O
ras	O
genes	O
for	O
point	O
mutations	O
by	O
PCR	O
-	O
SSCP	O
and	O
direct	O
sequencing	O
of	O
46	O
oral	B-malignancy-type
SCCs	I-malignancy-type
that	O
were	O
previously	O
analyzed	O
for	O
p53	O
mutations	O
revealed	O
that	O
9	O
(	O
20	O
%	O
)	O
had	O
point	O
mutations	O
in	O
either	O
the	O
H-ras	O
or	O
the	O
N-ras	O
.	O
A	O
novel	O
mutation	O
at	O
codon	O
59	O
(	O
GCC	O
-	O
ACC	O
)	O
of	O
H-ras	O
thus	O
far	O
reported	O
only	O
in	O
v-H-ras	O
of	O
Harvey	O
murine	O
sarcoma	B-malignancy-type
virus	O
was	O
observed	O
in	O
a	O
tumor	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
cheek	I-malignancy-type
.	O
Majority	O
(	O
8	O
/	O
9	O
)	O
of	O
these	O
mutations	O
were	O
observed	O
in	O
H-ras	O
,	O
one	O
in	O
N-ras	O
and	O
none	O
in	O
K-ras	O
.	O
This	O
study	O
indicated	O
that	O
the	O
ras	O
gene	O
mutation	O
was	O
relatively	O
high	O
in	O
oral	B-malignancy-type
cancers	I-malignancy-type
associated	O
with	O
tobacco	O
chewing	O
and	O
the	O
ras	O
and	O
p53	O
mutational	O
events	O
seem	O
to	O
be	O
independent	O
and	O
mutually	O
exclusive	O
.	O
PMID	O
:	O
9772288	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Chem	O
1998	O
Oct;44(	O
10	O
)	O
:2103	O
-	O
7	O
K-ras	O
mutations	O
in	O
stools	O
and	O
tissue	O
samples	O
from	O
patients	O
with	O
malignant	B-malignancy-type
and	O
nonmalignant	O
pancreatic	B-malignancy-type
diseases	I-malignancy-type
.	O
Berndt	O
C	O
,	O
Haubold	O
K	O
,	O
Wenger	O
F	O
,	O
Brux	O
B	O
,	O
Muller	O
J,	O
Bendzko	O
P	O
,	O
Hillebrand	O
T	O
,	O
Kottgen	O
E	O
,	O
Zanow	O
J.	O
Institute	O
of	O
Laboratory	O
Medicine	O
and	O
Pathobiochemistry	O
,	O
Medical	O
Faculty	O
Charite	O
,	O
Humboldt	O
-	O
University	O
,	O
Berlin	O
,	O
Germany	O
.	O
christoph	O
.berndt@charite	O
.de	O
Mutant	O
-	O
enriched	O
PCR	O
and	O
reverse	O
dot	O
blot	O
hybridization	O
in	O
microplates	O
were	O
applied	O
for	O
examining	O
K-ras	O
status	O
in	O
stools	O
and	O
tissue	O
samples	O
from	O
patients	O
with	O
pancreatic	B-malignancy-type
tumors	I-malignancy-type
and	O
chronic	O
pancreatitis	O
.	O
In	O
tissue	O
samples	O
,	O
K-ras	O
mutations	O
were	O
found	O
in	O
32	O
of	O
35	O
cases	O
of	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
in	O
5	O
of	O
7	O
periampullary	B-malignancy-type
cancers	I-malignancy-type
,	O
in	O
1	O
cystadenocarcinoma	B-malignancy-type
,	O
and	O
in	O
3	O
of	O
5	O
patients	O
with	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
.	O
In	O
stools	O
,	O
mutated	O
K-ras	O
was	O
seen	O
in	O
10	O
of	O
25	O
cases	O
of	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
in	O
1	O
case	O
of	O
cystadenocarcinoma	B-malignancy-type
,	O
and	O
in	O
2	O
of	O
6	O
cases	O
of	O
chronic	O
pancreatitis	O
.	O
These	O
data	O
indicate	O
that	O
the	O
K-ras	O
status	O
of	O
stool	O
samples	O
may	O
help	O
identify	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
and	O
persons	O
at	O
risk	O
for	O
cancer	O
development	O
;	O
however	O
,	O
it	O
does	O
not	O
allow	O
discrimination	O
of	O
malignant	O
from	O
nonmalignant	O
diseases	O
.	O
PMID	O
:	O
9761241	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Oncol	O
1998	O
Sep;16(9	O
)	O
:3061	O
-	O
8	O
Detection	O
of	O
K-ras	O
point	O
mutations	O
in	O
sputum	O
from	O
patients	O
with	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
by	O
point	O
-	O
EXACCT	O
.	O
Somers	O
VA	O
,	O
Pietersen	O
AM	O
,	O
Theunissen	O
PH	O
,	O
Thunnissen	O
FB.	O
Department	O
of	O
Pathology	O
,	O
Maastricht	O
University	O
,	O
The	O
Netherlands	O
.	O
vso@lpat	O
.azm	O
.nl	O
PURPOSE	O
:	O
Kirsten	O
ras	O
(	O
K-ras	O
)	O
point	O
mutations	O
are	O
found	O
in	O
30	O
%	O
to	O
56	O
%	O
of	O
pulmonary	B-malignancy-type
adenocarcinomas	I-malignancy-type
by	O
means	O
of	O
highly	O
sensitive	O
techniques	O
.	O
Recently	O
,	O
the	O
Point	O
-	O
EXACCT	O
(	O
point	O
mutation	O
detection	O
using	O
exonuclease	O
amplification	O
coupled	O
capture	O
technique	O
)	O
method	O
was	O
described	O
,	O
which	O
detected	O
one	O
cell	O
with	O
a	O
mutation	O
in	O
15,000	O
normal	O
cells	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
whether	O
K-ras	O
point	O
mutations	O
could	O
be	O
found	O
with	O
this	O
rapid	O
method	O
in	O
the	O
sputum	O
of	O
patients	O
with	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
DNA	O
from	O
paraffin	O
-	O
embedded	O
adenocarcinoma	B-malignancy-type
and	O
corresponding	O
sputum	O
samples	O
were	O
analyzed	O
for	O
mutations	O
of	O
the	O
K-ras	O
gene	O
.	O
Twenty-eight	O
biopsy	O
specimens	O
and	O
54	O
sputum	O
samples	O
of	O
22	O
patients	O
were	O
used	O
for	O
amplification	O
and	O
K-ras	O
codon	O
12	O
point	O
mutation	O
detection	O
.	O
RESULTS	O
:	O
In	O
11	O
of	O
22	O
patients	O
(	O
50	O
%	O
)	O
,	O
a	O
mutation	O
in	O
K-ras	O
codon	O
12	O
was	O
shown	O
in	O
the	O
tumor	O
sample	O
.	O
In	O
five	O
of	O
11	O
patients	O
(	O
45	O
%	O
)	O
with	O
a	O
K-ras	O
mutation	O
in	O
the	O
tumor	O
,	O
the	O
same	O
type	O
of	O
mutation	O
was	O
identified	O
in	O
at	O
least	O
one	O
sputum	O
sample	O
.	O
A	O
mutation	O
could	O
not	O
be	O
detected	O
in	O
any	O
of	O
the	O
sputum	O
samples	O
from	O
patients	O
with	O
a	O
K-ras	O
-	O
negative	O
tumor	O
.	O
Time	O
between	O
K-ras	O
point	O
mutation	O
detection	O
in	O
sputum	O
and	O
clinical	O
diagnosis	O
of	O
lung	B-malignancy-type
cancer	I-malignancy-type
varied	O
from	O
1	O
month	O
to	O
almost	O
4	O
years	O
.	O
In	O
two	O
of	O
the	O
five	O
patients	O
with	O
K-ras	O
-	O
positive	O
sputum	O
specimens	O
,	O
malignant	O
cells	O
were	O
found	O
with	O
cytologic	O
examination	O
.	O
CONCLUSION	O
:	O
Point	O
-	O
EXACCT	O
is	O
suitable	O
for	O
the	O
detection	O
of	O
K-ras	O
point	O
mutations	O
in	O
sputum	O
samples	O
of	O
patients	O
with	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
.	O
This	O
approach	O
may	O
be	O
an	O
important	O
adjunct	O
to	O
cytology	O
in	O
the	O
early	O
diagnosis	O
of	O
lung	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
9738576	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mutat	O
Res	O
1998	O
Jul	O
17;403(	O
1	O
-	O
2	O
)	O
:103	O
-	O
12	O
Mutation	O
analyses	O
of	O
KRAS	O
exon	O
1	O
comparing	O
three	O
different	O
techniques	O
:	O
temporal	O
temperature	O
gradient	O
electrophoresis	O
,	O
constant	O
denaturant	O
capillary	O
electrophoresis	O
and	O
allele	O
specific	O
polymerase	O
chain	O
reaction	O
.	O
Bjorheim	O
J,	O
Lystad	O
S,	O
Lindblom	O
A	O
,	O
Kressner	O
U	O
,	O
Westring	O
S,	O
Wahlberg	O
S,	O
Lindmark	O
G	O
,	O
Gaudernack	O
G	O
,	O
Ekstrom	O
P	O
,	O
Roe	O
J,	O
Thilly	O
WG	O
,	O
Borresen	O
-	O
Dale	O
AL	O
.	O
Department	O
of	O
Immunology	O
,	O
Norwegian	O
Radium	O
Hospital	O
,	O
Oslo	O
,	O
Norway	O
.	O
Mutations	O
in	O
the	O
KRAS	O
gene	O
is	O
a	O
key	O
event	O
in	O
the	O
carcinogenesis	O
of	O
many	O
human	O
cancers	O
and	O
may	O
serve	O
as	O
a	O
diagnostic	O
marker	O
and	O
a	O
target	O
for	O
therapeutic	O
intervention	O
.	O
In	O
this	O
study	O
we	O
have	O
applied	O
three	O
different	O
techniques	O
for	O
mutation	O
detection	O
of	O
KRAS	O
exon	O
1	O
mutations	O
:	O
Allele	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
AS-PCR	O
)	O
,	O
temporal	O
temperature	O
gradient	O
electrophoresis	O
(	O
TTGE	O
)	O
and	O
constant	O
denaturant	O
capillary	O
electrophoresis	O
(	O
CDCE	O
)	O
.	O
Samples	O
from	O
191	O
sporadic	B-malignancy-type
colon	I-malignancy-type
carcinomas	I-malignancy-type
were	O
analyzed	O
.	O
AS-PCR	O
were	O
performed	O
with	O
oligonucleotides	O
specific	O
for	O
know	O
mutations	O
in	O
codon	O
12	O
and	O
13	O
of	O
the	O
KRAS	O
gene	O
.	O
In	O
TTGE	O
analyses	O
,	O
linear	O
ramping	O
of	O
the	O
temperature	O
were	O
performed	O
during	O
electrophoresis	O
in	O
a	O
constant	O
denaturant	O
gel	O
.	O
CDCE	O
analyses	O
were	O
performed	O
using	O
fluorescin	O
labeled	O
PCR	O
-	O
products	O
.	O
Separation	O
was	O
achieved	O
under	O
constant	O
denaturing	O
conditions	O
using	O
high	O
temperature	O
in	O
a	O
gel	O
-	O
filled	O
capillary	O
followed	O
by	O
laser	O
detection	O
.	O
A	O
mutated	O
KRAS	O
gene	O
was	O
found	O
in	O
42	O
/	O
191	O
(	O
22.0	O
%	O
)	O
of	O
the	O
samples	O
using	O
AS-PCR	O
,	O
in	O
62	O
/	O
191	O
(	O
32.5	O
%	O
)	O
using	O
TTGE	O
and	O
in	O
66	O
/	O
191	O
(	O
34.6	O
%	O
)	O
of	O
the	O
samples	O
using	O
CDCE	O
.	O
In	O
the	O
TTGE	O
and	O
CDCE	O
analyses	O
the	O
sequence	O
of	O
the	O
mutant	O
were	O
determined	O
by	O
comparing	O
the	O
electrophoretic	O
pattern	O
to	O
that	O
of	O
known	O
mutations	O
or	O
by	O
mixing	O
the	O
sample	O
with	O
known	O
mutations	O
prior	O
to	O
reanalysis	O
.	O
In	O
a	O
titration	O
experiment	O
mixing	O
mutant	O
and	O
wild	O
-	O
type	O
alleles	O
prior	O
to	O
PCR	O
,	O
the	O
sensitivity	O
for	O
mutation	O
detection	O
was	O
shown	O
to	O
be	O
10(-2)	O
for	O
TTGE	O
and	O
under	O
optimized	O
conditions	O
10(-3)	O
for	O
CDCE	O
.	O
PMID	O
:	O
9726011	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Endocrinol	O
1998	O
Aug;139(	O
2	O
)	O
:209	O
-	O
16	O
Variability	O
of	O
Ha-ras	O
(	O
codon	O
12	O
)	O
proto	O
-	O
oncogene	O
mutations	O
in	O
diverse	O
thyroid	B-malignancy-type
cancers	I-malignancy-type
.	O
Bouras	O
M,	O
Bertholon	O
J,	O
Dutrieux	O
-	O
Berger	O
N	O
,	O
Parvaz	O
P	O
,	O
Paulin	O
C	O
,	O
Revol	O
A.	O
Laboratoire	O
de	O
Biologie	O
Moleculaire	O
et	O
Pediatrique	O
,	O
Centre	O
Hospitalier	O
Lyon	O
-	O
Sud	O
,	O
Pierre	O
-	O
Benite	O
,	O
France	O
.	O
Structural	O
alterations	O
to	O
proto	O
-	O
oncogene	O
sequences	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
human	O
thyroid	B-malignancy-type
neoplasms	I-malignancy-type
.	O
We	O
studied	O
128	O
thyroid	B-malignancy-type
tumours	I-malignancy-type
(	O
35	O
benign	B-malignancy-type
and	O
93	O
malignant	B-malignancy-type
)	O
for	O
ras	O
gene	O
point	O
mutations	O
in	O
three	O
different	O
codons	O
(	O
12	O
,	O
13	O
and	O
61	O
)	O
using	O
a	O
restriction	O
fragment	O
length	O
polymorphism	O
technique	O
and	O
direct	O
sequencing	O
of	O
double	O
-	O
stranded	O
DNA	O
on	O
polymerase	O
chain	O
-	O
reaction	O
-	O
amplified	O
tumour	O
DNA	O
.	O
We	O
found	O
a	O
high	O
frequency	O
of	O
ras	O
mutation	O
for	O
the	O
Ha-ras	O
codon	O
12	O
in	O
follicular	B-malignancy-type
adenomas	I-malignancy-type
(	O
7	O
of	O
35	O
)	O
,	O
particularly	O
in	O
atypical	B-malignancy-type
adenomas	I-malignancy-type
(	O
5	O
of	O
17	O
)	O
,	O
in	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
6	O
of	O
19	O
)	O
,	O
with	O
a	O
high	O
percentage	O
for	O
Hurthle	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
6	O
of	O
11	O
)	O
,	O
and	O
in	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
(	O
4	O
of	O
66	O
)	O
.	O
Point	O
mutations	O
for	O
other	O
ras	O
genes	O
in	O
different	O
codons	O
studied	O
were	O
weak	O
to	O
absent	O
.	O
No	O
mutation	O
was	O
found	O
in	O
undifferentiated	B-malignancy-type
carcinomas	I-malignancy-type
(	O
n	O
=	O
8	O
)	O
.	O
The	O
predominant	O
amino	O
acid	O
substitution	O
both	O
in	O
the	O
adenomas	B-malignancy-type
and	O
in	O
the	O
differentiated	B-malignancy-type
tumours	I-malignancy-type
was	O
glycine	O
to	O
valine	O
(	O
GGC	O
to	O
GTC	O
)	O
at	O
position	O
12	O
of	O
the	O
Ha-ras	O
gene	O
.	O
Our	O
results	O
obtained	O
on	O
a	O
large	O
series	O
confirm	O
the	O
frequent	O
occurrence	O
of	O
Ha-ras	O
codon	O
12	O
gene	O
mutations	O
both	O
in	O
adenomas	B-malignancy-type
and	O
in	O
carcinomas	B-malignancy-type
.	O
The	O
frequency	O
of	O
ras	O
mutations	O
is	O
linked	O
to	O
the	O
geographical	O
origin	O
of	O
the	O
population	O
studied	O
and	O
varies	O
(	O
0	O
-	O
85	O
%	O
)	O
from	O
one	O
cancer	O
type	O
to	O
another	O
according	O
to	O
published	O
data	O
.	O
Therefore	O
,	O
these	O
mutations	O
are	O
merely	O
an	O
expression	O
of	O
cellular	O
transformation	O
.	O
PMID	O
:	O
9724079	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1998	O
Aug	O
15;58(	O
16	O
)	O
:3526	O
-	O
8	O
Beta-catenin	O
mutation	O
in	O
carcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
uterine	I-malignancy-type
endometrium	I-malignancy-type
.	O
Fukuchi	O
T	O
,	O
Sakamoto	O
M,	O
Tsuda	O
H	O
,	O
Maruyama	O
K	O
,	O
Nozawa	O
S,	O
Hirohashi	O
S.	O
Pathology	O
Division	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tokyo	O
,	O
Japan	O
.	O
Beta-catenin	O
forms	O
complexes	O
with	O
Tcf	O
and	O
Lef-1	O
and	O
functions	O
as	O
a	O
transcriptional	O
activator	O
downstream	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
.	O
Activation	O
of	O
the	O
pathway	O
by	O
stabilization	O
of	O
beta-catenin	O
has	O
been	O
shown	O
to	O
be	O
important	O
in	O
the	O
development	O
of	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
,	O
which	O
is	O
mainly	O
caused	O
by	O
inactivating	O
mutations	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
tumor	O
suppressor	O
gene	O
or	O
by	O
activating	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
.	O
Here	O
,	O
we	O
analyzed	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
in	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
cases	O
in	O
which	O
loss	O
of	O
heterozygosity	O
at	O
the	O
adenomatous	O
polyposis	O
coli	O
tumor	O
suppressor	O
gene	O
locus	O
has	O
been	O
rarely	O
reported	O
.	O
We	O
found	O
that	O
10	O
of	O
76	O
cases	O
had	O
beta-catenin	O
gene	O
mutations	O
.	O
All	O
mutations	O
identified	O
were	O
single	O
-	O
base	O
missense	O
mutations	O
on	O
serine	O
/	O
threonine	O
residues	O
(	O
codons	O
33	O
,	O
37	O
,	O
41	O
,	O
and	O
45	O
)	O
,	O
altering	O
the	O
glycogen	O
synthase	O
kinase	O
3	O
beta	O
phosphorylation	O
consensus	O
motif	O
,	O
which	O
participates	O
in	O
the	O
degradation	O
of	O
beta-catenin	O
.	O
To	O
determine	O
whether	O
these	O
beta-catenin	O
mutations	O
actually	O
led	O
to	O
stabilization	O
of	O
this	O
protein	O
,	O
expression	O
of	O
beta-catenin	O
was	O
analyzed	O
immunohistochemically	O
,	O
and	O
9	O
of	O
10	O
cases	O
with	O
the	O
beta-catenin	O
mutation	O
and	O
20	O
of	O
66	O
cases	O
without	O
it	O
showed	O
accumulation	O
of	O
beta-catenin	O
in	O
the	O
cytoplasm	O
and/or	O
nucleus	O
.	O
In	O
total	O
,	O
38	O
%	O
of	O
cases	O
showed	O
accumulation	O
of	O
beta-catenin	O
.	O
These	O
data	O
indicate	O
that	O
stabilization	O
of	O
beta-catenin	O
due	O
to	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
and	O
other	O
mechanisms	O
may	O
have	O
an	O
important	O
role	O
in	O
development	O
of	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
9721853	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
Cells	O
Mol	O
Dis	O
1998	O
Jun;24(	O
2	O
)	O
:262	O
-	O
70	O
In	O
vivo	O
differentiation	O
of	O
mast	O
cells	O
from	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
blasts	I-malignancy-type
carrying	O
a	O
novel	O
activating	O
ligand	O
-	O
independent	O
C-kit	O
mutation	O
.	O
Beghini	O
A	O
,	O
Cairoli	O
R,	O
Morra	O
E	O
,	O
Larizza	O
L.	O
Department	O
of	O
Biology	O
and	O
Genetics	O
,	O
Medical	O
Faculty	O
,	O
University	O
of	O
Milan	O
,	O
Italy	O
.	O
The	O
primary	O
role	O
of	O
protooncogene	O
c-kit	O
in	O
mast	O
cell	O
differentiation	O
is	O
supported	O
by	O
the	O
development	O
of	O
mast	O
cells	O
from	O
CD34	O
+	O
/	O
CD117	O
+	O
(	O
c-kit	O
)	O
myeloid	O
precursors	O
.	O
Growth	O
factor	O
independence	O
,	O
neoplastic	O
transformation	O
and	O
differentiation	O
of	O
mast	O
cells	O
were	O
found	O
in	O
association	O
with	O
c-kit	O
activating	O
mutations	O
in	O
both	O
murine	O
and	O
human	O
mastocytoma	B-malignancy-type
and	O
mast	B-malignancy-type
cell	I-malignancy-type
diseases	I-malignancy-type
.	O
We	O
have	O
identified	O
a	O
novel	O
c-kit	O
mutation	O
(	O
D	O
816	O
Y	O
)	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
a	O
patient	O
with	O
AML	B-malignancy-type
(	I-malignancy-type
M2	I-malignancy-type
)	I-malignancy-type
,	O
massive	O
presence	O
of	O
mast	O
cells	O
in	O
bone	O
marrow	O
and	O
rapid	O
progression	O
of	O
the	O
disease	O
.	O
The	O
mutation	O
,	O
a	O
G	O
-->	O
T	O
transversion	O
at	O
nt	O
2467	O
of	O
the	O
c-kit	O
gene	O
resulting	O
in	O
Asp	O
816	O
-->	O
Tyr	O
substitution	O
,	O
corresponds	O
to	O
the	O
D	O
814	O
Y	O
and	O
D	O
817	O
Y	O
mutations	O
identified	O
and	O
characterized	O
in	O
the	O
murine	O
P815	O
mastocytoma	B-malignancy-type
and	O
the	O
rat	O
RBL-2H3	O
mast	B-malignancy-type
cell	I-malignancy-type
leukemia	I-malignancy-type
cell	O
lines	O
.	O
The	O
absence	O
of	O
SCF	O
transcripts	O
that	O
we	O
found	O
by	O
RTPCR	O
in	O
the	O
patient	O
's	O
blasts	O
indicates	O
that	O
,	O
also	O
in	O
humans	O
,	O
this	O
activating	O
mutation	O
leads	O
to	O
SCF	O
independent	O
growth	O
.	O
The	O
expression	O
of	O
the	O
mutant	O
allele	O
on	O
Kit	O
signaling	O
may	O
be	O
further	O
enhanced	O
by	O
trisomy	O
of	O
chromosome	O
4	O
(	O
carrying	O
the	O
c-kit	O
gene	O
)	O
in	O
the	O
patient	O
's	O
blasts	O
.	O
From	O
these	O
findings	O
it	O
is	O
concluded	O
that	O
mast	O
cells	O
could	O
be	O
generated	O
from	O
a	O
leukemic	O
CD34	O
/	O
CD117	O
-	O
positive	O
clone	O
,	O
that	O
combines	O
the	O
antigenic	O
expression	O
of	O
mast	O
cell	O
precursor	O
to	O
the	O
growth	O
and	O
differentiation	O
factor	O
-	O
independence	O
which	O
was	O
derived	O
by	O
the	O
c-kit	O
D	O
816	O
Y	O
mutation	O
.	O
PMID	O
:	O
9714703	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Oncol	O
1998	O
Jun;12(	O
6)	O
:1333	O
-	O
8	O
Detection	O
of	O
ras	O
gene	O
mutations	O
in	O
peripheral	O
blood	O
of	O
carcinoma	B-malignancy-type
patients	O
using	O
CD45	O
immunomagnetic	O
separation	O
and	O
nested	O
mutant	O
allele	O
specific	O
amplification	O
.	O
Shibata	O
K	O
,	O
Mori	O
M,	O
Kitano	O
S,	O
Akiyoshi	O
T.	O
Department	O
of	O
Surgery	O
,	O
Medical	O
Institute	O
of	O
Bioregulation	O
,	O
Kyushu	O
University	O
,	O
Beppu	O
,	O
Japan	O
.	O
We	O
developed	O
a	O
sensitive	O
technique	O
of	O
detecting	O
circulating	O
tumor	O
cells	O
in	O
carcinoma	B-malignancy-type
patients	O
,	O
using	O
CD45	O
immunomagnetic	O
separation	O
to	O
isolate	O
epithelial	O
cells	O
in	O
blood	O
samples	O
and	O
specific	O
polymerase	O
chain	O
reaction	O
analysis	O
to	O
identify	O
point	O
mutations	O
of	O
the	O
K-ras	O
gene	O
.	O
The	O
method	O
is	O
based	O
on	O
the	O
fact	O
that	O
the	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
that	O
express	O
CD45	O
antigen	O
are	O
trapped	O
with	O
anti	O
-	O
CD45	O
conjugated	O
supramagnetic	O
microbeads	O
while	O
the	O
carcinoma	B-malignancy-type
cells	O
that	O
do	O
not	O
express	O
CD45	O
antigen	O
are	O
not	O
trapped	O
and	O
pass	O
through	O
the	O
magnetic	O
fields	O
.	O
This	O
method	O
concentrated	O
the	O
number	O
of	O
carcinoma	B-malignancy-type
cells	O
3.3	O
times	O
.	O
After	O
this	O
separation	O
,	O
the	O
modified	O
method	O
of	O
mutant	O
allele	O
specific	O
amplification	O
was	O
applied	O
and	O
this	O
method	O
was	O
able	O
to	O
ten	O
control	O
carcinoma	B-malignancy-type
cells	O
in	O
a	O
background	O
of	O
107	O
PBMC	O
.	O
A	O
preliminary	O
clinical	O
study	O
demonstrated	O
that	O
six	O
cases	O
of	O
end	O
-	O
stage	O
carcinoma	B-malignancy-type
with	O
K-ras	O
mutations	O
in	O
the	O
primary	O
tumor	O
showed	O
the	O
same	O
mutations	O
in	O
the	O
peripheral	O
blood	O
samples	O
,	O
while	O
two	O
cases	O
without	O
K-ras	O
mutation	O
in	O
the	O
primary	O
tumor	O
and	O
10	O
healthy	O
volunteers	O
showed	O
no	O
mutation	O
in	O
the	O
peripheral	O
blood	O
samples	O
.	O
The	O
results	O
suggest	O
that	O
this	O
method	O
may	O
be	O
very	O
useful	O
to	O
detect	O
circulating	O
carcinoma	B-malignancy-type
cells	O
in	O
the	O
patient	O
whose	O
primary	O
tumor	O
shows	O
K-ras	O
mutations	O
.	O
PMID	O
:	O
9592195	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Surg	O
1998	O
Mar;175(	O
3	O
)	O
:198	O
-	O
202	O
The	O
type	O
of	O
K-ras	O
mutation	O
determines	O
prognosis	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Cerottini	O
JP	O
,	O
Caplin	O
S,	O
Saraga	O
E	O
,	O
Givel	O
JC	O
,	O
Benhattar	O
J.	O
Department	O
of	O
Surgery	O
,	O
Centre	O
Hospitalier	O
Universitaire	O
Vaudois	O
,	O
Lausanne	O
,	O
Switzerland	O
.	O
BACKGROUND	O
:	O
Mutations	O
involving	O
the	O
oncogene	O
K-ras	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
may	O
be	O
related	O
to	O
tumor	O
aggressiveness	O
.	O
However	O
,	O
the	O
value	O
of	O
K-ras	O
gene	O
determination	O
as	O
a	O
prognostic	O
marker	O
has	O
not	O
been	O
clearly	O
established	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
The	O
results	O
from	O
98	O
patients	O
recruited	O
in	O
a	O
prospective	O
study	O
analyzing	O
the	O
effect	O
of	O
a	O
K-ras	O
mutation	O
as	O
a	O
prognostic	O
factor	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
are	O
reported	O
.	O
RESULTS	O
:	O
Disease	O
-	O
free	O
(	O
P	O
=	O
0.02	O
)	O
and	O
overall	O
survival	O
(	O
P	O
=	O
0.03	O
)	O
were	O
significantly	O
reduced	O
for	O
patients	O
harboring	O
a	O
K-ras	O
mutation	O
.	O
Two	O
specific	O
mutations	O
demonstrated	O
a	O
significantly	O
increased	O
risk	O
of	O
disease	O
recurrence	O
,	O
namely	O
,	O
12	O
-	O
TGT	O
(	O
P	O
=	O
0.04	O
)	O
and	O
13	O
-	O
GAC	O
substitutions	O
(	O
P	O
=	O
0.002	O
)	O
.	O
Patients	O
with	O
either	O
of	O
these	O
substitutions	O
had	O
a	O
2	O
-	O
year	O
disease	O
-	O
free	O
survival	O
rate	O
of	O
37	O
%	O
compared	O
with	O
that	O
of	O
67	O
%	O
for	O
the	O
group	O
of	O
patients	O
harboring	O
any	O
other	O
mutation	O
type	O
or	O
a	O
wild	O
-	O
type	O
status	O
(	O
P	O
=	O
0.01	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
results	O
herein	O
presented	O
suggest	O
that	O
K-ras	O
acts	O
as	O
a	O
prognostic	O
factor	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
and	O
that	O
this	O
effect	O
is	O
probably	O
related	O
to	O
a	O
limited	O
number	O
of	O
defined	O
mutations	O
.	O
PMID	O
:	O
9560119	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
1998	O
Mar;77(	O
5	O
)	O
:760	O
-	O
5	O
Molecular	O
pathogenesis	O
of	O
sporadic	B-malignancy-type
duodenal	I-malignancy-type
cancer	I-malignancy-type
.	O
Achille	O
A	O
,	O
Baron	O
A	O
,	O
Zamboni	O
G	O
,	O
Orlandini	O
S,	O
Bogina	O
G	O
,	O
Bassi	O
C	O
,	O
Iacono	O
C	O
,	O
Scarpa	O
A.	O
Istituto	O
di	O
Anatomia	O
Patologica	O
,	O
Universita	O
di	O
Verona	O
,	O
Italy	O
.	O
Whether	O
duodenal	B-malignancy-type
adenocarcinoma	I-malignancy-type
should	O
be	O
considered	O
as	O
a	O
gastrointestinal	B-malignancy-type
or	O
as	O
a	O
peripancreatic	B-malignancy-type
cancer	I-malignancy-type
is	O
a	O
matter	O
of	O
debate	O
,	O
as	O
is	O
the	O
opportunity	O
and	O
type	O
of	O
treatment	O
.	O
We	O
investigated	O
12	O
such	O
cancers	O
for	O
the	O
genetic	O
anomalies	O
involved	O
in	O
the	O
pathogenesis	O
of	O
gastrointestinal	B-malignancy-type
malignancies	I-malignancy-type
,	O
including	O
(a)	O
those	O
occurring	O
in	O
common	O
-	O
type	O
cancers	O
-	O
allelic	O
losses	O
at	O
chromosomes	O
3p	O
,	O
5q	O
,	O
17p	O
and	O
18q	O
,	O
and	O
Ki-ras	O
and	O
p53	O
alterations	O
;	O
and	O
(b)	O
those	O
characteristic	O
of	O
mutator	O
-	O
phenotype	O
cancers	O
-	O
microsatellite	O
instability	O
and	O
TGF-betaRII	O
gene	O
mutations	O
.	O
We	O
found	O
Ki-ras	O
and	O
p53	O
mutations	O
in	O
five	O
(	O
42	O
%	O
)	O
and	O
eight	O
cancers	O
(	O
67	O
%	O
)	O
,	O
respectively	O
;	O
chromosome	O
3p	O
,	O
5q	O
,	O
17p	O
and	O
18q	O
allelic	O
losses	O
in	O
two	O
of	O
nine	O
(	O
22	O
%	O
)	O
,	O
six	O
of	O
ten	O
(	O
60	O
%	O
)	O
,	O
six	O
of	O
nine	O
(	O
67	O
%	O
)	O
and	O
three	O
of	O
ten	O
(	O
30	O
%	O
)	O
informative	O
cancers	O
,	O
respectively	O
.	O
Finally	O
,	O
three	O
cancers	O
(	O
25	O
%	O
)	O
showed	O
widespread	O
microsatellite	O
instability	O
and	O
two	O
of	O
them	O
had	O
a	O
TGF-betaRII	O
gene	O
mutation	O
.	O
Our	O
data	O
suggest	O
that	O
duodenal	B-malignancy-type
cancers	I-malignancy-type
may	O
arise	O
from	O
either	O
of	O
the	O
two	O
known	O
pathogenetic	O
molecular	O
pathways	O
of	O
gastric	O
and	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
.	O
The	O
majority	O
of	O
our	O
cases	O
were	O
highly	O
aggressive	O
cancers	O
with	O
frequent	O
chromosomal	O
changes	O
and	O
p53	O
mutations	O
as	O
observed	O
in	O
the	O
common	O
-	O
type	O
gastrointestinal	B-malignancy-type
malignancies	I-malignancy-type
,	O
while	O
widespread	O
subtle	O
alterations	O
characteristic	O
of	O
mutator	O
-	O
phenotype	O
cancers	O
occurred	O
in	O
a	O
minority	O
,	O
which	O
also	O
showed	O
a	O
favourable	O
long	O
-	O
term	O
outcome	O
.	O
PMID	O
:	O
9514055	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Clin	O
Oncol	O
1997	O
Oct;20(	O
5	O
)	O
:527	O
-	O
9	O
Irinotecan	O
hydrochloride	O
(	O
CPT-11	O
)	O
resistance	O
identified	O
by	O
K-ras	O
mutation	O
in	O
patients	O
with	O
progressive	B-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
after	O
treatment	O
with	O
5-fluorouracil	O
(	O
5-FU	O
)	O
.	O
Nemunaitis	O
J,	O
Cox	O
J,	O
Meyer	O
W	O
,	O
Courtney	O
A	O
,	O
Mues	O
G.	O
Physician	O
Reliance	O
Network	O
,	O
Inc.	O
,	O
Dallas	O
,	O
Texas	O
,	O
USA	O
.	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
prognostic	O
role	O
of	O
a	O
K-ras	O
mutation	O
in	O
tumor	O
tissue	O
of	O
patients	O
with	O
refractory	B-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
who	O
received	O
irinotecan	O
hydrochloride	O
(	O
CPT-11	O
)	O
.	O
METHODS	O
:	O
DNA	O
was	O
extracted	O
from	O
paraffin	O
-	O
stored	O
tumor	O
tissue	O
of	O
35	O
patients	O
with	O
progressive	B-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
failing	O
treatment	O
with	O
5-fluorouracil	O
who	O
subsequently	O
received	O
CPT-11	O
(	O
100	O
mg	O
/	O
m2	O
i.v.	O
per	O
week	O
x	O
4	O
weeks	O
with	O
2	O
weeks	O
off	O
per	O
course	O
)	O
.	O
The	O
first	O
exon	O
of	O
the	O
K-ras	O
gene	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
by	O
using	O
K-ras	O
-	O
specific	O
primers	O
followed	O
by	O
mutant	O
enrichment	O
sequencing	O
.	O
Survival	O
differences	O
of	O
patients	O
with	O
a	O
K-ras	O
mutation	O
were	O
compared	O
with	O
those	O
of	O
patients	O
with	O
a	O
normal	O
K-ras	O
status	O
.	O
RESULTS	O
:	O
A	O
total	O
of	O
21	O
patients	O
had	O
a	O
normal	O
K-ras	O
sequence	O
and	O
14	O
patients	O
had	O
a	O
K-ras	O
mutation	O
[	O
GAT	O
,	O
n	O
=	O
7	O
;	O
TGT	O
,	O
n	O
=	O
3	O
;	O
and	O
GCT	O
,	O
AGT	O
,	O
GTT	O
,	O
GAC	O
(	O
codon	O
13	O
)	O
,	O
n	O
=	O
1	O
each	O
]	O
.	O
Median	O
survival	O
of	O
patients	O
with	O
a	O
normal	O
ras	O
sequence	O
from	O
time	O
of	O
treatment	O
with	O
CPT-11	O
was	O
332	O
days	O
compared	O
with	O
169	O
days	O
for	O
patients	O
with	O
a	O
K-ras	O
mutation	O
(	O
p	O
=	O
0.0036	O
)	O
.	O
No	O
differences	O
in	O
age	O
,	O
sex	O
,	O
cancer	O
stage	O
,	O
surgical	O
treatment	O
,	O
or	O
chemotherapy	O
treatment	O
were	O
observed	O
.	O
CONCLUSION	O
:	O
Determination	O
of	O
the	O
presence	O
of	O
a	O
K-ras	O
mutation	O
may	O
predict	O
survival	O
in	O
patients	O
with	O
progressive	B-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
after	O
treatment	O
with	O
5-fluorouracil	O
who	O
receive	O
CPT-11	O
.	O
PMID	O
:	O
9345343	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Surg	O
1997	O
Jun;84(	O
6)	O
:826	O
-	O
9	O
p53	O
and	O
K-ras	O
status	O
in	O
duodenal	B-malignancy-type
adenomas	I-malignancy-type
in	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
.	O
Kashiwagi	O
H	O
,	O
Spigelman	O
AD	O
,	O
Talbot	O
IC	O
,	O
Debinski	O
HS	O
,	O
McKie	O
AB	O
,	O
Lemoine	O
NR	O
,	O
Phillips	O
RK.	O
Polyposis	O
Registry	O
,	O
St	O
Mark	O
's	O
Hospital	O
,	O
Harrow	O
,	O
Middlesex	O
,	O
UK.	O
BACKGROUND	O
:	O
The	O
genetic	O
alterations	O
in	O
patients	O
with	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
(	O
FAP	B-malignancy-type
)	O
and	O
duodenal	B-malignancy-type
adenomas	I-malignancy-type
are	O
poorly	O
characterized	O
when	O
compared	O
with	O
data	O
relating	O
to	O
colorectal	O
tumorigenesis	O
in	O
the	O
same	O
patients	O
.	O
METHODS	O
:	O
Point	O
mutation	O
of	O
the	O
K-ras	O
oncogene	O
and	O
point	O
mutation	O
and	O
overexpression	O
of	O
the	O
TP53	O
tumour	O
suppressor	O
gene	O
were	O
investigated	O
in	O
32	O
duodenal	B-malignancy-type
polyps	I-malignancy-type
(	O
seven	O
without	O
mucosal	O
pathology	O
,	O
23	O
with	O
mildly	O
dysplastic	B-malignancy-type
adenomas	I-malignancy-type
and	O
two	O
with	O
moderately	O
dysplastic	B-malignancy-type
adenomas	I-malignancy-type
)	O
from	O
21	O
patients	O
with	O
FAP	B-malignancy-type
.	O
RESULTS	O
:	O
K-ras	O
mutation	O
,	O
TP53	O
mutation	O
or	O
positive	O
p53	O
staining	O
were	O
not	O
found	O
in	O
duodenal	B-malignancy-type
polyps	I-malignancy-type
without	O
histological	O
abnormality	O
.	O
Of	O
25	O
duodenal	B-malignancy-type
adenomas	I-malignancy-type
,	O
K-ras	O
mutation	O
was	O
found	O
in	O
three	O
(	O
two	O
mildly	O
dysplastic	B-malignancy-type
,	O
one	O
moderately	O
dysplastic	B-malignancy-type
)	O
,	O
20	O
showed	O
positive	O
p53	O
immunostaining	O
,	O
and	O
mutation	O
of	O
the	O
TP53	O
gene	O
was	O
found	O
in	O
one	O
moderately	O
dysplastic	B-malignancy-type
adenoma	I-malignancy-type
.	O
p53	O
protein	O
overexpression	O
in	O
duodenal	B-malignancy-type
adenomas	I-malignancy-type
was	O
significantly	O
more	O
frequent	O
than	O
mutation	O
of	O
either	O
K-ras	O
or	O
TP53	O
(	O
P	O
<	O
0.01	O
)	O
.	O
CONCLUSION	O
:	O
p53	O
dysfunction	O
is	O
a	O
hallmark	O
of	O
duodenal	B-malignancy-type
adenomas	I-malignancy-type
in	O
patients	O
with	O
FAP	B-malignancy-type
.	O
Overexpression	O
may	O
indicate	O
DNA	O
damage	O
and	O
thus	O
an	O
early	O
step	O
in	O
tumorigenesis	O
.	O
PMID	O
:	O
9189100	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gastroenterology	O
1997	O
Feb;112(	O
2	O
)	O
:561	O
-	O
6	O
Multiple	O
hyperplastic	B-malignancy-type
polyps	I-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
stomach	I-malignancy-type
:	O
evidence	O
for	O
clonality	O
and	O
neoplastic	O
potential	O
.	O
Dijkhuizen	O
SM	O
,	O
Entius	O
MM	O
,	O
Clement	O
MJ	O
,	O
Polak	O
MM	O
,	O
Van	O
den	O
Berg	O
FM	O
,	O
Craanen	O
ME	O
,	O
Slebos	O
RJ	O
,	O
Offerhaus	O
GJ.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Amsterdam	O
,	O
The	O
Netherlands	O
.	O
The	O
origin	O
and	O
neoplastic	O
potential	O
of	O
gastric	B-malignancy-type
epithelial	I-malignancy-type
polyps	I-malignancy-type
remains	O
an	O
area	O
of	O
great	O
interest	O
,	O
and	O
treatment	O
choices	O
are	O
a	O
topic	O
of	O
controversy	O
.	O
This	O
report	O
describes	O
a	O
patient	O
diagnosed	O
with	O
three	O
concurrent	O
hyperplastic	B-malignancy-type
gastric	I-malignancy-type
polyps	I-malignancy-type
that	O
were	O
studied	O
for	O
genetic	O
alterations	O
.	O
The	O
polyps	B-malignancy-type
were	O
investigated	O
for	O
alterations	O
in	O
the	O
K-ras	O
oncogene	O
and	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
and	O
for	O
p21WAF1	O
/	O
Cip1	O
and	O
MDM2	O
protein	O
overexpression	O
.	O
In	O
addition	O
,	O
loss	O
of	O
heterozygosity	O
at	O
several	O
loci	O
that	O
are	O
frequently	O
involved	O
in	O
human	O
cancer	O
was	O
analyzed	O
,	O
microsatellite	O
instability	O
,	O
a	O
hallmark	O
of	O
the	O
"	O
mutator	O
"	O
phenotype	O
,	O
was	O
determined	O
,	O
and	O
Epstein	O
-	O
Barr	O
virus	O
infection	O
was	O
investigated	O
.	O
All	O
separate	O
areas	O
from	O
the	O
three	O
independent	O
polyps	B-malignancy-type
harbored	O
the	O
same	O
activating	O
point	O
mutation	O
in	O
codon	O
12	O
of	O
the	O
K-ras	O
oncogene	O
,	O
indicating	O
a	O
clonal	O
origin	O
.	O
DNA	O
sequence	O
alterations	O
in	O
p53	O
were	O
not	O
found	O
,	O
although	O
high	O
p53	O
protein	O
levels	O
could	O
be	O
shown	O
by	O
immunohistochemistry	O
in	O
areas	O
of	O
carcinoma	B-malignancy-type
within	O
the	O
largest	O
polyp	B-malignancy-type
.	O
No	O
alterations	O
in	O
any	O
of	O
the	O
other	O
molecular	O
markers	O
were	O
observed	O
.	O
The	O
results	O
strongly	O
favor	O
a	O
clonal	O
origin	O
of	O
the	O
three	O
independent	O
gastric	B-malignancy-type
polyps	I-malignancy-type
and	O
support	O
the	O
notion	O
that	O
these	O
hyperplastic	B-malignancy-type
polyps	I-malignancy-type
may	O
carry	O
a	O
risk	O
for	O
malignancy	O
.	O
PMID	O
:	O
9024310	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Detect	O
Prev	O
1996;20(	O
1	O
)	O
:20	O
-	O
30	O
A	O
possible	O
role	O
for	O
human	O
papillomaviruses	O
and	O
c-myc	O
,	O
c-Ha-ras	O
,	O
and	O
p53	O
gene	O
alterations	O
in	O
malignant	B-malignancy-type
cutaneous	I-malignancy-type
lesions	I-malignancy-type
from	O
renal	O
transplant	O
recipients	O
.	O
Pelisson	O
I	O
,	O
Soler	O
C	O
,	O
Chardonnet	O
Y	O
,	O
Euvrard	O
S,	O
Schmitt	O
D.	O
Edouard	O
Herriot	O
Hospital	O
,	O
Lyon	O
,	O
France	O
.	O
Several	O
years	O
after	O
transplantation	O
,	O
renal	O
transplant	O
recipients	O
develop	O
numerous	O
cutaneous	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
SCC	B-malignancy-type
)	O
,	O
in	O
which	O
human	O
papillomaviruses	O
(	O
HPV	O
)	O
may	O
be	O
detected	O
.	O
Alterations	O
in	O
c-myc	O
,	O
c-Ha-ras	O
,	O
and	O
p53	O
genes	O
were	O
studied	O
in	O
34	O
SCC	O
,	O
in	O
correlation	O
with	O
the	O
presence	O
of	O
HPV	O
.	O
In	O
situ	O
hybridization	O
(	O
ISH	O
)	O
and	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
showed	O
that	O
many	O
SCC	O
contained	O
several	O
HPV	O
types	O
infecting	O
different	O
foci	O
of	O
epithelial	O
cells	O
.	O
Using	O
Southern	O
blot	O
and	O
ISH	O
,	O
c-myc	O
and/or	O
c-Ha-ras	O
gene	O
amplification	O
was	O
detected	O
in	O
7	O
/	O
13	O
SCC	B-malignancy-type
tested	O
.	O
With	O
PCR	O
and	O
oligoprobe	O
hybridization	O
,	O
a	O
GGC	O
->	O
GAC	O
mutation	O
was	O
found	O
at	O
codon	O
12	O
of	O
c-Ha-ras	O
gene	O
in	O
1	O
/	O
21	O
SCC	B-malignancy-type
tested	O
,	O
while	O
no	O
mutation	O
was	O
detected	O
at	O
codon	O
61	O
.	O
Using	O
immunohistochemistry	O
,	O
p53	O
protein	O
expression	O
was	O
detected	O
either	O
along	O
the	O
basal	O
cell	O
layer	O
or	O
spotted	O
in	O
foci	O
of	O
basal	O
cells	O
.	O
Our	O
results	O
show	O
an	O
abnormal	O
distribution	O
of	O
HPV	O
types	O
in	O
SCC	B-malignancy-type
from	O
renal	O
transplant	O
recipients	O
,	O
and	O
alterations	O
of	O
c-myc	O
,	O
c-Ha-ras	O
,	O
and	O
p53	O
genes	O
without	O
any	O
direct	O
link	O
with	O
the	O
presence	O
of	O
any	O
studied	O
HPV	O
type	O
.	O
Thus	O
,	O
viral	O
infection	O
and	O
oncogene	O
activation	O
may	O
represent	O
factors	O
involved	O
in	O
the	O
etiology	O
of	O
skin	B-malignancy-type
SCC	I-malignancy-type
from	O
transplant	O
recipients	O
.	O
PMID	O
:	O
8907200	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Gastroenterol	O
1996	O
Mar;91(	O
3	O
)	O
:587	O
-	O
91	O
K-ras	O
mutation	O
in	O
a	O
tubular	B-malignancy-type
adenoma	I-malignancy-type
originating	O
at	O
an	O
ileostomy	O
in	O
a	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
patient	O
.	O
Herring	O
JA	O
,	O
Hall	O
CC	O
,	O
Johnson	O
JA	O
,	O
Poole	O
GV	O
,	O
Subramony	O
C	O
,	O
Suvarna	O
-	O
Gurram	O
V	O
,	O
Hall	O
TJ.	O
Department	O
of	O
Biochemistry	O
,	O
University	O
of	O
Mississippi	O
Medical	O
Center	O
,	O
Jackson	O
USA	O
.	O
Genetic	O
alterations	O
in	O
a	O
tubular	B-malignancy-type
adenoma	I-malignancy-type
with	O
severe	O
dysplasia	B-malignancy-type
arising	O
in	O
a	O
Brooke	O
ileostomy	O
of	O
a	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
patient	O
were	O
analyzed	O
.	O
Clinical	O
and	O
morphological	O
characteristics	O
suggest	O
that	O
ileal	O
mucosa	O
progressed	O
to	O
colonic	B-malignancy-type
metaplasia	I-malignancy-type
and	O
then	O
to	O
dysplastic	B-malignancy-type
adenoma	I-malignancy-type
.	O
Such	O
changes	O
at	O
ileostomy	O
sites	O
are	O
rare	O
,	O
and	O
little	O
is	O
known	O
about	O
the	O
associated	O
genetic	O
alterations	O
.	O
To	O
determine	O
whether	O
metaplastic	O
epithelium	O
progression	O
to	O
adenoma	B-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
ileum	I-malignancy-type
is	O
subject	O
to	O
the	O
same	O
mutations	O
identified	O
in	O
colon	O
carcinogenesis	O
,	O
we	O
evaluated	O
somatic	O
genetic	O
alterations	O
associated	O
with	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
development	O
.	O
Sequences	O
examined	O
included	O
mutation	O
cluster	O
regions	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
and	O
the	O
k-ras	O
oncogene	O
.	O
Using	O
polymerase	O
chain	O
reaction	O
and	O
DNA	O
sequencing	O
,	O
we	O
identified	O
a	O
point	O
mutation	O
at	O
codon	O
12	O
of	O
the	O
K-ras	O
oncogene	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
ras	O
mutation	O
occurring	O
in	O
a	O
tumor	O
originating	O
from	O
ileal	O
mucosa	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
of	O
Reported	O
Cases	O
PMID	O
:	O
8633516	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gynecol	O
Oncol	O
1993	O
Jun	O
;	O
49	O
(	O
3	O
)	O
:	O
359	O
-	O
64	O
Analysis	O
of	O
ras	O
point	O
mutations	O
and	O
human	O
papillomavirus	O
16	O
and	O
18	O
in	O
cervical	B-malignancy-type
carcinomata	I-malignancy-type
and	O
their	O
metastases	B-malignancy-type
.	O
Willis	O
G	O
,	O
Jennings	O
B	O
,	O
Ball	O
RY	O
,	O
New	O
NE	O
,	O
Gibson	O
I	O
.	O
Department	O
of	O
Biological	O
Sciences	O
,	O
University	O
of	O
East	O
Anglia	O
,	O
Norwich	O
,	O
England	O
.	O
Paraffin	O
-	O
wax	O
-	O
embedded	O
samples	O
of	O
normal	O
cervical	O
tissue	O
and	O
of	O
primary	O
cervical	B-malignancy-type
carcinomata	I-malignancy-type
and	O
nodal	B-malignancy-type
metastases	I-malignancy-type
were	O
obtained	O
from	O
each	O
of	O
15	O
patients	O
.	O
They	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
ras	O
point	O
mutations	O
and	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
types	O
16	O
and	O
18	O
using	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
hybridization	O
to	O
oligomer	O
probes	O
.	O
Only	O
1	O
patient	O
was	O
found	O
to	O
have	O
a	O
ras	O
mutation	O
:	O
a	O
codon	O
13	O
mutation	O
of	O
Ki-ras	O
which	O
was	O
present	O
in	O
only	O
two	O
lymph	B-malignancy-type
node	I-malignancy-type
metastases	I-malignancy-type
,	O
but	O
not	O
in	O
the	O
primary	O
tumor	O
or	O
in	O
a	O
third	B-malignancy-type
metastasis	I-malignancy-type
.	O
These	O
results	O
suggest	O
that	O
ras	O
point	O
mutation	O
is	O
not	O
a	O
common	O
factor	O
in	O
the	O
development	O
of	O
primary	O
or	O
metastatic	O
cervical	B-malignancy-type
cancer	I-malignancy-type
.	O
HPV	O
16	O
was	O
detected	O
in	O
7	O
of	O
the	O
15	O
patients	O
and	O
was	O
present	O
in	O
both	O
primary	O
and	O
metastatic	O
tumors	O
in	O
6	O
of	O
these	O
7	O
cases	O
.	O
HPV	O
18	O
was	O
not	O
detected	O
in	O
any	O
of	O
the	O
15	O
patients	O
.	O
These	O
results	O
do	O
not	O
suggest	O
a	O
role	O
for	O
HPVs	O
16	O
and	O
18	O
in	O
producing	O
metastatic	O
behavior	O
.	O
PMID	O
:	O
8390962	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leukemia	O
1994	O
Jan;8(	O
1	O
)	O
:102	O
-	O
5	O
Ras	O
point	O
mutations	O
occur	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
with	O
illegitimate	O
T-cell	O
receptor	O
delta	O
gene	O
rearrangement	O
.	O
Schmidt	O
CA	O
,	O
Przybylski	O
G	O
,	O
Vogel	O
D	O
,	O
Ludwig	O
WD	O
,	O
Oettle	O
H	O
,	O
Neubauer	O
A	O
,	O
Siegert	O
W.	O
Abt	O
.	O
Hamatologie	O
,	O
Klinikum	O
Rudolf	O
Virchow	O
,	O
Freie	O
Universitat	O
Berlin	O
,	O
Germany	O
.	O
Mutations	O
in	O
the	O
ras	O
proto	O
-	O
oncogenes	O
are	O
the	O
most	O
frequently	O
observed	O
molecular	O
alteration	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
Whether	O
ras	O
mutations	O
occur	O
as	O
late	O
or	O
relatively	O
early	O
events	O
in	O
the	O
multistep	O
process	O
of	O
myeloid	O
transformation	O
,	O
remains	O
an	O
open	O
question	O
.	O
We	O
previously	O
described	O
illegitimate	O
T-cell	O
receptor	O
(	O
TCR	O
)	O
-	O
delta	O
gene	O
rearrangements	O
in	O
a	O
subset	O
of	O
AML	B-malignancy-type
.	O
These	O
recombinations	O
were	O
detected	O
in	O
9	O
out	O
of	O
100	O
de	B-malignancy-type
novo	I-malignancy-type
AML	I-malignancy-type
cases	O
.	O
Southern	O
blot	O
analysis	O
suggested	O
the	O
presence	O
of	O
these	O
recombinations	O
in	O
the	O
vast	O
majority	O
of	O
AML	B-malignancy-type
cells	O
and	O
thus	O
could	O
be	O
used	O
as	O
clonal	O
markers	O
.	O
In	O
order	O
to	O
more	O
accurately	O
define	O
the	O
role	O
of	O
ras	O
proto	O
-	O
oncogene	O
mutations	O
in	O
the	O
multistep	O
process	O
of	O
malignant	O
transformation	O
in	O
myeloid	B-malignancy-type
leukemias	I-malignancy-type
,	O
we	O
performed	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
assays	O
,	O
slot	O
blot	O
and	O
direct	O
sequencing	O
analysis	O
on	O
these	O
nine	O
cases	O
with	O
illegitimate	O
TCR	O
delta	O
gene	O
rearrangements	O
.	O
Ras	O
proto	O
-	O
oncogene	O
mutations	O
were	O
found	O
in	O
three	O
of	O
nine	O
cases	O
.	O
Interestingly	O
,	O
SSCP	O
,	O
slot	O
blot	O
and	O
sequencing	O
suggested	O
the	O
presence	O
of	O
the	O
respective	O
mutations	O
in	O
most	O
of	O
the	O
leukemic	O
cells	O
.	O
Thus	O
,	O
ras	O
mutations	O
presumably	O
occurred	O
early	O
in	O
the	O
process	O
of	O
transformation	O
in	O
these	O
three	O
cases	O
.	O
PMID	O
:	O
8289473	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1994	O
Jul	O
15;54(	O
14	O
)	O
:3934	O
-	O
8	O
Absence	O
of	O
N-ras	O
mutations	O
in	O
myeloid	O
and	O
lymphoid	O
blast	O
crisis	O
of	O
chronic	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
Watzinger	O
F	O
,	O
Gaiger	O
A	O
,	O
Karlic	O
H	O
,	O
Becher	O
R,	O
Pillwein	O
K	O
,	O
Lion	O
T.	O
Children	O
's	O
Cancer	O
Research	O
Institute	O
,	O
St.	O
Anna	O
Kinderspital	O
,	O
Vienna	O
,	O
Austria	O
.	O
Mutations	O
within	O
N-ras	O
oncogene	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
occur	O
in	O
approximately	O
25	O
-	O
30	O
%	O
of	O
patients	O
with	O
acute	B-malignancy-type
nonlymphocytic	I-malignancy-type
leukemia	I-malignancy-type
and	O
at	O
a	O
lower	O
frequency	O
(	O
6	O
-	O
20	O
%	O
)	O
in	O
patients	O
with	O
acute	B-malignancy-type
lymphocytic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Moreover	O
,	O
N-ras	O
mutations	O
have	O
been	O
described	O
in	O
patients	O
with	O
chronic	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
in	O
blast	O
crisis	O
but	O
have	O
not	O
been	O
observed	O
during	O
the	O
chronic	O
phase	O
of	O
the	O
disease	O
.	O
In	O
view	O
of	O
the	O
morphological	O
and	O
clinical	O
similarities	O
between	O
acute	B-malignancy-type
leukemia	I-malignancy-type
and	O
the	O
blast	O
crisis	O
of	O
CML	B-malignancy-type
,	O
the	O
question	O
was	O
raised	O
whether	O
the	O
presence	O
of	O
N-ras	O
mutations	O
is	O
associated	O
with	O
the	O
phenotype	O
of	O
acute	B-malignancy-type
leukemia	I-malignancy-type
.	O
We	O
investigated	O
leukemic	O
cells	O
from	O
100	O
patients	O
with	O
CML	B-malignancy-type
for	O
the	O
presence	O
of	O
N-ras	O
mutations	O
in	O
the	O
mutational	O
hot	O
spot	O
codons	O
.	O
The	O
cases	O
analyzed	O
included	O
87	O
diagnosed	O
with	O
different	O
types	O
of	O
blast	O
crisis	O
and	O
13	O
cases	O
in	O
accelerated	O
or	O
chronic	O
phase	O
of	O
the	O
disease	O
.	O
Fragments	O
from	O
N-ras	O
exons	O
I	O
and	O
II	O
containing	O
the	O
codons	O
of	O
interest	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
analyzed	O
for	O
the	O
presence	O
of	O
point	O
mutations	O
by	O
three	O
different	O
technical	O
approaches	O
,	O
including	O
specific	O
oligonucleotide	O
hybridization	O
,	O
direct	O
sequencing	O
,	O
and	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O
N-ras	O
mutations	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
CML	B-malignancy-type
patients	O
investigated	O
.	O
Only	O
one	O
patient	O
,	O
in	O
whom	O
the	O
initial	O
diagnosis	O
of	O
CML	B-malignancy-type
-	O
blast	O
crisis	O
had	O
been	O
revised	O
to	O
chronic	B-malignancy-type
myelomonocytic	I-malignancy-type
leukemia	I-malignancy-type
,	O
displayed	O
an	O
N-ras	O
mutation	O
within	O
codon	O
13	O
.	O
Our	O
data	O
strongly	O
suggest	O
that	O
N-ras	O
mutations	O
do	O
not	O
play	O
a	O
role	O
in	O
myeloid	O
or	O
lymphoid	O
blast	O
crisis	O
of	O
CML	B-malignancy-type
.	O
PMID	O
:	O
8033117	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Surgery	O
1994	O
Dec;116(	O
6)	O
:1010	O
-	O
6	O
N-ras	O
mutation	O
:	O
an	O
independent	O
prognostic	O
factor	O
for	O
aggressiveness	O
of	O
papillary	B-malignancy-type
thyroid	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Hara	O
H	O
,	O
Fulton	O
N	O
,	O
Yashiro	O
T	O
,	O
Ito	O
K	O
,	O
DeGroot	O
LJ	O
,	O
Kaplan	O
EL.	O
Department	O
of	O
Surgery	O
,	O
University	O
of	O
Chicago	O
Pritzker	O
School	O
of	O
Medicine	O
,	O
Ill	O
60637	O
.	O
BACKGROUND	O
.	O
The	O
clinical	O
importance	O
of	O
point	O
mutations	O
of	O
ras	O
oncogene	O
in	O
differentiated	B-malignancy-type
thyroid	I-malignancy-type
cancers	I-malignancy-type
has	O
not	O
been	O
fully	O
clarified	O
.	O
The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
prognostic	O
importance	O
of	O
ras	O
mutation	O
in	O
papillary	B-malignancy-type
thyroid	I-malignancy-type
carcinoma	I-malignancy-type
.	O
METHODS	O
.	O
Tumors	O
of	O
91	O
patients	O
with	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
were	O
studied	O
;	O
mean	O
follow	O
-	O
up	O
was	O
14.1	O
years	O
(	O
range	O
,	O
1	O
to	O
40	O
years	O
)	O
.	O
Patients	O
were	O
grouped	O
as	O
follows	O
:	O
class	O
I	O
,	O
intrathyroidal	B-malignancy-type
disease	I-malignancy-type
,	O
n	O
=	O
21	O
;	O
class	O
II	O
,	O
cervical	B-malignancy-type
node	I-malignancy-type
metastases	I-malignancy-type
,	O
n	O
=	O
22	O
;	O
class	O
III	O
,	O
extrathyroidal	B-malignancy-type
disease	I-malignancy-type
,	O
n	O
=	O
19	O
;	O
and	O
class	O
IV	O
,	O
distant	B-malignancy-type
metastases	I-malignancy-type
,	O
n	O
=	O
29	O
.	O
DNA	O
was	O
analyzed	O
with	O
polymerase	O
chain	O
reaction	O
,	O
oligonucleotide	O
hybridization	O
,	O
and	O
DNA	O
sequence	O
analysis	O
techniques	O
.	O
RESULTS	O
.	O
Thirteen	O
(	O
14.3	O
%	O
)	O
of	O
91	O
tumors	O
showed	O
an	O
N-ras	O
point	O
mutation	O
:	O
4.8	O
%	O
(	O
1	O
of	O
21	O
)	O
patients	O
in	O
class	O
I	O
;	O
4.5	O
%	O
(	O
1	O
of	O
22	O
)	O
patients	O
in	O
class	O
II	O
;	O
15.8	O
%	O
(	O
3	O
of	O
19	O
)	O
patients	O
in	O
class	O
III	O
;	O
and	O
27.8	O
%	O
(	O
8	O
of	O
29	O
)	O
patients	O
in	O
class	O
IV	O
.	O
Each	O
mutation	O
changed	O
codon	O
61	O
from	O
glutamine	O
to	O
arginine	O
.	O
Patients	O
with	O
distant	B-malignancy-type
metastases	I-malignancy-type
(	O
8	O
of	O
29	O
)	O
had	O
a	O
significantly	O
higher	O
incidence	O
of	O
ras	O
mutations	O
than	O
others	O
(	O
5	O
of	O
62	O
,	O
p	O
=	O
0.01	O
)	O
.	O
Patients	O
in	O
classes	O
III	O
and	O
IV	O
also	O
had	O
a	O
higher	O
incidence	O
of	O
mutations	O
(	O
11	O
of	O
48	O
)	O
than	O
patients	O
in	O
classes	O
I	O
and	O
II	O
(	O
2	O
of	O
43	O
,	O
p	O
=	O
0.01	O
)	O
.	O
The	O
incidence	O
of	O
ras	O
mutations	O
was	O
significantly	O
higher	O
in	O
patients	O
who	O
died	O
of	O
papillary	B-malignancy-type
cancer	I-malignancy-type
(	O
5	O
of	O
15	O
,	O
33.3	O
%	O
)	O
than	O
in	O
patients	O
who	O
are	O
still	O
alive	O
(	O
8	O
of	O
76	O
,	O
10.5	O
%	O
)	O
(	O
p	O
=	O
0.02	O
)	O
.	O
Kaplan	O
-	O
Meier	O
survival	O
curves	O
also	O
showed	O
a	O
greater	O
mortality	O
from	O
tumor	O
(	O
p	O
<	O
0.05	O
)	O
and	O
a	O
higher	O
recurrence	O
rate	O
(	O
p	O
<	O
0.01	O
)	O
in	O
ras	O
-	O
positive	O
tumors	O
than	O
in	O
the	O
ras	O
-	O
negative	O
group	O
.	O
Finally	O
,	O
in	O
studies	O
by	O
multivariate	O
analyses	O
,	O
positive	O
ras	O
mutation	O
and	O
age	O
were	O
shown	O
to	O
be	O
two	O
independent	O
prognostic	O
factors	O
for	O
prediction	O
of	O
death	O
from	O
papillary	B-malignancy-type
cancer	I-malignancy-type
and	O
recurrence	O
of	O
cancer	O
.	O
CONCLUSIONS	O
.	O
Mutation	O
of	O
N-ras	O
gene	O
at	O
codon	O
61	O
is	O
an	O
independent	O
prognostic	O
factor	O
for	O
aggressiveness	O
of	O
papillary	B-malignancy-type
thyroid	I-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
7985080	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Ann	O
Acad	O
Med	O
Singapore	O
1995	O
May	O
;24(	O
3	O
)	O
:393	O
-	O
8	O
Association	O
of	O
activated	O
proto	O
-	O
oncogenes	O
ras	O
and	O
myc	O
in	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Smith	O
DR	O
,	O
Elnatan	O
J,	O
Myint	O
T	O
,	O
Goh	O
HS	O
.	O
Department	O
of	O
Colorectal	O
Surgery	O
,	O
Singapore	O
General	O
Hospital	O
.	O
We	O
have	O
examined	O
60	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
for	O
activation	O
of	O
two	O
proto	O
-	O
oncogenes	O
,	O
c-myc	O
and	O
c-Ki-ras	O
.	O
Over	O
-	O
expression	O
of	O
c-myc	O
mRNA	O
as	O
determined	O
by	O
Northern	O
analysis	O
was	O
found	O
in	O
58	O
%	O
of	O
cases	O
(	O
35	O
/	O
60	O
)	O
.	O
Activation	O
of	O
the	O
c-Ki-ras	O
gene	O
by	O
point	O
mutations	O
in	O
codons	O
12	O
or	O
13	O
as	O
determined	O
by	O
mismatch	O
specific	O
oligonucleotide	O
hybridisation	O
was	O
found	O
in	O
35	O
%	O
(	O
21	O
/	O
60	O
)	O
of	O
cases	O
.	O
There	O
was	O
a	O
statistically	O
significant	O
association	O
between	O
activation	O
of	O
c-Ki-ras	O
and	O
over	O
-	O
expression	O
of	O
c-myc	O
(	O
P	O
=	O
0.03	O
)	O
,	O
with	O
76	O
%	O
of	O
tumours	O
with	O
an	O
activated	O
c-Ki-ras	O
proto	O
-	O
oncogene	O
showing	O
over	O
-	O
expression	O
of	O
c-myc	O
.	O
The	O
association	O
was	O
significant	O
in	O
left-sided	B-malignancy-type
colorectal	I-malignancy-type
tumours	I-malignancy-type
(	O
P	O
=	O
0.03	O
)	O
but	O
not	O
right-sided	B-malignancy-type
(	O
P	O
=	O
0.5	O
)	O
.	O
However	O
,	O
whereas	O
only	O
59	O
%	O
of	O
left	B-malignancy-type
side	I-malignancy-type
tumours	I-malignancy-type
showed	O
at	O
least	O
one	O
of	O
the	O
two	O
changes	O
(	O
ras	O
activation	O
only	O
,	O
or	O
myc	O
activation	O
only	O
or	O
both	O
)	O
,	O
93	O
%	O
of	O
right	B-malignancy-type
side	I-malignancy-type
tumours	I-malignancy-type
showed	O
at	O
least	O
one	O
of	O
the	O
changes	O
(	O
P	O
=	O
0.01	O
)	O
.	O
Twenty-two	O
percent	O
of	O
left	B-malignancy-type
side	I-malignancy-type
tumours	I-malignancy-type
showed	O
both	O
changes	O
compared	O
with	O
35	O
%	O
of	O
right	B-malignancy-type
side	I-malignancy-type
tumours	I-malignancy-type
,	O
although	O
this	O
result	O
did	O
not	O
achieve	O
significance	O
(	O
P	O
=	O
0.2	O
)	O
.	O
These	O
results	O
suggest	O
that	O
in	O
left-sided	B-malignancy-type
colorectal	I-malignancy-type
tumours	I-malignancy-type
ras	O
and	O
myc	O
cooperate	O
,	O
as	O
established	O
in	O
vitro	O
,	O
to	O
produce	O
neoplastic	O
transformation	O
while	O
different	O
pathway(s)	O
are	O
involved	O
in	O
right-sided	B-malignancy-type
tumours	I-malignancy-type
.	O
PMID	O
:	O
7574421	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
1989	O
Oct;73(	O
2	O
)	O
:165	O
-	O
7	O
Co	O
-	O
incident	O
N	O
and	O
K	O
ras	O
gene	O
mutations	O
in	O
a	O
case	O
of	O
AML	B-malignancy-type
,	O
restricted	O
to	O
differing	O
cell	O
lineages	O
.	O
Hiorns	O
LR	O
,	O
Cotter	O
FE	O
,	O
Young	O
BD.	O
Imperial	O
Cancer	O
Research	O
Fund	O
,	O
Department	O
of	O
Medical	O
Oncology	O
,	O
St	O
Bartholomew	O
's	O
Hospital	O
,	O
London	O
.	O
Peripheral	O
blood	O
from	O
a	O
patient	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
of	O
M5	B-malignancy-type
FAB	I-malignancy-type
classification	O
,	O
was	O
shown	O
to	O
have	O
mutations	O
to	O
both	O
the	O
N	O
and	O
K	O
ras	O
genes	O
.	O
Leucophoresed	O
blood	O
was	O
separated	O
on	O
a	O
discontinuous	O
Percoll	O
density	O
gradient	O
to	O
provide	O
fractions	O
enriched	O
for	O
different	O
cell	O
lineages	O
.	O
DNA	O
extracted	O
from	O
these	O
fractions	O
was	O
amplified	O
using	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
technique	O
,	O
and	O
hybridized	O
with	O
oligonucleotide	O
probes	O
specific	O
for	O
the	O
single	O
base	O
mutations	O
previously	O
demonstrated	O
.	O
The	O
N-ras	O
mutation	O
was	O
shown	O
to	O
be	O
restricted	O
to	O
the	O
blast	O
and	O
monocytic	O
cell	O
fractions	O
,	O
concordant	O
with	O
the	O
FAB	O
subtype	O
of	O
M5	O
.	O
The	O
K-ras	O
mutation	O
,	O
however	O
,	O
was	O
present	O
in	O
all	O
fractions	O
,	O
suggesting	O
it	O
had	O
occurred	O
in	O
a	O
multi	O
-	O
potential	O
stem	O
cell	O
representing	O
an	O
earlier	O
stage	O
in	O
the	O
generation	O
of	O
the	O
leukaemia	B-malignancy-type
,	O
or	O
possibly	O
an	O
incidental	O
background	O
phenomenon	O
.	O
PMID	O
:	O
2684256	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1990	O
Apr;5(	O
4)	O
:565	O
-	O
70	O
Presence	O
of	O
mutations	O
in	O
all	O
three	O
ras	O
genes	O
in	O
human	O
thyroid	B-malignancy-type
tumors	I-malignancy-type
.	O
Suarez	O
HG	O
,	O
du	O
Villard	O
JA	O
,	O
Severino	O
M,	O
Caillou	O
B	O
,	O
Schlumberger	O
M,	O
Tubiana	O
M,	O
Parmentier	O
C	O
,	O
Monier	O
R.	O
Institut	O
de	O
recherches	O
scientifiques	O
sur	O
le	O
cancer	O
-	O
CNRS	O
,	O
Villejuif	O
,	O
France	O
.	O
Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
followed	O
by	O
oligonucleotide	O
probing	O
was	O
used	O
to	O
investigate	O
the	O
presence	O
of	O
ras	O
genes	O
mutations	O
in	O
human	O
thyroid	B-malignancy-type
adenomas	I-malignancy-type
and	O
carcinomas	B-malignancy-type
.	O
The	O
results	O
confirm	O
the	O
frequent	O
occurrence	O
of	O
mutations	O
in	O
all	O
three	O
ras	O
genes	O
in	O
both	O
adenomas	B-malignancy-type
and	O
carcinomas	B-malignancy-type
,	O
in	O
agreement	O
with	O
the	O
hypothesis	O
that	O
the	O
ras	O
mutations	O
may	O
constitute	O
early	O
steps	O
in	O
thyroid	O
tumorigenesis	O
.	O
No	O
evident	O
correlation	O
between	O
the	O
frequency	O
of	O
ras	O
mutations	O
,	O
the	O
identity	O
of	O
the	O
mutated	O
ras	O
gene	O
,	O
the	O
position	O
affected	O
in	O
the	O
ras	O
gene	O
or	O
the	O
type	O
of	O
mutation	O
and	O
the	O
pathological	O
features	O
is	O
apparent	O
.	O
However	O
,	O
definitive	O
conclusion	O
on	O
this	O
point	O
is	O
precluded	O
because	O
of	O
the	O
small	O
number	O
of	O
tumors	O
examined	O
at	O
the	O
present	O
time	O
.	O
PMID	O
:	O
2183158	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
1990	O
Sep	O
1;66(	O
5	O
)	O
:930	O
-	O
5	O
Analysis	O
of	O
ras	O
gene	O
mutations	O
in	O
biliary	B-malignancy-type
and	O
pancreatic	B-malignancy-type
tumors	I-malignancy-type
by	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
.	O
Tada	O
M,	O
Yokosuka	O
O	O
,	O
Omata	O
M,	O
Ohto	O
M,	O
Isono	O
K.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Chiba	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
Ras	O
gene	O
is	O
one	O
of	O
the	O
oncogenes	O
most	O
commonly	O
detected	O
in	O
human	O
cancers	O
and	O
consists	O
of	O
three	O
families	O
(	O
H-ras	O
,	O
K-ras	O
,	O
N-ras	O
)	O
that	O
are	O
converted	O
to	O
active	O
oncogenes	O
by	O
point	O
mutations	O
occurring	O
in	O
codon	O
12	O
,	O
13	O
,	O
or	O
61	O
.	O
The	O
authors	O
analyzed	O
mutations	O
of	O
these	O
codons	O
in	O
12	O
extrahepatic	B-malignancy-type
bile	I-malignancy-type
duct	I-malignancy-type
carcinomas	I-malignancy-type
,	O
nine	O
gallbladder	B-malignancy-type
carcinomas	I-malignancy-type
,	O
and	O
20	O
pancreatic	B-malignancy-type
tumors	I-malignancy-type
(	O
18	O
pancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
and	O
two	O
islet	B-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
)	O
by	O
a	O
method	O
to	O
directly	O
sequence	O
nucleotides	O
,	O
using	O
polymerase	O
chain	O
reaction	O
and	O
a	O
direct	O
sequencing	O
method	O
.	O
Point	O
mutations	O
at	O
K-ras	O
codon	O
12	O
were	O
found	O
in	O
all	O
of	O
18	O
pancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
and	O
in	O
one	O
bile	B-malignancy-type
duct	I-malignancy-type
carcinoma	I-malignancy-type
,	O
but	O
there	O
were	O
no	O
mutations	O
in	O
the	O
remaining	O
11	O
bile	B-malignancy-type
duct	I-malignancy-type
carcinomas	I-malignancy-type
,	O
in	O
all	O
of	O
9	O
gallbladder	B-malignancy-type
carcinomas	I-malignancy-type
,	O
or	O
in	O
two	O
islet	B-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
.	O
A	O
very	O
high	O
incidence	O
of	O
ras	O
gene	O
mutations	O
may	O
be	O
used	O
clinically	O
for	O
the	O
diagnosis	O
of	O
debatable	O
cases	O
of	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
PMID	O
:	O
2167148	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1992	O
Apr;6(	O
4)	O
:342	O
-	O
6	O
Low	O
frequency	O
of	O
ras	O
oncogene	O
mutations	O
in	O
Philadelphia	O
-	O
positive	O
acute	B-malignancy-type
leukemia	I-malignancy-type
and	O
report	O
of	O
a	O
novel	O
mutation	O
H	O
61	O
Leu	O
in	O
a	O
single	O
case	O
.	O
Urbano	O
-	O
Ispizua	O
A	O
,	O
Gill	O
R,	O
Matutes	O
E	O
,	O
Levi	O
S,	O
Wiedemann	O
LM	O
,	O
Catovsky	O
D	O
,	O
Marshall	O
CJ.	O
Academic	O
Department	O
of	O
Hematology	O
and	O
Cytogenetics	O
,	O
Institute	O
of	O
Cancer	O
Research	O
,	O
London	O
,	O
UK.	O
Activating	O
ras	O
mutations	O
are	O
frequent	O
(	O
25	O
-	O
60	O
%	O
)	O
in	O
chronic	B-malignancy-type
myelomonocytic	I-malignancy-type
leukemia	I-malignancy-type
(	O
CMML	B-malignancy-type
)	O
and	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
(	O
30	O
%	O
)	O
,	O
in	O
contrast	O
to	O
chronic	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
in	O
which	O
the	O
incidence	O
is	O
very	O
low	O
(	O
0	O
-	O
3	O
%	O
)	O
.	O
This	O
might	O
reflect	O
that	O
the	O
leukemic	O
cell	O
in	O
CML	B-malignancy-type
is	O
at	O
a	O
level	O
of	O
differentiation	O
in	O
which	O
ras	O
gene	O
activation	O
is	O
not	O
involved	O
or	O
,	O
alternatively	O
,	O
might	O
be	O
due	O
to	O
the	O
presence	O
in	O
CML	B-malignancy-type
of	O
the	O
bcr	O
l	O
abl	O
fused	O
gene	O
.	O
We	O
have	O
analyzed	O
the	O
presence	O
of	O
point	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
,	O
59	O
,	O
61	O
and	O
63	O
of	O
N	O
-	O
,	O
K	O
-	O
,	O
and	O
H	O
-	O
ras	O
genes	O
,	O
in	O
26	O
cases	O
of	O
Philadelphia	O
-	O
chromosome	O
-	O
positive	O
,	O
bcr	O
l	O
abl	O
-	O
positive	O
acute	B-malignancy-type
leukemia	I-malignancy-type
(	O
Ph	O
+	O
AL	B-malignancy-type
)	O
,	O
and	O
in	O
eight	O
CMML	B-malignancy-type
cases	O
by	O
using	O
the	O
polymerase	O
chain	O
reaction	O
.	O
Aberrant	O
ras	O
genes	O
were	O
detected	O
in	O
a	O
single	O
Ph	O
+	O
AL	B-malignancy-type
case	O
,	O
and	O
in	O
four	O
out	O
of	O
eight	O
CMML	B-malignancy-type
patients	O
.	O
The	O
Ph	O
+	O
AL	B-malignancy-type
showing	O
altered	O
ras	O
allele	O
had	O
an	O
unusual	O
point	O
mutation	O
in	O
H-ras	O
gene	O
,	O
substituting	O
leucine	O
for	O
glutamine	O
.	O
This	O
mutation	O
has	O
not	O
been	O
previously	O
found	O
in	O
any	O
hematological	O
disease	O
.	O
Our	O
findings	O
suggest	O
that	O
ras	O
mutations	O
are	O
probably	O
not	O
involved	O
in	O
the	O
pathogenesis	O
of	O
those	O
leukemias	B-malignancy-type
in	O
which	O
blast	O
cells	O
contain	O
bcr	O
l	O
abl	O
oncogene	O
activation	O
.	O
PMID	O
:	O
1588796	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Natl	O
Cancer	O
Inst	O
1992	O
Nov	O
4;84(	O
21	O
)	O
:1626	O
-	O
32	O
Comment	O
in	O
:	O
J	O
Natl	O
Cancer	O
Inst	O
.	O
1992	O
Nov	O
4;84(	O
21	O
)	O
:1614	O
-5	O
.	O
J	O
Natl	O
Cancer	O
Inst	O
.	O
1993	O
Jun	O
2;85(	O
11	O
)	O
:920	O
-	O
1	O
.	O
ras	O
oncogene	O
activation	O
and	O
occupational	O
exposures	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
Taylor	O
JA	O
,	O
Sandler	O
DP	O
,	O
Bloomfield	O
CD	O
,	O
Shore	O
DL	O
,	O
Ball	O
ED	O
,	O
Neubauer	O
A	O
,	O
McIntyre	O
OR	O
,	O
Liu	O
E.	O
Environmental	O
and	O
Molecular	O
Epidemiology	O
Section	O
,	O
National	O
Institute	O
of	O
Environmental	O
Health	O
Sciences	O
,	O
Research	O
Triangle	O
Park	O
,	O
N.C	O
.	O
27709	O
.	O
BACKGROUND	O
:	O
Epidemiologic	O
studies	O
of	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemias	I-malignancy-type
(	O
AMLs	B-malignancy-type
)	O
show	O
small	O
increases	O
in	O
risk	O
of	O
disease	O
associated	O
with	O
certain	O
occupations	O
and	O
chemical	O
exposures	O
.	O
PURPOSE	O
:	O
This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
the	O
presence	O
of	O
mutationally	O
activated	O
ras	O
oncogenes	O
in	O
AML	B-malignancy-type
are	O
associated	O
with	O
occupational	O
and	O
chemical	O
exposures	O
.	O
METHODS	O
:	O
We	O
interviewed	O
62	O
patients	O
with	O
newly	O
diagnosed	O
AML	B-malignancy-type
(	O
or	O
their	O
next	O
-	O
of	O
-	O
kin	O
)	O
,	O
all	O
of	O
whom	O
were	O
enrolled	O
in	O
a	O
national	O
multicenter	O
clinical	O
trial	O
,	O
and	O
630	O
healthy	O
control	O
subjects	O
.	O
DNA	O
extracted	O
from	O
patients	O
'	O
pretreatment	O
bone	O
marrow	O
samples	O
was	O
amplified	O
by	O
using	O
the	O
polymerase	O
chain	O
reaction	O
and	O
probed	O
with	O
allele	O
-	O
specific	O
oligonucleotides	O
for	O
activating	O
point	O
mutations	O
at	O
the	O
12th	O
,	O
13th	O
,	O
and	O
61st	O
codons	O
of	O
three	O
protooncogenes	O
:	O
H-ras	O
(	O
also	O
known	O
as	O
HRAS	O
)	O
,	O
K-ras	O
(	O
also	O
known	O
as	O
KRAS2	O
)	O
,	O
and	O
N-ras	O
(	O
also	O
known	O
as	O
NRAS	O
)	O
.	O
RESULTS	O
:	O
Patients	O
with	O
ras	O
mutation	O
-	O
positive	O
AML	B-malignancy-type
had	O
a	O
higher	O
frequency	O
(	O
six	O
of	O
10	O
patients	O
)	O
of	O
working	O
5	O
or	O
more	O
years	O
in	O
an	O
a	O
priori	O
high	O
-	O
risk	O
occupation	O
than	O
did	O
patients	O
with	O
ras	O
mutation	O
-	O
negative	O
AML	B-malignancy-type
(	O
eight	O
of	O
52	O
;	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
6.8	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
1.3	O
-	O
36	O
)	O
.	O
Patients	O
with	O
ras	O
mutation	O
-	O
positive	O
AML	B-malignancy-type
were	O
more	O
likely	O
than	O
patients	O
with	O
ras	O
mutation	O
-	O
negative	O
AML	B-malignancy-type
to	O
have	O
breathed	O
chemical	O
vapor	O
on	O
the	O
job	O
(	O
OR	O
=	O
9.1	O
;	O
95	O
%	O
CI	O
=	O
1.3	O
-	O
64	O
)	O
or	O
to	O
have	O
had	O
skin	O
contact	O
with	O
chemicals	O
(	O
OR	O
=	O
6.9	O
;	O
95	O
%	O
CI	O
=	O
1.3	O
-	O
37	O
)	O
.	O
When	O
ras	O
-	O
positive	O
patients	O
were	O
compared	O
with	O
healthy	O
control	O
subjects	O
,	O
the	O
ORs	O
for	O
occupation	O
and	O
occupational	O
exposures	O
remained	O
elevated	O
,	O
while	O
patients	O
with	O
ras	O
mutation	O
-	O
negative	O
AML	B-malignancy-type
showed	O
no	O
increased	O
risk	O
when	O
compared	O
with	O
control	O
subjects	O
.	O
CONCLUSION	O
:	O
Activation	O
of	O
ras	O
proto	O
-	O
oncogenes	O
may	O
identify	O
an	O
etiologic	O
subgroup	O
of	O
AML	B-malignancy-type
caused	O
by	O
occupation	O
and	O
chemical	O
exposure	O
.	O
IMPLICATION	O
:	O
Disease	O
etiology	O
may	O
be	O
better	O
understood	O
if	O
epidemiologic	O
measures	O
of	O
exposure	O
are	O
integrated	O
with	O
molecular	O
assays	O
of	O
the	O
genetic	O
defects	O
responsible	O
for	O
cancer	O
initiation	O
and	O
promotion	O
.	O
Publication	O
Types	O
:	O
Multicenter	O
Study	O
PMID	O
:	O
1433344	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Hematol	O
1992	O
Aug;56(	O
1	O
)	O
:9	O
-	O
15	O
N-RAS	O
activation	O
in	O
the	O
terminal	O
stage	O
of	O
undifferentiated	B-malignancy-type
chronic	I-malignancy-type
myeloproliferative	I-malignancy-type
disease	I-malignancy-type
.	O
Inokuchi	O
K	O
,	O
Futaki	O
M,	O
Miyake	O
K	O
,	O
Kuwabara	O
T	O
,	O
Shinohara	O
T	O
,	O
Dan	O
K	O
,	O
Nomura	O
T.	O
Third	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Nippon	O
Medical	O
School	O
,	O
Tokyo	O
,	O
Japan	O
.	O
The	O
relationship	O
between	O
activation	O
of	O
the	O
N-RAS	O
gene	O
and	O
the	O
leukemic	O
progression	O
of	O
undifferentiated	B-malignancy-type
chronic	I-malignancy-type
myeloproliferative	I-malignancy-type
disease	I-malignancy-type
(	O
UCMPD	B-malignancy-type
)	O
was	O
investigated	O
in	O
a	O
71	O
-	O
year	O
-	O
old	O
male	O
.	O
Hematologically	O
,	O
it	O
was	O
difficult	O
to	O
differentiate	O
the	O
UCMPD	B-malignancy-type
from	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
.	O
Chromosomal	O
analysis	O
revealed	O
no	O
Philadelphia	O
chromosome	O
(	O
Ph1	O
-	O
)	O
,	O
and	O
DNA	O
analysis	O
revealed	O
no	O
BCR	O
rearrangement	O
(	O
BCR	O
-	O
)	O
either	O
at	O
the	O
beginning	O
or	O
in	O
the	O
terminal	O
stages	O
of	O
the	O
disease	O
.	O
We	O
performed	O
a	O
tumorigenicity	O
assay	O
,	O
using	O
NIH3T3	O
cells	O
,	O
and	O
molecular	O
analysis	O
,	O
using	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
direct	O
sequencing	O
.	O
The	O
DNA	O
of	O
leukemic	O
cells	O
at	O
the	O
beginning	O
of	O
the	O
leukemic	O
progression	O
did	O
not	O
show	O
any	O
abnormalities	O
,	O
but	O
at	O
the	O
terminal	O
stage	O
of	O
the	O
disease	O
the	O
DNA	O
showed	O
a	O
point	O
mutation	O
in	O
codon	O
12	O
(	O
GGT	O
----	O
GCT	O
)	O
of	O
the	O
N-RAS	O
gene	O
.	O
Interestingly	O
,	O
a	O
codon	O
13	O
mutation	O
(	O
GGT	O
----	O
GTT	O
)	O
was	O
also	O
detected	O
by	O
tumorigenicity	O
assay	O
.	O
These	O
observations	O
suggest	O
that	O
the	O
activated	O
N-RAS	O
gene	O
contributes	O
to	O
the	O
hematologic	O
progression	O
of	O
UCMPD	B-malignancy-type
.	O
PMID	O
:	O
1391809	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

FEBS	O
Lett	O
.	O
1992	O
Dec	O
7;314(	O
1	O
)	O
:	O
20	O
-2.	O
Na	O
(	O
+	O
)	O
-	O
dependent	O
AIB	O
transport	O
by	O
neuroblastoma	B-malignancy-type
cells	O
.	O
del	O
Castillo-Olivares	O
A	O
,	O
Medina	O
MA.	O
Ruprecht	O
-	O
Karls	O
-Universitat	O
,	O
Heidelberg	O
,	O
Germany	O
.	O
Na	O
(	O
+	O
)	O
-	O
dependent	O
amino	O
isobutyric	O
acid	O
transport	O
by	O
two	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
with	O
and	O
without	O
amplification	O
of	O
the	O
oncogene	O
N-myc	O
is	O
studied	O
.	O
Surprisingly	O
,	O
the	O
contribution	O
of	O
system	O
A	O
is	O
greater	O
in	O
the	O
cell	O
line	O
showing	O
no	O
N-myc	O
amplification	O
.	O
Preliminary	O
data	O
support	O
a	O
role	O
for	O
essential	O
tyrosine	O
and	O
cysteine	O
residues	O
in	O
the	O
active	O
center	O
of	O
the	O
carriers	O
,	O
mainly	O
in	O
system	O
A	O
.	O
PMID	O
:	O
1451799	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurosurg	O
Sci	O
.	O
1990	O
Jan-Mar;34(	O
1	O
)	O
:	O
61	O
-3.	O
Brain	B-malignancy-type
ganglioglioma	I-malignancy-type
with	O
large	O
extension	O
to	O
subarachnoid	O
space	O
.	O
Garcia	O
Salazar	O
FJ	O
,	O
Sanchez-Alarcos	O
S	O
,	O
Gonzalez	O
R	O
,	O
Coca	O
S	O
,	O
Martinez	O
R	O
,	O
Vaquero	O
J.	O
Department	O
of	O
Neurosurgery	O
,	O
Hospital	O
General	O
Gregorio	O
Maranon	O
,	O
Madrid	O
,	O
Spain	O
.	O
A	O
case	O
of	O
temporal	B-malignancy-type
ganglioglioma	I-malignancy-type
with	O
large	O
leptomeningeal	O
growth	O
is	O
presented	O
.	O
This	O
unusual	O
spread	O
has	O
not	O
been	O
previously	O
described	O
in	O
these	B-malignancy-type
tumors	I-malignancy-type
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
2401916	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pediatr	O
Med	O
Chir	O
.	O
1983	O
Mar	O
-	O
Apr;	O
5	O
(	O
1-2	O
)	O
:	O
137	O
-	O
9.	O
[	O
Right	B-malignancy-type
temporo	I-malignancy-type
-	I-malignancy-type
occipital	I-malignancy-type
ganglioglioma	I-malignancy-type
in	O
a	O
10	O
-	O
year	O
-	O
old	O
patient	O
]	O
[	O
Article	O
in	O
Italian	O
]	O
Bruni	O
P,	O
Ierardi	O
A	O
,	O
Albrizio	O
M.	O
Authors	O
describe	O
an	O
operated	O
case	O
of	O
ganglioglioma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
right	I-malignancy-type
temporo	I-malignancy-type
-	I-malignancy-type
occipital	I-malignancy-type
region	I-malignancy-type
in	O
a	O
ten	O
year	O
old	O
patient	O
.	O
After	O
case	O
presentation	O
and	O
an	O
analysis	O
of	O
the	O
literature	O
,	O
the	O
diagnostic	O
pre	O
-	O
operative	O
problems	O
are	O
discussed	O
analysing	O
the	O
CT	O
aspects	O
of	O
the	B-malignancy-type
lesion	I-malignancy-type
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
6634436	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Pathol	O
.	O
1999	O
Aug;30(	O
8	O
)	O
:	O
887	O
-	O
90	O
.	O
Recommendations	O
for	O
reporting	O
of	O
tumors	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
adrenal	I-malignancy-type
cortex	I-malignancy-type
and	O
medulla	B-malignancy-type
.	O
Association	O
of	O
Directors	O
of	O
Anatomic	O
and	O
Surgical	O
Pathology	O
.	O
[No	O
authors	O
listed	O
]	O
The	O
Association	O
of	O
Directors	O
of	O
Anatomic	O
and	O
Surgical	O
Pathology	O
has	O
developed	O
recommendations	O
for	O
the	O
surgical	O
pathology	O
report	O
for	O
common	O
malignant	B-malignancy-type
tumors	I-malignancy-type
.	O
The	O
recommendations	O
for	O
tumors	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
adrenal	I-malignancy-type
are	O
reported	O
herein	O
.	O
Publication	O
Types	O
:	O
Guideline	O
Practice	O
Guideline	O
PMID	O
:	O
10452499	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Bull	O
Cancer	O
.	O
1997	O
Nov;8	O
4	O
(	O
11	O
)	O
:	O
1081	O
-2.	O
[	O
P73	O
:	O
a	O
kin	O
to	O
the	O
p52	O
tumor	O
suppressor	O
gene	O
]	O
[	O
Article	O
in	O
French	O
]	O
Caput	O
D.	O
Sanofi	O
Recherche	O
,	O
Labege	O
Innopole	O
.	O
A	O
gene	O
with	O
remarkable	O
sequence	O
homology	O
with	O
the	O
tumour	O
suppressor	O
gene	O
p53	O
is	O
located	O
at	O
the	O
tip	O
of	O
the	O
short	O
arm	O
of	O
human	O
chromosome	O
1	O
which	O
is	O
often	O
found	O
to	O
be	O
deleted	O
in	O
neuroblastomas	B-malignancy-type
,	O
melanomas	B-malignancy-type
and	O
breast	B-malignancy-type
cancers	I-malignancy-type
.	O
Despite	O
their	O
structural	O
and	O
functional	O
similarities	O
,	O
p53	O
and	O
p73	O
may	O
have	O
distinct	O
roles	O
in	O
cell	O
grow	O
regulation	O
.	O
PMID	O
:	O
9536991	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Physiol	O
Paris	O
.	O
1998	O
Apr;9	O
2	O
(	O
2	O
)	O
:	O
149-52	O
.	O
Regulation	O
of	O
the	O
cholinergic	O
gene	O
locus	O
.	O
Tanaka	O
H,	O
Shimojo	O
M,	O
Wu	O
D	O
,	O
Hersh	O
LB.	O
Department	O
of	O
Biochemistry	O
,	O
University	O
of	O
Kentucky	O
,	O
Lexington	O
40536	O
-0084	O
,	O
USA	O
.	O
DNase	O
I	O
hypersensitive	O
site	O
mapping	O
of	O
the	O
human	O
cholinergic	O
gene	O
locus	O
has	O
been	O
used	O
to	O
detect	O
cholinergic	O
specific	O
potential	O
regulatory	O
sites	O
.	O
Analysis	O
of	O
mutant	O
PC12	O
cell	O
lines	O
provides	O
evidence	O
that	O
protein	O
kinase	O
A	O
II	O
is	O
required	O
and	O
coordinately	O
regulates	O
basal	O
expression	O
of	O
both	O
the	O
ChAT	O
and	O
VAChT	O
genes	O
.	O
PMID	O
:	O
9782460	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

S	O
Afr	O
Med	O
J.	O
1975	O
Mar	O
8;49(	O
10	O
)	O
:	O
358-60	O
.	O
The	O
treatment	O
of	O
neuroblastoma	B-malignancy-type
.	O
Spitz	O
L,	O
Dinner	O
M.	O
A	O
protocol	O
for	O
the	O
management	O
of	O
children	O
with	O
neuroblastoma	B-malignancy-type
is	O
described	O
.	O
The	O
appearance	O
of	O
peri	O
-	O
orbital	O
ecchymosis	O
and	O
radiologically	O
demonstrable	O
skeletal	B-malignancy-type
metastases	I-malignancy-type
are	O
of	O
poor	O
prognostic	O
significance	O
.	O
The	O
relatively	O
infrequent	O
occurrence	O
of	O
neuroblastoma	B-malignancy-type
in	O
the	O
Black	O
population	O
of	O
Johannesburg	O
is	O
stressed	O
.	O
PMID	O
:	O
1114394	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pediatr	O
Radiol	O
.	O
1988	O
;18	O
(	O
5	O
)	O
:	O
406	O
.	O
Cystic	O
neuroblastoma	B-malignancy-type
with	O
colonic	O
fistula	O
.	O
Thajunnisa	O
bte	O
Hassan	O
Mohd	O
,	O
Yip	O
CH.	O
Departments	O
of	O
Radiology	O
,	O
University	O
Hospital	O
,	O
Kuala	O
Lumpur	O
,	O
Malaysia	O
.	O
Neuroblastoma	B-malignancy-type
is	O
the	O
most	O
common	O
malignant	O
tumour	O
in	O
infancy	O
originating	O
in	O
about	O
70	O
%	O
of	O
cases	O
in	O
the	O
adrenal	O
gland	O
.	O
Haemorrhage	O
and	O
necrosis	O
is	O
often	O
seen	O
in	O
neuroblastoma	B-malignancy-type
but	O
cyst	O
formation	O
is	O
uncommon	O
.	O
Fistulous	O
communication	O
between	O
an	O
adrenal	B-malignancy-type
cystic	I-malignancy-type
neuroblastoma	I-malignancy-type
and	O
the	O
large	O
bowel	O
has	O
never	O
to	O
our	O
knowledge	O
been	O
reported	O
before	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
3050845	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Bull	O
Cancer	O
.	O
1988;75	O
(	O
1	O
)	O
:	O
87	O
-	O
90	O
.	O
[	O
Prognostic	O
value	O
of	O
the	O
N-myc	O
oncogene	O
in	O
neuroblastoma	B-malignancy-type
]	O
[	O
Article	O
in	O
French	O
]	O
Benard	O
J.	O
Laboratoire	O
de	O
pharmacologie	O
clinique	O
et	O
moleculaire	O
,	O
Institut	O
Gustave-Roussy	O
,	O
Villejuif	O
,	O
France	O
.	O
Activation	O
of	O
cellular	O
proto	O
-	O
oncogenes	O
can	O
be	O
detected	O
in	O
several	O
human	O
cancers	O
.	O
In	O
neuroblastoma	B-malignancy-type
,	O
amplification	O
and	O
overexpression	O
of	O
N-myc	O
oncogene	O
have	O
been	O
shown	O
to	O
be	O
associated	O
with	O
advanced	O
stages	O
of	O
disease	O
and	O
rapid	O
tumor	B-malignancy-type
progression	O
.	O
These	O
results	O
suggest	O
the	O
clinical	O
importance	O
of	O
the	O
N-myc	O
oncogene	O
.	O
Other	O
oncogenes	O
might	O
also	O
be	O
activated	O
in	O
this	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
3162815	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pediatr	O
.	O
1978	O
Aug;9	O
3	O
(	O
2	O
)	O
:	O
18	O
5	O
-7.	O
The	O
course	O
of	O
five	O
-	O
year	O
survivors	O
of	O
cancer	O
in	O
childhood	O
.	O
Li	O
FP	O
,	O
Myers	O
MH	O
,	O
Heise	O
HW	O
,	O
Jaffe	O
N	O
.	O
A	O
follow	O
-	O
up	O
study	O
was	O
made	O
of	O
two	O
independent	O
series	O
of	O
1,807	O
and	O
425	O
children	O
who	O
were	O
alive	O
five	O
years	O
after	O
diagnosis	O
of	O
a	O
malignant	B-malignancy-type
neoplasm	I-malignancy-type
.	O
Over	O
the	O
subsequent	O
20	O
years	O
(	O
5	O
to	O
24	O
years	O
after	O
initial	O
diagnosis	O
)	O
,	O
actuarial	O
survival	O
rates	O
for	O
the	O
cohorts	O
were	O
83	O
%	O
and	O
79	O
%	O
,	O
respectively	O
,	O
compared	O
to	O
97	O
%	O
for	O
matched	O
control	O
subjects	O
in	O
the	O
general	O
population	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O
Cure	O
was	O
achieved	O
in	O
a	O
large	O
majority	O
of	O
the	O
5	O
-	O
year	O
relapse	O
-	O
free	O
survivors	O
of	O
cancer	O
in	O
this	O
study	O
.	O
PMID	O
:	O
209161	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Curr	O
Biol	O
.	O
1998	O
Jan	O
29;	O
8	O
(	O
3	O
)	O
:R80	O
-2.	O
Axon	O
guidance	O
:	O
GTPases	O
help	O
axons	O
reach	O
their	O
targets	O
.	O
Gallo	O
G	O
,	O
Letourneau	O
PC	O
.	O
Department	O
of	O
Cell	O
Biology	O
and	O
Neuroanatomy	O
,	O
4-144	O
Jackson	O
Hall	O
,	O
The	O
University	O
of	O
Minnesota	O
,	O
Minneapolis	O
,	O
Minnesota	O
55455	O
,	O
USA	O
.	O
During	O
development	O
and	O
regeneration	O
of	O
the	O
nervous	O
system	O
,	O
axons	O
must	O
correctly	O
navigate	O
to	O
their	O
specific	O
targets	O
through	O
a	O
complex	O
molecular	O
environment	O
.	O
Recent	O
work	O
has	O
shed	O
light	O
on	O
how	O
GTPases	O
of	O
the	O
Ras	O
family	O
are	O
involved	O
in	O
transducing	O
extracellular	O
signals	O
into	O
responses	O
that	O
lead	O
to	O
directed	O
neurite	O
outgrowth	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
9443904	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Genet	O
Couns	O
.	O
1994	O
;	O
5	O
(	O
3	O
)	O
:	O
303	O
-5	O
.	O
Neurocristopathy	B-malignancy-type
in	O
mother	O
(	O
ganglioneuroblastoma	B-malignancy-type
)	O
and	O
daughter	O
(	O
aganglionosis	B-malignancy-type
)	O
:	O
incidental	O
or	O
causal	O
?	O
Hamel	O
CJ	O
,	O
Severijnen	O
RS	O
,	O
De	O
Vaan	O
GA.	O
Department	O
of	O
Human	O
Genetics	O
,	O
Center	O
S.E.	O
Netherlands	O
,	O
University	O
Hospital	O
Nijmegen	O
.	O
We	O
report	O
on	O
a	O
mother	O
who	O
had	O
been	O
treated	O
for	O
a	O
ganglioneuroblastoma	B-malignancy-type
and	O
her	O
daughter	O
who	O
had	O
a	O
long	B-malignancy-type
segment	I-malignancy-type
aganglionosis	I-malignancy-type
.	O
Review	O
of	O
the	O
relevant	O
literature	O
and	O
recent	O
molecular	O
findings	O
warrant	O
the	O
conclusion	O
that	O
most	O
likely	O
,	O
there	O
is	O
a	O
causal	O
relation	O
between	O
these	O
two	O
neurocristopathies	B-malignancy-type
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
7811432	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Science	O
.	O
1976	O
Jun	O
4;19	O
2	O
(	O
4243	O
)	O
:	O
1018	O
-20	O
.	O
Monoamine	O
oxidase	O
activity	O
decreased	O
in	O
cells	O
lacking	O
hypoxanthine	O
phosphoribosyltransferase	O
activity	O
.	O
Breakefield	O
XO	O
,	O
Castiglione	O
CM	O
,	O
Edelstein	O
SB	O
.	O
The	O
Lesch	B-malignancy-type
-	I-malignancy-type
Nyhan	I-malignancy-type
syndrome	I-malignancy-type
in	O
humans	O
is	O
characterized	O
by	O
lack	O
of	O
hypoxanthine	O
phosphoribosyltransferase	O
activity	O
and	O
neurologic	O
abnormalities	O
that	O
suggest	O
changes	O
in	O
catecholamine	O
metabolism	O
.	O
Monoamine	O
oxidase	O
,	O
which	O
degrades	O
biogenic	O
amines	O
,	O
has	O
decreased	O
activity	O
in	O
noradrenergic	O
murine	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
lacking	O
hypoxanthine	O
phosphoribosyltransferase	O
activity	O
and	O
in	O
skin	O
fibroblasts	O
from	O
patients	O
with	O
the	O
Lesch	B-malignancy-type
-	I-malignancy-type
Nyhan	I-malignancy-type
syndrome	I-malignancy-type
.	O
PMID	O
:	O
1273584	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

C	O
R	O
Seances	O
Soc	O
Biol	O
Fil	O
.	O
1976	O
;170	O
(	O
1	O
)	O
:	O
183	O
-	O
7.	O
[	O
Guanyl	O
cyclase	O
activities	O
in	O
clonal	O
lines	O
of	O
cultured	O
astroblasts	O
and	O
neuroblasts	O
]	O
[	O
Article	O
in	O
French	O
]	O
Zwiller	O
J,	O
Ciesielski	O
-	O
Treska	O
J,	O
Mandel	O
P.	O
Guanylate	O
cyclase	O
was	O
found	O
to	O
be	O
present	O
in	O
a	O
number	O
of	O
astroblast	O
and	O
neuroblast	O
clones	O
.	O
No	O
correlations	O
were	O
observed	O
between	O
the	O
enzyme	O
activity	O
and	O
the	O
nature	O
of	O
the	O
clone	O
.	O
The	O
enzyme	O
shows	O
a	O
requirement	O
for	O
manganese	O
ions	O
and	O
is	O
stimulated	O
by	O
calcium	O
.	O
When	O
the	O
astroblast	O
clone	O
NN	O
is	O
cultured	O
together	O
with	O
the	O
neuroblast	O
clone	O
M1	O
for	O
two	O
months	O
and	O
the	O
astroblast	O
cells	O
again	O
isolated	O
,	O
a	O
reduced	O
guanylate	O
cyclase	O
activity	O
was	O
found	O
.	O
PMID	O
:	O
9182	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
Mol	O
Brain	O
Res	O
.	O
1997	O
Dec	O
15	O
;52(	O
2	O
)	O
:	O
323	O
-5	O
.	O
DNA	O
regions	O
supporting	O
hippocalcin	O
gene	O
expression	O
in	O
cell	O
lines	O
.	O
Grant	O
AL	O
,	O
Wisden	O
W	O
.	O
MRC	O
Laboratory	O
of	O
Molecular	O
Biology	O
,	O
MRC	O
Centre	O
,	O
Cambridge	O
,	O
UK.	O
The	O
rat	O
hippocalcin	O
gene	O
-	O
3.2	O
to	O
+	O
0.6	O
kb	O
region	O
activates	O
reporter	O
gene	O
expression	O
in	O
the	O
NG108-15	O
and	O
PC12	O
neuronal	O
cell	O
lines	O
,	O
but	O
not	O
in	O
NIH3T3	O
or	O
HEK-293	O
cells	O
.	O
Three	O
fragments	O
(	O
-	O
3.2	O
to	O
-	O
2.6	O
,	O
-	O
2.6	O
to	O
-	O
2.3	O
and	O
-	O
2.3	O
to	O
-	O
1.8	O
kb	O
)	O
weakly	O
activate	O
transcription	O
,	O
and	O
"	O
-	O
1.8	O
to	O
-	O
1.5	O
"	O
kb	O
is	O
a	O
strong	O
activator	O
.	O
Thus	O
cell	O
type	O
-	O
specific	O
expression	O
of	O
the	O
rat	O
hippocalcin	O
gene	O
is	O
regulated	O
by	O
distributed	O
elements	O
in	O
the	O
-	O
3.2	O
to	O
-	O
1.5	O
kb	O
region	O
.	O
PMID	O
:	O
9495555	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gan	O
To	O
Kagaku	O
Ryoho	O
.	O
1987	O
Jan;14(	O
1	O
)	O
:	O
44	O
-	O
9.	O
[	O
Neuroblastoma	B-malignancy-type
;	O
biology	O
and	O
prognostic	O
factors	O
]	O
[	O
Article	O
in	O
Japanese	O
]	O
Shimada	O
H,	O
Aotama	O
C	O
,	O
Newton	O
WA	O
Jr	O
.	O
Recently	O
accumulated	O
data	O
on	O
the	O
biology	O
of	O
the	O
tumors	O
of	O
neuroblastoma	B-malignancy-type
group	O
are	O
reviewed	O
.	O
Histopathological	O
classification	O
system	O
developed	O
by	O
Shimada	O
et	O
al	O
,	O
elevated	O
levels	O
of	O
serum	O
neuron	O
-	O
specific	O
enolase	O
and	O
ferritin	O
,	O
and	O
gene	O
abnormalities	O
including	O
partial	O
deletion	O
of	O
the	O
short	O
arm	O
of	O
chromosome	O
#	O
1	O
and	O
N-myc	O
gene	O
amplification	O
are	O
discussed	O
as	O
well	O
as	O
their	O
prognostic	O
significance	O
.	O
Also	O
,	O
the	O
current	O
activities	O
of	O
CCSG	O
(	O
Childrens	O
Cancer	O
Study	O
Group	O
)	O
neuroblastoma	B-malignancy-type
studies	O
are	O
briefly	O
reported	O
.	O
PMID	O
:	O
3800408	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cytogenet	O
Cell	O
Genet	O
.	O
1996	O
;72(	O
2-3	O
)	O
:	O
189	O
-	O
90	O
.	O
Reassignment	O
of	O
MYCL1	O
to	O
human	O
chromosome	O
1p34.3	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O
Speleman	O
F	O
,	O
Van	O
Camp	O
G	O
,	O
Van	O
Roy	O
N	O
.	O
Department	O
of	O
Medical	O
Genetics	O
,	O
University	O
Hospital	O
,	O
Gent	O
,	O
Belgium	O
.	O
MYCL1	O
has	O
been	O
previously	O
mapped	O
to	O
1p32	O
.	O
This	O
position	O
was	O
in	O
contradiction	O
with	O
our	O
mapping	O
data	O
of	O
1p	O
deletions	O
in	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Using	O
FISH	O
on	O
high	O
resolution	O
R	O
-	O
banded	O
chromosomes	O
with	O
a	O
YAC	O
clone	O
for	O
MYCL1	O
we	O
were	O
able	O
to	O
reassign	O
the	O
gene	O
to	O
subband	O
1p34.3	O
.	O
This	O
new	O
map	O
position	O
is	O
of	O
importance	O
for	O
the	O
establishment	O
of	O
an	O
integrated	O
map	O
for	O
chromosome	O
1	O
and	O
the	O
search	O
for	O
disease	O
genes	O
in	O
this	O
region	O
.	O
PMID	O
:	O
8978772	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Science	O
.	O
1981	O
Oct	O
23;214(4519	O
)	O
:468	O
-	O
9.	O
Multiple	O
opiate	O
receptors	O
:	O
alcohol	O
selectively	O
inhibits	O
binding	O
to	O
delta	O
receptors	O
.	O
Hiller	O
JM	O
,	O
Angel	O
LM	O
,	O
Simon	O
EJ.	O
The	O
addition	O
of	O
ethanol	O
or	O
other	O
aliphatic	O
alcohols	O
to	O
rat	O
brain	O
membranes	O
strongly	O
inhibits	O
binding	O
of	O
enkephalins	O
at	O
concentrations	O
at	O
which	O
little	O
inhibition	O
of	O
opiate	O
alkaloids	O
is	O
seen	O
.	O
Inhibition	O
is	O
reversible	O
,	O
and	O
potency	O
increases	O
with	O
chain	O
length	O
of	O
the	O
alcohol	O
.	O
The	O
results	O
suggest	O
that	O
delta	O
receptors	O
are	O
considerably	O
more	O
sensitive	O
to	O
alcohols	O
than	O
mu	O
receptors	O
.	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
selective	O
inhibition	O
of	O
one	O
of	O
the	O
postulated	O
classes	O
of	O
opiate	O
receptors	O
by	O
a	O
reagent	O
that	O
is	O
not	O
a	O
ligand	O
for	O
the	O
receptor	O
.	O
PMID	O
:	O
6270788	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nurs	O
Clin	O
North	O
Am	O
.	O
1994	O
Dec;29(	O
4	O
)	O
:	O
58	O
5	O
-98	O
.	O
Solid	O
tumors	O
in	O
children	O
.	O
Nemes	O
J,	O
Donahue	O
MC	O
.	O
Department	O
of	O
Surgery	O
,	O
Children	O
's	O
Hospital	O
,	O
Boston	O
,	O
Massachusetts	O
.	O
A	O
thorough	O
understanding	O
of	O
the	O
incidence	O
,	O
clinical	O
presentation	O
,	O
treatment	O
,	O
prognosis	O
,	O
and	O
psychosocial	O
issues	O
surrounding	O
children	O
with	O
solid	O
tumors	O
enables	O
the	O
nurse	O
to	O
actively	O
participate	O
on	O
the	O
health	O
care	O
team	O
.	O
Although	O
significant	O
advances	O
over	O
the	O
past	O
two-and-a-half	O
decades	O
to	O
improve	O
the	O
outcomes	O
of	O
children	O
with	O
cancer	O
have	O
occurred	O
,	O
there	O
remains	O
room	O
for	O
continued	O
improvement	O
,	O
especially	O
among	O
children	O
with	O
advanced	O
-	O
stage	O
nephroblastoma	B-malignancy-type
,	O
neuroblastoma	B-malignancy-type
,	O
HCC	B-malignancy-type
,	O
and	O
teratoma	B-malignancy-type
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
7527519	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Arkh	O
Patol	O
.	O
1979	O
;41(	O
9	O
)	O
:60	O
-	O
6.	O
[	O
Neuroblastoma	B-malignancy-type
]	O
[	O
Article	O
in	O
Russian	O
]	O
Karseladze	O
AI.	O
The	O
review	O
deals	O
with	O
neuroblastoma	B-malignancy-type
,	O
its	O
frequency	O
,	O
localization	O
,	O
features	O
of	O
its	O
clinical	O
course	O
and	O
microscopic	O
patterns	O
.	O
The	O
ability	O
of	O
neuroblastoma	B-malignancy-type
for	O
maturation	O
and	O
sometimes	O
for	O
spontaneous	O
regression	O
as	O
well	O
as	O
the	O
relationship	O
between	O
tumors	O
of	O
the	O
autonomous	O
nervous	O
system	O
and	O
the	O
so	O
-	O
called	O
neuroblastoma	B-malignancy-type
in	O
situ	O
and	O
von	B-malignancy-type
Recklinghausen	I-malignancy-type
's	I-malignancy-type
disease	I-malignancy-type
are	O
discussed	O
.	O
Some	O
light	O
and	O
electron	O
microscope	O
differential	O
diagnostic	O
criteria	O
are	O
given	O
.	O
An	O
attempt	O
is	O
made	O
to	O
explain	O
certain	O
clinico	O
-	O
biological	O
features	O
of	O
neuroblastoma	B-malignancy-type
from	O
the	O
point	O
of	O
view	O
of	O
current	O
embryological	O
data	O
.	O
Publication	O
Types	O
:	O
Review	O
PMID	O
:	O
115446	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Ann	O
N	O
Y	O
Acad	O
Sci	O
.	O
2002	O
Nov;973	O
:70	O
-4.	O
Signaling	O
pathways	O
mediate	O
the	O
neuroprotective	O
effects	O
of	O
GDNF	O
.	O
Neff	O
F	O
,	O
Noelker	O
C	O
,	O
Eggert	O
K,	O
Schlegel	O
J.	O
Division	O
of	O
Neuropathology	O
,	O
Institute	O
of	O
Pathology	O
,	O
Munich	O
Technical	O
University	O
,	O
Munich	O
,	O
Germany	O
.	O
neff@neuropathologie	O
-	O
muenchen	O
.de	O
We	O
show	O
that	O
the	O
glial	O
cell	O
line	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
GDNF	O
)	O
activates	O
the	O
PI3K	O
/	O
Akt	O
-	O
signaling	O
pathway	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
that	O
express	O
functional	O
Ret	O
-	O
receptor	O
complexes	O
.	O
Consistent	O
with	O
this	O
finding	O
we	O
show	O
PI3K	O
-	O
dependent	O
Bad	O
-	O
inactivation	O
by	O
binding	O
to	O
14-3-3	O
proteins	O
in	O
response	O
to	O
GDNF	O
.	O
Using	O
differential	O
display	O
techniques	O
we	O
detected	O
several	O
cDNA	O
clones	O
differentially	O
expressed	O
after	O
treatment	O
with	O
GDNF	O
or	O
6-OHDA	O
.	O
PMID	O
:	O
12485836	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Med	O
Genet	O
.	O
1990	O
Feb;27	O
(	O
2	O
)	O
:	O
130	O
-2.	O
Neuroblastoma	B-malignancy-type
in	O
a	O
patient	O
with	O
Sotos	O
'	O
syndrome	O
.	O
Nance	O
MA	O
,	O
Neglia	O
JP	O
,	O
Talwar	O
D	O
,	O
Berry	O
SA	O
.	O
Department	O
of	O
Pediatrics	O
,	O
University	O
of	O
Minnesota	O
,	O
Minneapolis	O
55455	O
.	O
Sotos	O
'	O
syndrome	O
,	O
or	O
cerebral	O
gigantism	O
,	O
is	O
a	O
disorder	O
of	O
growth	O
regulation	O
.	O
Tumours	O
have	O
occasionally	O
been	O
reported	O
in	O
children	O
with	O
Sotos	O
'	O
syndrome	O
,	O
but	O
it	O
is	O
uncertain	O
whether	O
this	O
is	O
a	O
coincidence	O
,	O
or	O
whether	O
it	O
is	O
aetiologically	O
related	O
to	O
the	O
underlying	O
disorder	O
of	O
growth	O
.	O
We	O
report	O
a	O
15	O
month	O
old	O
child	O
with	O
a	O
paraspinal	B-malignancy-type
neuroblastoma	I-malignancy-type
and	O
Sotos	O
'	O
syndrome	O
and	O
suggest	O
that	O
children	O
with	O
this	O
condition	O
may	O
be	O
at	O
higher	O
risk	O
for	O
developing	O
tumours	O
than	O
the	O
general	O
population	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
2319581	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Vopr	O
Onkol	O
.	O
1997;43(	O
4	O
)	O
:439	O
-	O
42	O
.	O
[	O
Clinical	O
problems	O
of	O
radiotherapy	O
in	O
pediatric	O
oncology	O
]	O
[	O
Article	O
in	O
Russian	O
]	O
Goldobenko	O
GV	O
,	O
Durnov	O
LA	O
,	O
Kanaev	O
SV	O
.	O
The	O
main	O
principles	O
of	O
radiation	O
therapy	O
as	O
well	O
as	O
the	O
role	O
of	O
ratio	O
Integral	O
Dose	O
/	O
Total	O
Dose	O
in	O
radiation	O
treatment	O
of	O
malignant	O
tumors	O
in	O
children	O
are	O
considered	O
.	O
Indications	O
for	O
radiation	O
therapy	O
of	O
nephroblastomas	B-malignancy-type
and	O
peculiarities	O
of	O
radiation	O
treatment	O
of	O
haemangiomas	B-malignancy-type
are	O
described	O
.	O
Expedience	O
is	O
proved	O
of	O
radiation	O
of	O
only	O
the	O
liver	O
part	O
affected	O
by	O
neuroblastoma	B-malignancy-type
.	O
Tactics	O
of	O
radiation	O
therapy	O
of	O
eosinophilic	B-malignancy-type
granuloma	I-malignancy-type
of	I-malignancy-type
bones	I-malignancy-type
in	O
analyzed	O
.	O
Possibility	O
of	O
conservative	O
therapy	O
including	O
radiation	O
component	O
in	O
treatment	O
of	O
retinoblastoma	B-malignancy-type
in	O
children	O
is	O
discussed	O
.	O
PMID	O
:	O
9381700	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochimie	O
.	O
1994;76	O
(	O
3-	O
4)	O
:315	O
-	O
9.	O
Heterologous	O
biosynthesis	O
and	O
processing	O
of	O
preprovasopressin	O
in	O
Neuro2A	B-malignancy-type
neuroblastoma	I-malignancy-type
cells	O
.	O
de	O
Bree	O
FM	O
,	O
Burbach	O
JP	O
.	O
Rudolf	O
Magnus	O
Institute	O
,	O
Utrecht	O
University	O
,	O
Stratenum	O
,	O
The	O
Netherlands	O
.	O
To	O
obtain	O
a	O
model	O
for	O
the	O
sorting	O
and	O
processing	O
of	O
preprovasopressin	O
(	O
preproVP	O
)	O
,	O
rat	O
VP	O
cDNA	O
was	O
transfected	O
in	O
murine	O
Neuro2A	B-malignancy-type
neuroblastoma	I-malignancy-type
cells	O
,	O
which	O
do	O
not	O
express	O
VP	O
.	O
The	O
precursor	O
of	O
VP	O
was	O
expressed	O
and	O
processed	O
into	O
the	O
authentic	O
VP	O
gene	O
products	O
VP	O
,	O
neurophysin	O
(	O
NP	O
)	O
and	O
glycopeptide	O
(	O
GP	O
)	O
as	O
determined	O
with	O
reversed	O
phase	O
HPLC	O
and	O
radioimmunoassay	O
.	O
In	O
addition	O
,	O
Neuro2A	O
-	O
specific	O
forms	O
of	O
NP	O
and	O
GP	O
were	O
observed	O
,	O
which	O
may	O
be	O
produced	O
in	O
the	O
constitutive	O
secretory	O
pathway	O
in	O
these	O
cells	O
.	O
PMID	O
:	O
7819342	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neurochem	O
Res	O
.	O
1979	O
Dec;	O
4	O
(	O
6	O
)	O
:	O
795-802	O
.	O
Phosphorus	O
31	O
NMR	O
of	O
neuroblastoma	B-malignancy-type
clonal	O
lines	O
.	O
Effect	O
of	O
cell	O
confluency	O
state	O
and	O
dibutyryl	O
cyclic	O
AMP	O
.	O
Pettegrew	O
JW	O
,	O
Glonek	O
T	O
,	O
Baskin	O
F	O
,	O
Rosenberg	O
RN	O
.	O
Phosphorus	O
nuclear	O
magnetic	O
resonance	O
is	O
used	O
to	O
study	O
changes	O
in	O
the	O
levels	O
of	O
the	O
major	O
phosphate	O
-	O
containing	O
intermediary	O
metabolites	O
concomitant	O
with	O
induced	O
cellular	O
differentiation	O
in	O
the	O
N-18	O
and	O
C-46	O
neuroblastoma	B-malignancy-type
clonal	O
lines	O
.	O
The	O
study	O
reveals	O
differences	O
between	O
the	O
31P	O
-	O
NMR	O
profiles	O
of	O
the	O
two	O
clonal	O
lines	O
and	O
also	O
striking	O
differences	O
attendant	O
to	O
dibutyryl	O
cAMP	O
-	O
mediated	O
morphological	O
differentiation	O
in	O
the	O
N-18	O
clone	O
.	O
Phosphorus	O
-	O
31	O
NMR	O
would	O
appear	O
to	O
provide	O
a	O
new	O
technique	O
with	O
which	O
to	O
study	O
genetic	O
differentiation	O
.	O
PMID	O
:	O
232546	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochim	O
Biophys	O
Acta	O
.	O
1978	O
May	O
4	O
;	O
509	O
(	O
1	O
)	O
:	O
188-93	O
.	O
Microviscosity	O
changes	O
during	O
differentiation	O
of	O
neuroblastoma	B-malignancy-type
cells	I-malignancy-type
.	O
de	O
Laat	O
SW	O
,	O
van	O
der	O
Saag	O
PT	O
,	O
Nelemans	O
SA	O
,	O
Shinitzky	O
M	O
.	O
Microviscosity	O
(	O
eta	O
)	O
of	O
the	O
plasma	O
-	O
membrane	O
lipid	O
matrix	O
was	O
measured	O
in	O
exponentially	O
growing	O
and	O
differentiating	O
C1300	O
mouse	O
neuroblastoma	B-malignancy-type
cells	I-malignancy-type
,	O
attached	O
to	O
a	O
glass	O
substratum	O
,	O
by	O
fluorescence	O
polarisation	O
of	O
1,6-diphenyl-1,3,5-hexatriene	O
.	O
Upon	O
differentiation	O
eta	O
decreases	O
progressively	O
,	O
reaching	O
values	O
below	O
those	O
observed	O
in	O
the	O
growth	O
phase	O
.	O
Treatment	O
of	O
the	B-malignancy-type
cells	I-malignancy-type
with	O
dipalmitoyl	O
phosphatidylcholine	O
vesicles	O
reversibly	O
inhibits	O
morphological	O
differentiation	O
.	O
The	O
results	O
show	O
that	O
a	O
high	O
membrane	O
fluidity	O
is	O
a	O
prerequisite	O
for	O
differentiation	O
.	O
PMID	O
:	O
348237	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Ann	O
N	O
Y	O
Acad	O
Sci	O
.	O
2002	O
Jun	O
;	O
963	O
:	O
63-73	O
.	O
Amplified	O
MYCN	O
in	O
human	O
neuroblastoma	B-malignancy-type
:	O
paradigm	O
for	O
the	O
translation	O
of	O
molecular	O
genetics	O
to	O
clinical	O
oncology	O
.	O
Schwab	O
M	O
.	O
Division	O
of	O
Cytogenetics	O
,	O
Deutsches	O
Krebsforschungszentrum	O
,	O
Im	O
Neuenheimer	O
Feld	O
280	O
,	O
D-69120	O
Heidelberg	O
,	O
Germany	O
.	O
m.schwab@dkfz.de	O
Increase	O
in	O
the	O
dosage	O
of	O
cellular	O
oncogenes	O
by	O
DNA	O
amplification	O
is	O
a	O
frequent	O
genetic	O
alteration	O
of	O
cancer	O
cells	O
.	O
In	O
neuroblastoma	B-malignancy-type
,	O
amplification	O
of	O
the	O
gene	O
MYCN	O
has	O
been	O
associated	O
with	O
aggressively	O
growing	O
cancers	O
and	O
is	O
an	O
indicator	O
for	O
poor	O
prognosis	O
.	O
MYCN	O
amplification	O
is	O
of	O
predictive	O
value	O
in	O
identifying	O
patients	O
with	O
neuroblastoma	B-malignancy-type
who	O
require	O
specific	O
therapeutic	O
regimens	O
and	O
those	O
who	O
do	O
not	O
benefit	O
from	O
chemotherapy	O
.	O
PMID	O
:	O
12095930	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Clin	O
Oncol	O
.	O
1985	O
Jan	O
;	O
3	O
(	O
1	O
)	O
:	O
117-20	O
.	O
Synchronous	O
neuroblastoma	B-malignancy-type
and	O
von	B-malignancy-type
Recklinghausen	I-malignancy-type
's	I-malignancy-type
disease	I-malignancy-type
:	O
a	O
review	O
of	O
the	O
literature	O
.	O
Kushner	O
BH	O
,	O
Hajdu	O
SI	O
,	O
Helson	O
L	O
.	O
We	O
report	O
an	O
unusual	O
case	O
of	O
progressive	O
disseminated	O
neuroblastoma	B-malignancy-type
occurring	O
in	O
a	O
child	O
with	O
a	O
family	O
history	O
and	O
stigmata	O
of	O
von	B-malignancy-type
Recklinghausen	I-malignancy-type
's	I-malignancy-type
disease	I-malignancy-type
.	O
A	O
review	O
of	O
the	O
literature	O
confirms	O
the	O
extreme	O
rarity	O
of	O
finding	O
these	O
two	O
neurocristopathies	O
in	O
a	O
single	O
individual	O
and	O
thus	O
undermines	O
the	O
widely	O
held	O
notion	O
of	O
an	O
association	O
--	O
genetic	O
or	O
otherwise	O
--	O
between	O
these	O
two	O
entities	O
.	O
We	O
propose	O
that	O
synchronous	O
neuroblastoma	B-malignancy-type
and	O
von	B-malignancy-type
Recklinghausen	I-malignancy-type
's	I-malignancy-type
disease	I-malignancy-type
is	O
accounted	O
for	O
by	O
chance	O
alone	O
and	O
therefore	O
represents	O
a	O
randomly	O
occurring	O
phenomenon	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
3917492	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Arch	O
Surg	O
.	O
1981	O
Apr	O
;	O
116	O
(	O
4	O
)	O
:	O
474-5	O
.	O
Recurrence	O
of	O
neuroblastoma	B-malignancy-type
following	O
prolonged	O
remission	O
.	O
Sutherland	O
CM	O
,	O
Krementz	O
ET	O
,	O
Harkin	O
JC	O
,	O
Culotta	O
V	O
Jr	O
.	O
A	O
6	O
-	O
year	O
-	O
old	O
girl	O
with	O
unresectable	O
and	O
metastatic	O
neuroblastoma	B-malignancy-type
had	O
a	O
complete	O
remission	O
with	O
irradiation	O
to	O
the	O
primary	O
tumor	O
and	O
systemic	O
administration	O
of	O
cyclophosphamide	O
.	O
The	O
patient	O
was	O
disease	O
-	O
free	O
for	O
16	O
years	O
but	O
had	O
an	O
explosive	O
recurrence	O
of	O
tumor	O
six	O
weeks	O
after	O
a	O
hysterectomy	O
.	O
Although	O
no	O
clear	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
exists	O
between	O
the	O
surgery	O
and	O
the	O
recurrence	O
,	O
this	O
case	O
illustrates	O
that	O
a	O
recurrence	O
is	O
possible	O
after	O
a	O
long	O
disease	O
-	O
free	O
interval	O
.	O
Diagnostic	O
and	O
therapeutic	O
procedures	O
in	O
such	O
patients	O
should	O
be	O
undertaken	O
with	O
caution	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
7213005	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Proc	O
Natl	O
Acad	O
Sci	O
U_S_A	O
.	O
1975	O
Jun	O
;	O
72	O
(	O
6	O
)	O
:	O
2289-93	O
.	O
Regulation	O
of	O
protein	O
synthesis	O
at	O
the	O
translational	O
level	O
in	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Zucco	O
F	O
,	O
Persico	O
M	O
,	O
Felsani	O
A	O
,	O
Metafora	O
S	O
,	O
Augusti-Tocco	O
G	O
.	O
Protein	O
synthesis	O
in	O
reuroblastoma	B-malignancy-type
cells	O
has	O
been	O
studied	O
in	O
a	O
cell	O
-	O
free	O
system	O
.	O
The	O
activity	O
of	O
lysates	O
from	O
cells	O
grown	O
in	O
suspension	O
and	O
monolayer	O
has	O
been	O
compared	O
.	O
A	O
higher	O
level	O
of	O
activity	O
has	O
been	O
found	O
in	O
monolayer	O
cells	O
.	O
The	O
activity	O
of	O
some	O
components	O
of	O
the	O
lysate	O
that	O
are	O
involved	O
in	O
protein	O
synthesis	O
has	O
been	O
analyzed	O
.	O
The	O
data	O
suggest	O
that	O
the	O
controlling	O
step	O
of	O
protein	O
synthesis	O
in	O
this	O
system	O
might	O
be	O
in	O
the	O
initiation	O
process	O
.	O
The	O
correlation	O
between	O
activation	O
of	O
protein	O
synthesis	O
and	O
neurite	O
outgrowth	O
in	O
monolayer	O
cultures	O
is	O
discussed	O
.	O
PMID	O
:	O
1056031	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Nagoya	O
J	O
Med	O
Sci	O
.	O
1995	O
Mar	O
;	O
58	O
(	O
1-2	O
)	O
:	O
29-33	O
.	O
Three	O
types	O
of	O
voltage	O
-	O
dependent	O
calcium	O
currents	O
in	O
cultured	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Kito	O
M	O
,	O
Maehara	O
M	O
,	O
Watanabe	O
K	O
.	O
Department	O
of	O
Pediatrics	O
,	O
Chubu	O
Rosai	O
Hospital	O
,	O
Nagoya	O
,	O
Japan	O
.	O
The	O
voltage	O
-	O
dependent	O
calcium	O
current	O
(	O
ICa	O
)	O
in	O
cultured	O
human	O
neuroblastoma	B-malignancy-type
cells	O
(	O
NB-I	O
)	O
was	O
studied	O
by	O
whole	O
-	O
cell	O
recording	O
.	O
The	O
low	O
-	O
threshold	O
current	O
(	O
Il	O
)	O
,	O
the	O
high	O
-	O
threshold	O
,	O
fast	O
inactivating	O
current	O
(	O
Ih.f.	O
)	O
,	O
and	O
the	O
high	O
-	O
threshold	O
,	O
slow	O
inactivating	O
current	O
(	O
Ih.s.	O
)	O
were	O
identified	O
.	O
Il.	O
was	O
blocked	O
by	O
Ni2	O
+	O
.	O
Ih.f.	O
was	O
blocked	O
by	O
omega-conotoxin	O
GVIA	O
.	O
Ih.s.	O
was	O
blocked	O
by	O
nifedipine	O
,	O
and	O
enhanced	O
by	O
Bay	O
K	O
8644	O
.	O
These	O
characteristics	O
indicate	O
that	O
Il	O
,	O
Ih.f.	O
and	O
Ih.s.	O
are	O
consistent	O
with	O
the	O
T	O
-	O
,	O
N	O
-	O
and	O
L	O
-	O
type	O
ICa	O
,	O
respectively	O
.	O
PMID	O
:	O
7659144	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Br	O
J	O
Radiol	O
.	O
2001	O
Jul	O
;	O
74	O
(	O
883	O
)	O
:	O
662-7	O
.	O
Imaging	O
of	O
giant	O
tumours	O
involving	O
the	O
anterior	O
skull	O
base	O
.	O
Connor	O
SE	O
,	O
Umaria	O
N	O
,	O
Chavda	O
SV	O
.	O
Department	O
of	O
Neuroimaging	O
,	O
King's	O
College	O
Hospital	O
,	O
Denmark	O
Hill	O
,	O
London	O
SE5	O
9RS	O
,	O
UK	O
.	O
Tumours	O
involving	O
the	O
anterior	O
skull	O
base	O
are	O
a	O
challenge	O
in	O
diagnosis	O
and	O
treatment	O
.	O
They	O
may	O
arise	O
from	O
the	O
bony	O
skull	O
base	O
itself	O
,	O
intracranially	O
or	O
from	O
the	O
sinonasal	O
tract	O
and	O
orbit	O
.	O
It	O
is	O
often	O
difficult	O
to	O
determine	O
the	O
site	O
of	O
origin	O
of	O
giant	O
tumours	O
as	O
anatomical	O
boundaries	O
are	O
frequently	O
breached	O
.	O
Accurate	O
imaging	O
evaluation	O
is	O
useful	O
in	O
planning	O
treatment	O
and	O
may	O
help	O
in	O
the	O
differential	O
diagnosis	O
.	O
We	O
review	O
those	O
CT	O
and	O
MRI	O
features	O
of	O
giant	B-malignancy-type
anterior	I-malignancy-type
cranial	I-malignancy-type
fossa	I-malignancy-type
tumours	I-malignancy-type
which	O
may	O
be	O
helpful	O
in	O
identifying	O
a	O
pre	O
-	O
operative	O
diagnosis	O
.	O
PMID	O
:	O
11509406	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Brain	O
Res	O
.	O
1991	O
Apr	O
5	O
;	O
545	O
(	O
1-2	O
)	O
:	O
312-4	O
.	O
Potent	O
blocking	O
action	O
of	O
lead	O
on	O
voltage	O
-	O
activated	O
calcium	O
channels	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
SH-SY5Y	O
.	O
Reuveny	O
E	O
,	O
Narahashi	O
T	O
.	O
Department	O
of	O
Pharmacology	O
,	O
Northwestern	O
University	O
Medical	O
School	O
,	O
Chicago	O
,	O
IL	O
60611	O
.	O
Human	O
neuroblastoma	B-malignancy-type
cells	O
(	O
SH-SY5Y	O
)	O
have	O
two	O
types	O
of	O
voltage	O
-	O
activated	O
calcium	O
channels	O
,	O
which	O
are	O
equivalent	O
to	O
the	O
N	O
and	O
L	O
types	O
.	O
Both	O
types	O
of	O
calcium	O
channels	O
were	O
equally	O
blocked	O
by	O
lead	O
in	O
a	O
concentration	O
-	O
dependent	O
and	O
reversible	O
manner	O
,	O
with	O
Ki	O
congruent	O
to	O
1	O
microM	O
.	O
This	O
lead	O
concentration	O
is	O
in	O
the	O
same	O
order	O
of	O
magnitude	O
as	O
that	O
found	O
in	O
the	O
blood	O
of	O
children	O
exhibiting	O
neuropsychological	O
disorders	O
.	O
Sodium	O
and	O
potassium	O
channel	O
currents	O
were	O
not	O
significantly	O
affected	O
by	O
lead	O
at	O
a	O
concentration	O
of	O
10	O
microM	O
.	O
PMID	O
:	O
1650279	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Neurochem	O
.	O
1986	O
Dec	O
;	O
47	O
(	O
6	O
)	O
:	O
1837-42	O
.	O
Subcellular	O
localization	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
in	O
cultured	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Clemens	O
DL	O
,	O
Okamura	O
T	O
,	O
Inagami	O
T.	O
Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
activity	O
of	O
Neuro-2A	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
was	O
found	O
predominantly	O
in	O
particulate	O
fractions	O
.	O
Density	O
gradient	O
centrifugation	O
of	O
the	O
particulate	O
fractions	O
showed	O
ACE	O
activity	O
in	O
light	O
fractions	O
of	O
the	O
gradient	O
,	O
a	O
result	O
suggesting	O
a	O
plasma	O
membrane	O
localization	O
.	O
This	O
was	O
confirmed	O
using	O
the	O
aqueous	O
two	O
-	O
phase	O
polymer	O
system	O
of	O
plasma	O
membrane	O
isolation	O
.	O
The	O
rapid	O
and	O
energy	O
-	O
independent	O
hydrolysis	O
of	O
exogenous	O
substrate	O
by	O
ACE	O
of	O
intact	O
cells	O
and	O
the	O
sensitivity	O
of	O
the	O
enzyme	O
of	O
intact	O
cells	O
to	O
proteases	O
indicate	O
further	O
that	O
the	O
active	O
site	O
of	O
ACE	O
is	O
oriented	O
extracellularly	O
.	O
PMID	O
:	O
3021907	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Biochim	O
Biophys	O
Acta	O
.	O
1984	O
Nov	O
7	O
;	O
777	O
(	O
2	O
)	O
:	O
339-42	O
.	O
Evidence	O
that	O
neutral	O
sphingomyelinase	O
of	O
cultured	O
murine	O
neuroblastoma	B-malignancy-type
cells	O
is	O
oriented	O
externally	O
on	O
the	O
plasma	O
membrane	O
.	O
Das	O
DV	O
,	O
Cook	O
HW	O
,	O
Spence	O
MW	O
.	O
The	O
activity	O
of	O
the	O
neutral	O
,	O
Mg2	O
+	O
-	O
stimulated	O
sphingomyelinase	O
of	O
cultured	O
neuroblastoma	B-malignancy-type
cells	O
(	O
N1E-115	O
)	O
is	O
enriched	O
in	O
the	O
plasma	O
membrane	O
fraction	O
and	O
is	O
reduced	O
following	O
treatment	O
of	O
intact	O
or	O
broken	O
cells	O
with	O
trypsin	O
,	O
alpha-chymotrypsin	O
,	O
papain	O
,	O
and	O
protease	O
.	O
Two	O
protease	O
-	O
sensitive	O
enzymes	O
of	O
the	O
cell	O
interior	O
(	O
lactate	O
dehydrogenase	O
and	O
NADPH	O
-	O
cytochrome	O
c	O
reductase	O
)	O
are	O
not	O
affected	O
by	O
protease	O
treatment	O
of	O
intact	O
cells	O
.	O
These	O
results	O
indicate	O
that	O
the	O
neutral	O
,	O
Mg2	O
+	O
-	O
stimulated	O
sphingomyelinase	O
is	O
oriented	O
externally	O
on	O
the	O
plasma	O
membrane	O
of	O
the	O
cultured	O
neuroblastoma	B-malignancy-type
cell	O
.	O
PMID	O
:	O
6091759	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Prog	O
Clin	O
Biol	O
Res	O
.	O
1985	O
;175	O
:229-	O
37	O
.	O
Glycosylation	O
changes	O
in	O
membrane	O
glycoproteins	O
after	O
transfection	O
of	O
NIH	O
3T3	O
with	O
human	O
tumor	O
DNA	O
.	O
Glick	O
MC	O
,	O
De	O
Santis	O
R	O
,	O
Santer	O
UV	O
.	O
Glycoproteins	O
from	O
NIH	O
3T3	O
transformed	O
by	O
transfection	O
with	O
human	O
tumor	O
DNA	O
had	O
altered	O
glycosylation	O
.	O
That	O
is	O
,	O
the	O
glycoproteins	O
have	O
a	O
decrease	O
in	O
biantennary	O
oligosaccharides	O
with	O
a	O
concomitant	O
increase	O
in	O
tri	O
-	O
and	O
tetra	O
antennary	O
oligosaccharides	O
.	O
After	O
swainsonine	O
treatment	O
,	O
glycosylation	O
of	O
oncogene	O
transfected	O
NIH	O
3T3	O
was	O
more	O
similar	O
to	O
the	O
normal	O
counterpart	O
.	O
Thus	O
,	O
this	O
inhibitor	O
of	O
glycoprotein	O
processing	O
is	O
able	O
to	O
reverse	O
at	O
least	O
one	O
phenotypic	O
expression	O
of	O
transformation	O
,	O
the	O
formation	O
of	O
more	O
highly	O
branched	O
oligosaccharides	O
.	O
The	O
mechanism	O
may	O
be	O
by	O
inhibition	O
of	O
a	O
specific	O
glycosyl	O
transferase	O
.	O
PMID	O
:	O
3991731	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
.	O
1975	O
Nov;36	O
(	O
5	O
)	O
:1567	O
-	O
76	O
.	O
Adriamycin	O
in	O
the	O
treatment	O
of	O
childhood	O
solid	O
tumors	O
.	O
A	O
Southwest	O
Oncology	O
Group	O
study	O
.	O
Ragab	O
AH	O
,	O
Sutow	O
WW	O
,	O
Komp	O
DM	O
,	O
Starling	O
KA	O
,	O
Lyon	O
GM	O
Jr	O
,	O
George	O
S.	O
Ninety-eight	O
children	O
with	O
solid	O
tumors	O
resistant	O
to	O
conventional	O
chemotherapy	O
received	O
adriamycin	O
90	O
mg	O
/	O
m2	O
,	O
either	O
as	O
a	O
single	O
intravenous	O
injection	O
or	O
in	O
6	O
divided	O
doses	O
administered	O
every	O
6	O
hours	O
.	O
Of	O
the	O
88	O
evaluable	O
children	O
,	O
6	O
(	O
7	O
%	O
)	O
achieved	O
a	O
complete	O
response	O
and	O
26	O
(	O
29	O
%	O
)	O
achieved	O
a	O
partial	O
response	O
.	O
Tumors	O
which	O
demonstrated	O
significant	O
response	O
rates	O
were	O
:	O
neuroblastoma	B-malignancy-type
(	O
9	O
/	O
18	O
)	O
,	O
Wilms	B-malignancy-type
'	I-malignancy-type
tumor	I-malignancy-type
(	O
7	O
/	O
13	O
)	O
,	O
rhabdomyosarcoma	B-malignancy-type
(	O
4	O
/	O
11	O
)	O
,	O
and	O
lymphoma	B-malignancy-type
(	O
4	O
/	O
8	O
)	O
.	O
The	O
toxicities	O
observed	O
with	O
this	O
regimen	O
included	O
:	O
alopecia	O
,	O
leukopenia	O
,	O
thrombocytopenia	O
,	O
nausea	O
,	O
vomiting	O
,	O
stomatitis	O
,	O
febrile	O
episodes	O
,	O
and	O
ST	O
-	O
segment	O
changes	O
.	O
PMID	O
:	O
1192348	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Klin	O
Padiatr	O
.	O
1997	O
Jul-	O
Aug;209	O
(	O
4	O
)	O
:	O
147	O
-	O
9.	O
New	O
genetic	O
loci	O
in	O
neuroblastoma	B-malignancy-type
.	O
Schwab	O
M,	O
Corvi	O
R	O
,	O
Savelyeva	O
L.	O
German	O
Cancer	O
Research	O
Center	O
,	O
Division	O
Cytogenetics	O
,	O
Heidelberg	O
.	O
Neuroblastoma	B-malignancy-type
has	O
been	O
associated	O
genetically	O
with	O
amplification	O
of	O
the	O
MYCN	O
gene	O
and	O
with	O
alteration	O
of	O
the	O
short	O
arm	O
of	O
chromosome	O
1	O
(	O
1p	O
)	O
.	O
In	O
pursuit	O
of	O
determining	O
the	O
spectrum	O
of	O
genetic	O
loci	O
damaged	O
recurrently	O
in	O
neuroblastoma	B-malignancy-type
cells	O
we	O
have	O
recently	O
encountered	O
two	O
additional	O
types	O
of	O
genomic	O
abnormalities	O
:	O
i.)	O
duplication	O
of	O
the	O
MYCN	O
gene	O
on	O
chromosome	O
2p24	O
;	O
and	O
ii.)	O
amplification	O
of	O
the	O
gene	O
MDM2	O
.	O
These	O
alterations	O
extend	O
the	O
spectrum	O
of	O
genetic	O
lesions	O
in	O
neuroblastoma	B-malignancy-type
cells	O
,	O
although	O
their	O
incidence	O
in	O
primary	O
tumor	O
tissues	O
has	O
not	O
been	O
determined	O
as	O
yet	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
9293445	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Pediatr	O
Oncol	O
.	O
1997	O
Sep;29(	O
3	O
)	O
:	O
206	O
-7.	O
Concomitant	O
p53	O
mutation	O
and	O
MYCN	O
amplification	O
in	O
neuroblastoma	B-malignancy-type
.	O
Manhani	O
R	O
,	O
Cristofani	O
LM	O
,	O
Odone	O
Filho	O
V	O
,	O
Bendit	O
I.	O
Research	O
and	O
Molecular	O
Biology	O
Division	O
,	O
Pro-Sangue	O
Hemocentro	O
de	O
Sao	O
Paulo	O
Foundation	O
,	O
Brazil	O
.	O
The	O
MYCN	O
oncogene	O
is	O
amplified	O
in	O
20	O
%	O
of	O
childhood	O
neuroblastoma	B-malignancy-type
and	O
is	O
associated	O
independently	O
with	O
poor	O
prognosis	O
.	O
Alteration	O
of	O
the	O
p53	O
tumor	O
supressor	O
gene	O
,	O
in	O
contrast	O
,	O
occurs	O
infrequently	O
in	O
these	O
tumors	B-malignancy-type
.	O
In	O
this	O
report	O
,	O
we	O
described	O
a	O
3	O
-	O
year	O
-	O
old	O
girl	O
with	O
stage	O
IV	O
neuroblastoma	B-malignancy-type
.	O
Molecular	O
analysis	O
revealed	O
,	O
both	O
MYCN	O
gene	O
amplification	O
and	O
a	O
point	O
mutation	O
of	O
the	O
p53	O
tumor	O
supressor	O
gene	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
neuroblastoma	B-malignancy-type
with	O
genetic	O
alterations	O
of	O
both	O
these	O
genes	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
9212845	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Genet	O
Cytogenet	O
.	O
1984	O
Jan;11(	O
1	O
)	O
:	O
113	O
-	O
9.	O
The	O
13p	O
HSR	O
in	O
a	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
does	O
not	O
contain	O
rRNA	O
genes	O
.	O
Gilbert	O
F	O
,	O
Grossman	O
A	O
,	O
Balaban	O
G	O
,	O
Schmickel	O
R.	O
We	O
have	O
studied	O
a	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
containing	O
a	O
homogeneously	O
staining	O
region	O
(	O
HSR	O
)	O
on	O
the	O
short	O
(	O
p	O
)	O
arm	O
of	O
chromosome	O
#	O
13	O
.	O
The	O
HSRs	O
are	O
believed	O
to	O
represent	O
sites	O
of	O
gene	O
amplification	O
,	O
containing	O
multiple	O
copies	O
of	O
one	O
or	O
a	O
small	O
number	O
of	O
genes	O
.	O
The	O
18S	O
and	O
28S	O
ribosomal	O
RNA	O
genes	O
are	O
the	O
only	O
structural	O
genes	O
so	O
far	O
assigned	O
to	O
the	O
p	O
arms	O
of	O
the	O
human	O
acrocentric	O
chromosomes	O
,	O
which	O
include	O
number	O
#	O
13	O
.	O
Using	O
two	O
recombinant	O
DNA	O
probes	O
specific	O
for	O
sequences	O
in	O
the	O
18S	O
/	O
28S	O
ribosomal	O
RNA	O
(	O
rRNA	O
)	O
gene	O
complex	O
for	O
in	O
situ	O
hybridization	O
,	O
we	O
have	O
been	O
able	O
to	O
establish	O
that	O
the	O
13p	O
HSR	O
in	O
this	O
line	O
does	O
not	O
contain	O
rRNA	O
genes	O
.	O
PMID	O
:	O
6197157	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Cancer	O
Res	O
Clin	O
Oncol	O
.	O
1985	O
;110(	O
2	O
)	O
:165	O
-	O
9.	O
Neuroepithelioma	B-malignancy-type
(	O
neuroblastoma	B-malignancy-type
)	O
arising	O
in	O
an	O
adult	O
.	O
A	O
case	O
report	O
.	O
Verwey	O
J,	O
Slater	O
R	O
,	O
Kamphorst	O
W	O
,	O
Pinedo	O
HM	O
.	O
Cytogenetic	O
studies	O
on	O
neuroblastomas	B-malignancy-type
arising	O
in	O
children	O
have	O
revealed	O
consistent	O
abnormalities	O
of	O
the	O
short	O
arm	O
of	O
chromosome	O
number	O
1	O
.	O
Partly	O
because	O
of	O
the	O
rare	O
occurrence	O
of	O
neuroblastomas	B-malignancy-type
in	O
adults	O
,	O
extensive	O
cytogenetic	O
studies	O
in	O
this	O
group	O
of	O
patients	O
have	O
not	O
been	O
performed	O
.	O
We	O
report	O
a	O
case	O
of	O
a	O
neuroepithelioma	B-malignancy-type
(	O
neuroblastoma	B-malignancy-type
)	O
arising	O
in	O
a	O
50	O
-	O
year	O
-	O
old	O
male	O
patient	O
.	O
On	O
chromosome	O
analysis	O
of	O
a	O
metastasis	O
,	O
a	O
stemline	O
with	O
karyotype	O
47	O
,	O
X	O
Y	O
,	O
+	O
der1	O
(	O
1	O
qter	O
---	O
1	O
cen	O
::	O
1q21	O
---	O
1	O
qter	O
)	O
was	O
identified	O
.	O
The	O
possible	O
consequences	O
of	O
this	O
result	O
and	O
those	O
of	O
results	O
previously	O
reported	O
in	O
the	O
literature	O
are	O
discussed	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
4044631	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Semin	O
Pediatr	O
Surg	O
.	O
1993	O
Feb;	O
2	O
(	O
1	O
)	O
:	O
37-46	O
.	O
Neuroblastoma	B-malignancy-type
in	O
the	O
first	O
year	O
of	O
life	O
:	O
clinical	O
and	O
biologic	O
factors	O
influencing	O
outcome	O
.	O
Grosfeld	O
JL	O
,	O
Rescorla	O
FJ	O
,	O
West	O
KW	O
,	O
Goldman	O
J.	O
Department	O
of	O
Surgery	O
,	O
Indiana	O
University	O
School	O
of	O
Medicine	O
,	O
Indianapolis	O
.	O
The	O
survival	O
for	O
infants	O
less	O
than	O
1	O
year	O
of	O
age	O
with	O
neuroblastoma	B-malignancy-type
is	O
twice	O
that	O
of	O
older	O
children	O
.	O
This	O
report	O
describes	O
70	O
babies	O
with	O
neuroblastoma	B-malignancy-type
who	O
experienced	O
an	O
84	O
%	O
survival	O
.	O
Survival	O
was	O
100	O
%	O
for	O
stages	O
I	O
,	O
II	O
,	O
and	O
III	O
,	O
81	O
%	O
for	O
stage	O
IV-S	O
,	O
and	O
50	O
%	O
for	O
stage	O
IV	O
.	O
Most	O
survivors	O
had	O
favorable	O
biologic	O
characteristics	O
including	O
spontaneous	O
regression	O
,	O
favorable	B-malignancy-type
Shimada	I-malignancy-type
histology	I-malignancy-type
,	O
normal	O
first	O
chromosome	O
,	O
aneuploid	O
tumors	B-malignancy-type
,	O
absent	O
or	O
low	O
N-myc	O
oncogene	O
expression	O
,	O
and	O
normal	O
serum	O
ferritin	O
levels	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
8062021	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
.	O
1997;75	O
(	O
12	O
)	O
:1779	O
-	O
81	O
.	O
Low	O
specificity	O
of	O
PGP9.5	O
expression	O
for	O
detection	O
of	O
micrometastatic	O
neuroblastoma	B-malignancy-type
.	O
Gilbert	O
J,	O
Norris	O
MD	O
,	O
Marshall	O
GM	O
,	O
Haber	O
M.	O
Children	O
's	O
Cancer	O
Research	O
Institute	O
,	O
Sydney	O
Children	O
's	O
Hospital	O
,	O
New	O
South	O
Wales	O
,	O
Australia	O
.	O
To	O
determine	O
the	O
specificity	O
of	O
neuroendocrine	O
protein	O
gene	O
product	O
(	O
PGP9.5	O
)	O
gene	O
transcripts	O
for	O
detecting	O
micrometastatic	O
neuroblastoma	B-malignancy-type
,	O
we	O
have	O
used	O
a	O
highly	O
sensitive	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
technique	O
to	O
evaluate	O
expression	O
of	O
this	O
gene	O
in	O
normal	O
blood	O
and	O
bone	O
marrow	O
.	O
While	O
expression	O
of	O
the	O
tyrosine	O
hydroxylase	O
gene	O
was	O
not	O
detected	O
in	O
any	O
normal	O
sample	O
,	O
low	O
-	O
level	O
PGP9.5	O
expression	O
was	O
detected	O
in	O
eight	O
out	O
of	O
ten	O
blood	O
and	O
seven	O
of	O
12	O
marrow	O
samples	O
.	O
PGP9.5	O
gene	O
transcripts	O
in	O
normal	O
tissues	O
have	O
the	O
potential	O
to	O
interfere	O
with	O
the	O
detection	O
of	O
micrometastatic	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
9192981	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Treat	O
Rep.	O
1979	O
Aug;6	O
3(	O
8	O
)	O
:	O
1331-3.	O
Evaluation	O
of	O
cyclocytidine	O
in	O
children	O
with	O
advanced	O
acute	B-malignancy-type
leukemia	I-malignancy-type
and	O
solid	O
tumors	O
.	O
Finklestein	O
JZ	O
,	O
Higgins	O
G	O
,	O
Krivit	O
W	O
,	O
Hammond	O
D.	O
Cyclocytidine	O
,	O
a	O
slow	O
-	O
release	O
form	O
of	O
cytosine	O
arabinoside	O
,	O
was	O
evaluated	O
in	O
69	O
children	O
with	O
advanced	O
acute	B-malignancy-type
leukemia	I-malignancy-type
and	O
solid	O
tumors	O
.	O
One	O
child	O
with	O
acute	B-malignancy-type
lymphocytic	I-malignancy-type
leukemia	I-malignancy-type
attained	O
a	O
complete	O
remission	O
.	O
This	O
child	O
had	O
received	O
intrathecal	O
cytosine	O
arabinoside	O
prior	O
to	O
the	O
cyclocytidine	O
.	O
Eighteen	O
of	O
the	O
31	O
patients	O
with	O
acute	B-malignancy-type
lymphocytic	I-malignancy-type
leukemia	I-malignancy-type
/	O
acute	B-malignancy-type
undifferentiated	I-malignancy-type
leukemia	I-malignancy-type
who	O
did	O
not	O
respond	O
received	O
two	O
or	O
more	O
courses	O
of	O
the	O
drug	O
.	O
There	O
were	O
no	O
responses	O
in	O
15	O
children	O
with	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
,	O
in	O
11	O
children	O
with	O
neuroblastoma	B-malignancy-type
,	O
or	O
in	O
11	O
children	O
with	O
various	O
solid	O
tumors	O
of	O
childhood	O
.	O
A	O
dose	O
of	O
600	O
ng	O
/	O
m2	O
/	O
day	O
for	O
10	O
consecutive	O
days	O
is	O
tolerated	O
in	O
children	O
.	O
PMID	O
:	O
89907	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neurosci	O
Lett	O
.	O
1999	O
Feb	O
26;262(	O
1	O
)	O
:	O
37-40	O
.	O
Effects	O
of	O
presenilin	O
N	O
-	O
terminal	O
fragments	O
on	O
production	O
of	O
amyloid	O
beta	O
peptide	O
and	O
accumulation	O
of	O
endogenous	O
presenilins	O
.	O
Shirotani	O
K,	O
Takahashi	O
K,	O
Tabira	O
T.	O
Division	O
of	O
Demyelinating	O
Disease	O
and	O
Aging	O
,	O
National	O
Institute	O
of	O
Neuroscience	O
,	O
NCNP	O
,	O
Tokyo	O
,	O
Japan	O
.	O
To	O
clarify	O
the	O
effects	O
of	O
the	O
proteolytic	O
cleavage	O
of	O
presenilin	O
1	O
(	O
PS1	O
)	O
and	O
presenilin	O
2	O
(	O
PS2	O
)	O
proteins	O
on	O
their	O
functions	O
,	O
we	O
established	O
stable	O
cell	O
lines	O
which	O
expressed	O
the	O
physiologically	O
cleaved	O
N	O
-	O
terminal	O
fragment	O
(	O
NTF	O
)	O
with	O
or	O
without	O
mutations	O
of	O
familial	O
Alzheimer	O
's	O
disease	O
(	O
FAD	O
)	O
.	O
We	O
found	O
that	O
exogenous	O
expression	O
of	O
the	O
PS1	O
-	O
NTF	O
or	O
PS2	O
-	O
NTF	O
harboring	O
FAD	O
mutations	O
was	O
insufficient	O
for	O
increased	O
production	O
of	O
amyloidogenic	O
A	O
beta	O
X-42	O
peptide	O
and	O
that	O
the	O
overexpressed	O
NTFs	O
had	O
no	O
effect	O
on	O
the	O
accumulation	O
of	O
endogenous	O
presenilin	O
fragments	O
.	O
PMID	O
:	O
10076867	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
.	O
1989	O
Apr;80(	O
4	O
)	O
:	O
299	O
-301	O
.	O
Coamplification	O
of	O
the	O
L-myc	O
and	O
N-myc	O
oncogenes	O
in	O
a	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
Jinbo	O
T	O
,	O
Iwamura	O
Y	O
,	O
Kaneko	O
M,	O
Sawaguchi	O
S.	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
University	O
of	O
Tsukuba	O
,	O
Ibaraki	O
.	O
The	O
L-myc	O
,	O
N-myc	O
and	O
c-myc	O
genes	O
are	O
members	O
of	O
the	O
myc	O
oncogene	O
family	O
.	O
In	O
particular	O
,	O
L-myc	O
is	O
novel	O
,	O
and	O
amplification	O
of	O
L-myc	O
is	O
still	O
unknown	O
except	O
in	O
small	B-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
carcinoma	I-malignancy-type
.	O
We	O
examined	O
L-myc	O
amplification	O
in	O
30	O
human	O
neuroblastomas	B-malignancy-type
using	O
Southern	O
blot	O
hybridization	O
,	O
and	O
found	O
that	O
the	O
L-myc	O
gene	O
was	O
amplified	O
approximately	O
5	O
-	O
fold	O
in	O
GOTO	O
,	O
a	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
The	O
N-myc	O
gene	O
was	O
also	O
amplified	O
approximately	O
60	O
-	O
fold	O
and	O
furthermore	O
,	O
over	O
-	O
expression	O
of	O
L-myc	O
and	O
N-myc	O
genes	O
was	O
observed	O
in	O
this	O
cell	O
line	O
.	O
In	O
this	O
report	O
,	O
we	O
describe	O
the	O
coamplification	O
of	O
the	O
myc	O
gene	O
family	O
in	O
the	O
GOTO	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
PMID	O
:	O
2501244	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
.	O
1991	O
Jan;56	O
(	O
1	O
)	O
:45-51	O
.	O
Transcription	O
of	O
N-myc	O
and	O
proliferation	O
-	O
related	O
genes	O
is	O
linked	O
in	O
human	O
neuroblastoma	B-malignancy-type
.	O
Raschella	O
G	O
,	O
Negroni	O
A	O
,	O
Giubilei	O
C	O
,	O
Romeo	O
A	O
,	O
Ferrari	O
S	O
,	O
Castello	O
MA	O
,	O
Dominici	O
C.	O
Division	O
of	O
Physics	O
and	O
Biomedical	O
Sciences	O
,	O
CRE	O
ENEA	O
Casaccia	O
,	O
Rome	O
,	O
Italy	O
.	O
A	O
definite	O
association	O
between	O
the	O
transcription	O
of	O
N-myc	O
oncogene	O
and	O
proliferation	O
-	O
related	O
genes	O
,	O
histone	O
H3	O
,	O
c-myc	O
and	O
p53	O
,	O
was	O
found	O
in	O
a	O
set	O
of	O
12	O
primary	B-malignancy-type
untreated	O
neuroblastomas	B-malignancy-type
and	O
a	O
metastasis	O
of	O
one	O
of	O
these	O
at	O
relapse	O
.	O
Molecular	O
analysis	O
allowed	O
us	O
to	O
discriminate	O
between	O
actually	O
proliferating	O
and	O
non	O
-	O
proliferating	O
tumors	O
,	O
and	O
suggested	O
a	O
link	O
between	O
N-myc	O
and	O
proliferation	O
.	O
Flow	O
cytometric	O
analysis	O
of	O
DNA	O
distribution	O
was	O
less	O
reliable	O
for	O
assessing	O
tumor	O
proliferative	O
activity	O
.	O
Our	O
data	O
also	O
seem	O
to	O
indicate	O
a	O
down	O
-	O
regulation	O
of	O
c-myc	O
by	O
N-myc	O
in	O
human	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
2004353	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pathology	O
(	O
Phila	O
)	O
.	O
1993	O
;	O
2	O
(	O
1	O
)	O
:43	O
-59	O
.	O
Tumors	O
of	O
the	O
neuroblastoma	B-malignancy-type
group	O
.	O
Shimada	O
H.	O
Department	O
of	O
Pathology	O
and	O
Laboratory	O
Medicine	O
,	O
Childrens	O
Hospital	O
Los	O
Angeles	O
,	O
California	O
90027	O
,	O
USA	O
.	O
The	O
basic	O
histologic	O
changes	O
associated	O
with	O
the	O
maturational	O
sequences	O
of	O
neuroblastoma	B-malignancy-type
tumors	O
are	O
reviewed	O
.	O
The	O
author	O
describes	O
a	O
histopathologic	O
classification	O
system	O
developed	O
for	O
distinguishing	O
favorable	O
and	O
unfavorable	O
prognoses	O
,	O
based	O
on	O
the	O
combination	O
of	O
tumor	O
morphology	O
and	O
patient	O
's	O
age	O
at	O
diagnosis	O
.	O
Also	O
discussed	O
are	O
the	O
results	O
of	O
recent	O
analyses	O
of	O
the	O
biologically	O
significant	O
relationship	O
between	O
histologic	O
findings	O
and	O
molecular	O
markers	O
,	O
such	O
as	O
amplification	O
of	O
the	O
N-myc	O
oncogene	O
and	O
expression	O
of	O
the	O
nerve	O
growth	O
factor	O
receptor	O
gene	O
.	O
Clinical	O
trials	O
involving	O
neuroblastoma	B-malignancy-type
tumors	O
are	O
briefly	O
reviewed	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
9420930	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Bioelectromagnetics	O
.	O
1984	O
;	O
5	O
(	O
1	O
)	O
:	O
71	O
-	O
8.	O
Microwave	O
radiation	O
-	O
induced	O
calcium	O
ion	O
efflux	O
from	O
human	O
neuroblastoma	B-malignancy-type
cells	O
in	O
culture	O
.	O
Dutta	O
SK	O
,	O
Subramoniam	O
A	O
,	O
Ghosh	O
B	O
,	O
Parshad	O
R.	O
Monolayer	O
cultures	O
of	O
human	O
neuroblastoma	B-malignancy-type
cells	O
were	O
exposed	O
to	O
915	O
-	O
MHz	O
radiation	O
,	O
with	O
or	O
without	O
sinusoidal	O
amplitude	O
modulation	O
(	O
80	O
%	O
)	O
at	O
16	O
Hz	O
,	O
at	O
specific	O
absorption	O
rates	O
(	O
SAR	O
)	O
for	O
the	O
culture	O
medium	O
and	O
cells	O
of	O
0.00	O
,	O
0.01	O
,	O
0.05	O
,	O
0.075	O
,	O
0.1	O
,	O
0.5	O
,	O
0.75	O
,	O
1.0	O
,	O
1.5	O
,	O
2	O
,	O
or	O
5	O
mW	O
/	O
g	O
.	O
A	O
significant	O
increase	O
in	O
the	O
efflux	O
of	O
calcium	O
ions	O
(	O
45	O
Ca2	O
+	O
)	O
as	O
compared	O
to	O
unexposed	O
control	O
cultures	O
occurred	O
at	O
two	O
SAR	O
values	O
:	O
0.05	O
and	O
1	O
mW	O
/	O
g	O
.	O
Increased	O
efflux	O
at	O
0.05	O
mW	O
/	O
g	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
amplitude	O
modulation	O
at	O
16	O
Hz	O
but	O
at	O
the	O
higher	O
value	O
it	O
was	O
not	O
.	O
These	O
results	O
indicate	O
that	O
human	O
neuroblastoma	B-malignancy-type
cells	O
are	O
sensitive	O
to	O
extremely	O
low	O
levels	O
of	O
microwave	O
radiation	O
at	O
certain	O
narrow	O
ranges	O
of	O
SAR	O
.	O
PMID	O
:	O
6712751	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Toxicon	O
.	O
1988	O
;26(	O
2	O
)	O
:191	O
-	O
7.	O
A	O
tissue	O
culture	O
assay	O
for	O
tetrodotoxin	O
,	O
saxitoxin	O
and	O
related	O
toxins	O
.	O
Kogure	O
K,	O
Tamplin	O
ML	O
,	O
Simidu	O
U	O
,	O
Colwell	O
RR.	O
Center	O
of	O
Marine	O
Biotechnology	O
,	O
University	O
of	O
Maryland	O
,	O
Baltimore	O
21202	O
.	O
In	O
the	O
presence	O
of	O
ouabain	O
,	O
veratridine	O
enhances	O
sodium	O
influx	O
in	O
the	O
mouse	O
neuroblastoma	B-malignancy-type
cell	O
line	O
Neuro-2A	O
(	O
ATCC	O
,	O
CCL131	O
)	O
,	O
causing	O
cellular	O
swelling	O
and	O
subsequent	O
death	O
.	O
Tetrodotoxin	O
(	O
puffer	O
fish	O
toxin	O
)	O
or	O
saxitoxin	O
(	O
paralytic	O
shellfish	O
poison	O
)	O
,	O
both	O
of	O
which	O
block	O
the	O
sodium	O
channel	O
of	O
excitable	O
membranes	O
,	O
antagonize	O
this	O
effect	O
,	O
enabling	O
cell	O
growth	O
to	O
continue	O
.	O
This	O
phenomenon	O
was	O
used	O
as	O
the	O
basis	O
of	O
a	O
new	O
assay	O
for	O
these	O
toxins	O
.	O
It	O
is	O
also	O
possible	O
to	O
estimate	O
the	O
quantity	O
of	O
TTX	O
from	O
the	O
relationship	O
between	O
TTX	O
concentration	O
and	O
percentage	O
of	O
living	O
cells	O
.	O
This	O
new	O
method	O
is	O
simple	O
,	O
inexpensive	O
,	O
and	O
sensitive	O
,	O
and	O
may	O
replace	O
the	O
conventional	O
mouse	O
bioassay	O
.	O
PMID	O
:	O
3363566	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Cell	O
Physiol	O
Suppl	O
.	O
1984	O
;3	O
:165	O
-	O
70	O
.	O
Solid	B-malignancy-type
tumors	I-malignancy-type
of	O
children	O
:	O
chromosome	O
abnormalities	O
and	O
the	O
development	O
of	O
cancer	O
.	O
Gilbert	O
F.	O
Chromosome	O
abnormalities	O
in	O
five	O
solid	O
tumors	O
which	O
occur	O
predominantly	O
in	O
children	O
and	O
young	O
adults	O
are	O
described	O
.	O
Four	O
of	O
the	O
tumors	O
are	O
associated	O
with	O
rearrangements	O
involving	O
particular	O
chromosome	O
segments	O
:	O
deletion	O
13q14	O
in	O
retinoblastoma	B-malignancy-type
,	O
deletion	O
11p13	O
in	O
Wilms	B-malignancy-type
'	I-malignancy-type
tumor	I-malignancy-type
,	O
deletions	O
/	O
rearrangements	O
of	O
1p	O
(	O
distal	O
to	O
band	O
1p31	O
)	O
in	O
neuroblastoma	B-malignancy-type
,	O
and	O
translocation	O
22	O
/	O
autosome	O
in	O
Ewing	B-malignancy-type
sarcoma	I-malignancy-type
.	O
Though	O
aneuploidy	O
for	O
a	O
number	O
of	O
chromosomes	O
may	O
occur	O
in	O
the	O
fifth	O
tumor	O
,	O
rhabdomyosarcoma	B-malignancy-type
,	O
it	O
has	O
yet	O
to	O
be	O
associated	O
with	O
a	O
consistent	O
marker	O
arrangement	O
.	O
A	O
general	O
classification	O
of	O
chromosome	O
abnormalities	O
in	O
cancer	O
is	O
presented	O
.	O
Possible	O
roles	O
for	O
the	O
gene	O
changes	O
produced	O
by	O
each	O
class	O
of	O
chromosome	O
abnormality	O
in	O
the	O
development	O
of	O
cancer	O
are	O
discussed	O
.	O
PMID	O
:	O
6086684	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Arch	O
Dis	O
Child	O
.	O
1986	O
Sep;61	O
(	O
9	O
)	O
:832-42	O
.	O
Prognostic	O
value	O
of	O
different	O
staging	O
systems	O
in	O
neuroblastomas	B-malignancy-type
and	O
completeness	O
of	O
tumour	O
excision	O
.	O
Carlsen	O
NL	O
,	O
Christensen	O
IJ	O
,	O
Schroeder	O
H,	O
Bro	O
PV	O
,	O
Hesselbjerg	O
U	O
,	O
Jensen	O
KB	O
,	O
Nielsen	O
OH.	O
Two	O
hundred	O
and	O
fifty	O
three	O
patients	O
were	O
retrospectively	O
assigned	O
to	O
eight	O
different	O
staging	O
systems	O
proposed	O
for	O
neuroblastomas	B-malignancy-type
,	O
and	O
the	O
prognostic	O
value	O
of	O
each	O
staging	O
system	O
was	O
evaluated	O
individually	O
.	O
The	O
ability	O
of	O
each	O
system	O
to	O
predict	O
prognosis	O
was	O
compared	O
with	O
the	O
others	O
and	O
the	O
system	O
proposed	O
by	O
Evans	O
et	O
al	O
found	O
to	O
be	O
the	O
best	O
predictor	O
,	O
even	O
better	O
than	O
the	O
recently	O
proposed	O
Tumour	O
-	O
Nodes	O
-	O
Metastases	O
staging	O
system	O
.	O
This	O
is	O
probably	O
due	O
to	O
the	O
fact	O
that	O
factors	O
other	O
than	O
the	O
resectability	O
of	O
the	O
tumour	O
play	O
a	O
major	O
role	O
in	O
the	O
survival	O
of	O
these	O
children	O
.	O
Age	O
was	O
found	O
to	O
have	O
independent	O
prognostic	O
significance	O
whatever	O
staging	O
system	O
was	O
used	O
.	O
PMID	O
:	O
3767412	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gen	O
Pharmacol	O
.	O
1992	O
May	O
;23(	O
3	O
)	O
:431-4.	O
Changes	O
in	O
microtubule	O
-	O
associated	O
tau	O
protein	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
after	O
phencyclidine	O
.	O
Lew	O
GM	O
.	O
Department	O
of	O
Anatomy	O
,	O
College	O
of	O
Human	O
Medicine	O
,	O
Michigan	O
State	O
University	O
,	O
East	O
Lansing	O
48824	O
.	O
1.	O
A	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
,	O
SH-SY5Y	O
,	O
was	O
used	O
to	O
study	O
the	O
effects	O
of	O
phencyclidine	O
(	O
PCP	O
)	O
on	O
microtubule	O
-	O
associated	O
tau	O
protein	O
,	O
which	O
acts	O
in	O
vivo	O
chiefly	O
to	O
induce	O
the	O
assembly	O
of	O
tubulin	O
and	O
in	O
vitro	O
to	O
promote	O
microtubule	O
polymerization	O
.	O
2.	O
PCP	O
(	O
1.0	O
mM	O
)	O
decreased	O
tau	O
protein	O
(	O
50	O
kD	O
)	O
in	O
the	O
cytoplasmic	O
(	O
supernatant	O
)	O
fraction	O
as	O
well	O
as	O
in	O
the	O
membrane	O
(	O
pellet	O
)	O
fraction	O
.	O
3.	O
These	O
changes	O
in	O
tau	O
protein	O
were	O
accompanied	O
by	O
decreases	O
of	O
30	O
-	O
95	O
%	O
in	O
cell	O
number	O
after	O
concentrations	O
of	O
PCP	O
,	O
0.25	O
-	O
1.0	O
mM	O
,	O
respectively	O
.	O
4.	O
After	O
0.5	O
mM	O
PCP	O
cytoplasmic	O
and	O
membrane	O
fractions	O
of	O
SH-SY5Y	O
cells	O
showed	O
100	O
and	O
84	O
%	O
increases	O
in	O
total	O
protein	O
,	O
respectively	O
.	O
PMID	O
:	O
1511852	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochim	O
Biophys	O
Acta	O
.	O
1988	O
Jul	O
7;942(	O
1	O
)	O
:	O
209	O
-	O
12	O
.	O
Conditional	O
open	O
and	O
delay	O
time	O
histograms	O
of	O
sodium	O
channels	O
.	O
Nagy	O
K.	O
I.	O
Physiologisches	O
Institut	O
des	O
Universitat	O
des	O
Saarlandes	O
,	O
Homburg	O
,	O
F.R.G.	O
Currents	O
through	O
single	O
sodium	O
channels	O
were	O
recorded	O
in	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Open	O
time	O
histograms	O
were	O
constructed	O
from	O
openings	O
which	O
appeared	O
between	O
2.0	O
and	O
5.0	O
ms	O
after	O
the	O
onset	O
of	O
the	O
depolarization	O
.	O
Histograms	O
constructed	O
from	O
openings	O
which	O
were	O
not	O
preceded	O
by	O
other	O
openings	O
showed	O
a	O
maximum	O
at	O
t	O
greater	O
than	O
0	O
in	O
contrast	O
to	O
those	O
,	O
which	O
were	O
preceded	O
by	O
other	O
openings	O
.	O
Time	O
constants	O
of	O
delay	O
time	O
histograms	O
fitted	O
by	O
the	O
sum	O
of	O
two	O
exponentials	O
were	O
different	O
for	O
the	O
first	O
,	O
second	O
and	O
third	O
records	O
of	O
runs	O
.	O
The	O
results	O
support	O
the	O
view	O
that	O
sodium	O
channels	O
have	O
multiple	O
open	O
and	O
closed	O
states	O
and	O
the	O
transition	O
probabilities	O
among	O
the	O
states	O
depend	O
on	O
local	O
conditions	O
of	O
the	O
membrane	O
.	O
PMID	O
:	O
2454666	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gene	O
.	O
1994	O
Sep	O
30	O
;147(	O
2	O
)	O
:	O
281	O
-5	O
.	O
Cloning	O
of	O
a	O
human	O
cDNA	O
encoding	O
a	O
putative	O
nucleotide	O
-	O
binding	O
protein	O
related	O
to	O
Escherichia	O
coli	O
MinD	O
.	O
Shahrestanifar	O
M,	O
Saha	O
DP	O
,	O
Scala	O
LA	O
,	O
Basu	O
A	O
,	O
Howells	O
RD.	O
Department	O
of	O
Biochemistry	O
and	O
Molecular	O
Biology	O
,	O
UMD-	O
New	O
Jersey	O
Medical	O
School	O
,	O
Newark	O
07103	O
.	O
A	O
novel	O
human	O
cDNA	O
encoding	O
a	O
putative	O
nucleotide	O
-	O
binding	O
protein	O
(	O
NBP	O
)	O
was	O
obtained	O
by	O
screening	O
a	O
human	O
SHSY5Y	O
neuroblastoma	B-malignancy-type
library	O
.	O
The	O
deduced	O
protein	O
contains	O
320	O
amino	O
acids	O
(	O
aa	O
)	O
with	O
a	O
M(r)	O
of	O
34,540	O
.	O
NBP	O
displays	O
sequence	O
similarity	O
with	O
the	O
product	O
of	O
the	O
minD	O
gene	O
from	O
Escherichia	O
coli	O
.	O
MinD	O
is	O
involved	O
in	O
the	O
proper	O
placement	O
of	O
the	O
division	O
septum	O
,	O
and	O
has	O
ATPase	O
activity	O
.	O
NBP	O
and	O
MinD	O
contain	O
consensus	O
nucleotide	O
(	O
nt	O
)	O
-	O
binding	O
domains	O
.	O
The	O
NBP	O
mRNA	O
is	O
approx.	O
1500	O
nt	O
in	O
length	O
and	O
is	O
expressed	O
in	O
several	O
human	O
cell	O
lines	O
and	O
in	O
all	O
rat	O
tissues	O
examined	O
,	O
with	O
the	O
highest	O
levels	O
in	O
lung	O
and	O
testis	O
.	O
PMID	O
:	O
7926816	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Somatic	O
Cell	O
Genet	O
.	O
1982	O
May;	O
8	O
(	O
3	O
)	O
:	O
377	O
-83	O
.	O
Coexpression	O
of	O
species	O
-	O
specific	O
histone	O
H1	O
and	O
H2B	O
genes	O
in	O
mouse	O
-	O
rat	O
hybrid	O
cells	O
.	O
Ajiro	O
K,	O
Kano-Tanaka	O
K,	O
Higashida	O
H,	O
Tanaka	O
T.	O
Five	O
different	O
clones	O
of	O
somatic	O
hybrid	O
cell	O
lines	O
between	O
mouse	O
and	O
rat	O
cells	O
were	O
examined	O
for	O
the	O
expression	O
of	O
species	O
-	O
specific	O
histone	O
H1	O
and	O
H2B	O
subtypes	O
.	O
It	O
was	O
found	O
that	O
one	O
hybrid	O
(	O
140-3	O
)	O
contained	O
only	O
mouse	O
specific	O
histones	O
and	O
the	O
other	O
four	O
clones	O
had	O
both	O
mouse	O
and	O
rat	O
specific	O
histones	O
in	O
various	O
ratios	O
.	O
In	O
three	O
cases	O
(	O
141-B	O
,	O
NBr10A	O
,	O
NBr20A	O
)	O
,	O
the	O
relative	O
amount	O
of	O
mouse	O
and	O
rat	O
specific	O
histones	O
was	O
correlated	O
with	O
the	O
karyotype	O
of	O
the	O
hybrids	O
.	O
However	O
,	O
this	O
was	O
not	O
true	O
in	O
one	O
case	O
(	O
NG108-15	O
)	O
.	O
The	O
results	O
indicate	O
that	O
a	O
single	O
mammalian	O
hybrid	O
clone	O
can	O
express	O
both	O
parental	O
types	O
of	O
histones	O
,	O
and	O
the	O
histone	O
expression	O
in	O
these	O
hybrids	O
is	O
not	O
regulated	O
by	O
an	O
allelic	O
exclusion	O
but	O
may	O
be	O
expressed	O
codominantly	O
by	O
gene	O
dosage	O
.	O
PMID	O
:	O
7112350	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
Mol	O
Brain	O
Res	O
.	O
1991	O
Jan;	O
9	O
(	O
1-2	O
)	O
:	O
149-52	O
.	O
Differential	O
expression	O
of	O
the	O
N-myc	O
,	O
c-fos	O
,	O
and	O
smg	O
p25A	O
genes	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
during	O
neuronal	O
and	O
Schwannian	O
differentiation	O
.	O
Sano	O
K,	O
Motoike	O
T	O
,	O
Nakamura	O
H,	O
Matsui	O
Y	O
,	O
Teranishi	O
Y	O
,	O
Takai	O
Y	O
.	O
Department	O
of	O
Pediatrics	O
,	O
Kobe	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
We	O
have	O
examined	O
expression	O
of	O
the	O
N-myc	O
,	O
c-fos	O
and	O
smg	O
p25A	O
genes	O
in	O
two	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
during	O
their	O
differentiation	O
.	O
The	O
decrease	O
in	O
the	O
N-myc	O
gene	O
expression	O
and	O
the	O
increase	O
in	O
the	O
c-fos	O
gene	O
expression	O
are	O
observed	O
during	O
the	O
differentiation	O
of	O
NB-1	O
cells	O
into	O
neuronal	O
cells	O
and	O
of	O
GOTO	O
cells	O
into	O
Schwann	O
-	O
type	O
cells	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
smg	O
p25A	O
,	O
a	O
ras	O
p21	O
-	O
like	O
small	O
GTP	O
-	O
binding	O
protein	O
,	O
gene	O
expression	O
is	O
increased	O
in	O
NB-1	O
cells	O
but	O
not	O
in	O
GOTO	O
cells	O
during	O
their	O
differentiation	O
,	O
suggesting	O
that	O
smg	O
p25A	O
is	O
closely	O
associated	O
with	O
the	O
neuronal	O
phenotype	O
of	O
neuroblastoma	B-malignancy-type
cells	O
.	O
PMID	O
:	O
1850070	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Mol	O
Biol	O
Int	O
.	O
1996	O
Apr;38(	O
4	O
)	O
:763	O
-72	O
.	O
Expression	O
of	O
mRNA	O
encoding	O
neurotrophic	O
factors	O
and	O
its	O
regulation	O
in	O
a	O
hybrid	O
neuronal	O
cell	O
line	O
.	O
Nakanishi	O
T	O
,	O
Ishii	O
K,	O
Fukushima	O
N	O
,	O
Asanuma	O
M,	O
Iwata	O
E	O
,	O
Ogawa	O
N	O
.	O
Department	O
of	O
Biochemistry	O
,	O
Okayama	O
University	O
Dental	O
School	O
,	O
Japan	O
.	O
In	O
a	O
cultured	O
hybrid	O
neuronal	O
cell	O
line	O
(	O
BIM	O
)	O
which	O
was	O
produced	O
between	O
human	O
neuroblastoma	B-malignancy-type
cells	O
(	O
IMR32	O
)	O
and	O
thymidine	O
auxotrophs	O
(	O
B3T	O
)	O
of	O
rat	O
nerve	O
-	O
like	O
cells	O
(	O
B103	O
)	O
,	O
the	O
mRNAs	O
encoding	O
ciliary	O
neurotrophic	O
factor	O
(	O
CNTF	O
)	O
and	O
neurotrophins	O
were	O
detected	O
by	O
the	O
polymerase	O
chain	O
reaction	O
method	O
.	O
The	O
conditioned	O
medium	O
of	O
BIM	O
cells	O
enhanced	O
choline	O
acetyltransferase	O
(	O
ChAT	O
)	O
activity	O
in	O
septal	O
neurons	O
and	O
survival	O
of	O
ciliary	O
ganglion	O
neurons	O
.	O
The	O
mRNA	O
expression	O
of	O
CNTF	O
and	O
neurotrophins	O
in	O
BIM	O
cells	O
was	O
differently	O
regulated	O
by	O
the	O
stimulation	O
with	O
cAMP	O
,	O
FGF	O
and	O
retinoic	O
acid	O
.	O
These	O
data	O
suggest	O
multiple	O
regulation	O
and	O
collaboration	O
of	O
neurotrophic	O
factors	O
.	O
PMID	O
:	O
8728106	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
1977	O
Mar;74	O
(	O
3	O
)	O
:	O
842-5	O
.	O
Embryonic	O
chicken	O
brain	O
and	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
N1E-115	O
and	O
N-18	O
contain	O
an	O
inhibitor	O
of	O
acid	O
deoxyribonuclease	O
.	O
Bhattacharya	O
P,	O
Moskal	O
JR	O
,	O
Basu	O
S.	O
Activity	O
of	O
a	O
trypsin	O
-	O
sensitive	O
acid	O
deoxyribonuclease	O
(	O
DNase	O
)	O
inhibitor	O
has	O
been	O
detected	O
in	O
13	O
-	O
to	O
21	O
-	O
day	O
-	O
old	O
embryonic	O
chicken	O
brains	O
and	O
in	O
clonal	O
lines	O
of	O
neuroblastoma	B-malignancy-type
cells	O
(	O
adrenergic	O
,	O
N1E-115	O
,	O
and	O
neurotransmitter	O
-	O
inactive	O
,	O
N-18	O
)	O
grown	O
for	O
48	O
hr	O
after	O
subculture	O
.	O
The	O
activities	O
of	O
purified	O
porcine	O
and	O
bovine	O
spleen	O
DNases	O
were	O
inhibited	O
60	O
--	O
75	O
%	O
in	O
the	O
presence	O
of	O
the	O
inhibitor	O
,	O
whereas	O
less	O
than	O
10	O
%	O
inhibition	O
was	O
observed	O
with	O
purified	O
pancreatic	O
DNase	O
.	O
Activities	O
of	O
an	O
acidic	O
DNase	O
and	O
its	O
inhibitor	O
reached	O
maxima	O
in	O
21	O
-	O
day	O
-	O
old	O
embryonic	O
chicken	O
brain	O
.	O
The	O
proteins	O
were	O
separated	O
by	O
isoelectric	O
focusing	O
and	O
affinity	O
column	O
chromatographic	O
techniques	O
.	O
The	O
pI	O
values	O
of	O
the	O
acid	O
DNase	O
and	O
its	O
inhibitor	O
were	O
5.4	O
and	O
4.2	O
,	O
respectively	O
.	O
PMID	O
:	O
265579	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

FEBS	O
Lett	O
.	O
1987	O
Aug	O
17;220(	O
2	O
)	O
:	O
302	O
-6.	O
Bradykinin	O
inhibits	O
potassium	O
(	O
M	O
)	O
currents	O
in	O
N1E-115	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Responses	O
resemble	O
those	O
in	O
NG108-15	O
neuroblastoma	B-malignancy-type
x	O
glioma	B-malignancy-type
hybrid	O
cells	O
.	O
Higashida	O
H,	O
Brown	O
DA	O
.	O
Application	O
of	O
bradykinin	O
to	O
voltage	O
-	O
clamped	O
N1E-115	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
evoked	O
sequential	O
outward	O
and	O
inward	O
membrane	O
currents	O
,	O
accompanied	O
by	O
an	O
increase	O
and	O
decrease	O
of	O
membrane	O
conductance	O
,	O
respectively	O
.	O
Methacholine	O
produced	O
an	O
inward	O
current	O
with	O
a	O
decreased	O
conductance	O
.	O
The	O
outward	O
current	O
response	O
to	O
bradykinin	O
was	O
imitated	O
by	O
intracellular	O
inositol	O
1,4,5-trisphosphate	O
(	O
IP3	O
)	O
.	O
Bath	O
application	O
of	O
phorbol	O
dibutyrate	O
induced	O
an	O
inward	O
current	O
and	O
potentiated	O
the	O
response	O
to	O
IP3	O
.	O
We	O
conclude	O
that	O
the	O
response	O
of	O
these	O
cells	O
to	O
bradykinin	O
is	O
identical	O
to	O
that	O
of	O
NG108-15	O
hybrid	O
cells	O
,	O
and	O
therefore	O
may	O
be	O
attributed	O
to	O
the	O
dual	O
effects	O
of	O
inositol	O
trisphosphate	O
and	O
diacylglycerol	O
formed	O
by	O
hydrolysis	O
of	O
phosphatidylinositide	O
.	O
PMID	O
:	O
2440728	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Cell	O
Biol	O
.	O
1993	O
Jun;13(	O
6	O
)	O
:	O
3221-30	O
.	O
Nucleolar	O
localization	O
of	O
myc	O
transcripts	O
.	O
Bond	O
VC	O
,	O
Wold	O
B.	O
Division	O
of	O
Biology	O
,	O
California	O
Institute	O
of	O
Technology	O
,	O
Pasadena	O
91125	O
.	O
In	O
situ	O
hybridization	O
has	O
revealed	O
a	O
striking	O
subnuclear	O
distribution	O
of	O
c-myc	O
RNA	O
transcripts	O
.	O
A	O
major	O
fraction	O
of	O
the	O
sense	O
-	O
strand	O
nuclear	O
c-myc	O
transcripts	O
was	O
localized	O
to	O
the	O
nucleoli	O
.	O
myc	O
intron	O
1	O
-	O
containing	O
RNAs	O
were	O
noticeably	O
absent	O
from	O
nucleoli	O
,	O
accumulating	O
instead	O
in	O
the	O
nucleoplasm	O
.	O
The	O
localization	O
of	O
myc	O
RNA	O
to	O
nucleoli	O
was	O
shown	O
to	O
be	O
common	O
to	O
a	O
number	O
of	O
diverse	O
cell	O
types	O
,	O
including	O
primary	O
Sertoli	O
cells	O
and	O
several	O
cell	O
lines	O
.	O
Furthermore	O
,	O
nucleolar	O
localization	O
was	O
not	O
restricted	O
to	O
c-myc	O
and	O
N-myc	O
and	O
myoD	O
transcripts	O
also	O
displayed	O
this	O
phenomenon	O
.	O
In	O
contrast	O
,	O
gamma-actin	O
or	O
lactate	O
dehydrogenase	O
transcripts	O
did	O
not	O
display	O
nucleolar	O
localization	O
.	O
These	O
observations	O
suggest	O
a	O
new	O
role	O
for	O
the	O
nucleolus	O
in	O
transport	O
and/or	O
turnover	O
of	O
potential	O
mRNAs	O
.	O
PMID	O
:	O
7684491	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Med	O
Today	O
.	O
1996	O
Oct;2	O
(	O
10	O
)	O
:432	O
-8.	O
Neurotrophin	O
receptors	O
,	O
tumor	O
progression	O
and	O
tumor	O
maturation	O
.	O
Pahlman	O
S	O
,	O
Hoehner	O
JC	O
.	O
Department	O
of	O
Medicine	O
,	O
Lund	O
University	O
,	O
University	O
Hospital	O
MAS	O
,	O
Malmo	O
,	O
Sweden	O
.	O
sven	O
.pahlman@medforsk.mas	O
.lu.se	O
The	O
nerve	O
growth	O
factor	O
receptor	O
TrkA	O
was	O
initially	O
isolated	O
as	O
a	O
transforming	O
oncogene	O
,	O
trk	O
,	O
in	O
which	O
most	O
of	O
the	O
extracellular	O
receptor	O
part	O
is	O
replaced	O
by	O
the	O
coding	O
sequence	O
for	O
a	O
tropomyosin	O
-	O
encoding	O
gene	O
.	O
The	O
impact	O
that	O
the	O
identification	O
of	O
the	O
first	O
neurotrophin	O
receptor	O
has	O
made	O
on	O
the	O
entire	O
field	O
of	O
developmental	O
neurobiology	O
cannot	O
be	O
overstated	O
.	O
Following	O
a	O
brief	O
introduction	O
to	O
the	O
biology	O
of	O
neurotrophins	O
and	O
their	O
receptors	O
,	O
this	O
review	O
will	O
focus	O
on	O
oncogenic	O
Trk	O
in	O
human	O
malignant	O
disorders	O
,	O
discuss	O
putative	O
tumorigenic	O
involvement	O
of	O
Trk	O
family	O
members	O
in	O
the	O
childhood	O
malignancy	O
neuroblastoma	B-malignancy-type
,	O
and	O
point	O
out	O
potential	O
neurotrophin	O
-	O
based	O
treatment	O
modalities	O
for	O
this	O
and	O
other	O
neuroendocrine	B-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
8897438	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pediatr	O
Med	O
Chir	O
.	O
1994	O
May-Jun;16	O
(	O
3	O
)	O
:	O
203	O
-	O
9.	O
[	O
Oncogenes	O
and	O
suppressor	O
genes	O
in	O
the	O
genesis	O
and	O
progression	O
of	O
solid	B-malignancy-type
tumors	I-malignancy-type
in	O
children	O
]	O
[	O
Article	O
in	O
Italian	O
]	O
Tonini	O
GP	O
,	O
Mazzocco	O
K,	O
Scaruffi	O
P.	O
Laboratorio	O
Scientifico	O
di	O
Oncologia	O
,	O
Istituto	O
Scientifico	O
G.	O
Gaslini	O
,	O
Genova	O
,	O
Italia	O
.	O
Molecular	O
and	O
genetic	O
analyses	O
of	O
tumor	O
cell	O
show	O
that	O
cellular	O
oncogenes	O
and	O
suppressor	O
genes	O
are	O
involved	O
in	O
neoplastic	O
transformation	O
.	O
In	O
pediatric	O
tumors	B-malignancy-type
oncogenes	O
as	O
N-myc	O
play	O
an	O
important	O
role	O
in	O
the	O
tumor	O
progression	O
.	O
In	O
retinoblastoma	B-malignancy-type
,	O
neuroblastoma	B-malignancy-type
,	O
Wilms	B-malignancy-type
'	I-malignancy-type
tumor	I-malignancy-type
,	O
and	O
rhabdomyosarcoma	B-malignancy-type
loss	O
of	O
heterozygosity	O
for	O
specific	O
chromosome	O
loci	O
has	O
been	O
suggested	O
to	O
be	O
a	O
critical	O
step	O
in	O
cancer	O
development	O
.	O
Oncogene	O
abnormalities	O
can	O
also	O
be	O
useful	O
as	O
a	O
molecular	O
tumor	O
factor	O
to	O
foresee	O
the	O
prognosis	O
of	O
the	O
disease	O
.	O
The	O
present	O
article	O
is	O
a	O
review	O
on	O
the	O
role	O
of	O
the	O
oncogenes	O
and	O
suppressor	O
genes	O
in	O
pediatric	O
solid	B-malignancy-type
tumors	I-malignancy-type
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
7971441	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neuroreport	O
.	O
1996	O
Sep	O
2;	O
7(	O
13	O
)	O
:	O
2191-5	O
.	O
Ethanol	O
exposure	O
increases	O
expression	O
of	O
c-jun	O
and	O
junD	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Ding	O
WQ	O
,	O
Larsson	O
C	O
,	O
Alling	O
C.	O
Department	O
of	O
Medical	O
Neurochemistry	O
,	O
Lund	O
University	O
Hospital	O
,	O
Sweden	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
ethanol	O
exposure	O
on	O
the	O
expression	O
of	O
fos	O
and	O
jun	O
genes	O
.	O
Exposure	O
of	O
human	O
neuroblastoma	B-malignancy-type
SH-SY5Y	O
cells	O
to	O
ethanol	O
for	O
2	O
-	O
4	O
days	O
caused	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
c-jun	O
and	O
junD	O
mRNA	O
levels	O
,	O
whereas	O
mRNAs	O
for	O
c-fos	O
,	O
fosB	O
and	O
junB	O
were	O
not	O
detectable	O
in	O
control	O
or	O
ethanol	O
-	O
treated	O
cells	O
.	O
Four	O
days	O
of	O
ethanol	O
exposure	O
also	O
enhanced	O
the	O
AP-1	O
binding	O
activity	O
.	O
Experiments	O
with	O
actinomycin	O
D	O
demonstrated	O
that	O
ethanol	O
did	O
not	O
influence	O
the	O
degradation	O
of	O
c-jun	O
and	O
junD	O
mRNAs	O
.	O
These	O
results	O
demonstrate	O
that	O
long	O
-	O
term	O
exposure	O
to	O
ethanol	O
increases	O
c-jun	O
and	O
junD	O
expression	O
.	O
This	O
effect	O
may	O
be	O
one	O
of	O
the	O
mechanisms	O
through	O
which	O
ethanol	O
influences	O
the	O
gene	O
regulatory	O
system	O
in	O
neuronal	O
cells	O
.	O
PMID	O
:	O
8930987	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Endocrinol	O
.	O
1999	O
Aug;13(	O
8	O
)	O
:	O
1237-48	O
.	O
A	O
requirement	O
for	O
the	O
POU	O
transcription	O
factor	O
,	O
Brn-2	O
,	O
in	O
corticotropin	O
-	O
releasing	O
hormone	O
expression	O
in	O
a	O
neuronal	O
cell	O
line	O
.	O
Ramkumar	O
T	O
,	O
Adler	O
S.	O
Division	O
of	O
Biology	O
and	O
Biomedical	O
Sciences	O
,	O
Washington	O
University	O
Medical	O
School	O
,	O
Saint	O
Louis	O
,	O
Missouri	O
63110	O
,	O
USA	O
.	O
The	O
expression	O
of	O
the	O
endogenous	O
CRF	O
gene	O
was	O
examined	O
in	O
the	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
,	O
BE(2)-M17	O
.	O
In	O
this	O
cell	O
line	O
,	O
treatment	O
with	O
retinoic	O
acid	O
induces	O
CRF	O
mRNA	O
transcription	O
.	O
We	O
examined	O
the	O
requirement	O
for	O
the	O
POU	O
transcription	O
factor	O
,	O
Bm-2	O
,	O
for	O
this	O
response	O
.	O
We	O
confirmed	O
that	O
Bm-2	O
is	O
expressed	O
in	O
retinoic	O
acid	O
-	O
induced	O
BE(2)-M17	O
cells	O
.	O
Expression	O
of	O
antisense	O
Bm-2	O
message	O
aborted	O
the	O
retinoic	O
acid	O
-	O
mediated	O
induction	O
of	O
CRF	O
transcription	O
.	O
However	O
,	O
overexpression	O
of	O
Bm-2	O
was	O
not	O
sufficient	O
for	O
CRF	O
expression	O
in	O
the	O
absence	O
of	O
retinoic	O
acid	O
.	O
These	O
experiments	O
support	O
the	O
hypothesis	O
that	O
Bm-2	O
is	O
an	O
intermediary	O
for	O
retinoic	O
acid	O
-	O
induced	O
CRF	O
expression	O
.	O
PMID	O
:	O
10446900	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
Mol	O
Brain	O
Res	O
.	O
1996	O
Jan;35	O
(	O
1-2	O
)	O
:	O
304	O
-	O
8.	O
The	O
helix	O
-	O
loop	O
-	O
helix	O
transcription	O
factor	O
USF	O
interacts	O
with	O
the	O
basal	O
promoter	O
of	O
human	O
amyloid	O
precursor	O
protein	O
.	O
Bourbonniere	O
M,	O
Nalbantoglu	O
J.	O
Department	O
of	O
Neurology	O
and	O
Neurosurgery	O
,	O
McGill	O
University	O
,	O
Montreal	O
,	O
Que	O
,	O
Canada	O
.	O
Nuclear	O
factors	O
from	O
HeLa	O
,	O
PC12	O
,	O
NG108-15	O
and	O
SK-N-SH	O
cell	O
lines	O
recognized	O
an	O
oligonucleotide	O
(	O
-	O
56	O
to	O
-	O
37	O
:	O
APP	O
-	O
E1	O
)	O
containing	O
an	O
E	O
box	O
(	O
CANNTG	O
)	O
which	O
had	O
previously	O
been	O
characterized	O
as	O
a	O
DNase	O
I	O
-	O
protected	O
sequence	O
in	O
the	O
basal	O
promoter	O
of	O
the	O
human	O
amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
gene	O
.	O
Binding	O
to	O
APP	O
-	O
E1	O
was	O
competed	O
with	O
an	O
oligonucleotide	O
encompassing	O
the	O
recognition	O
site	O
of	O
the	O
transcription	O
factor	O
USF	O
.	O
Antibodies	O
directed	O
against	O
USF	O
interacted	O
with	O
the	O
APP	O
-	O
E1	O
-	O
protein	O
complex	O
and	O
in	O
vitro	O
synthesized	O
USF	O
could	O
bind	O
APP	O
-	O
E1	O
.	O
Co	O
-	O
expression	O
of	O
USF	O
cDNA	O
transactivated	O
a	O
human	O
APP	O
-	O
reporter	O
gene	O
construct	O
.	O
These	O
results	O
suggest	O
that	O
USF	O
may	O
play	O
a	O
role	O
in	O
the	O
expression	O
of	O
the	O
APP	O
gene	O
.	O
PMID	O
:	O
8717367	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Prog	O
Clin	O
Biol	O
Res	O
.	O
1988	O
;271	O
:31	O
-	O
9.	O
Biological	O
characteristics	O
of	O
N-myc	O
amplified	O
neuroblastoma	B-malignancy-type
in	O
patients	O
over	O
one	O
year	O
of	O
age	O
.	O
Nakagawara	O
A	O
,	O
Ikeda	O
K,	O
Tsuda	O
T	O
,	O
Higashi	O
K.	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
Faculty	O
of	O
Medicine	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
,	O
Japan	O
.	O
1.	O
A	O
genomic	O
amplification	O
of	O
N-myc	O
of	O
neuroblastoma	B-malignancy-type
was	O
frequently	O
observed	O
in	O
patients	O
in	O
the	O
advanced	O
stage	O
of	O
the	O
disease	O
,	O
in	O
those	O
with	O
the	O
tumor	O
originating	O
from	O
the	O
suprarenal	O
region	O
,	O
and	O
in	O
those	O
with	O
a	O
histologically	O
undifferentiated	O
neuroblastoma	B-malignancy-type
.	O
Thus	O
,	O
N-myc	O
may	O
be	O
one	O
of	O
the	O
most	O
pertinent	O
prognostic	O
factors	O
of	O
neuroblastoma	B-malignancy-type
in	O
patients	O
over	O
one	O
year	O
of	O
age	O
.	O
2.	O
The	O
neuroblastoma	B-malignancy-type
patient	O
with	O
1	O
-	O
10	O
copies	O
of	O
N-myc	O
responded	O
to	O
aggressive	O
multidisciplinary	O
therapy	O
,	O
even	O
those	O
over	O
one	O
year	O
of	O
age	O
.	O
3.	O
Rapid	O
invasion	O
and	O
progression	O
of	O
the	O
tumor	O
was	O
evident	O
in	O
children	O
with	O
more	O
than	O
10	O
copies	O
of	O
N-myc	O
.	O
4.	O
N-myc	O
amplification	O
may	O
correlate	O
with	O
immaturity	O
of	O
catecholamine	O
metabolism	O
of	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
3406005	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Mol	O
Neurosci	O
.	O
1993	O
Summer;4(	O
2	O
)	O
:	O
117-	O
23	O
.	O
Desensitization	O
of	O
D1	O
dopamine	O
receptors	O
down	O
-	O
regulates	O
the	O
Gs	O
alpha	O
subunit	O
of	O
G	O
protein	O
in	O
SK-N-MC	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Gupta	O
SK	O
,	O
Mishra	O
RK	O
.	O
Department	O
of	O
Psychiatry	O
,	O
Faculty	O
of	O
Health	O
Sciences	O
,	O
McMaster	O
University	O
,	O
Hamilton	O
,	O
Ontario	O
,	O
Canada	O
.	O
The	O
effect	O
of	O
long	O
-	O
term	O
(	O
72	O
h	O
)	O
treatment	O
with	O
dopamine	O
D1	O
receptor	O
agonists	O
,	O
SKF	O
38393	O
and	O
dopamine	O
on	O
D1	O
dopamine	O
receptor	O
and	O
G-protein	O
(	O
Gs	O
alpha	O
)	O
was	O
investigated	O
in	O
SK-N-MC	O
neuroblastoma	B-malignancy-type
cells	O
.	O
The	O
prolonged	O
treatment	O
of	O
cells	O
with	O
10	O
microM	O
SKF	O
38393	O
or	O
10	O
microM	O
dopamine	O
resulted	O
in	O
a	O
decrease	O
in	O
dopamine	O
D1	O
receptor	O
by	O
41	O
and	O
81	O
%	O
,	O
respectively	O
,	O
as	O
measured	O
by	O
specific	O
antagonist	O
[3H]SCH	O
23390	O
binding	O
.	O
Similarly	O
,	O
the	O
prolonged	O
treatment	O
of	O
SK-N-MC	O
cells	O
with	O
10	O
microM	O
SKF	O
38393	O
or	O
10	O
microM	O
dopamine	O
resulted	O
in	O
a	O
reduction	O
of	O
the	O
level	O
of	O
Gs	O
alpha	O
subunit	O
of	O
G-protein	O
.	O
The	O
results	O
indicate	O
that	O
agonist	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
D1	O
dopamine	O
receptor	O
may	O
also	O
modulate	O
G-proteins	O
.	O
PMID	O
:	O
8105856	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Radiat	O
Oncol	O
Biol	O
Phys	O
.	O
1992	O
;22	O
(	O
2	O
)	O
:	O
375	O
-	O
81	O
.	O
Charged	O
particle	O
therapy	O
to	O
pediatric	O
tumors	O
of	O
the	O
retroperitoneal	O
region	O
:	O
a	O
possible	O
indication	O
.	O
Gademann	O
G	O
,	O
Wannenmacher	O
M.	O
Radiological	O
Clinic	O
,	O
University	O
of	O
Heidelberg	O
,	O
Germany	O
.	O
Despite	O
a	O
very	O
successful	O
interdisciplinary	O
therapy	O
regimen	O
for	O
pediatric	O
solid	B-malignancy-type
tumors	I-malignancy-type
dominated	O
by	O
surgery	O
and	O
chemotherapy	O
,	O
the	O
role	O
of	O
radiotherapy	O
might	O
become	O
again	O
more	O
important	O
if	O
new	O
techniques	O
will	O
allow	O
a	O
better	O
dose	O
localization	O
to	O
the	O
target	O
volume	O
combined	O
with	O
a	O
better	O
protection	O
of	O
the	O
normal	O
tissue	O
.	O
This	O
characteristic	O
is	O
known	O
for	O
charged	O
particle	O
beams	O
.	O
In	O
a	O
field	O
study	O
based	O
on	O
German	O
cooperative	O
trials	O
,	O
the	O
possibility	O
of	O
a	O
charged	O
particle	O
radiotherapy	O
to	O
retroperitoneal	B-malignancy-type
tumors	I-malignancy-type
of	O
childhood	O
will	O
be	O
discussed	O
regarding	O
indications	O
in	O
risk	O
groups	O
and	O
recurrences	O
.	O
Absolute	O
patient	O
numbers	O
are	O
estimated	O
from	O
the	O
clinical	O
experiences	O
and	O
the	O
incidences	O
of	O
the	O
diseases	O
.	O
A	O
stepwise	O
introduction	O
of	O
this	O
new	O
therapy	O
modality	O
is	O
proposed	O
.	O
PMID	O
:	O
1310973	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Curr	O
Opin	O
Oncol	O
.	O
1991	O
Jun;	O
3(	O
3	O
)	O
:	O
48	O
5	O
-	O
96	O
.	O
Neuroblastoma	B-malignancy-type
,	O
retinoblastoma	B-malignancy-type
,	O
and	O
brain	B-malignancy-type
tumors	I-malignancy-type
in	O
children	O
.	O
Brodeur	O
GM	O
,	O
Saylors	O
RL	O
3rd	O
.	O
Department	O
of	O
Pediatrics	O
,	O
Washington	O
University	O
School	O
of	O
Medicine	O
,	O
St.	O
Louis	O
,	O
MO	O
63110	O
.	O
Considerable	O
progress	O
has	O
been	O
made	O
recently	O
in	O
the	O
biologic	O
understanding	O
and	O
the	O
clinical	O
management	O
of	O
pediatric	O
tumors	O
of	O
the	O
peripheral	O
and	O
central	O
nervous	O
system	O
.	O
Here	O
we	O
review	O
important	O
representative	O
studies	O
published	O
primarily	O
in	O
the	O
past	O
2	O
years	O
regarding	O
neuroblastoma	B-malignancy-type
,	O
retinoblastoma	B-malignancy-type
,	O
and	O
brain	B-malignancy-type
tumors	I-malignancy-type
in	O
children	O
.	O
Highlights	O
include	O
1)	O
the	O
importance	O
of	O
tumor	O
DNA	O
content	O
,	O
N-myc	O
amplification	O
,	O
and	O
chromosome	O
1	O
deletion	O
in	O
predicting	O
outcome	O
of	O
patients	O
with	O
neuroblastoma	B-malignancy-type
;	O
2)	O
the	O
impact	O
of	O
mass	O
screening	O
for	O
neuroblastoma	B-malignancy-type
in	O
Japan	O
and	O
elsewhere	O
;	O
3)	O
improvements	O
in	O
the	O
clinical	O
management	O
of	O
neuroblastoma	B-malignancy-type
,	O
retinoblastoma	B-malignancy-type
,	O
and	O
brain	B-malignancy-type
tumors	I-malignancy-type
;	O
and	O
4)	O
neurologic	O
sequelae	O
of	O
these	O
tumors	O
and	O
their	O
treatment	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
Literature	O
PMID	O
:	O
1892917	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Histochem	O
Cytochem	O
.	O
1981	O
Jul;29(	O
7	O
)	O
:	O
851	O
-	O
7.	O
Probability	O
paper	O
analysis	O
of	O
flow	O
cytofluorometric	O
measurements	O
of	O
cellular	O
deoxyribonucleic	O
acid	O
content	O
.	O
Neely	O
JE	O
,	O
Combs	O
JW	O
.	O
A	O
graphic	O
analysis	O
of	O
cellular	O
deoxyribonucleic	O
acid	O
(	O
DNA	O
)	O
histograms	O
obtained	O
by	O
flow	O
cytofluorometry	O
is	O
described	O
.	O
This	O
technique	O
utilizes	O
probability	O
paper	O
that	O
graphs	O
data	O
in	O
cumulative	O
percentile	O
form	O
.	O
From	O
this	O
graphic	O
representation	O
,	O
individual	O
normal	O
distributions	O
contributing	O
to	O
the	O
histogram	O
may	O
be	O
isolated	O
and	O
statistically	O
describe	O
.	O
G0G1	O
and	O
G2M	O
distributions	O
are	O
independently	O
described	O
and	O
S	O
phase	O
is	O
fit	O
to	O
1	O
--	O
5	O
overlapping	O
normal	O
distributions	O
as	O
dictated	O
by	O
the	O
analysis	O
results	O
.	O
This	O
technique	O
offers	O
several	O
advantages	O
,	O
including	O
relatively	O
simple	O
mathematical	O
calculations	O
and	O
few	O
assumptions	O
or	O
restraints	O
placed	O
on	O
the	O
analysis	O
.	O
It	O
has	O
proved	O
to	O
be	O
useful	O
in	O
analyzing	O
proliferating	O
and	O
nonproliferating	O
populations	O
as	O
well	O
as	O
distributions	O
with	O
unusual	O
findings	O
such	O
as	O
debris	O
or	O
aberrant	O
DNA	O
contents	O
.	O
PMID	O
:	O
7021670	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neuroreport	O
.	O
2002	O
May	O
7;13(	O
6	O
)	O
:	O
867	O
-	O
70	O
.	O
Truncated	O
apoE	O
forms	O
tangle	O
-	O
like	O
structures	O
in	O
a	O
neuronal	O
cell	O
line	O
.	O
Ljungberg	O
MC	O
,	O
Dayanandan	O
R	O
,	O
Asuni	O
A	O
,	O
Rupniak	O
TH	O
,	O
Anderton	O
BH	O
,	O
Lovestone	O
S.	O
Department	O
of	O
Neuroscience	O
,	O
Institute	O
of	O
Psychiatry	O
,	O
King	O
's	O
College	O
London	O
,	O
De	O
Crespigny	O
Park	O
,	O
London	O
SE5	O
8AF	O
,	O
UK.	O
Apolipoprotein	O
E	O
is	O
the	O
predominant	O
brain	O
lipoprotein	O
and	O
polymorphic	O
variation	O
in	O
the	O
APOE	O
gene	O
the	O
major	O
genetic	O
susceptibly	O
factor	O
for	O
late	O
onset	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O
Recently	O
it	O
was	O
reported	O
that	O
carboxyl	O
-	O
truncated	O
ApoE	O
fragments	O
induce	O
tangle	O
-	O
like	O
structures	O
in	O
neurons	O
.	O
We	O
confirm	O
the	O
finding	O
:	O
in	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
truncated	O
apoE	O
fragments	O
lacking	O
the	O
carboxyterminus	O
induce	O
structures	O
that	O
have	O
the	O
appearance	O
of	O
neurofibrillary	O
tangles	O
.	O
However	O
these	O
tangles	O
are	O
not	O
induced	O
in	O
non	O
-	O
neuronal	O
cells	O
even	O
in	O
the	O
presence	O
of	O
co	O
-	O
expressed	O
neurofilaments	O
or	O
tau	O
.	O
Further	O
understanding	O
of	O
the	O
basis	O
of	O
this	O
cell	O
specificity	O
might	O
add	O
to	O
understanding	O
of	O
the	O
cell	O
specificity	O
of	O
tangles	O
in	O
AD	O
.	O
PMID	O
:	O
11997703	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
1980	O
Aug;40(	O
8	O
Pt	O
1	O
)	O
:	O
2884	O
-	O
9.	O
Cyclic	O
adenosine	O
3':5'-monophosphate	O
-	O
binding	O
protein	O
,	O
a	O
biochemical	O
marker	O
of	O
neuroblastoma	B-malignancy-type
differentiation	O
.	O
Prashad	O
N	O
,	O
Rosenberg	O
R	O
,	O
Baskin	O
F	O
,	O
Sparkman	O
D	O
,	O
Ulrich	O
C	O
,	O
Wischmeyer	O
B.	O
Mouse	O
neuroblastoma	B-malignancy-type
tumors	I-malignancy-type
show	O
reduced	O
amounts	O
of	O
cyclic	O
adenosine	O
3':5'-monophosphate	O
(	O
cAMP	O
)	O
binding	O
protein	O
.	O
However	O
,	O
the	O
levels	O
of	O
cAMP	O
-	O
binding	O
protein	O
were	O
increased	O
by	O
2	O
-	O
fold	O
when	O
the	O
tumor	O
cells	O
were	O
established	O
in	O
tissue	O
culture	O
,	O
and	O
these	O
levels	O
were	O
comparable	O
to	O
that	O
found	O
in	O
mouse	O
brain	O
.	O
This	O
binding	O
protein	O
is	O
a	O
free	O
cAMP	O
-	O
binding	O
protein	O
that	O
is	O
not	O
associated	O
with	O
protein	O
kinase	O
.	O
The	O
reduced	O
amounts	O
of	O
free	O
cAMP	O
-	O
binding	O
protein	O
in	O
tumors	O
are	O
not	O
a	O
consequence	O
of	O
a	O
defective	O
gene	O
,	O
but	O
the	O
synthesis	O
of	O
this	O
protein	O
is	O
regulated	O
at	O
the	O
transcriptional	O
and/or	O
translational	O
levels	O
.	O
The	O
free	O
cAMP	O
-	O
binding	O
protein	O
like	O
the	O
neurotransmitter	O
-	O
synthesizing	O
enzymes	O
can	O
be	O
used	O
as	O
a	O
biochemical	O
marker	O
of	O
differentiation	O
,	O
and	O
this	O
protein	O
may	O
play	O
a	O
role	O
in	O
neuronal	O
differentiation	O
.	O
PMID	O
:	O
6248216	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochim	O
Biophys	O
Acta	O
.	O
1998	O
Jan	O
21;139	O
5	O
(	O
2	O
)	O
:151	O
-	O
8.	O
Cloning	O
and	O
expression	O
of	O
a	O
human	O
/	O
mouse	O
Polycomb	O
group	O
gene	O
,	O
ENX-2	O
/	O
Enx-2	O
.	O
Ogawa	O
M,	O
Hiraoka	O
Y	O
,	O
Taniguchi	O
K,	O
Aiso	O
S.	O
Department	O
of	O
Anatomy	O
,	O
Keio	O
University	O
School	O
of	O
Medicine	O
,	O
Tokyo	O
,	O
Japan	O
.	O
The	O
Drosophila	O
Polycomb	O
group	O
(	O
Pc-G	O
)	O
genes	O
encode	O
transcriptional	O
factors	O
involved	O
in	O
development	O
.	O
Little	O
is	O
known	O
about	O
members	O
of	O
the	O
vertebrate	O
Pc-G	O
genes	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
isolated	O
a	O
cDNA	O
encoding	O
a	O
human	O
Pc-G	O
protein	O
and	O
the	O
mouse	O
equivalent	O
.	O
The	O
human	O
and	O
mouse	O
genes	O
,	O
which	O
were	O
named	O
ENX-2	O
and	O
Enx-2	O
,	O
encode	O
702	O
and	O
750	O
amino	O
acids	O
,	O
respectively	O
.	O
ENX-2	O
/	O
Enx-2	O
protein	O
exhibits	O
a	O
high	O
homology	O
(	O
53	O
-	O
55	O
%	O
identity	O
)	O
to	O
Drosophila	O
Enhancer	O
of	O
zeste	O
[	O
E(z)	O
]	O
protein	O
belonging	O
to	O
the	O
Pc-G	O
.	O
The	O
expression	O
of	O
Enx-2	O
was	O
observed	O
in	O
mouse	O
kidney	O
,	O
adrenal	O
gland	O
,	O
testis	O
and	O
brain	O
at	O
high	O
levels	O
by	O
Northern	O
blot	O
analysis	O
.	O
A	O
cell	O
line	O
of	O
mouse	O
neuroblastoma	B-malignancy-type
,	O
Neuro-2a	O
,	O
also	O
expresses	O
Enx-2	O
mRNA	O
and	O
its	O
level	O
is	O
elevated	O
by	O
induction	O
of	O
neuronal	O
differentiation	O
of	O
the	O
cell	O
.	O
PMID	O
:	O
9473645	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neuropeptides	O
.	O
1992	O
Sep;23(	O
1	O
)	O
:45-	O
9.	O
Interleukin-6	O
and	O
corticotrophin	O
-	O
releasing	O
hormone	O
mRNA	O
are	O
modulated	O
during	O
differentiation	O
of	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Stephanou	O
A	O
,	O
Melino	O
G	O
,	O
Knight	O
RA	O
,	O
Annicchiarico-Petruzzelli	O
M,	O
Sarlis	O
NJ	O
,	O
Finazzi-	O
Agro	O
A	O
,	O
Lightman	O
SL	O
.	O
Department	O
of	O
Neuroendocrinology	O
,	O
Charing	O
Cross	O
and	O
Westminster	O
Medical	O
School	O
,	O
Charing	O
Cross	O
Hospital	O
,	O
London	O
,	O
UK.	O
Two	O
cell	O
clones	O
[	O
BE(2)-C	O
and	O
BE(2)-M17	O
]	O
derived	O
from	O
the	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
SK-N-BE(2)	O
express	O
corticotrophin	O
-	O
releasing	O
hormone	O
as	O
well	O
as	O
interleukin-6	O
mRNA	O
.	O
Both	O
genes	O
are	O
overexpressed	O
,	O
although	O
with	O
a	O
different	O
time	O
course	O
,	O
following	O
exposure	O
to	O
5	O
microM	O
retinoic	O
acid	O
,	O
in	O
parallel	O
to	O
the	O
induction	O
of	O
neuroblastic	O
differentiation	O
.	O
On	O
the	O
contrary	O
,	O
we	O
are	O
unable	O
to	O
detect	O
interleukin-1	O
beta	O
mRNA	O
in	O
these	O
cell	O
lines	O
.	O
Both	O
cytokines	O
are	O
known	O
to	O
increase	O
hypothalamic	O
CRH	O
mRNA	O
.	O
The	O
production	O
of	O
cytokines	O
and	O
neuropeptides	O
by	O
neuroblastoma	B-malignancy-type
cells	O
indicate	O
a	O
complex	O
dialogue	O
between	O
tumour	O
cells	O
and	O
anti	O
-	O
tumour	O
immunity	O
.	O
PMID	O
:	O
1407416	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pharmacol	O
Exp	O
Ther	O
.	O
1989	O
Jun;249(	O
3	O
)	O
:	O
90	O
6-10	O
.	O
Neocarzinostatin	O
induces	O
neuronal	O
morphology	O
of	O
mouse	O
neuroblastoma	B-malignancy-type
in	O
culture	O
.	O
Schor	O
NF	O
.	O
Department	O
of	O
Pediatrics	O
,	O
University	O
of	O
Pittsburgh	O
,	O
Pennsylvania	O
.	O
Neocarzinostatin	O
,	O
an	O
antineoplastic	O
agent	O
which	O
consists	O
of	O
a	O
chromophore	O
noncovalently	O
bound	O
to	O
a	O
protein	O
of	O
approximately	O
10,000D	O
MW	O
,	O
induces	O
the	O
morphological	O
differentiation	O
of	O
cells	O
of	O
the	O
C1300	O
murine	O
neuroblastoma	B-malignancy-type
line	O
in	O
vitro	O
.	O
It	O
also	O
has	O
antimitotic	O
activity	O
,	O
ascribed	O
previously	O
in	O
other	O
cell	O
lines	O
to	O
the	O
action	O
of	O
the	O
chromophore	O
upon	O
DNA	O
.	O
The	O
chromophore	O
is	O
antimitotic	O
for	O
neuroblastoma	B-malignancy-type
cells	O
,	O
as	O
well	O
.	O
The	O
morphology	O
-	O
altering	O
effect	O
of	O
neocarzinostatin	O
can	O
also	O
be	O
mimicked	O
by	O
chromophore	O
alone	O
.	O
The	O
morphology	O
-	O
altering	O
effect	O
becomes	O
apparent	O
at	O
doses	O
of	O
the	O
agent	O
which	O
decrease	O
the	O
culture	O
growth	O
rate	O
to	O
approximately	O
50	O
%	O
of	O
control	O
values	O
.	O
It	O
appears	O
that	O
induction	O
of	O
morphological	O
neural	O
differentiation	O
of	O
neuroblastoma	B-malignancy-type
cells	O
requires	O
an	O
increase	O
in	O
the	O
doubling	O
time	O
above	O
a	O
critical	O
value	O
.	O
PMID	O
:	O
2525186	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gerontology	O
.	O
1994	O
;40	O
Suppl	O
2	O
:	O
57	O
-64	O
.	O
The	O
toxic	O
effect	O
of	O
Alzheimer	O
amyloid	O
protein	O
precursor	O
overexpressed	O
in	O
the	O
neuroblastoma	B-malignancy-type
cell	O
line	O
NB-1	O
on	O
neurite	O
outgrowth	O
.	O
Maruyama	O
K,	O
Kumagae	O
Y	O
,	O
Saito	O
Y	O
,	O
Yamao-Harigaya	O
W	O
,	O
Usami	O
M,	O
Ishiura	O
S	O
,	O
Kawashima	O
S	O
,	O
Obata	O
K.	O
Department	O
of	O
Molecular	O
Biology	O
,	O
Tokyo	O
Metropolitan	O
Institute	O
of	O
Medical	O
Sciences	O
,	O
Japan	O
.	O
The	O
neuroblastoma	B-malignancy-type
cell	O
line	O
NB-1	O
is	O
induced	O
to	O
start	O
neurite	O
outgrowth	O
by	O
dibutyryl	O
cyclic	O
AMP	O
(	O
Bt2cAMP	O
)	O
.	O
To	O
study	O
the	O
function	O
of	O
Alzheimer	O
amyloid	O
protein	O
precursor	O
(	O
APP	O
)	O
,	O
a	O
stable	O
cell	O
line	O
overexpressing	O
APP	O
was	O
established	O
by	O
cDNA	O
transfection	O
.	O
The	O
APP	O
cDNA	O
was	O
driven	O
by	O
the	O
cytomegalovirus	O
early	O
gene	O
promoter	O
.	O
The	O
transformant	O
underwent	O
degeneration	O
as	O
well	O
as	O
neurite	O
outgrowth	O
in	O
the	O
presence	O
of	O
Bt2cAMP	O
,	O
which	O
also	O
increased	O
the	O
amount	O
of	O
APP	O
mRNA	O
and	O
protein	O
.	O
The	O
expressed	O
APP	O
was	O
mainly	O
processed	O
in	O
the	O
secretory	O
pathway	O
and	O
few	O
amyloidogenic	O
fragments	O
were	O
observed	O
.	O
Hence	O
,	O
not	O
only	O
the	O
beta	O
/	O
A4	O
protein	O
but	O
also	O
the	O
overexpressed	O
APP	O
itself	O
might	O
be	O
neurotoxic	O
.	O
PMID	O
:	O
7926867	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Treat	O
Rep.	O
1977	O
Aug;	O
61	O
(	O
5	O
)	O
:835	O
-	O
9.	O
Clinical	O
response	O
and	O
toxicity	O
with	O
cis-dichlorodiammineplatinum(II)	O
in	O
children	O
.	O
Kamalakar	O
P,	O
Freeman	O
AI	O
,	O
Higby	O
DJ	O
,	O
Wallace	O
HJ	O
Jr	O
,	O
Sinks	O
LF.	O
cis-Dichlorodiammineplatinum(II)	O
(	O
DDP	O
)	O
was	O
studied	O
in	O
16	O
children	O
with	O
far	O
-	O
advanced	O
malignancies	O
.	O
Three	O
dosage	O
schedules	O
were	O
tried	O
:	O
regimen	O
A	O
,	O
20	O
mg	O
/	O
m2	O
/	O
day	O
x	O
5	O
days	O
for	O
3	O
-	O
4	O
weeks	O
(	O
11	O
patients	O
)	O
;	O
regimen	O
B	O
,	O
50	O
mg	O
/	O
m2	O
once	O
a	O
week	O
(	O
four	O
patients	O
)	O
;	O
and	O
regimen	O
C	O
,	O
60	O
mg	O
/	O
m2	O
/	O
day	O
x	O
2	O
days	O
every	O
3	O
-	O
4	O
weeks	O
(	O
one	O
patient	O
)	O
.	O
Four	O
of	O
16	O
patients	O
(	O
25	O
%	O
)	O
showed	O
partial	O
response	O
,	O
including	O
one	O
with	O
osteogenic	B-malignancy-type
sarcoma	I-malignancy-type
,	O
one	O
with	O
neuroblastoma	B-malignancy-type
,	O
one	O
with	O
seminoma	B-malignancy-type
,	O
and	O
one	O
with	O
medullary	B-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
thyroid	I-malignancy-type
.	O
Two	O
patients	O
showed	O
clinical	O
improvement	O
.	O
The	O
major	O
toxic	O
manifestations	O
included	O
nausea	O
and	O
vomiting	O
(	O
16	O
of	O
16	O
)	O
,	O
renal	O
toxicity	O
(	O
three	O
of	O
16	O
)	O
,	O
transient	O
pancytopenia	O
(	O
six	O
of	O
12	O
)	O
,	O
and	O
hearing	O
loss	O
(	O
two	O
of	O
16	O
)	O
.	O
It	O
is	O
apparent	O
that	O
DDP	O
has	O
activity	O
in	O
pediatric	O
tumors	O
;	O
however	O
,	O
a	O
more	O
precise	O
response	O
rate	O
must	O
be	O
delineated	O
in	O
a	O
larger	O
series	O
of	O
patients	O
.	O
PMID	O
:	O
890692	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1996	O
Sep	O
27;271	O
(	O
39	O
)	O
:	O
23619	O
-22	O
.	O
Glial	O
cell	O
line	O
-	O
derived	O
neurotrophic	O
factor	O
signals	O
through	O
the	O
RET	O
receptor	O
and	O
activates	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O
Worby	O
CA	O
,	O
Vega	O
QC	O
,	O
Zhao	O
Y	O
,	O
Chao	O
HH	O
,	O
Seasholtz	O
AF	O
,	O
Dixon	O
JE.	O
Department	O
of	O
Biological	O
Chemistry	O
,	O
University	O
of	O
Michigan	O
School	O
of	O
Medicine	O
,	O
Ann	O
Arbor	O
,	O
Michigan	O
48109	O
-0606	O
,	O
USA	O
.	O
Glial	O
cell	O
line	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
GDNF	O
)	O
,	O
a	O
member	O
of	O
the	O
transforming	O
growth	O
factor	O
-	O
beta	O
family	O
of	O
growth	O
factors	O
,	O
was	O
first	O
identified	O
by	O
its	O
ability	O
to	O
promote	O
the	O
survival	O
of	O
midbrain	O
dopaminergic	O
neurons	O
in	O
culture	O
.	O
We	O
demonstrate	O
that	O
GDNF	O
treatment	O
of	O
several	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
leads	O
to	O
dose	O
-	O
dependent	O
tyrosine	O
phosphorylation	O
of	O
the	O
RET	O
receptor	O
and	O
that	O
other	O
transforming	O
growth	O
factor	O
-	O
beta	O
family	O
members	O
are	O
not	O
able	O
to	O
activate	O
the	O
RET	O
receptor	O
.	O
GDNF	O
treatment	O
of	O
neuroblastoma	B-malignancy-type
cells	O
also	O
results	O
in	O
increased	O
transcription	O
of	O
an	O
Elk	O
luciferase	O
reporter	O
gene	O
,	O
suggesting	O
that	O
GDNF	O
activates	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
signal	O
transduction	O
pathway	O
.	O
PMID	O
:	O
8798576	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gynecol	O
Oncol	O
.	O
1989	O
Jun;33	O
(	O
3	O
)	O
:	O
356	O
-	O
9.	O
N-myc	O
amplification	O
and	O
neuron	O
-	O
specific	O
enolase	O
production	O
of	O
a	O
neuroblastoma	B-malignancy-type
cell	O
line	O
and	O
germ	B-malignancy-type
cell	I-malignancy-type
tumor	I-malignancy-type
cell	O
lines	O
.	O
Ishiwata	O
I	O
,	O
Ishiwata	O
C	O
,	O
Soma	O
M,	O
Ono	O
I	O
,	O
Nakaguchi	O
T	O
,	O
Nozawa	O
S	O
,	O
Ishikawa	O
H.	O
Ishiwata	O
Obstetrics	O
and	O
Gynecologic	O
Hospital	O
,	O
Ibaraki	O
-ken	O
,	O
Japan	O
.	O
N-myc	O
gene	O
amplification	O
of	O
the	O
gynecological	B-malignancy-type
malignant	I-malignancy-type
tumor	I-malignancy-type
cell	O
lines	O
and	O
a	O
neuroblastoma	B-malignancy-type
cell	O
line	O
was	O
studied	O
by	O
the	O
Southern	O
hybridization	O
method	O
along	O
with	O
the	O
production	O
of	O
neuron	O
-	O
specific	O
enolase	O
(	O
NSE	O
)	O
by	O
these	O
cell	O
lines	O
.	O
N-myc	O
amplification	O
and	O
NSE	O
production	O
were	O
observed	O
side	O
by	O
side	O
in	O
three	O
cell	O
lines	O
:	O
neuroblastoma	B-malignancy-type
cell	O
line	O
HSNB	O
,	O
endodermal	B-malignancy-type
sinus	I-malignancy-type
tumor	I-malignancy-type
cell	O
line	O
HAEST	O
,	O
and	O
malignant	B-malignancy-type
teratoma	I-malignancy-type
cell	O
line	O
HUOT	O
	O
However	O
,	O
N-myc	O
amplification	O
and	O
NSE	O
production	O
disappeared	O
gradually	O
following	O
successive	O
passages	O
of	O
the	O
HAEST	O
and	O
HUOT	O
lines	O
.	O
With	O
respect	O
to	O
the	O
HUOT	O
line	O
,	O
these	O
parameters	O
disappeared	O
along	O
with	O
the	O
cells	O
of	O
nervous	O
origin	O
.	O
N-myc	O
amplification	O
and	O
NSE	O
production	O
were	O
not	O
observed	O
in	O
nine	O
other	O
cell	O
lines	O
.	O
PMID	O
:	O
2542141	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Pediatr	O
Oncol	O
.	O
1988	O
;16	O
(	O
5	O
)	O
:	O
33	O
7-40	O
.	O
I-131	O
metaiodobenzylguanidine	O
:	O
diagnostic	O
use	O
in	O
neuroblastoma	B-malignancy-type
patients	O
in	O
relapse	O
.	O
Heyman	O
S	O
,	O
Evans	O
AE	O
,	O
D'Angio	O
GJ.	O
Division	O
of	O
Nuclear	O
Medicine	O
,	O
Children	O
's	O
Hospital	O
,	O
Philadelphia	O
,	O
PA	O
19104	O
.	O
Metaiodobenzylguanidine	O
(	O
MIBG	O
)	O
has	O
been	O
used	O
for	O
the	O
detection	O
and	O
treatment	O
of	O
neuroectodermal	B-malignancy-type
tumors	I-malignancy-type
,	O
including	O
neuroblastoma	B-malignancy-type
.	O
We	O
report	O
our	O
experience	O
with	O
131I-MIBG	O
used	O
diagnostically	O
in	O
neuroblastoma	B-malignancy-type
patients	O
with	O
relapse	O
.	O
Thirty-eight	O
studies	O
were	O
performed	O
in	O
26	O
patients	O
.	O
There	O
were	O
24	O
children	O
(	O
range	O
3	O
months	O
-	O
14	O
years	O
)	O
and	O
two	O
adults	O
.	O
While	O
the	O
study	O
was	O
found	O
to	O
be	O
both	O
sensitive	O
and	O
specific	O
for	O
the	O
presence	O
of	O
disease	O
,	O
there	O
are	O
instances	O
of	O
discordance	O
.	O
False	O
-	O
negative	O
studies	O
were	O
found	O
with	O
a	O
markedly	O
anaplastic	O
tumor	O
and	O
with	O
two	O
mature	O
ganglioneuromas	B-malignancy-type
.	O
A	O
bone	B-malignancy-type
lesion	I-malignancy-type
was	O
negative	O
with	O
131I-MIBG	O
,	O
but	O
positive	O
on	O
bone	O
scan	O
.	O
A	O
biopsy	O
confirmed	O
the	O
presence	O
of	O
neuroblastoma	B-malignancy-type
.	O
Caution	O
should	O
be	O
exercised	O
when	O
scanning	O
pretreated	O
patients	O
,	O
and	O
perhaps	O
with	O
newly	O
diagnosed	O
patients	O
as	O
well	O
.	O
PMID	O
:	O
3185361	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Mol	O
Genet	O
.	O
1993	O
Nov;2	O
(	O
11	O
)	O
:	O
1883	O
-	O
8.	O
A	O
housekeeping	O
type	O
promoter	O
,	O
located	O
in	O
the	O
3	O
'	O
region	O
of	O
the	O
Duchenne	O
muscular	O
dystrophy	O
gene	O
,	O
controls	O
the	O
expression	O
of	O
Dp71	O
,	O
a	O
major	O
product	O
of	O
the	O
gene	O
.	O
Lederfein	O
D	O
,	O
Yaffe	O
D	O
,	O
Nudel	O
U	O
.	O
Department	O
of	O
Cell	O
Biology	O
,	O
Weizmann	O
Institute	O
of	O
Science	O
,	O
Rehovot	O
,	O
Israel	O
.	O
The	O
70.8	O
kDa	O
protein	O
product	O
of	O
the	O
distal	O
part	O
of	O
the	O
giant	O
Duchenne	O
muscular	O
dystrophy	O
(	O
DMD	O
)	O
gene	O
,	O
Dp71	O
,	O
is	O
expressed	O
in	O
many	O
cell	O
types	O
and	O
tissues	O
.	O
Anchored	O
PCR	O
,	O
primer	O
extension	O
and	O
functional	O
analysis	O
of	O
transfected	O
constructs	O
were	O
used	O
to	O
determine	O
the	O
5	O
'	O
end	O
of	O
the	O
mRNA	O
and	O
characterize	O
the	O
promoter	O
of	O
this	O
major	O
DMD	O
gene	O
product	O
.	O
The	O
5	O
'	O
untranslated	O
region	O
(	O
5'UTR	O
)	O
of	O
Dp71	O
is	O
transcribed	O
from	O
a	O
single	O
exon	O
;	O
the	O
promoter	O
does	O
not	O
contain	O
a	O
TATA	O
box	O
,	O
and	O
has	O
a	O
very	O
high	O
GC	O
content	O
and	O
several	O
potential	O
Sp1	O
binding	O
sites	O
.	O
It	O
is	O
located	O
more	O
than	O
2000	O
kb	O
3	O
'	O
to	O
the	O
muscle	O
and	O
brain	O
type	O
dystrophin	O
promoters	O
and	O
only	O
150	O
kb	O
from	O
the	O
3	O
'	O
end	O
of	O
the	O
gene	O
,	O
suggesting	O
that	O
in	O
most	O
DMD	O
patients	O
the	O
expression	O
of	O
Dp71	O
is	O
unaffected	O
.	O
PMID	O
:	O
8281151	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Regul	O
Pept	O
.	O
1998	O
Oct	O
16;77	O
(	O
1-3	O
)	O
:	O
9-15	O
.	O
The	O
renin	O
-	O
angiotensin	O
system	O
in	O
hybrid	O
NG108-15	O
cells	O
.	O
Renin	O
gene	O
is	O
from	O
mouse	O
neuroblastoma	B-malignancy-type
,	O
angiotensinogen	O
and	O
angiotensin	O
-	O
converting	O
enzyme	O
genes	O
are	O
of	O
rat	O
glioma	B-malignancy-type
origin	O
.	O
Laflamme	O
L,	O
Brechler	O
V	O
,	O
Reudelhuber	O
TL	O
,	O
Gallo-Payet	O
N	O
,	O
Deschepper	O
CF.	O
Service	O
of	O
Endocrinology	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Sherbrooke	O
,	O
Canada	O
.	O
Angiotensin	O
II	O
(	O
Ang	O
II	O
)	O
increases	O
the	O
level	O
of	O
tyrosine	O
phosphorylation	O
of	O
several	O
proteins	O
in	O
nondifferentiated	O
NG108-15	O
cells	O
,	O
a	O
hybrid	O
derived	O
from	O
the	O
fusion	O
of	O
mouse	O
neuroblastoma	B-malignancy-type
and	O
rat	O
glioma	B-malignancy-type
cells	O
.	O
Conversely	O
,	O
incubation	O
of	O
NG108-15	O
cells	O
with	O
an	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
decreased	O
the	O
basal	O
level	O
of	O
tyrosine	O
phosphorylation	O
of	O
proteins	O
,	O
suggesting	O
that	O
locally	O
secreted	O
Ang	O
II	O
may	O
act	O
as	O
an	O
autocrine	O
regulator	O
.	O
By	O
RT	O
-	O
PCR	O
,	O
we	O
found	O
that	O
nondifferentiated	O
NG108-15	O
cells	O
contained	O
the	O
mRNA	O
transcript	O
of	O
the	O
rat	O
angiotensinogen	O
,	O
mouse	O
renin	O
and	O
rat	O
ACE	O
genes	O
,	O
thus	O
confirming	O
that	O
NG108-15	O
cells	O
contain	O
all	O
the	O
elements	O
of	O
a	O
local	O
renin	O
-	O
angiotensin	O
system	O
.	O
PMID	O
:	O
9809791	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Viral	O
Immunol	O
.	O
2003	O
;16	O
(	O
1	O
)	O
:	O
87	O
-	O
96	O
.	O
PKR	O
is	O
not	O
required	O
for	O
interferon-gamma	O
inhibition	O
of	O
VSV	O
replication	O
in	O
neurons	O
.	O
Chesler	O
DA	O
,	O
Munoz-Jordan	O
JL	O
,	O
Donelan	O
N	O
,	O
Garcia-Sastre	O
A	O
,	O
Reiss	O
CS	O
.	O
Department	O
of	O
Biology	O
,	O
New	O
York	O
University	O
,	O
New	O
York	O
,	O
New	O
York	O
10003	O
,	O
USA	O
.	O
In	O
this	O
report	O
,	O
the	O
contribution	O
of	O
PKR	O
to	O
the	O
IFN-gamma	O
mediated	O
inhibition	O
of	O
VSV	O
replication	O
in	O
neurons	O
was	O
examined	O
.	O
IFN-gamma	O
treatment	O
of	O
NB41A3	O
murine	O
neuroblastoma	B-malignancy-type
cells	O
resulted	O
in	O
the	O
reduced	O
expression	O
of	O
VSV	O
protein	O
during	O
infection	O
.	O
PKR	O
was	O
found	O
to	O
be	O
modestly	O
upregulated	O
in	O
NB41A3	O
cells	O
following	O
IFN-gamma	O
treatment	O
.	O
The	O
phosphorylation	O
state	O
of	O
PKR	O
and	O
its	O
downstream	O
target	O
,	O
eIF2alpha	O
,	O
were	O
unaffected	O
by	O
either	O
IFN-gamma	O
or	O
VSV	O
infection	O
.	O
Inhibition	O
of	O
PKR	O
through	O
the	O
use	O
of	O
2-aminopurine	O
or	O
the	O
expression	O
of	O
the	O
Influenza	O
A	O
NS1	O
gene	O
had	O
no	O
effect	O
on	O
the	O
ability	O
of	O
IFN-gamma	O
to	O
inhibit	O
the	O
replication	O
of	O
VSV	O
in	O
vitro	O
.	O
These	O
data	O
indicate	O
that	O
endogenously	O
expressed	O
PKR	O
is	O
not	O
required	O
for	O
the	O
IFN-gamma	O
mediated	O
inhibition	O
of	O
VSV	O
replication	O
in	O
NB41A3	O
neuroblastoma	B-malignancy-type
cells	O
.	O
PMID	O
:	O
12725691	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Hum	O
Genet	O
.	O
1993	O
Jan;52(	O
1	O
)	O
:176-82	O
.	O
Constitutional	O
1p36	O
deletion	O
in	O
a	O
child	O
with	O
neuroblastoma	B-malignancy-type
.	O
Biegel	O
JA	O
,	O
White	O
PS	O
,	O
Marshall	O
HN	O
,	O
Fujimori	O
M,	O
Zackai	O
EH	O
,	O
Scher	O
CD	O
,	O
Brodeur	O
GM	O
,	O
Emanuel	O
BS	O
.	O
Division	O
of	O
Human	O
Genetics	O
,	O
Children	O
's	O
Hospital	O
of	O
Philadelphia	O
,	O
PA	O
19104	O
.	O
We	O
describe	O
a	O
child	O
with	O
dysmorphic	O
features	O
,	O
as	O
well	O
as	O
developmental	O
and	O
growth	O
delay	O
,	O
who	O
developed	O
neuroblastoma	B-malignancy-type
at	O
5	O
mo	O
of	O
age	O
.	O
Cytogenetic	O
analysis	O
of	O
blood	O
lymphocytes	O
revealed	O
an	O
interstitial	O
deletion	O
of	O
1p36.1	O
-->	O
1p36.2	O
,	O
which	O
was	O
apparent	O
only	O
with	O
high	O
-	O
resolution	O
banding	O
.	O
Molecular	O
analysis	O
with	O
a	O
collection	O
of	O
polymorphic	O
DNA	O
probes	O
for	O
1p	O
confirmed	O
an	O
interstitial	O
deletion	O
involving	O
subbands	O
of	O
1p36	O
.	O
Deletions	O
of	O
this	O
region	O
are	O
a	O
common	O
finding	O
in	O
neuroblastoma	B-malignancy-type
cells	O
from	O
patients	O
with	O
advanced	O
stages	O
of	O
disease	O
.	O
Therefore	O
,	O
these	O
results	O
(a)	O
suggest	O
that	O
constitutional	O
deletion	O
of	O
this	O
region	O
predisposed	O
the	O
patient	O
to	O
the	O
development	O
of	O
neuroblastoma	B-malignancy-type
and	O
(b)	O
support	O
the	O
localization	O
of	O
a	O
neuroblastoma	B-malignancy-type
tumor	O
-	O
suppressor	O
locus	O
to	O
1p36	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
8434586	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neurosci	O
Lett	O
.	O
1991	O
Nov	O
25	O
;133	O
(	O
1	O
)	O
:	O
41-4.	O
Comparison	O
of	O
fast	O
responses	O
to	O
serotonin	O
and	O
2-methyl-serotonin	O
in	O
voltage	O
-	O
clamped	O
N1E-115	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Mienville	O
JM	O
.	O
SANOFI	O
Recherche	O
,	O
Montpellier	O
,	O
France	O
.	O
The	O
activation	O
of	O
5-HT3	O
receptors	O
by	O
5-HT	O
and	O
2-methyl-5-HT	O
was	O
studied	O
with	O
'	O
concentration	O
-	O
jump	O
'	O
techniques	O
in	O
voltage	O
-	O
clamped	O
N1E-115	O
cells	O
grown	O
in	O
culture	O
.	O
When	O
applied	O
to	O
single	O
cells	O
with	O
a	O
fast	O
perfusion	O
technique	O
,	O
both	O
agonists	O
induced	O
currents	O
the	O
on	O
-	O
rate	O
kinetics	O
of	O
which	O
were	O
concentration	O
-	O
dependent	O
.	O
Based	O
on	O
the	O
time	O
constants	O
of	O
current	O
kinetics	O
and	O
subsequent	O
estimates	O
of	O
agonist	O
association	O
and	O
dissociation	O
rates	O
,	O
an	O
apparent	O
Kd	O
of	O
1.3	O
microM	O
was	O
determined	O
for	O
5-HT	O
,	O
a	O
value	O
in	O
agreement	O
with	O
binding	O
and	O
functional	O
studies	O
.	O
Receptor	O
activation	O
by	O
2-methyl-5-HT	O
was	O
slower	O
,	O
consistent	O
with	O
its	O
lower	O
potency	O
as	O
compared	O
to	O
the	O
parent	O
compound	O
.	O
In	O
addition	O
,	O
the	O
rise	O
time	O
of	O
2-methyl-5-HT	O
-	O
mediated	O
currents	O
was	O
affected	O
by	O
hyperpolarizing	O
membrane	O
potential	O
.	O
The	O
results	O
show	O
evidence	O
of	O
different	O
molecular	O
behaviors	O
for	O
the	O
two	O
agonists	O
.	O
PMID	O
:	O
1791997	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
.	O
1993	O
Apr	O
15	O
;69	O
(	O
1	O
)	O
:27	O
-	O
32	O
.	O
Partial	O
reversion	O
of	O
transformed	O
phenotype	O
of	O
B104	O
cancer	O
cells	O
by	O
antisense	O
nucleic	O
acids	O
.	O
Shaw	O
YT	O
,	O
Chang	O
SH	O
,	O
Chiou	O
ST	O
,	O
Chang	O
WC	O
,	O
Lai	O
MD.	O
Union	O
Biotechnology	O
Inc.	O
,	O
Taipei	O
,	O
Taiwan	O
,	O
Republic	O
of	O
China	O
.	O
We	O
used	O
antisense	O
RNA	O
to	O
inhibit	O
the	O
expression	O
of	O
oncogene	O
neu	O
and	O
investigated	O
the	O
effects	O
of	O
diminished	O
neu	O
expression	O
on	O
the	O
phenotypes	O
of	O
B104	O
cells	O
containing	O
activated	O
oncogene	O
neu	O
.	O
Antisense	O
MT-neu	O
and	O
pSV-neo	O
plasmids	O
were	O
cotransfected	O
into	O
neuroblastoma	B-malignancy-type
B104	O
cells	O
.	O
Southern	O
analysis	O
showed	O
the	O
integration	O
of	O
anti	O
-	O
neu	O
DNA	O
into	O
B104	O
cells	O
.	O
The	O
expression	O
of	O
neu	O
was	O
inhibited	O
up	O
to	O
90	O
%	O
as	O
quantitated	O
by	O
immunoprecipitation	O
.	O
The	O
growth	O
rate	O
and	O
the	O
potential	O
to	O
differentiate	O
in	O
these	O
transfectants	O
were	O
not	O
affected	O
as	O
compared	O
to	O
the	O
parental	O
cell	O
lines	O
.	O
The	O
ability	O
to	O
grow	O
in	O
soft	O
agar	O
was	O
inhibited	O
more	O
than	O
90	O
%	O
in	O
these	O
transfectants	O
.	O
Our	O
results	O
indicated	O
that	O
antisense	O
-	O
RNA	O
against	O
a	O
specific	O
oncogene	O
can	O
decrease	O
the	O
tumorigenicity	O
of	O
tumor	O
cells	O
but	O
may	O
not	O
be	O
able	O
to	O
revert	O
it	O
to	O
normal	O
cells	O
completely	O
.	O
PMID	O
:	O
8097670	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
1996	O
Dec	O
1;56	O
(	O
23	O
)	O
:	O
5356	O
-	O
9.	O
IGF2	O
but	O
not	O
H19	O
shows	O
loss	O
of	O
imprinting	O
in	O
human	O
glioma	B-malignancy-type
.	O
Uyeno	O
S	O
,	O
Aoki	O
Y	O
,	O
Nata	O
M,	O
Sagisaka	O
K,	O
Kayama	O
T	O
,	O
Yoshimoto	O
T	O
,	O
Ono	O
T.	O
Department	O
of	O
Radiation	O
Research	O
,	O
Tohoku	O
University	O
School	O
of	O
Medicine	O
,	O
Aoba-ku	O
,	O
Sendai	O
,	O
Japan	O
.	O
Genomic	O
imprinting	O
is	O
a	O
gamete	O
-	O
specific	O
modification	O
resulting	O
in	O
the	O
allele	O
-	O
specific	O
expression	O
of	O
genes	O
in	O
somatic	O
cells	O
.	O
A	O
loss	O
of	O
imprinting	O
(	O
LOI	O
)	O
has	O
been	O
found	O
in	O
many	O
embryonal	O
and	O
adult	O
tumors	O
,	O
suggesting	O
that	O
it	O
plays	O
a	O
role	O
in	O
tumor	O
development	O
.	O
The	O
incidence	O
of	O
LOI	O
,	O
however	O
,	O
does	O
not	O
seem	O
to	O
be	O
ubiquitous	O
among	O
tumors	O
because	O
neuroblastoma	B-malignancy-type
and	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
revealed	O
no	O
LOI	O
.	O
We	O
examined	O
the	O
involvement	O
of	O
LOI	O
of	O
IGF2	O
and	O
H19	O
genes	O
in	O
human	O
gliomas	B-malignancy-type
.	O
The	O
two	O
genes	O
were	O
imprinted	O
in	O
normal	O
brain	O
subcortex	O
tissues	O
.	O
In	O
glioma	B-malignancy-type
,	O
8	O
of	O
14	O
informative	O
cases	O
(	O
57	O
%	O
)	O
revealed	O
LOI	O
in	O
IGF2	O
.	O
The	O
frequency	O
did	O
not	O
depend	O
on	O
the	O
tumor	O
grade	O
.	O
For	O
H19	O
,	O
in	O
contrast	O
,	O
all	O
13	O
informative	O
cases	O
maintained	O
imprinting	O
.	O
These	O
results	O
suggest	O
that	O
LOI	O
of	O
IGF2	O
but	O
not	O
H19	O
plays	O
a	O
role	O
in	O
the	O
development	O
of	O
human	O
glioma	B-malignancy-type
.	O
PMID	O
:	O
8968084	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
1998	O
Sep	O
29	O
;250(	O
3	O
)	O
:786-	O
90	O
.	O
Calcium	O
buffering	O
capacity	O
of	O
neuronal	O
cell	O
cytosol	O
measured	O
by	O
flash	O
photolysis	O
of	O
calcium	O
buffer	O
NP-EGTA	O
.	O
Fleet	O
A	O
,	O
Ellis	O
-	O
Davies	O
G	O
,	O
Bolsover	O
S.	O
School	O
of	O
Biomedical	O
Sciences	O
,	O
University	O
of	O
St.	O
Andrews	O
,	O
Fife	O
,	O
KY16	O
9AJ	O
,	O
Scotland	O
.	O
N1E-115	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
were	O
injected	O
with	O
a	O
calcium	O
buffer	O
/	O
indicator	O
solution	O
to	O
allow	O
both	O
ratiometric	O
measurement	O
of	O
free	O
calcium	O
concentration	O
and	O
the	O
release	O
of	O
calcium	O
ions	O
upon	O
UV	O
flash	O
.	O
The	O
solution	O
contained	O
sulforhodamine	O
,	O
a	O
marker	O
dye	O
used	O
to	O
estimate	O
the	O
volume	O
injected	O
;	O
fluo-3	O
,	O
a	O
calcium	O
indicator	O
,	O
and	O
NP-EGTA	O
,	O
a	O
high	O
affinity	O
calcium	O
-	O
selective	O
buffer	O
that	O
is	O
converted	O
by	O
UV	O
flash	O
to	O
products	O
with	O
negligible	O
calcium	O
affinity	O
.	O
The	O
calcium	O
increase	O
recorded	O
upon	O
UV	O
irradiation	O
(	O
Delta[Ca2+]i	O
)	O
was	O
small	O
for	O
small	O
injection	O
volumes	O
,	O
increased	O
with	O
larger	O
injection	O
volumes	O
,	O
but	O
approached	O
a	O
plateau	O
at	O
the	O
largest	O
injection	O
volumes	O
.	O
From	O
this	O
relation	O
we	O
estimate	O
the	O
buffering	O
capacity	O
of	O
the	O
cytosol	O
as	O
1700	O
ions	O
bound	O
per	O
ion	O
free	O
.	O
Copyright	O
1998	O
Academic	O
Press	O
.	O
PMID	O
:	O
9784424	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
.	O
2001	O
Jan	O
26;162(	O
2	O
)	O
:	O
237-43	O
.	O
DAP-5	O
is	O
involved	O
in	O
MycN	O
/	O
IFNgamma	O
-	O
induced	O
apoptosis	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Wittke	O
I	O
,	O
Madge	O
B	O
,	O
Wiedemeyer	O
R	O
,	O
Kimchi	O
A	O
,	O
Schwab	O
M.	O
Department	O
of	O
Cytogenetics-H0400	O
,	O
German	O
Cancer	O
Research	O
Center	O
,	O
Im	O
Neuenheimer	O
Feld	O
280	O
,	O
D	O
69120	O
,	O
Heidelberg	O
,	O
Germany	O
.	O
Death	O
associated	O
protein-5	O
(	O
DAP-5	O
)	O
is	O
a	O
ubiquitously	O
expressed	O
member	O
of	O
the	O
translation	O
initiation	O
factor	O
eIF4G	O
family	O
that	O
lacks	O
the	O
eIF4E	O
binding	O
site	O
.	O
A	O
dominant	O
negative	O
fragment	O
of	O
DAP-5	O
protects	O
HeLa	O
cells	O
from	O
IFNgamma	O
-	O
induced	O
cell	O
death	O
.	O
By	O
employing	O
a	O
functional	O
approach	O
we	O
examined	O
the	O
role	O
of	O
DAP-5	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
that	O
are	O
sensitized	O
for	O
IFNgamma	O
-	O
induced	O
apoptosis	O
by	O
tetracycline	O
controlled	O
MYCN	O
expression	O
.	O
DAP-5	O
fragment	O
transcribed	O
at	O
high	O
levels	O
and	O
translated	O
into	O
a	O
functional	O
miniprotein	O
of	O
28	O
kDa	O
protected	O
neuroblastoma	B-malignancy-type
cells	O
from	O
IFNgamma	O
-	O
induced	O
apoptosis	O
.	O
Reduced	O
serum	O
levels	O
were	O
toxic	O
to	O
cells	O
constitutively	O
expressing	O
DAP-5	O
fragment	O
suggesting	O
that	O
DAP-5	O
protein	O
is	O
essential	O
for	O
both	O
viability	O
and	O
death	O
of	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
PMID	O
:	O
11146231	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
.	O
1986	O
Sep	O
3;381	O
(	O
2	O
)	O
:	O
237-43	O
.	O
Immunoreactive	O
thymopoietin	O
in	O
the	O
mouse	O
central	O
nervous	O
system	O
.	O
Brown	O
RH	O
Jr	O
,	O
Schweitzer	O
JS	O
,	O
Audhya	O
T	O
,	O
Goldstein	O
G	O
,	O
Dichter	O
MA.	O
A	O
thymopoietin	O
-	O
immunoreactive	O
substance	O
(	O
TP	O
-	O
IRS	O
)	O
has	O
been	O
detected	O
in	O
homogenates	O
of	O
mouse	O
spinal	O
cord	O
and	O
brain	O
using	O
a	O
radioimmunoassay	O
;	O
levels	O
were	O
maximal	O
at	O
birth	O
.	O
TP	O
-	O
IRS	O
was	O
also	O
detected	O
in	O
supernatants	O
of	O
mouse	O
neuroblastoma	B-malignancy-type
(	O
NIE-115	O
)	O
and	O
primary	O
spinal	O
cord	O
cultures	O
but	O
not	O
human	O
astrocytic	B-malignancy-type
and	O
meningeal	B-malignancy-type
tumors	I-malignancy-type
or	O
mouse	O
primary	O
astrocyte	O
cultures	O
.	O
With	O
affinity	O
purified	O
rabbit	O
anti	O
-	O
TP	O
globulin	O
,	O
immunofluorescent	O
staining	O
was	O
seen	O
in	O
mouse	O
spinal	O
cord	O
cultures	O
in	O
association	O
with	O
nuclear	O
membranes	O
of	O
neurons	O
and	O
,	O
to	O
a	O
lesser	O
degree	O
,	O
flat	O
background	O
cells	O
.	O
From	O
supernatants	O
of	O
NIE-115	O
cells	O
grown	O
in	O
tritiated	O
leucine	O
and	O
lysine	O
,	O
proteins	O
of	O
approximately	O
8000	O
and	O
4500	O
Da	O
were	O
isolated	O
by	O
TP	O
affinity	O
chromatography	O
(	O
compared	O
with	O
5562	O
Da	O
for	O
thymic	O
thymopoietin	O
)	O
.	O
When	O
injected	O
into	O
mice	O
,	O
these	O
neural	O
proteins	O
partially	O
blocked	O
neuromuscular	O
transmission	O
in	O
a	O
manner	O
similar	O
to	O
thymic	O
thymopoietin	O
.	O
PMID	O
:	O
3530377	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gene	O
.	O
1993	O
Oct	O
15	O
;132(	O
2	O
)	O
:	O
285	O
-	O
9.	O
Human	O
ribosomal	O
protein	O
L37a	O
:	O
cloning	O
of	O
the	O
cDNA	O
and	O
analysis	O
of	O
differential	O
gene	O
expression	O
in	O
tissues	O
and	O
cell	O
lines	O
.	O
Saha	O
DP	O
,	O
Tirumalai	O
PS	O
,	O
Scala	O
LA	O
,	O
Howells	O
RD.	O
Department	O
of	O
Biochemistry	O
and	O
Molecular	O
Biology	O
,	O
UMDNJ-New	O
Jersey	O
Medical	O
School	O
07103	O
.	O
A	O
cDNA	O
corresponding	O
to	O
human	O
ribosomal	O
protein	O
L37a	O
(	O
hL37a	O
)	O
was	O
obtained	O
by	O
screening	O
a	O
SHSY5Y	O
neuroblastoma	B-malignancy-type
library	O
.	O
The	O
full	O
-	O
length	O
cDNA	O
contained	O
366	O
nucleotides	O
(	O
nt	O
)	O
in	O
addition	O
to	O
a	O
poly(A)	O
tail	O
.	O
The	O
pyrimidine	O
-	O
rich	O
sequence	O
,	O
CTTTCT	O
,	O
that	O
is	O
common	O
to	O
many	O
ribosomal	O
protein	O
-	O
encoding	O
cDNAs	O
was	O
present	O
at	O
the	O
5	O
'	O
terminus	O
.	O
The	O
nt	O
sequence	O
displayed	O
85	O
%	O
identity	O
with	O
rat	O
L37a	O
(	O
rL37a	O
)	O
cDNA	O
.	O
The	O
predicted	O
protein	O
contains	O
92	O
amino	O
acids	O
with	O
a	O
M(r)	O
of	O
10,277	O
,	O
is	O
highly	O
basic	O
,	O
and	O
has	O
100	O
%	O
sequence	O
identity	O
with	O
rL37a	O
.	O
A	O
putative	O
zinc	O
-	O
finger	O
domain	O
is	O
present	O
in	O
the	O
central	O
region	O
of	O
the	O
protein	O
.	O
Human	O
lymphocytes	O
and	O
several	O
human	O
cell	O
lines	O
express	O
hL37a	O
mRNA	O
at	O
significantly	O
higher	O
levels	O
than	O
the	O
rat	O
cell	O
lines	O
and	O
rat	O
tissues	O
tested	O
.	O
The	O
hL37a	O
gene	O
does	O
not	O
contain	O
introns	O
.	O
PMID	O
:	O
8224875	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Anticancer	O
Res	O
.	O
1994	O
Mar	O
-	O
Apr;14(	O
2A	O
)	O
:437-	O
41	O
.	O
Regulation	O
of	O
retinoic	O
acid	O
receptor	O
alpha	O
expression	O
in	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
and	O
tumor	O
tissue	O
.	O
Marshall	O
GM	O
,	O
Cheung	O
B	O
,	O
Stacey	O
KP	O
,	O
Norris	O
MD	O
,	O
Haber	O
M.	O
Children	O
's	O
Leukaemia	O
and	O
Cancer	O
Research	O
Centre	O
,	O
Prince	O
of	O
Wales	O
Children	O
's	O
Hospital	O
,	O
Randwick	O
,	O
Sydney	O
,	O
Australia	O
.	O
Human	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
cell	O
lines	O
treated	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
differentiate	O
in	O
culture	O
,	O
forming	O
neurites	O
and	O
exhibiting	O
growth	O
arrest	O
.	O
We	O
treated	O
5	O
human	O
NB	B-malignancy-type
cell	O
lines	O
with	O
RA	O
,	O
and	O
observed	O
a	O
2	O
-	O
5	O
fold	O
induction	O
of	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RAR	O
alpha	O
)	O
mRNA	O
expression	O
in	O
4	O
of	O
the	O
5	O
cell	O
lines	O
,	O
as	O
an	O
early	O
cellular	O
response	O
.	O
Induction	O
of	O
RAR	O
alpha	O
expression	O
was	O
specific	O
for	O
RA	O
among	O
several	O
differentiating	O
agents	O
tested	O
.	O
RAR	O
alpha	O
mRNA	O
expression	O
in	O
13	O
primary	O
neuroblastoma	B-malignancy-type
tumor	O
samples	O
was	O
3	O
fold	O
higher	O
in	O
localised	O
compared	O
with	O
advanced	O
tumors	O
(	O
p	O
<	O
0.05	O
)	O
.	O
RAR	O
alpha	O
expression	O
may	O
be	O
necessary	O
for	O
the	O
effects	O
of	O
RA	O
on	O
NB	B-malignancy-type
cells	O
in	O
vitro	O
and	O
reduced	O
expression	O
of	O
this	O
gene	O
in	O
vivo	O
may	O
contribute	O
to	O
the	O
process	O
of	O
NB	B-malignancy-type
tumorigenesis	O
.	O
PMID	O
:	O
8017844	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

FEBS	O
Lett	O
.	O
1992	O
Mar	O
24;299	O
(	O
1	O
)	O
:	O
10-4.	O
Differentiation	O
of	O
neuroblastoma	B-malignancy-type
cells	O
correlates	O
with	O
an	O
altered	O
splicing	O
pattern	O
of	O
tau	O
RNA	O
.	O
Montejo	O
de	O
Garcini	O
E	O
,	O
Corrochano	O
L,	O
Wischik	O
CM	O
,	O
Diaz	O
Nido	O
J,	O
Correas	O
I	O
,	O
Avila	O
J.	O
MRC	O
Laboratory	O
of	O
Molecular	O
Biology	O
,	O
Cambridge	O
,	O
UK.	O
Morphological	O
differentiation	O
of	O
N2A	O
neuroblastoma	B-malignancy-type
cells	O
is	O
associated	O
with	O
an	O
altered	O
splicing	O
of	O
the	O
gene	O
of	O
the	O
microtubule	O
-	O
associated	O
protein	O
,	O
tau	O
.	O
Two	O
populations	O
of	O
RNA	O
(	O
coding	O
for	O
tau	O
proteins	O
containing	O
three	O
or	O
four	O
tubulin	O
-	O
binding	O
motifs	O
)	O
are	O
present	O
in	O
a	O
similar	O
proportion	O
in	O
undifferentiated	O
neuroblastoma	B-malignancy-type
cells	O
while	O
in	O
differentiated	O
cells	O
the	O
proportion	O
is	O
changed	O
in	O
favour	O
of	O
that	O
population	O
coding	O
for	O
tau	O
protein	O
containing	O
four	O
tubulin	O
-	O
binding	O
motifs	O
.	O
An	O
increase	O
in	O
a	O
high	O
molecular	O
weight	O
tau	O
isoforms	O
correlates	O
with	O
the	O
increase	O
in	O
the	O
RNA	O
population	O
coding	O
for	O
four	O
tubulin	O
-	O
binding	O
motifs	O
.	O
A	O
possible	O
consequence	O
of	O
expressing	O
a	O
higher	O
proportion	O
of	O
the	O
tau	O
protein	O
containing	O
four	O
tubulin	O
-	O
binding	O
motifs	O
could	O
be	O
an	O
increase	O
in	O
microtubule	O
stability	O
of	O
differentiated	O
neuroblastoma	B-malignancy-type
cells	O
.	O
PMID	O
:	O
1544466	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Ai	O
Zheng	O
.	O
2004	O
Jan;23(	O
1	O
)	O
:95-	O
8.	O
[	O
Study	O
Progress	O
of	O
p73	O
Gene	O
in	O
Digestive	B-malignancy-type
System	I-malignancy-type
Carcinoma	I-malignancy-type
]	O
[	O
Article	O
in	O
Chinese	O
]	O
Xin	O
T	O
,	O
Fang	O
LP	O
.	O
Department	O
of	O
Oncology	O
,The	O
Second	O
Affiliated	O
Hospital	O
of	O
Harbin	O
Medical	O
University,Harbin,Heilongjiang	O
,	O
150086	O
,P.R.China	O
.	O
xintao1234@263.net	O
p73	O
gene	O
is	O
a	O
new	O
member	O
of	O
the	O
tumor	O
suppressor	O
gene	O
p53	O
family	O
.	O
They	O
are	O
similar	O
in	O
the	O
structure	O
and	O
function	O
of	O
the	O
coding	O
protein	O
,	O
but	O
they	O
also	O
have	O
notable	O
distinctions	O
in	O
other	O
aspects	O
.	O
Many	O
studies	O
have	O
shown	O
that	O
the	O
abnormal	O
p73	O
gene	O
is	O
associated	O
with	O
neuroblastoma	B-malignancy-type
,	O
malignant	O
melanoma	B-malignancy-type
,	O
prostatic	B-malignancy-type
carcinoma	I-malignancy-type
,	O
and	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
et	O
al	O
.	O
Recently	O
,	O
many	O
studies	O
have	O
demonstrated	O
that	O
p73	O
gene	O
may	O
involve	O
the	O
occurrence	O
and	O
development	O
of	O
a	O
portion	O
of	O
the	O
digestive	B-malignancy-type
system	I-malignancy-type
carcinoma	I-malignancy-type
.	O
This	O
review	O
summarized	O
the	O
present	O
conditions	O
of	O
the	O
p73	O
gene	O
and	O
its	O
correlation	O
with	O
the	O
occurrence	O
,	O
development	O
,	O
prognosis	O
,	O
and	O
expression	O
in	O
the	O
digestive	B-malignancy-type
system	I-malignancy-type
carcinoma	I-malignancy-type
.	O
We	O
suggested	O
that	O
the	O
further	O
study	O
about	O
the	O
p73	O
gene	O
may	O
be	O
helpful	O
to	O
recognize	O
the	O
nature	O
of	O
the	O
carcinoma	B-malignancy-type
and	O
bring	O
wish	O
to	O
overcome	O
it	O
finally	O
.	O
PMID	O
:	O
14720384	O
[	O
PubMed	O
-	O
in	O
process	O
]	O

Neurosci	O
Lett	O
.	O
2000	O
Nov	O
17;294(	O
2	O
)	O
:	O
121-4.	O
Isolation	O
and	O
purification	O
of	O
an	O
epidermal	O
growth	O
factor	O
receptor	O
-	O
related	O
inhibitor	O
of	O
cell	O
growth	O
from	O
cultured	O
rat	O
astrocytes	O
.	O
Chestnutt	O
K,	O
Bird	O
J,	O
Carroll	O
K.	O
National	O
Diagnostics	O
Centre	O
,	O
BioResearch	O
Ireland	O
,	O
c/o	O
National	O
University	O
of	O
Ireland	O
,	O
Galway	O
,	O
Ireland	O
.	O
Astrocytes	O
rarely	O
undergo	O
mitotic	O
cell	O
division	O
in	O
the	O
developed	O
adult	O
.	O
However	O
,	O
following	O
injury	O
to	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
astrocytes	O
undergo	O
rapid	O
cell	O
division	O
and	O
reactive	O
astrocytes	O
encapsulate	O
exposed	O
areas	O
of	O
the	O
CNS	O
producing	O
a	O
glial	O
scar	O
.	O
Studies	O
indicate	O
the	O
existence	O
of	O
a	O
family	O
of	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFr	O
)	O
related	O
glycosidic	O
mitogen	O
inhibitors	O
with	O
growth	O
inhibiting	O
properties	O
for	O
astrocytes	O
.	O
Here	O
,	O
for	O
the	O
first	O
time	O
,	O
we	O
describe	O
the	O
isolation	O
of	O
such	O
a	O
factor	O
from	O
cultured	O
rat	O
astrocytes	O
by	O
ion	O
-	O
exchange	O
and	O
immunoaffinity	O
chromatography	O
.	O
The	O
isolated	O
factor	O
is	O
glycosidic	O
in	O
nature	O
,	O
cross	O
reacts	O
with	O
the	O
anti	O
-	O
EGFr	O
monoclonal	O
antibody	O
Clone	O
29.1	O
,	O
and	O
inhibits	O
the	O
growth	O
of	O
primary	O
astrocytes	O
and	O
N2a	O
neuroblastoma	B-malignancy-type
cells	O
in	O
vitro	O
.	O
PMID	O
:	O
11058802	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1992	O
May	O
15	O
;267	O
(	O
14	O
)	O
:9689	O
-	O
94	O
.	O
S100	O
beta	O
stimulates	O
calcium	O
fluxes	O
in	O
glial	O
and	O
neuronal	O
cells	O
.	O
Barger	O
SW	O
,	O
Van	O
Eldik	O
LJ.	O
Department	O
of	O
Cell	O
Biology	O
,	O
Vanderbilt	O
University	O
,	O
Nashville	O
,	O
Tennessee	O
37232	O
.	O
The	O
glial	O
-	O
derived	O
protein	O
S100	O
beta	O
can	O
act	O
as	O
a	O
mitogen	O
or	O
a	O
neurotrophic	O
factor	O
,	O
stimulating	O
proliferation	O
of	O
glial	O
cells	O
or	O
differentiation	O
of	O
immature	O
neurons	O
.	O
We	O
report	O
here	O
that	O
dimeric	O
S100	O
beta	O
evokes	O
increases	O
in	O
intracellular	O
free	O
calcium	O
concentrations	O
(	O
[Ca2+]i	O
)	O
in	O
both	O
glial	O
cells	O
and	O
neuronal	O
cells	O
.	O
The	O
[Ca2+]i	O
increase	O
exhibited	O
a	O
rapid	O
transient	O
component	O
which	O
was	O
not	O
affected	O
by	O
removal	O
of	O
extracellular	O
calcium	O
and	O
a	O
sustained	O
component	O
which	O
appeared	O
to	O
require	O
influx	O
of	O
extracellular	O
calcium	O
through	O
Ni(2+)	O
-	O
sensitive	O
channels	O
.	O
S100	O
beta	O
also	O
stimulated	O
hydrolysis	O
of	O
phosphoinositides	O
,	O
suggesting	O
a	O
mobilization	O
of	O
calcium	O
from	O
intracellular	O
stores	O
.	O
These	O
data	O
suggest	O
that	O
although	O
the	O
final	O
biological	O
responses	O
of	O
neuronal	O
and	O
glial	O
cells	O
to	O
S100	O
beta	O
are	O
different	O
,	O
transduction	O
of	O
the	O
S100	O
beta	O
signal	O
in	O
both	O
cell	O
types	O
involves	O
changes	O
in	O
[Ca2+]i	O
.	O
PMID	O
:	O
1315768	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neuroimmunol	O
.	O
1987	O
Jun;15	O
(	O
2	O
)	O
:	O
137-45	O
.	O
Anti	O
-	O
neurofilament	O
protein	O
antibodies	O
in	O
opsoclonus	O
-	O
myoclonus	O
.	O
Noetzel	O
MJ	O
,	O
Cawley	O
LP	O
,	O
James	O
VL	O
,	O
Minard	O
BJ	O
,	O
Agrawal	O
HC.	O
Opsoclonus	O
-	O
myoclonus	O
(	O
OM	O
)	O
is	O
a	O
neurological	O
disorder	O
usually	O
occurring	O
in	O
infancy	O
,	O
clinically	O
manifested	O
by	O
various	O
involuntary	O
movements	O
.	O
The	O
pathogenesis	O
of	O
OM	O
is	O
unknown	O
,	O
but	O
since	O
the	O
disease	O
often	O
is	O
associated	O
with	O
viral	O
infection	O
or	O
with	O
neuroblastoma	B-malignancy-type
,	O
an	O
immunologic	O
basis	O
for	O
OM	O
has	O
been	O
postulated	O
.	O
We	O
have	O
studied	O
two	O
children	O
with	O
OM	O
whose	O
serum	O
contained	O
antibodies	O
directed	O
against	O
the	O
210	O
kDa	O
neurofilament	O
protein	O
;	O
these	O
antibodies	O
were	O
not	O
seen	O
in	O
the	O
serum	O
of	O
21	O
children	O
with	O
other	O
neurological	O
disorders	O
.	O
Neurofilament	O
proteins	O
,	O
which	O
are	O
found	O
only	O
in	O
neurons	O
,	O
may	O
be	O
of	O
prime	O
importance	O
in	O
neuronal	O
function	O
,	O
especially	O
during	O
development	O
of	O
the	O
nervous	O
system	O
.	O
Our	O
findings	O
suggest	O
that	O
generation	O
of	O
antibodies	O
to	O
the	O
neurofilament	O
proteins	O
can	O
occur	O
in	O
patients	O
with	O
opsoclonus	O
-	O
myoclonus	O
;	O
the	O
role	O
of	O
the	O
anti	O
-	O
NF210K	O
antibodies	O
in	O
the	O
pathogenesis	O
of	O
OM	O
,	O
however	O
,	O
is	O
uncertain	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
3294894	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
1994	O
Oct;6	O
3(	O
4	O
)	O
:	O
1261	O
-	O
70	O
.	O
Nerve	O
growth	O
factor	O
-	O
induced	O
differentiation	O
in	O
neuroblastoma	B-malignancy-type
cells	O
expressing	O
TrkA	O
but	O
lacking	O
p75NGFR	O
.	O
Hartman	O
DS	O
,	O
Hertel	O
C.	O
F.	O
Hoffmann	O
-	O
La	O
Roche	O
AG	O
,	O
Basel	O
,	O
Switzerland	O
.	O
Nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
binds	O
to	O
two	O
distinct	O
cell	O
surface	O
receptors	O
,	O
TrkA	O
,	O
which	O
is	O
a	O
receptor	O
tyrosine	O
kinase	O
,	O
and	O
p75NGFR	O
,	O
whose	O
role	O
in	O
NGF	O
-	O
induced	O
signal	O
transduction	O
remains	O
unclear	O
.	O
We	O
have	O
found	O
that	O
human	O
neuroblastoma	B-malignancy-type
IMR-32	O
cells	O
express	O
TrkA	O
,	O
but	O
p75NGFR	O
expression	O
was	O
not	O
detectable	O
in	O
these	O
cells	O
by	O
northern	O
blot	O
analysis	O
,	O
immunoblotting	O
,	O
or	O
chemical	O
crosslinking	O
experiments	O
.	O
Despite	O
the	O
lack	O
of	O
p75NGFR	O
expression	O
,	O
subnanomolar	O
concentrations	O
of	O
recombinant	O
human	O
NGF	O
induced	O
neurite	O
outgrowth	O
,	O
tyrosine	O
phosphorylation	O
,	O
and	O
immediate	O
early	O
gene	O
expression	O
in	O
these	O
cells	O
.	O
These	O
results	O
strongly	O
suggest	O
that	O
NGF	O
-	O
induced	O
neuronal	O
differentiation	O
in	O
IMR-32	O
cells	O
is	O
initiated	O
through	O
TrkA	O
in	O
the	O
absence	O
of	O
p75NGFR	O
.	O
Thus	O
,	O
IMR-32	O
cells	O
may	O
provide	O
a	O
model	O
for	O
studying	O
neurotrophic	O
effects	O
of	O
NGF	O
on	O
adult	O
striatal	O
cholinergic	O
neurons	O
,	O
which	O
also	O
lack	O
p75NGFR	O
expression	O
.	O
PMID	O
:	O
7523588	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neurosci	O
Lett	O
.	O
2001	O
Jul	O
13;307	O
(	O
2	O
)	O
:	O
117-	O
21	O
.	O
Characterization	O
of	O
5	O
'	O
flanking	O
region	O
of	O
alpha	O
isoform	O
of	O
rat	O
Ca2+	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
II	O
gene	O
and	O
neuronal	O
cell	O
type	O
specific	O
promoter	O
activity	O
.	O
Mima	O
K,	O
Deguchi	O
S	O
,	O
Yamauchi	O
T.	O
Department	O
of	O
Biochemistry	O
,	O
Faculty	O
of	O
Pharmaceutical	O
Sciences	O
,	O
The	O
University	O
of	O
Tokushima	O
,	O
Shomachi	O
1	O
,	O
770	O
-	O
8505	O
,	O
Tokushima	O
,	O
Japan	O
.	O
The	O
5	O
'	O
flanking	O
region	O
of	O
the	O
alpha	O
isoform	O
of	O
the	O
rat	O
Ca2+	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
II	O
(	O
alpha	O
CaM	O
kinase	O
II	O
)	O
gene	O
was	O
isolated	O
in	O
2.3	O
kbp	O
of	O
genomic	O
sequence	O
.	O
Functional	O
analysis	O
of	O
alpha	O
CaM	O
kinase	O
II	O
promoter	O
deletion	O
mutants	O
fused	O
to	O
a	O
reporter	O
gene	O
in	O
neuroblastoma	B-malignancy-type
,	O
including	O
N18TG2	O
,	O
NG108-15	O
,	O
and	O
CAD	O
cells	O
revealed	O
strong	O
transcriptional	O
activity	O
localized	O
100	O
-	O
145	O
bp	O
,	O
and	O
a	O
potent	O
silencer	O
199	O
-	O
275	O
bp	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O
The	O
promoter	O
is	O
inactive	O
in	O
non	O
-	O
neuronal	O
cells	O
including	O
BALB	O
/	O
c	O
3T3	O
,	O
Chinese	O
hamster	O
ovary	O
,	O
HT1080	O
,	O
and	O
C6	O
glioma	B-malignancy-type
cells	O
.	O
These	O
results	O
indicated	O
that	O
the	O
alpha	O
CaM	O
kinase	O
II	O
gene	O
is	O
transcribed	O
from	O
a	O
tissue	O
-	O
specific	O
promoter	O
which	O
is	O
under	O
intense	O
negative	O
control	O
.	O
PMID	O
:	O
11427314	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neuroreport	O
.	O
2000	O
Aug	O
21;11(	O
12	O
)	O
:	O
2635	O
-	O
8.	O
Parkin	O
is	O
metabolized	O
by	O
the	O
ubiquitin	O
/	O
proteosome	O
system	O
.	O
Choi	O
P,	O
Ostrerova-Golts	O
N	O
,	O
Sparkman	O
D	O
,	O
Cochran	O
E	O
,	O
Lee	O
JM	O
,	O
Wolozin	O
B.	O
Department	O
of	O
Pharmacology	O
,	O
Loyola	O
University	O
Medical	O
Center	O
,	O
Maywood	O
,	O
IL	O
60153	O
,	O
USA	O
.	O
Mutations	O
in	O
the	O
parkin	O
gene	O
cause	O
autosomal	O
recessive	O
juvenile	O
parkinsonism	O
.	O
Immunostaining	O
of	O
substantia	O
nigra	O
sections	O
from	O
sporadic	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
cases	O
shows	O
that	O
Parkin	O
accumulates	O
in	O
axonal	O
spheroids	O
and	O
in	O
some	O
Lewy	O
bodies	O
.	O
Because	O
ubiquitin	O
is	O
a	O
major	O
component	O
of	O
Lewy	O
bodies	O
and	O
axonal	O
spheroids	O
,	O
we	O
investigated	O
whether	O
Parkin	O
is	O
metabolized	O
via	O
the	O
ubiquitin	O
/	O
proteosomal	O
pathway	O
.	O
Treatment	O
of	O
BE-M17	O
neuroblastoma	B-malignancy-type
cells	O
with	O
the	O
proteosomal	O
inhibitor	O
,	O
MG132	O
,	O
produced	O
a	O
band	O
corresponding	O
to	O
di	O
-	O
ubiquitinated	O
Parkin	O
that	O
was	O
apparent	O
by	O
immunoblot	O
using	O
two	O
different	O
anti	O
-	O
Parkin	O
antibodies	O
.	O
This	O
higher	O
mol.	O
wt	O
band	O
also	O
co	O
-	O
immunoprecipitated	O
with	O
Parkin	O
.	O
These	O
data	O
suggest	O
that	O
Parkin	O
plays	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
sporadic	O
PD	O
,	O
and	O
that	O
Parkin	O
is	O
a	O
substrate	O
for	O
ubiquitination	O
that	O
is	O
degraded	O
by	O
the	O
proteosomal	O
complex	O
.	O
PMID	O
:	O
10976934	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1990	O
Dec	O
5;265	O
(	O
34	O
)	O
:	O
2073	O
5	O
-	O
8.	O
Anionic	O
site	O
interactions	O
in	O
human	O
butyrylcholinesterase	O
disrupted	O
by	O
two	O
single	O
point	O
mutations	O
.	O
Neville	O
LF	O
,	O
Gnatt	O
A	O
,	O
Padan	O
R	O
,	O
Seidman	O
S	O
,	O
Soreq	O
H.	O
Department	O
of	O
Biological	O
Chemistry	O
,	O
Hebrew	O
University	O
of	O
Jerusalem	O
,	O
Israel	O
.	O
Structure	O
-	O
function	O
relationships	O
of	O
recombinant	O
human	O
butyrylcholinesterase	O
(	O
CHE	O
)	O
variants	O
were	O
investigated	O
by	O
Xenopus	O
oocyte	O
microinjection	O
.	O
A	O
Ser	O
-	O
425	O
to	O
Pro	O
-	O
425	O
mutation	O
failed	O
to	O
modify	O
ligand	O
binding	O
properties	O
.	O
In	O
contrast	O
,	O
Asp	O
-	O
70	O
to	O
Gly	O
-	O
70	O
substitution	O
significantly	O
reduced	O
CHE	O
binding	O
capacity	O
for	O
succinylcholine	O
and	O
specific	O
inhibitors	O
,	O
demonstrating	O
Asp	O
-	O
70	O
as	O
a	O
key	O
anionic	O
site	O
component	O
for	O
certain	O
ligands	O
.	O
Furthermore	O
,	O
the	O
presence	O
of	O
both	O
mutations	O
rendered	O
CHE	O
totally	O
resistant	O
to	O
succinylcholine	O
and	O
dibucaine	O
inhibition	O
,	O
while	O
all	O
mutant	O
proteins	O
bound	O
butyrylthiocholine	O
,	O
benzoylcholine	O
,	O
and	O
propionylcholine	O
normally	O
.	O
These	O
findings	O
imply	O
structural	O
interactions	O
between	O
the	O
conserved	O
Asp	O
-	O
70	O
and	O
Ser	O
-	O
425	O
regions	O
in	O
cholinesterases	O
and	O
suggest	O
the	O
contribution	O
of	O
additional	O
electronegative	O
amino	O
acids	O
to	O
anionic	O
site	O
binding	O
.	O
PMID	O
:	O
2249982	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
1995	O
Oct	O
15	O
;55	O
(	O
20	O
)	O
:4664	O
-	O
9.	O
Significance	O
of	O
chromosome	O
1p	O
loss	O
of	O
heterozygosity	O
in	O
neuroblastoma	B-malignancy-type
.	O
Maris	O
JM	O
,	O
White	O
PS	O
,	O
Beltinger	O
CP	O
,	O
Sulman	O
EP	O
,	O
Castleberry	O
RP	O
,	O
Shuster	O
JJ	O
,	O
Look	O
AT	O
,	O
Brodeur	O
GM	O
.	O
Division	O
of	O
Oncology	O
,	O
Children	O
's	O
Hospital	O
of	O
Philadelphia	O
,	O
University	O
of	O
Pennsylvania	O
,	O
Philadepphia	O
School	O
of	O
Medicine	O
19104	O
,	O
USA	O
.	O
We	O
analyzed	O
156	O
primary	O
neuroblastoma	B-malignancy-type
tumor	O
samples	O
for	O
loss	O
of	O
heterozygosity	O
at	O
the	O
distal	O
short	O
arm	O
of	O
chromosome	O
1	O
(	O
1p	O
LOH	O
)	O
.	O
We	O
also	O
compared	O
1p	O
LOH	O
with	O
known	O
clinical	O
and	O
genetic	O
prognostic	O
variables	O
as	O
well	O
as	O
patient	O
outcome	O
.	O
1p	O
LOH	O
was	O
detected	O
in	O
30	O
of	O
156	O
tumors	O
(	O
19	O
%	O
)	O
and	O
was	O
strongly	O
associated	O
with	O
adverse	O
clinical	O
and	O
biological	O
features	O
.	O
1p	O
LOH	O
was	O
also	O
strongly	O
predictive	O
of	O
a	O
poor	O
outcome	O
in	O
univariate	O
analyses	O
(	O
estimated	O
4	O
-	O
year	O
survival	O
,	O
32	O
+/-	O
10	O
%	O
SE	O
versus	O
76	O
+/-	O
5	O
%	O
SE	O
;	O
P	O
<	O
0.001	O
)	O
.	O
However	O
,	O
the	O
prognostic	O
value	O
of	O
1p	O
LOH	O
was	O
equivocal	O
when	O
stratified	O
for	O
amplification	O
of	O
the	O
MYCN	O
oncogene	O
(	O
P	O
=	O
0.16	O
)	O
.	O
We	O
conclude	O
that	O
1p	O
LOH	O
is	O
an	O
important	O
component	O
of	O
a	O
pattern	O
of	O
genetic	O
abnormalities	O
in	O
neuroblastoma	B-malignancy-type
associated	O
with	O
an	O
aggressive	O
clinical	O
course	O
.	O
PMID	O
:	O
7553646	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
.	O
2003	O
Jul	O
18;19	O
7	O
(	O
1-2	O
)	O
:	O
111	O
-	O
7.	O
Biological	O
and	O
clinical	O
role	O
of	O
p73	O
in	O
neuroblastoma	B-malignancy-type
.	O
Romani	O
M,	O
Tonini	O
GP	O
,	O
Banelli	O
B	O
,	O
Allemanni	O
G	O
,	O
Mazzocco	O
K,	O
Scaruffi	O
P,	O
Boni	O
L,	O
Ponzoni	O
M,	O
Pagnan	O
G	O
,	O
Raffaghello	O
L,	O
Ferrini	O
S	O
,	O
Croce	O
M,	O
Casciano	O
I.	O
Laboratory	O
of	O
Tumor	O
Genetics	O
,	O
Istituto	O
Nazionale	O
per	O
la	O
Ricerca	O
sul	O
Cancro	O
(	O
IST	O
)	O
,	O
Largo	O
Rosanna	O
Benzi	O
10	O
,	O
16132	O
Genova	O
,	O
Italy	O
.	O
massimo.romani@istge	O
.it	O
The	O
p73	O
gene	O
is	O
a	O
p53	O
homologue	O
localized	O
at	O
1p36.3	O
,	O
a	O
chromosomal	O
region	O
frequently	O
deleted	O
in	O
neuroblastoma	B-malignancy-type
.	O
p73	O
was	O
originally	O
considered	O
an	O
oncosuppressor	O
gene	O
.	O
However	O
,	O
it	O
was	O
soon	O
realized	O
that	O
its	O
mode	O
of	O
action	O
did	O
not	O
resemble	O
that	O
of	O
a	O
classic	O
anti	O
-	O
oncogene	O
.	O
The	O
recent	O
discovery	O
of	O
N	O
-	O
terminal	O
truncated	O
isoforms	O
,	O
with	O
oncogenic	O
properties	O
,	O
showed	O
that	O
p73	O
has	O
a	O
'	O
two	O
in	O
one	O
'	O
structure	O
.	O
Indeed	O
,	O
the	O
full	O
-	O
length	O
variants	O
are	O
strong	O
inducers	O
of	O
apoptosis	O
while	O
the	O
truncated	O
isoforms	O
inhibit	O
the	O
pro	O
-	O
apoptotic	O
activity	O
of	O
p53	O
and	O
of	O
the	O
full	O
-	O
length	O
p73	O
.	O
This	O
review	O
summarizes	O
some	O
aspects	O
of	O
p73	O
biology	O
with	O
particular	O
reference	O
to	O
its	O
possible	O
role	O
in	O
neuroblastoma	B-malignancy-type
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
12880969	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

FEBS	O
Lett	O
.	O
1997	O
Dec	O
8;419(	O
1	O
)	O
:76-82	O
.	O
Sequence	O
and	O
characterisation	O
of	O
the	O
RET	O
proto	O
-	O
oncogene	O
5	O
'	O
flanking	O
region	O
:	O
analysis	O
of	O
retinoic	O
acid	O
responsiveness	O
at	O
the	O
transcriptional	O
level	O
.	O
Patrone	O
G	O
,	O
Puliti	O
A	O
,	O
Bocciardi	O
R	O
,	O
Ravazzolo	O
R	O
,	O
Romeo	O
G.	O
Universita	O
di	O
Genova	O
,	O
Facolta	O
di	O
Medicina	O
e	O
Laboratorio	O
di	O
Genetica	O
Molecolare	O
,	O
Istituto	O
G.	O
Gaslini	O
,	O
Genoa	O
,	O
Italy	O
.	O
genetica@unige	O
.it	O
The	O
RET	O
proto	O
-	O
oncogene	O
encodes	O
a	O
receptor	O
tyrosine	O
kinase	O
expressed	O
during	O
neural	O
crest	O
development	O
.	O
RET	O
expression	O
is	O
enhanced	O
in	O
vitro	O
by	O
several	O
differentiating	O
agents	O
,	O
including	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
which	O
up	O
-	O
regulates	O
RET	O
expression	O
in	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
In	O
the	O
present	O
work	O
we	O
sequenced	O
and	O
analysed	O
a	O
5	O
kbp	O
genomic	O
fragment	O
5	O
'	O
to	O
RET	O
.	O
Three	O
deletion	O
fragments	O
of	O
this	O
region	O
were	O
tested	O
for	O
their	O
RA	O
inducibility	O
in	O
transient	O
transfection	O
assays	O
and	O
failed	O
to	O
support	O
the	O
hypothesis	O
of	O
a	O
direct	O
transcriptional	O
activation	O
.	O
Finally	O
,	O
our	O
functional	O
analysis	O
of	O
a	O
candidate	O
RA	O
response	O
element	O
present	O
in	O
the	O
RET	O
promoter	O
provides	O
new	O
hints	O
for	O
the	O
understanding	O
of	O
the	O
interaction	O
between	O
nuclear	O
receptors	O
and	O
their	O
specific	O
recognition	O
sites	O
.	O
PMID	O
:	O
9426223	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurol	O
Neurosurg	O
Psychiatry	O
.	O
1989	O
Jun;52(	O
6	O
)	O
:778	O
-	O
81	O
.	O
Long	O
term	O
survival	O
with	O
early	O
childhood	O
intracerebral	B-malignancy-type
tumours	I-malignancy-type
.	O
Hankey	O
GJ	O
,	O
Davies	O
L,	O
Gubbay	O
SS	O
.	O
Department	O
of	O
Neurology	O
,	O
Royal	O
Perth	O
Hospital	O
,	O
Western	O
Australia	O
.	O
Three	O
young	O
adults	O
are	O
described	O
who	O
presented	O
during	O
early	O
childhood	O
with	O
a	O
seizure	O
disorder	O
due	O
to	O
an	O
underlying	O
intracerebral	B-malignancy-type
tumour	I-malignancy-type
.	O
The	O
tumours	O
were	O
excised	O
incompletely	O
14	O
-	O
19	O
years	O
later	O
.	O
The	O
histological	O
findings	O
were	O
those	O
of	O
a	O
temporal	B-malignancy-type
lobe	I-malignancy-type
benign	I-malignancy-type
capillary	I-malignancy-type
haemangioblastoma	I-malignancy-type
(	O
Case	O
1	O
)	O
,	O
parietal	B-malignancy-type
lobe	I-malignancy-type
subependymoma	I-malignancy-type
(	O
Case	O
2	O
)	O
,	O
and	O
parietal	B-malignancy-type
lobe	I-malignancy-type
ganglioglioma	I-malignancy-type
(	O
Case	O
3	O
)	O
.	O
After	O
a	O
mean	O
period	O
of	O
follow	O
-	O
up	O
of	O
22	O
years	O
(	O
range	O
18	O
-	O
26	O
)	O
,	O
only	O
mild	O
residual	O
physical	O
disabilities	O
exist	O
in	O
each	O
patient	O
.	O
These	O
three	O
cases	O
illustrate	O
(1)	O
the	O
need	O
promptly	O
to	O
investigate	O
children	O
who	O
present	O
with	O
focal	O
seizures	O
or	O
whose	O
EEG	O
shows	O
definite	O
focal	O
abnormalities	O
,	O
(2)	O
the	O
relevant	O
investigations	O
should	O
include	O
cranial	O
CT	O
or	O
MRI	O
in	O
such	O
cases	O
and	O
(3)	O
that	O
certain	O
supratentorial	B-malignancy-type
tumours	I-malignancy-type
have	O
a	O
favourable	O
outcome	O
due	O
to	O
their	O
benign	O
biological	O
behaviour	O
rather	O
than	O
their	O
location	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
2746271	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Anticancer	O
Res	O
.	O
1997	O
Jul-	O
Aug;17(	O
4B	O
)	O
:3145-7.	O
Distribution	O
of	O
disialoganglioside	O
GD2	O
-	O
antigen	O
and	O
binding	O
of	O
anti	O
-	O
GD2	O
antibodies	O
on	O
spheroids	O
of	O
neuroblastoma	B-malignancy-type
cell	O
line	O
.	O
Heiss	O
P,	O
Bermatz	O
S	O
,	O
Wehnes	O
H,	O
Heinzmann	O
U	O
,	O
Senekowitsch-Schmidtke	O
R.	O
Nuklearmedizinische	O
Klinik	O
,	O
Technischen	O
Universitat	O
Munchen	O
,	O
Germany	O
.	O
The	O
ganglioside	O
GD2	O
is	O
highly	O
expressed	O
on	O
human	O
tumors	O
of	O
neuroectodermal	O
origin	O
.	O
We	O
investigated	O
by	O
scanning	O
electron	O
microscopy	O
the	O
ganglioside	O
GD2	O
distribution	O
on	O
the	O
surface	O
of	O
spheroids	O
of	O
the	O
neuroblastoma	B-malignancy-type
cell	O
line	O
SK-N-LO	O
.	O
About	O
50	O
%	O
of	O
cells	O
showed	O
GD2	O
on	O
the	O
plasma	O
membrane	O
and	O
the	O
distribution	O
of	O
GD2	O
on	O
most	O
of	O
these	O
cells	O
was	O
heterogeneous	O
,	O
with	O
more	O
GD2	O
at	O
the	O
contact	O
sites	O
of	O
the	O
cells	O
.	O
The	O
binding	O
kinetics	O
of	O
the	O
chimeric	O
anti	O
-	O
GD2	O
antibody	O
ch14.18	O
labelled	O
with	O
I-125	O
on	O
spheroids	O
(	O
average	O
diameter	O
:	O
450	O
microns	O
)	O
was	O
determined	O
by	O
gamma	O
counting	O
.	O
Over	O
4	O
hours	O
the	O
antibody	O
concentration	O
was	O
raised	O
substantially	O
but	O
up	O
to	O
24	O
hours	O
there	O
was	O
only	O
a	O
very	O
slow	O
further	O
increase	O
.	O
A	O
clustered	O
pattern	O
of	O
bound	O
chimeric	O
anti	O
-	O
GD2	O
antibody	O
ch14.18	O
was	O
found	O
on	O
a	O
cross	O
-	O
section	O
of	O
the	O
spheroid	O
by	O
autoradiography	O
.	O
PMID	O
:	O
9329622	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cell	O
Mol	O
Life	O
Sci	O
.	O
2002	O
Oct;5	O
9	O
(	O
10	O
)	O
:1706-13	O
.	O
Melatonin	O
regulation	O
of	O
antioxidant	O
enzyme	O
gene	O
expression	O
.	O
Mayo	O
JC	O
,	O
Sainz	O
RM	O
,	O
Antoli	O
I	O
,	O
Herrera	O
F	O
,	O
Martin	O
V	O
,	O
Rodriguez	O
C.	O
Departamento	O
de	O
Morfologia	O
y	O
Biologia	O
Celular	O
,	O
Facultad	O
de	O
Medicina	O
,	O
c/	O
Julian	O
Claveria	O
s	O
/	O
n	O
,	O
33006	O
Oviedo	O
,	O
Austurias	O
,	O
Spain	O
.	O
Antioxidant	O
enzymes	O
(	O
AOEs	O
)	O
are	O
part	O
of	O
the	O
primary	O
cellular	O
defense	O
against	O
free	O
radicals	O
induced	O
by	O
toxins	O
and/or	O
spontaneously	O
formed	O
in	O
cells	O
.	O
Melatonin	O
(	O
MLT	O
)	O
has	O
received	O
much	O
attention	O
in	O
recent	O
years	O
due	O
to	O
its	O
direct	O
free	O
radical	O
scavenging	O
and	O
antioxidant	O
properties	O
.	O
In	O
the	O
present	O
work	O
we	O
report	O
that	O
MLT	O
,	O
at	O
physiological	O
serum	O
concentrations	O
(	O
1	O
nM	O
)	O
,	O
increases	O
the	O
mRNA	O
of	O
both	O
superoxide	O
dismutases	O
(	O
SODs	O
)	O
and	O
glutathione	O
peroxidase	O
(	O
GPx	O
)	O
in	O
two	O
neuronal	O
cell	O
lines	O
.	O
The	O
MLT	O
effect	O
on	O
both	O
SODs	O
and	O
GPx	O
mRNA	O
was	O
mediated	O
by	O
a	O
de	O
novo	O
synthesized	O
protein	O
.	O
MLT	O
alters	O
mRNA	O
stability	O
for	O
Cu-Zn	O
SOD	O
and	O
GPx	O
.	O
Experiments	O
with	O
a	O
short	O
time	O
treatment	O
(	O
pulse	O
action	O
)	O
of	O
MLT	O
suggest	O
that	O
the	O
regulation	O
of	O
AOE	O
gene	O
expression	O
is	O
likely	O
to	O
be	O
receptor	O
mediated	O
,	O
because	O
1	O
-	O
h	O
treatment	O
with	O
MLT	O
results	O
in	O
the	O
same	O
response	O
as	O
a	O
24	O
-	O
h	O
treatment	O
.	O
PMID	O
:	O
12475181	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
1991	O
Dec;	O
6	O
(	O
12	O
)	O
:	O
2333	O
-	O
8.	O
Expression	O
of	O
the	O
ret	O
proto	O
-	O
oncogene	O
in	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
and	O
its	O
increase	O
during	O
neuronal	O
differentiation	O
induced	O
by	O
retinoic	O
acid	O
.	O
Tahira	O
T	O
,	O
Ishizaka	O
Y	O
,	O
Itoh	O
F	O
,	O
Nakayasu	O
M,	O
Sugimura	O
T	O
,	O
Nagao	O
M.	O
Carcinogenesis	O
Division	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tokyo	O
,	O
Japan	O
.	O
Previously	O
we	O
observed	O
specific	O
expression	O
of	O
the	O
ret	O
proto	O
-	O
oncogene	O
(	O
proto	O
-	O
ret	O
)	O
in	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
A	O
neuronal	O
subline	O
and	O
non	O
-	O
neuronal	O
sublines	O
were	O
isolated	O
from	O
the	O
SK-N-SH	O
cell	O
line	O
,	O
which	O
is	O
composed	O
of	O
a	O
heterogeneous	O
cell	O
population	O
.	O
Expression	O
of	O
proto	O
-	O
ret	O
was	O
detected	O
in	O
the	O
neuronal	O
subline	O
,	O
named	O
SH-4305	O
,	O
but	O
not	O
in	O
three	O
non	O
-	O
neuronal	O
sublines	O
.	O
Expression	O
of	O
proto	O
-	O
ret	O
in	O
the	O
SH-4305	O
cells	O
increased	O
markedly	O
after	O
treatment	O
with	O
retinoic	O
acid	O
for	O
1	O
day	O
,	O
with	O
concomitant	O
morphological	O
change	O
,	O
namely	O
neurite	O
outgrowth	O
,	O
and	O
induction	O
of	O
neurofilament	O
mRNA	O
expression	O
.	O
Induction	O
of	O
proto	O
-	O
ret	O
expression	O
seemed	O
to	O
be	O
correlated	O
with	O
neurite	O
outgrowth	O
and	O
increase	O
of	O
neurofilament	O
mRNA	O
expression	O
.	O
These	O
data	O
suggest	O
that	O
the	O
proto	O
-	O
ret	O
product	O
plays	O
a	O
role	O
in	O
neuronal	O
differentiation	O
.	O
PMID	O
:	O
1766678	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurooncol	O
.	O
1997	O
Jan;31(	O
1-2	O
)	O
:	O
115-22	O
.	O
A	O
possible	O
growth	O
factor	O
role	O
of	O
IL-6	O
in	O
neuroectodermal	B-malignancy-type
tumours	I-malignancy-type
.	O
Candi	O
E	O
,	O
Knight	O
RA	O
,	O
Spinedi	O
A	O
,	O
Guerrieri	O
P,	O
Melino	O
G.	O
IDI-IRCCS	O
Biochemistry	O
Laboratory	O
,	O
Department	O
of	O
Experimental	O
Medicine	O
and	O
Biochemical	O
Sciences	O
,	O
University	O
of	O
Rome	O
Tor	O
Vergata	O
,	O
Italy	O
.	O
Preliminary	O
data	O
have	O
shown	O
that	O
IL-6	O
may	O
act	O
as	O
an	O
autocrine	O
growth	O
factor	O
to	O
control	O
proliferation	O
.	O
We	O
further	O
characterised	O
the	O
role	O
of	O
IL-6	O
in	O
tumour	O
growth	O
as	O
an	O
autocrine	O
/	O
paracrine	O
growth	O
factor	O
in	O
neuroectodermal	B-malignancy-type
tumours	I-malignancy-type
.	O
We	O
evaluated	O
the	O
production	O
and	O
secretion	O
of	O
IL-6	O
by	O
seven	O
human	O
melanoma	B-malignancy-type
,	O
five	O
neuroblastoma	B-malignancy-type
and	O
one	O
glioblastoma	B-malignancy-type
cell	O
lines	O
.	O
Moreover	O
,	O
we	O
determined	O
their	O
IL-6	O
-	O
dependent	O
growth	O
in	O
serum	O
free	O
-	O
medium	O
or	O
under	O
minimal	O
growth	O
-	O
supplement	O
conditions	O
:	O
IL-6	O
dependent	O
growth	O
was	O
observed	O
in	O
two	O
non	O
-	O
IL-6	O
producing	O
melanoma	B-malignancy-type
and	O
in	O
one	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
In	O
addition	O
,	O
expression	O
of	O
IL-6	O
mRNA	O
and	O
peptide	O
was	O
increased	O
by	O
retinoic	O
acid	O
.	O
The	O
data	O
support	O
the	O
hypothesis	O
that	O
IL-6	O
contributes	O
to	O
neuroectodermal	B-malignancy-type
tumour	I-malignancy-type
growth	O
,	O
even	O
though	O
it	O
shows	O
a	O
less	O
potent	O
effect	O
than	O
other	O
reported	O
growth	O
factor	O
such	O
as	O
IGF-II	O
.	O
PMID	O
:	O
9049837	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Anaesth	O
Intensive	O
Care	O
.	O
1990	O
Nov;18	O
(	O
4	O
)	O
:460	O
-5	O
.	O
Response	O
to	O
nondepolarizing	O
muscle	O
relaxants	O
in	O
children	O
with	O
tumours	O
.	O
Brown	O
TC	O
,	O
Gregory	O
M,	O
Bell	O
B	O
,	O
Clare	O
D.	O
Department	O
of	O
Anaesthesia	O
,	O
Royal	O
Children	O
's	O
Hospital	O
,	O
Melbourne	O
,	O
Victoria	O
,	O
Australia	O
.	O
The	O
rate	O
of	O
onset	O
of	O
action	O
of	O
d-tubocurarine	O
(	O
64	O
patients	O
)	O
or	O
alcuronium	O
(	O
36	O
patients	O
)	O
was	O
studied	O
electromyographically	O
in	O
100	O
children	O
who	O
had	O
abdominal	B-malignancy-type
,	O
bone	B-malignancy-type
or	O
cerebral	B-malignancy-type
tumours	I-malignancy-type
.	O
It	O
was	O
found	O
that	O
there	O
was	O
a	O
significantly	O
delayed	O
onset	O
(	O
over	O
three	O
times	O
longer	O
than	O
controls	O
)	O
or	O
additional	O
doses	O
were	O
required	O
in	O
patients	O
with	O
malignant	O
liver	B-malignancy-type
,	O
renal	B-malignancy-type
and	O
bone	B-malignancy-type
tumours	I-malignancy-type
who	O
received	O
d-tubocurarine	O
.	O
The	O
onset	O
of	O
alcuronium	O
blockade	O
was	O
also	O
prolonged	O
but	O
to	O
a	O
lesser	O
extent	O
.	O
When	O
tumours	O
with	O
an	O
abnormal	O
prolongation	O
of	O
onset	O
of	O
relaxation	O
were	O
successfully	O
treated	O
by	O
chemotherapy	O
and/or	O
surgery	O
,	O
the	O
response	O
reverted	O
to	O
normal	O
.	O
Children	O
with	O
benign	O
tumours	O
or	O
masses	O
had	O
normal	O
responses	O
.	O
In	O
contrast	O
,	O
neuroblastomas	B-malignancy-type
were	O
associated	O
with	O
little	O
prolongation	O
of	O
onset	O
.	O
Cerebral	B-malignancy-type
tumours	I-malignancy-type
showed	O
a	O
variable	O
response	O
,	O
with	O
the	O
observed	O
changes	O
being	O
unreliable	O
indicators	O
of	O
degree	O
of	O
malignancy	O
.	O
PMID	O
:	O
2176439	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
1991	O
Sep	O
30	O
;179	O
(	O
3	O
)	O
:	O
1449-	O
54	O
.	O
Enhanced	O
MYCN	O
oncogene	O
expression	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
is	O
associated	O
with	O
altered	O
FGF	O
receptor	O
expression	O
and	O
cellular	O
growth	O
response	O
to	O
basic	O
FGF	O
.	O
Schweigerer	O
L,	O
Ledoux	O
D	O
,	O
Fleischmann	O
G	O
,	O
Barritault	O
D.	O
Sektion	O
Onkologie	O
/	O
Immunologie	O
,	O
Universitats	O
-Kinderklinik	O
,	O
Ruprecht	O
-	O
Karls	O
-Universitat	O
,	O
Heidelberg	O
,	O
FRG.	O
We	O
have	O
examined	O
the	O
effect	O
of	O
human	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
on	O
the	O
proliferation	O
of	O
human	O
neuroblastoma	B-malignancy-type
cells	O
with	O
normal	O
and	O
enhanced	O
MYCN	O
oncogene	O
expression	O
.	O
bFGF	O
stimulated	O
the	O
proliferation	O
of	O
the	O
neuroblastoma	B-malignancy-type
cells	O
with	O
enhanced	O
,	O
but	O
not	O
normal	O
,	O
MYCN	O
expression	O
.	O
Both	O
cell	O
species	O
express	O
FGFR-1	O
,	O
but	O
not	O
FGFR-2	O
,	O
receptors	O
and	O
both	O
harbor	O
FGF	O
receptor	O
species	O
of	O
Mr	O
145.000	O
,	O
but	O
they	O
differ	O
in	O
their	O
pattern	O
of	O
lower	O
and	O
higher	O
-	O
molecular	O
weight	O
FGF	O
receptor	O
species	O
.	O
Our	O
results	O
demonstrate	O
that	O
enhanced	O
MYCN	O
expression	O
confers	O
to	O
neuroblastoma	B-malignancy-type
cells	O
the	O
ability	O
to	O
respond	O
to	O
bFGF	O
,	O
possibly	O
by	O
inducing	O
functional	O
FGF	O
receptors	O
.	O
This	O
mechanism	O
may	O
contribute	O
to	O
the	O
advanced	O
malignant	O
phenotype	O
of	O
human	O
neuroblastomas	B-malignancy-type
with	O
enhanced	O
MYCN	O
expression	O
.	O
PMID	O
:	O
1656953	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neurosci	O
Lett	O
.	O
2000	O
Oct	O
13;292	O
(	O
3	O
)	O
:	O
147	O
-	O
50	O
.	O
Synergy	O
between	O
5	O
'	O
and	O
3	O
'	O
flanking	O
regions	O
of	O
the	O
human	O
tyrosine	O
hydroxylase	O
gene	O
ensures	O
specific	O
,	O
high	O
-	O
level	O
expression	O
in	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Gardaneh	O
M,	O
Gilbert	O
J,	O
Haber	O
M,	O
Norris	O
MD	O
,	O
Cohn	O
SL	O
,	O
Schmidt	O
ML	O
,	O
Marshall	O
GM	O
.	O
Children	O
's	O
Cancer	O
Institute	O
Australia	O
for	O
Medical	O
Research	O
,	O
NSW	O
,	O
Randwick	O
,	O
Australia	O
.	O
Factors	O
regulating	O
tyrosine	O
hydroxylase	O
(	O
TH	O
)	O
gene	O
transcription	O
are	O
of	O
major	O
importance	O
in	O
the	O
studies	O
of	O
malignant	O
and	O
degenerative	O
diseases	O
of	O
catecholamine	O
-	O
synthesizing	O
tissues	O
.	O
In	O
this	O
study	O
,	O
we	O
used	O
transient	O
transfection	O
of	O
a	O
reporter	O
gene	O
to	O
show	O
that	O
high	O
-	O
level	O
,	O
tissue	O
-	O
specific	O
TH	O
expression	O
was	O
only	O
achieved	O
when	O
the	O
reporter	O
gene	O
was	O
cloned	O
between	O
a	O
5	O
'	O
TH	O
promoter	O
sequence	O
(	O
-	O
513	O
-	O
+	O
1	O
)	O
,	O
and	O
,	O
a	O
3	O
'	O
TH	O
gene	O
flanking	O
sequence	O
(	O
end	O
of	O
exon	O
14	O
-	O
+	O
976	O
)	O
.	O
We	O
also	O
show	O
that	O
TH	O
mRNA	O
expression	O
level	O
is	O
closely	O
linked	O
to	O
the	O
expression	O
level	O
of	O
the	O
proto	O
-	O
oncogene	O
,	O
MYCN	O
in	O
neuroblastoma	B-malignancy-type
tumor	O
cell	O
lines	O
.	O
Taken	O
together	O
our	O
data	O
indicate	O
that	O
MYCN	O
may	O
regulate	O
TH	O
expression	O
in	O
neuroblastoma	B-malignancy-type
cells	O
,	O
but	O
not	O
through	O
binding	O
to	O
the	O
5	O
'	O
or	O
3	O
'	O
TH	O
gene	O
flanking	O
sequences	O
used	O
in	O
our	O
experiments	O
.	O
PMID	O
:	O
11018298	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
1997	O
Apr	O
17;233	O
(	O
2	O
)	O
:	O
36	O
5	O
-	O
9.	O
Cell	O
-	O
type	O
-	O
specific	O
modulation	O
of	O
Hox	O
gene	O
expression	O
by	O
members	O
of	O
the	O
TGF-beta	O
superfamily	O
:	O
a	O
comparison	O
between	O
human	O
osteosarcoma	B-malignancy-type
and	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Kloen	O
P,	O
Visker	O
MH	O
,	O
Olijve	O
W	O
,	O
van	O
Zoelen	O
EJ	O
,	O
Boersma	O
CJ.	O
Department	O
of	O
Orthopaedic	O
Surgery	O
,	O
Massachusetts	O
General	O
Hospital	O
,	O
and	O
Harvard	O
Medical	O
School	O
,	O
Boston	O
,	O
USA	O
.	O
Homeobox	O
gene	O
expression	O
in	O
osteoblast	O
-	O
like	O
cells	O
was	O
investigated	O
using	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O
A	O
total	O
of	O
13	O
homeobox	O
genes	O
was	O
detected	O
in	O
U-2	O
OS	O
(	O
human	O
osteosarcoma	B-malignancy-type
)	O
and	O
MC3T3-E1	O
(	O
mouse	O
osteoblast	O
)	O
cells	O
by	O
sequencing	O
cloned	O
PCR	O
products	O
.	O
Using	O
specific	O
primers	O
,	O
a	O
different	O
pattern	O
of	O
Hox	O
gene	O
expression	O
was	O
shown	O
for	O
the	O
neuroblastoma	B-malignancy-type
cell	O
line	O
SK-N-SH	O
relative	O
to	O
U-2	O
OS	O
and	O
MC3T3-E1	O
.	O
Additionally	O
,	O
we	O
showed	O
that	O
expression	O
of	O
HOXC6	O
in	O
U-2	O
OS	O
and	O
SK-N-SH	O
was	O
differentially	O
regulated	O
by	O
rhBMP-2	O
,	O
TGF-beta	O
and	O
activin-A	O
.	O
This	O
suggests	O
that	O
specific	O
Hox	O
genes	O
may	O
be	O
target	O
genes	O
for	O
TGF-beta	O
superfamily	O
members	O
,	O
and	O
allows	O
us	O
to	O
further	O
understand	O
the	O
complex	O
functions	O
of	O
these	O
growth	O
factors	O
and	O
how	O
they	O
relate	O
to	O
growth	O
and	O
development	O
.	O
PMID	O
:	O
9144540	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neuroendocrinology	O
.	O
1999	O
Oct	O
;	O
70	O
(	O
4	O
)	O
:	O
288-94	O
.	O
Natriuretic	O
peptide	O
receptors	O
of	O
type	O
A	O
in	O
human	O
neuroblastomas	B-malignancy-type
.	O
Forgeur	O
A	O
,	O
Willems	O
F	O
,	O
Winand	O
J	O
,	O
Robberecht	O
P	O
,	O
Delporte	O
C	O
.	O
Department	O
of	O
Biochemistry	O
,	O
Medical	O
School	O
,	O
Universite	O
Libre	O
de	O
Bruxelles	O
,	O
Brussels	O
,	O
Belgium	O
.	O
Functional	O
natriuretic	O
peptide	O
receptors	O
of	O
type	O
A	O
(	O
NPR-A	O
)	O
were	O
detected	O
in	O
the	O
human	O
neuroblastoma	B-malignancy-type
NB-OK-1	O
,	O
SK-N-SH	O
and	O
SK-N-BE	O
,	O
but	O
not	O
the	O
SH-SY5Y	O
,	O
cell	O
lines	O
.	O
Also	O
,	O
NPR-A	O
mRNA	O
was	O
detected	O
in	O
19	O
of	O
the	O
25	O
tumor	O
neuroblastoma	B-malignancy-type
samples	O
tested	O
in	O
this	O
study	O
.	O
Five	O
of	O
the	O
eight	O
tumor	O
neuroblastoma	B-malignancy-type
samples	O
that	O
were	O
assayed	O
for	O
atrial	O
natriuretic	O
peptide	O
(	O
ANP	O
)	O
binding	O
revealed	O
the	O
presence	O
of	O
ANP	O
-	O
binding	O
sites	O
.	O
In	O
the	O
human	O
neuroblastoma	B-malignancy-type
NB-OK-1	O
cell	O
line	O
,	O
[	O
(3)H	O
]	O
thymidine	O
incorporation	O
was	O
increased	O
in	O
response	O
to	O
ANP	O
,	O
decreased	O
in	O
response	O
to	O
pituitary	O
adenylate	O
cyclase	O
-	O
activating	O
polypeptide	O
(	O
PACAP-27	O
)	O
,	O
and	O
the	O
stimulatory	O
effect	O
of	O
ANP	O
was	O
inhibited	O
by	O
PACAP-27	O
.	O
Tissue	O
transglutaminase	O
activity	O
was	O
decreased	O
by	O
ANP	O
and	O
PACAP-27	O
,	O
and	O
their	O
effects	O
were	O
additive	O
.	O
However	O
,	O
neither	O
cell	O
cycle	O
phases	O
,	O
cell	O
growth	O
,	O
or	O
cell	O
apoptosis	O
were	O
modified	O
by	O
ANP	O
or	O
PACAP-27	O
treatments	O
.	O
PMID	O
:	O
10529624	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Med	O
Pediatr	O
Oncol	O
.	O
1993	O
;	O
21	O
(	O
4	O
)	O
:	O
280-2	O
.	O
Phase	O
I	O
trial	O
of	O
trimetrexate	O
in	O
pediatric	O
solid	B-malignancy-type
tumors	I-malignancy-type
:	O
a	O
Pediatric	O
Oncology	O
Group	O
study	O
.	O
Pappo	O
AS	O
,	O
Vats	O
T	O
,	O
Williams	O
TE	O
,	O
Bernstein	O
M	O
,	O
Kamen	O
BA	O
.	O
University	O
of	O
Texas	O
Southwestern	O
Medical	O
Center	O
,	O
Dallas	O
.	O
Trimetrexate	O
(	O
TMTX	O
)	O
,	O
a	O
lipophilic	O
antifol	O
,	O
was	O
evaluated	O
in	O
a	O
Pediatric	O
Oncology	O
Group	O
(	O
POG	O
)	O
Phase	O
I	O
trial	O
in	O
children	O
with	O
refractory	O
solid	B-malignancy-type
tumors	I-malignancy-type
.	O
TMTX	O
was	O
administered	O
intravenously	O
daily	O
x	O
5	O
every	O
three	O
weeks	O
.	O
Starting	O
dose	O
was	O
6.4	O
mg	O
/	O
m2	O
/	O
day	O
.	O
Dose	O
was	O
escalated	O
by	O
20	O
%	O
until	O
the	O
maximal	O
tolerated	O
dose	O
was	O
reached	O
.	O
A	O
total	O
of	O
75	O
courses	O
were	O
administered	O
to	O
26	O
children	O
.	O
The	O
major	O
toxicity	O
was	O
myelosuppression	O
,	O
of	O
which	O
neutropenia	O
and	O
thrombocytopenia	O
were	O
most	O
prominent	O
.	O
Rash	O
,	O
mucositis	O
,	O
and	O
transient	O
liver	O
enzyme	O
elevations	O
were	O
infrequently	O
seen	O
.	O
Responses	O
were	O
observed	O
in	O
children	O
with	O
brainstem	B-malignancy-type
glioma	I-malignancy-type
,	O
neuroblastoma	B-malignancy-type
,	O
and	O
renal	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
The	O
recommended	O
Phase	O
II	O
dose	O
using	O
this	O
schedule	O
is	O
9.2	O
-	O
11	O
mg	O
/	O
m2	O
/	O
day	O
depending	O
on	O
how	O
heavily	O
the	O
patient	O
has	O
been	O
treated	O
prior	O
to	O
initiating	O
this	O
therapy	O
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
Clinical	O
Trial	O
,	O
Phase	O
I	O
Multicenter	O
Study	O
PMID	O
:	O
8469224	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cell	O
Growth	O
Differ	O
.	O
1991	O
Dec	O
;	O
2	O
(	O
12	O
)	O
:	O
631-6	O
Up	O
-	O
regulation	O
of	O
Jun	O
/	O
AP-1	O
during	O
differentiation	O
of	O
N1E-115	O
neuroblastoma	B-malignancy-type
cells	O
.	O
de	O
Groot	O
RP	O
,	O
Kruijer	O
W	O
.	O
Laboratoire	O
de	O
Genetique	O
Moleculaire	O
des	O
Eucaryotes	O
,	O
Unite	O
184	O
de	O
l'Institut	O
National	O
de	O
la	O
Sante	O
et	O
de	O
la	O
Recherche	O
Medicale	O
,	O
Faculte	O
de	O
Medecine	O
,	O
Strasbourg	O
,	O
France	O
.	O
Neuroblastoma	B-malignancy-type
cell	O
lines	O
isolated	O
from	O
neuroblastoma	B-malignancy-type
tumors	O
can	O
be	O
induced	O
to	O
differentiate	O
into	O
neuronal	O
cell	O
types	O
by	O
treatment	O
with	O
chemical	O
agents	O
,	O
such	O
as	O
dimethyl	O
sulfoxide	O
and	O
retinoic	O
acid	O
.	O
The	O
molecular	O
mechanisms	O
underlying	O
this	O
differentiation	O
process	O
,	O
however	O
,	O
are	O
completely	O
obscure	O
.	O
In	O
this	O
paper	O
,	O
we	O
show	O
that	O
neuronal	O
differentiation	O
of	O
mouse	O
N1E-115	O
neuroblastoma	B-malignancy-type
cells	O
by	O
dimethyl	O
sulfoxide	O
is	O
accompanied	O
by	O
a	O
prolonged	O
rise	O
in	O
c-jun	O
,	O
junB	O
,	O
and	O
junD	O
expression	O
and	O
AP-1	O
activity	O
.	O
Multiple	O
sequence	O
elements	O
in	O
the	O
Jun	O
promoters	O
are	O
involved	O
in	O
this	O
process	O
.	O
Furthermore	O
,	O
we	O
show	O
that	O
c-jun	O
and	O
junD	O
,	O
but	O
not	O
junB	O
,	O
are	O
expressed	O
at	O
high	O
levels	O
in	O
the	O
neuronal	O
cell	O
types	O
obtained	O
after	O
dimethyl	O
sulfoxide	O
treatment	O
.	O
These	O
results	O
suggest	O
an	O
important	O
role	O
for	O
c-jun	O
and	O
junD	O
in	O
neuronal	O
differentiation	O
of	O
N1E-115	O
cells	O
.	O
PMID	O
:	O
1809375	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
1994	O
Aug	O
30	O
;	O
203	O
(	O
1	O
)	O
:	O
459-64	O
.	O
Delivery	O
of	O
anti	O
-	O
GAP-43	O
antibodies	O
into	O
neuroblastoma	B-malignancy-type
cells	O
reduces	O
growth	O
cone	O
size	O
.	O
Shea	O
TB	O
.	O
Laboratory	O
for	O
Molecular	O
Neuroscience	O
,	O
McLean	O
Hospital	O
,	O
Belmont	O
,	O
MA	O
02178	O
.	O
We	O
have	O
previously	O
demonstrated	O
that	O
antibodies	O
to	O
the	O
growth	O
-	O
associated	O
protein	O
,	O
GAP-43	O
,	O
introduced	O
intracellularly	O
using	O
a	O
lipid	O
carrier	O
inhibited	O
neurite	O
outgrowth	O
in	O
NB	O
2a	O
/	O
d1	O
neuroblastoma	B-malignancy-type
cells	O
,	O
and	O
that	O
culturing	O
of	O
these	O
cells	O
on	O
adhesive	O
substrates	O
such	O
as	O
laminin	O
or	O
poly-L-lysine	O
overcame	O
this	O
restriction	O
.	O
These	O
findings	O
suggest	O
that	O
GAP-43	O
may	O
facilitate	O
neuritogenesis	O
by	O
increasing	O
membrane	O
adhesiveness	O
.	O
To	O
address	O
this	O
issue	O
,	O
in	O
the	O
present	O
study	O
we	O
examined	O
the	O
effect	O
of	O
intracellular	O
delivery	O
of	O
this	O
antibody	O
on	O
growth	O
cone	O
size	O
.	O
A	O
statistically	O
significant	O
percentage	O
of	O
those	O
neurites	O
that	O
did	O
elaborate	O
following	O
intracellular	O
delivery	O
of	O
GAP-43	O
exhibited	O
either	O
no	O
observable	O
growth	O
cones	O
or	O
smaller	O
growth	O
cones	O
versus	O
cells	O
receiving	O
pre	O
-	O
immune	O
IgG	O
.	O
These	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
requirement	O
for	O
GAP-43	O
in	O
neuritogenesis	O
may	O
be	O
related	O
to	O
growth	O
cone	O
formation	O
and	O
membrane	O
adhesiveness	O
.	O
PMID	O
:	O
8074690	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Neuroradiol	O
.	O
1991	O
;	O
18	O
(	O
2	O
)	O
:	O
189-99	O
.	O
Magnetic	O
resonance	O
imaging	O
in	O
gangliogliomas	B-malignancy-type
and	O
gangliocytomas	B-malignancy-type
of	O
the	O
nervous	O
system	O
.	O
[	O
Article	O
in	O
English	O
,	O
French	O
]	O
Peretti	O
-	O
Viton	O
P	O
,	O
Perez-Castillo	O
AM	O
,	O
Raybaud	O
C	O
,	O
Grisoli	O
F	O
,	O
Bernard	O
F	O
,	O
Poncet	O
M	O
,	O
Salamon	O
G	O
.	O
Service	O
de	O
Neuroradiologie	O
,	O
CHU	O
Timone	O
,	O
Marseille	O
,	O
France	O
.	O
Gangliogliomas	B-malignancy-type
and	O
gangliocytomas	B-malignancy-type
are	O
rare	O
and	O
benign	O
neuronal	B-malignancy-type
tumors	I-malignancy-type
which	O
affect	O
young	O
subjects	O
.	O
This	O
study	O
concerns	O
3	O
cases	O
of	O
ganglioglioma	B-malignancy-type
and	O
3	O
cases	O
of	O
gangliocytoma	B-malignancy-type
explored	O
by	O
CT	O
and	O
MRI	O
and	O
confirmed	O
by	O
pathological	O
examination	O
.	O
The	O
most	O
typical	O
CT	O
image	O
was	O
that	O
of	O
an	O
often	O
calcified	O
contrast	O
-	O
enhanced	O
cystic	B-malignancy-type
tumor	I-malignancy-type
.	O
At	O
MRI	O
,	O
each	O
tumor	O
emitted	O
a	O
low	O
-	O
intensity	O
signal	O
on	O
T1	O
-	O
weighted	O
sequences	O
and	O
a	O
high	O
-	O
intensity	O
signal	O
on	O
T2	O
-	O
weighted	O
sequences	O
.	O
Contrast	O
enhancement	O
after	O
gadolinium	O
injection	O
was	O
frequent	O
.	O
Neuroradiology	O
is	O
not	O
specific	O
,	O
and	O
these	O
tumors	O
are	O
usually	O
diagnosed	O
at	O
pathology	O
.	O
However	O
,	O
the	O
diagnosis	O
may	O
be	O
considered	O
in	O
young	O
patients	O
with	O
a	O
history	O
of	O
old	O
,	O
drug	O
-	O
resistant	O
partial	O
epilepsy	O
and	O
having	O
a	O
contrast	O
-	O
enhanced	O
,	O
calcified	O
cystic	B-malignancy-type
lesion	I-malignancy-type
in	O
the	O
temporal	O
lobe	O
or	O
the	O
cerebellum	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
1919684	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
2000	O
Dec	O
20;27	O
9(	O
2	O
)	O
:	O
589	O
-	O
94	O
.	O
Human	O
neuroblastoma	B-malignancy-type
cell	O
differentiation	O
requires	O
protein	O
kinase	O
C-theta	O
.	O
Sparatore	O
B	O
,	O
Patrone	O
M,	O
Passalacqua	O
M,	O
Pedrazzi	O
M,	O
Pontremoli	O
S	O
,	O
Melloni	O
E.	O
Department	O
of	O
Experimental	O
Medicine	O
,	O
Biochemistry	O
Section	O
,	O
University	O
of	O
Genoa	O
,	O
Viale	O
Benedetto	O
XV	O
,	O
Genoa	O
,	O
1-16132	O
,	O
Italy	O
.	O
traspar@csita	O
.unige	O
.it	O
Neuroblastoma	B-malignancy-type
LAN-5	O
cells	O
exposed	O
to	O
retinoic	O
acid	O
cease	O
to	O
multiply	O
and	O
extend	O
neurite	O
outgrowths	O
acquiring	O
a	O
neuronal	O
phenotype	O
.	O
We	O
now	O
report	O
that	O
protein	O
kinase	O
C-theta	O
;	O
(	O
PKC-theta	O
;	O
)	O
isozyme	O
is	O
involved	O
in	O
this	O
differentiation	O
process	O
due	O
to	O
the	O
following	O
findings	O
:	O
(i)	O
PKC-theta	O
;	O
is	O
expressed	O
by	O
LAN-5	O
cells	O
as	O
a	O
nuclear	O
and	O
perinuclear	O
protein	O
;	O
(ii)	O
cell	O
stimulation	O
with	O
retinoic	O
acid	O
promotes	O
in	O
a	O
large	O
increase	O
in	O
the	O
expression	O
level	O
of	O
the	O
kinase	O
and	O
its	O
intracellular	O
redistribution	O
;	O
and	O
(iii)	O
a	O
PKC-theta	O
;	O
antisense	O
oligonucleotide	O
reduces	O
at	O
the	O
same	O
time	O
the	O
expression	O
level	O
of	O
the	O
kinase	O
and	O
the	O
cell	O
response	O
to	O
retinoic	O
acid	O
.	O
Altogether	O
these	O
data	O
are	O
consistent	O
with	O
a	O
specific	O
role	O
played	O
by	O
PKC-theta	O
;	O
in	O
the	O
differentiation	O
program	O
of	O
neuronal	O
cells	O
.	O
Copyright	O
2000	O
Academic	O
Press	O
.	O
PMID	O
:	O
11118330	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Protein	O
Chem	O
.	O
2000	O
Nov;19(	O
8	O
)	O
:699	O
-	O
707	O
.	O
Recombinant	O
derivatives	O
of	O
clostridial	O
neurotoxins	O
as	O
delivery	O
vehicles	O
for	O
proteins	O
and	O
small	O
organic	O
molecules	O
.	O
Zdanovskaia	O
MV	O
,	O
Los	O
G	O
,	O
Zdanovsky	O
AG.	O
Promega	O
Corporation	O
,	O
Madison	O
,	O
Wisconsin	O
53711-5399	O
,	O
USA	O
.	O
Clostridial	O
neurotoxins	O
are	O
the	O
most	O
powerful	O
toxins	O
known	O
.	O
Nevertheless	O
,	O
derivatives	O
of	O
these	O
toxins	O
may	O
find	O
broad	O
applications	O
both	O
in	O
science	O
and	O
medicine	O
because	O
of	O
their	O
unique	O
abilities	O
to	O
recognize	O
neurons	O
and	O
deliver	O
small	O
and	O
large	O
molecules	O
into	O
them	O
.	O
In	O
this	O
paper	O
we	O
describe	O
the	O
construction	O
of	O
two	O
types	O
of	O
such	O
derivatives	O
.	O
Proteins	O
belonging	O
to	O
the	O
first	O
class	O
were	O
designed	O
to	O
allow	O
direct	O
conjugation	O
with	O
one	O
or	O
few	O
molecules	O
of	O
interest	O
.	O
Proteins	O
belonging	O
to	O
the	O
second	O
class	O
contain	O
biotin	O
residue	O
and	O
therefore	O
could	O
be	O
easily	O
connected	O
to	O
streptavidin	O
loaded	O
with	O
multiple	O
molecules	O
of	O
interest	O
.	O
Only	O
C	O
-	O
terminal	O
regions	O
of	O
neurotoxin	O
heavy	O
chains	O
were	O
incorporated	O
in	O
the	O
structure	O
of	O
recombinant	O
proteins	O
.	O
Nevertheless	O
,	O
recombinant	O
proteins	O
were	O
found	O
to	O
be	O
able	O
to	O
recognize	O
specific	O
neuronal	O
receptors	O
and	O
target	O
model	O
molecules	O
to	O
rat	O
synaptosomes	O
and	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
PMID	O
:	O
11307955	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Pediatr	O
Oncol	O
.	O
2000	O
Dec;35	O
(	O
6	O
)	O
:651	O
-5	O
.	O
Telomerase	O
is	O
a	O
strong	O
indicator	O
for	O
assessing	O
the	O
proneness	O
to	O
progression	O
in	O
neuroblastomas	B-malignancy-type
.	O
Poremba	O
C	O
,	O
Hero	O
B	O
,	O
Heine	O
B	O
,	O
Scheel	O
C	O
,	O
Schaefer	O
KL	O
,	O
Christiansen	O
H,	O
Berthold	O
F	O
,	O
Kneif	O
S	O
,	O
Stein	O
H,	O
Juergens	O
H,	O
Boecker	O
W	O
,	O
Dockhorn	O
-	O
Dworniczak	O
B.	O
Gerhard	O
-	O
Domagk-	O
Institute	O
of	O
Pathology	O
,	O
Westfalische	O
Wilhelms	O
-University	O
,	O
Munster	O
,	O
Germany	O
.	O
poremba@uni-	O
muenster	O
.de	O
BACKGROUND	O
:	O
As	O
traditional	O
parameters	O
do	O
not	O
ensure	O
completely	O
accurate	O
prognostic	O
grouping	O
in	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
,	O
new	O
molecular	O
markers	O
are	O
needed	O
for	O
assessing	O
the	O
individual	O
patient	O
's	O
prognosis	O
more	O
precisely	O
.	O
PROCEDURE	O
,	O
RESULTS	O
,	O
AND	O
CONCLUSIONS	O
:	O
Based	O
on	O
133	O
NB	B-malignancy-type
,	O
we	O
show	O
that	O
telomerase	O
activity	O
(	O
TA	O
)	O
is	O
a	O
powerful	O
,	O
independent	O
prognostic	O
marker	O
for	O
all	O
stages	O
and	O
is	O
capable	O
of	O
differentiating	O
between	O
good	O
and	O
poor	O
outcome	O
in	O
putative	O
'	O
favorable	O
'	O
clinical	O
or	O
biological	O
subgroups	O
of	O
NB	B-malignancy-type
patients	O
.	O
Analysis	O
of	O
gene	O
and	O
protein	O
expression	O
of	O
telomerase	O
subunits	O
suggests	O
that	O
the	O
presence	O
or	O
absence	O
of	O
TA	O
in	O
NB	B-malignancy-type
is	O
strongly	O
correlated	O
with	O
expression	O
levels	O
of	O
both	O
the	O
catalytic	O
subunit	O
hTERT	O
and	O
the	O
internal	O
RNA	O
component	O
(	O
hTR	O
)	O
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11107139	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Acta	O
Paediatr	O
Taiwan	O
.	O
1999	O
Jul-	O
Aug;40	O
(	O
4	O
)	O
:277	O
-	O
9.	O
Cystic	B-malignancy-type
neuroblastoma	I-malignancy-type
with	O
hepatic	B-malignancy-type
metastasis	O
:	O
report	O
of	O
one	O
case	O
.	O
Chou	O
HC	O
,	O
Lin	O
KH.	O
Department	O
of	O
Pediatrics	O
,	O
National	O
Taiwan	O
University	O
Hospital	O
,	O
Taipei	O
,	O
Taiwan	O
.	O
Neuroblastoma	B-malignancy-type
is	O
the	O
most	O
common	O
infant	O
malignancy	O
,	O
but	O
cystic	B-malignancy-type
neuroblastoma	I-malignancy-type
is	O
a	O
rare	O
presentation	O
of	O
this	O
disease	O
.	O
There	O
were	O
only	O
thirty-one	O
reported	O
cases	O
in	O
literature	O
.	O
Here	O
we	O
report	O
another	O
case	O
.	O
A	O
4	O
-	O
month	O
-	O
old	O
female	O
baby	O
presented	O
with	O
a	O
huge	O
abdominal	B-malignancy-type
mass	I-malignancy-type
which	O
was	O
histologically	O
proved	O
to	O
be	O
a	O
cystic	B-malignancy-type
neuroblastoma	I-malignancy-type
.	O
Her	O
urinary	O
vanillylmandelic	O
acid	O
(	O
VMA	O
)	O
was	O
elevated	O
.	O
The	O
image	O
studies	O
,	O
including	O
abdominal	O
sonography	O
,	O
computed	O
tomography	O
,	O
and	O
magnetic	O
resonance	O
image	O
,	O
revealed	O
a	O
huge	O
main	O
mass	O
with	O
calcification	O
and	O
septa	O
in	O
the	O
abdominal	O
cavity	O
,	O
and	O
multiple	O
metastatic	O
nodules	O
with	O
septation	O
in	O
the	O
liver	O
.	O
A	O
three	O
-	O
layer	O
fluid	O
-	O
fluid	O
level	O
was	O
found	O
in	O
the	O
main	O
mass	O
and	O
also	O
in	O
the	O
metastatic	O
nodules	O
.	O
No	O
previous	O
report	O
showed	O
a	O
three	O
-	O
layer	O
fluid	O
-	O
fluid	O
level	O
in	O
the	O
cystic	O
component	O
of	O
neuroblastoma	B-malignancy-type
like	O
the	O
case	O
presented	O
here	O
.	O
It	O
may	O
be	O
evidence	O
of	O
easy	O
hemorrhagic	O
character	O
of	O
this	O
tumor	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
10910630	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1982	O
Dec	O
10	O
;257	O
(	O
23	O
)	O
:	O
14035-40	O
.	O
Modulation	O
of	O
sodium	O
-	O
sensitive	O
GTPase	O
by	O
partial	O
opiate	O
agonists	O
.	O
An	O
explanation	O
for	O
the	O
dual	O
requirement	O
for	O
Na+	O
and	O
GTP	O
in	O
inhibitory	O
regulation	O
of	O
adenylate	O
cyclase	O
.	O
Koski	O
G	O
,	O
Streaty	O
RA	O
,	O
Klee	O
WA	O
.	O
Opiates	O
and	O
opioid	O
peptides	O
inhibit	O
adenylate	O
cyclase	O
and	O
stimulate	O
specific	O
low	O
Km	O
GTPase	O
activity	O
in	O
membranes	O
from	O
neuroblastoma	B-malignancy-type
x	O
glioma	B-malignancy-type
NG108-15	O
hybrid	O
cells	O
.	O
The	O
effects	O
of	O
opiate	O
agonists	O
on	O
both	O
enzymes	O
are	O
mediated	O
by	O
high	O
affinity	O
stereospecific	O
receptors	O
and	O
require	O
Mg2+	O
,	O
GTP	O
,	O
and	O
Na+	O
.	O
In	O
the	O
presence	O
of	O
Mg2+	O
,	O
Na+	O
inhibits	O
basal	O
GTPase	O
activity	O
;	O
opiates	O
stimulate	O
GTP	O
hydrolysis	O
by	O
antagonizing	O
the	O
Na+	O
-	O
induced	O
inhibition	O
.	O
Activation	O
of	O
GTPase	O
leads	O
,	O
in	O
turn	O
,	O
to	O
inactivation	O
of	O
GTP	O
-	O
stimulated	O
adenylate	O
cyclase	O
activity	O
.	O
The	O
intrinsic	O
activities	O
(	O
or	O
efficacies	O
)	O
of	O
a	O
series	O
of	O
opiates	O
are	O
identical	O
for	O
stimulation	O
of	O
GTPase	O
and	O
inhibition	O
of	O
adenylate	O
cyclase	O
.	O
These	O
results	O
provide	O
a	O
mechanism	O
for	O
the	O
dual	O
requirement	O
for	O
Na+	O
and	O
GTP	O
in	O
the	O
inhibitory	O
coupling	O
of	O
opiate	O
receptors	O
to	O
the	O
adenylate	O
cyclase	O
system	O
in	O
these	O
cells	O
and	O
may	O
be	O
of	O
general	O
significance	O
to	O
the	O
action	O
of	O
other	O
inhibitory	O
hormones	O
.	O
PMID	O
:	O
6128341	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
1993	O
Dec;	O
8	O
(	O
12	O
)	O
:	O
3353	O
-	O
8.	O
Translocation	O
junctions	O
cluster	O
at	O
the	O
distal	O
short	O
arm	O
of	O
chromosome	O
1	O
(	O
1p36.1-2	O
)	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Barker	O
PE	O
,	O
Savelyeva	O
L,	O
Schwab	O
M.	O
Department	O
of	O
Cytogenetics	O
,	O
German	O
Cancer	O
Research	O
Center	O
,	O
Heidelberg	O
.	O
Human	O
neuroblastoma	B-malignancy-type
cells	O
show	O
at	O
high	O
frequency	O
structural	O
changes	O
of	O
the	O
distal	O
short	O
arm	O
of	O
chromosome	O
1	O
(	O
1p	O
)	O
.	O
The	O
commonly	O
altered	O
region	O
has	O
been	O
identified	O
in	O
previous	O
loss	O
-	O
of	O
-	O
heterozygosity	O
(	O
LOH	O
)	O
studies	O
to	O
involve	O
deletion	O
of	O
1p36.1-2	O
.	O
These	O
bands	O
are	O
also	O
the	O
site	O
of	O
constitutional	O
alterations	O
in	O
patients	O
with	O
neuroblastoma	B-malignancy-type
.	O
In	O
an	O
approach	O
to	O
define	O
the	O
1p36.1-2	O
alterations	O
in	O
more	O
detail	O
we	O
here	O
employ	O
four	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
to	O
map	O
translocation	O
breaks	O
involving	O
1p36.1-2	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O
A	O
chromosomal	O
interval	O
flanked	O
by	O
loci	O
DIS96	O
and	O
DIS98	O
contained	O
translocation	O
junctions	O
in	O
each	O
of	O
four	O
lines	O
.	O
This	O
analysis	O
identifies	O
in	O
1p	O
a	O
restricted	O
genomic	O
region	O
as	O
involved	O
in	O
chromosomal	O
rearrangement	O
in	O
different	O
neuroblastomas	B-malignancy-type
.	O
The	O
specificity	O
of	O
neuroblastoma	B-malignancy-type
translocation	O
junctions	O
at	O
the	O
molecular	O
level	O
implicates	O
this	O
genomic	O
region	O
in	O
tumor	O
development	O
.	O
PMID	O
:	O
8247537	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nucleic	O
Acids	O
Res	O
.	O
1982	O
Nov	O
11	O
;10(	O
21	O
)	O
:	O
6763	O
-	O
75	O
.	O
Hypoxanthine	O
-	O
guanine	O
phosphoribosyltransferase	O
genes	O
of	O
mouse	O
and	O
Chinese	O
hamster	O
:	O
construction	O
and	O
sequence	O
analysis	O
of	O
cDNA	O
recombinants	O
.	O
Konecki	O
DS	O
,	O
Brennand	O
J,	O
Fuscoe	O
JC	O
,	O
Caskey	O
CT	O
,	O
Chinault	O
AC	O
.	O
Recombinant	O
plasmids	O
containing	O
DNA	O
inserts	O
complementary	O
to	O
mRNA	O
coding	O
for	O
hypoxanthine	O
-	O
guanine	O
phosphoribosyltransferase	O
(	O
HPRT	O
)	O
from	O
mouse	O
and	O
Chinese	O
hamster	O
cell	O
lines	O
have	O
been	O
isolated	O
from	O
cDNA	O
libraries	O
and	O
characterized	O
by	O
DNA	O
sequence	O
analysis	O
.	O
A	O
total	O
of	O
1292	O
nucleotides	O
of	O
the	O
mouse	O
cDNA	O
sequence	O
and	O
1301	O
nucleotides	O
of	O
the	O
Chinese	O
hamster	O
cDNA	O
sequence	O
has	O
been	O
determined	O
.	O
Each	O
of	O
these	O
sequences	O
includes	O
an	O
open	O
reading	O
frame	O
of	O
654	O
nucleotides	O
(	O
218	O
amino	O
acids	O
)	O
corresponding	O
to	O
the	O
HPRT	O
protein	O
coding	O
region	O
.	O
The	O
deduced	O
amino	O
acid	O
sequences	O
for	O
the	O
mouse	O
and	O
Chinese	O
hamster	O
enzymes	O
are	O
presented	O
and	O
compared	O
to	O
that	O
of	O
human	O
HPRT	O
.	O
At	O
least	O
95	O
%	O
of	O
the	O
amino	O
acids	O
are	O
conserved	O
in	O
the	O
three	O
species	O
.	O
In	O
addition	O
,	O
we	O
present	O
evidence	O
that	O
two	O
species	O
of	O
HPRT	O
mRNA	O
,	O
which	O
differ	O
in	O
the	O
site	O
of	O
polyadenylation	O
that	O
is	O
utilized	O
during	O
processing	O
of	O
the	O
RNA	O
transcripts	O
,	O
exist	O
in	O
Chinese	O
hamster	O
cells	O
.	O
PMID	O
:	O
6294614	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Mol	O
Biol	O
Int	O
.	O
1995	O
Aug;36	O
(	O
6	O
)	O
:	O
1135-41	O
.	O
Coexpression	O
of	O
the	O
myc	O
gene	O
family	O
members	O
in	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Hemmi	O
H,	O
Yamada	O
K,	O
Yoon	O
UH	O
,	O
Kato	O
M,	O
Taniguchi	O
F	O
,	O
Tsuchida	O
Y	O
,	O
Shimatake	O
H.	O
Department	O
of	O
Molecular	O
Biology	O
,	O
Toho	O
University	O
School	O
of	O
Medicine	O
,	O
Tokyo	O
,	O
Japan	O
.	O
Members	O
of	O
the	O
myc	O
oncogene	O
family	O
such	O
as	O
c	O
,	O
N	O
-	O
,	O
and	O
L	O
-	O
myc	O
are	O
expressed	O
in	O
many	O
malignant	O
tumors	O
.	O
Expression	O
of	O
c	O
-	O
,	O
N	O
-	O
,	O
and	O
L	O
-	O
myc	O
oncogenes	O
in	O
7	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
(	O
GOTO	O
,	O
IMR-32	O
,	O
TGW	O
,	O
SCCH-26	O
,	O
TNB	O
9	O
,	O
NBL-S	O
,	O
and	O
SK-N-SH	O
)	O
,	O
a	O
human	O
small	B-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
carcinoma	I-malignancy-type
SBC-5	O
cell	O
line	O
,	O
and	O
a	O
human	O
monocytic	B-malignancy-type
leukemia	I-malignancy-type
THP-1-S	O
cell	O
line	O
at	O
mRNA	O
and	O
protein	O
levels	O
was	O
studied	O
to	O
know	O
the	O
specificity	O
of	O
a	O
newly	O
developed	O
antibody	O
against	O
homologous	O
region	O
at	O
C-terminus	O
of	O
N-Myc	O
,	O
designated	O
as	O
anti	O
pan	O
-	O
Myc	O
antibody	O
.	O
By	O
RT	O
-	O
PCR	O
and	O
immunoblot	O
analysis	O
,	O
coexpression	O
of	O
three	O
myc	O
genes	O
was	O
detected	O
in	O
all	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
tested	O
.	O
c	O
-	O
and	O
L	O
-	O
myc	O
expression	O
were	O
observed	O
that	O
anti	O
pan	O
-	O
Myc	O
antibody	O
recognizes	O
c-Myc	O
and	O
N-Myc	O
proteins	O
but	O
not	O
L-Myc	O
.	O
These	O
results	O
indicate	O
that	O
neuroblastoma	B-malignancy-type
cells	O
may	O
acquire	O
an	O
aberrant	O
transcriptional	O
control	O
system	O
in	O
myc	O
family	O
gene	O
expression	O
.	O
PMID	O
:	O
8535284	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Surv	O
.	O
1992	O
;12	O
:	O
5	O
-	O
24	O
.	O
Functional	O
evidence	O
for	O
human	O
tumour	O
suppressor	O
genes	O
:	O
chromosome	O
and	O
molecular	O
genetic	O
studies	O
.	O
Stanbridge	O
EJ.	O
Ludwig	O
Institute	O
for	O
Cancer	O
Research	O
,	O
Melbourne	O
Tumour	O
Biology	O
Branch	O
,	O
Royal	O
Melbourne	O
Hospital	O
,	O
Victoria	O
,	O
Australia	O
.	O
There	O
is	O
now	O
ample	O
genetic	O
and	O
some	O
functional	O
evidence	O
for	O
the	O
existence	O
of	O
tumour	O
suppressor	O
genes	O
.	O
Although	O
much	O
of	O
the	O
functional	O
evidence	O
has	O
been	O
derived	O
from	O
somatic	O
cell	O
hybrid	O
and	O
chromosome	O
transfer	O
studies	O
,	O
it	O
is	O
critical	O
that	O
cloned	O
candidate	O
tumour	O
suppressor	O
genes	O
be	O
used	O
in	O
such	O
functional	O
assays	O
.	O
Our	O
experience	O
with	O
RB	O
and	O
p53	O
indicates	O
that	O
much	O
will	O
be	O
learned	O
about	O
the	O
control	O
of	O
the	O
cell	O
cycle	O
from	O
studies	O
of	O
tumour	O
suppressor	O
genes	O
.	O
However	O
,	O
the	O
handful	O
of	O
candidate	O
genes	O
cloned	O
to	O
date	O
also	O
indicates	O
a	O
variety	O
of	O
cellular	O
localizations	O
and	O
cellular	O
functions	O
.	O
Thus	O
,	O
just	O
as	O
oncogenes	O
seem	O
to	O
act	O
to	O
promote	O
growth	O
at	O
many	O
levels	O
of	O
metabolic	O
control	O
,	O
it	O
would	O
seem	O
that	O
tumour	O
suppressor	O
genes	O
act	O
in	O
complementary	O
ways	O
to	O
control	O
cell	O
proliferation	O
.	O
The	O
molecular	O
genetic	O
study	O
of	O
cancer	O
has	O
truly	O
entered	O
an	O
exciting	O
phase	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
1353413	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biochem	O
(	O
Tokyo	O
)	O
.	O
1983	O
Jul;94	O
(	O
1	O
)	O
:	O
303	O
-	O
6.	O
GQ1b	O
,	O
a	O
bioactive	O
ganglioside	O
that	O
exhibits	O
novel	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
-	O
like	O
activities	O
in	O
the	O
two	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Tsuji	O
S	O
,	O
Arita	O
M,	O
Nagai	O
Y	O
.	O
To	O
clarify	O
the	O
role	O
of	O
gangliosides	O
in	O
the	O
morphological	O
and	O
biochemical	O
differentiation	O
of	O
neuronal	O
cell	O
cultures	O
,	O
the	O
model	O
cell	O
culture	O
system	O
represented	O
by	O
two	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
,	O
GOTO	O
and	O
NB-1	O
,	O
which	O
were	O
established	O
from	O
adrenal	O
gland	O
and	O
metastatic	O
neck	O
lymph	O
node	O
,	O
respectively	O
,	O
was	O
examined	O
.	O
We	O
found	O
that	O
the	O
total	O
ganglioside	O
fraction	O
from	O
human	O
brain	O
had	O
two	O
remarkable	O
effects	O
on	O
these	O
cell	O
lines	O
,	O
which	O
are	O
similar	O
to	O
those	O
of	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
:	O
(a)	O
an	O
increase	O
in	O
the	O
cell	O
number	O
,	O
and	O
(b)	O
an	O
increase	O
in	O
the	O
neurite	O
number	O
and	O
the	O
total	O
length	O
of	O
neurites	O
.	O
In	O
these	O
cases	O
,	O
the	O
genuine	O
effector	O
in	O
total	O
gangliosides	O
could	O
not	O
be	O
ascribed	O
to	O
a	O
possibly	O
contaminating	O
NGF	O
-	O
like	O
protein	O
,	O
but	O
rather	O
to	O
a	O
particular	O
molecular	O
species	O
of	O
the	O
gangliosides	O
,	O
GQ1b	O
,	O
which	O
could	O
completely	O
replace	O
the	O
effector	O
function	O
not	O
only	O
qualitatively	O
but	O
also	O
quantitatively	O
.	O
Our	O
results	O
provide	O
direct	O
evidence	O
for	O
the	O
participation	O
of	O
gangliosides	O
in	O
such	O
functions	O
.	O
PMID	O
:	O
6619115	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Beijing	O
Da	O
Xue	O
Xue	O
Bao	O
.	O
2003	O
Jun	O
18;35	O
(	O
3	O
)	O
:	O
261	O
-5	O
.	O
[	O
Deletion	O
mutation	O
of	O
beta-amyloid	O
precursor	O
protein	O
decreases	O
the	O
secretion	O
of	O
beta-amyloid	O
in	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
cells	O
]	O
[	O
Article	O
in	O
Chinese	O
]	O
Zha	O
Q	O
,	O
Ruan	O
Y	O
,	O
Liu	O
Z	O
,	O
Cao	O
L,	O
Zhang	O
D.	O
Institute	O
of	O
Mental	O
Health	O
,	O
Peking	O
University	O
,	O
Beijing	O
100083	O
,	O
China	O
.	O
OBJECTIVE	O
:	O
To	O
explore	O
the	O
effect	O
of	O
A	O
beta	O
secretion	O
lacking	O
exons	O
2	O
and	O
3	O
of	O
APP695	O
(	O
delta	O
APP695	O
)	O
on	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
cells	O
.	O
METHODS	O
:	O
APP695	O
cDNA	O
and	O
delta	O
APP695	O
cDNA	O
eukaryotic	O
expression	O
vectors	O
were	O
constructed	O
by	O
gene	O
recombination	O
.	O
Immunoprecipitation	O
Western	O
blotting	O
was	O
used	O
to	O
analyse	O
the	O
A	O
beta	O
secretion	O
and	O
MTT	O
assay	O
to	O
observe	O
the	O
cell	O
viability	O
's	O
change	O
after	O
being	O
stably	O
transfected	O
with	O
the	O
plasmids	O
by	O
lipofectamine	O
method	O
.	O
RESULTS	O
:	O
Stable	O
transfectants	O
were	O
selected	O
in	O
0.6	O
g	O
.	O
L-1	O
G418	O
.	O
delta	O
APP695	O
cDNA	O
construct	O
transfection	O
decreased	O
significantly	O
the	O
production	O
of	O
beta	O
amyloid	O
in	O
the	O
SH-SY5Y	O
compared	O
with	O
APP695	O
cDNA	O
construct	O
.	O
It	O
did	O
not	O
affect	O
the	O
cell	O
viability	O
by	O
MTT	O
method	O
.	O
CONCLUSION	O
:	O
This	O
result	O
suggests	O
that	O
the	O
alternative	O
splicing	O
of	O
APP	O
exons	O
2	O
and	O
3	O
modulates	O
the	O
secretion	O
of	O
A	O
beta	O
by	O
influencing	O
the	O
processing	O
of	O
APP	O
.	O
PMID	O
:	O
12914241	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Hematol	O
.	O
1995	O
Oct;62(	O
3	O
)	O
:151	O
-6.	O
In	O
vitro	O
neuroblastomal	B-malignancy-type
clump	O
formations	O
as	O
an	O
indicator	O
of	O
a	O
bone	B-malignancy-type
marrow	I-malignancy-type
metastasis	I-malignancy-type
.	O
Ito	O
T	O
,	O
Hattori	O
T	O
,	O
Okano	O
S	O
,	O
Abe	O
T.	O
Department	O
of	O
Pediatrics	O
,	O
Teikyo	O
University	O
School	O
of	O
Medicine	O
,	O
Tokyo	O
,	O
Japan	O
.	O
In	O
a	O
long	O
-	O
term	O
culture	O
of	O
bone	O
marrow	O
taken	O
from	O
a	O
child	O
with	O
a	O
suspected	O
abdominal	B-malignancy-type
tumor	I-malignancy-type
,	O
a	O
large	O
number	O
of	O
globular	O
in	O
vitro	O
clumps	O
developed	O
within	O
5	O
days	O
,	O
although	O
the	O
bone	O
marrow	O
used	O
had	O
tested	O
negative	O
to	O
the	O
presence	O
of	O
abnormal	O
cells	O
.	O
Light	O
microscopic	O
and	O
marker	O
studies	O
of	O
these	O
clumps	O
provided	O
evidence	O
of	O
neuroblastomal	B-malignancy-type
origin	O
,	O
and	O
the	O
diagnosis	O
of	O
a	O
neuroblastoma	B-malignancy-type
was	O
confirmed	O
by	O
a	O
subsequent	O
cathecholamine	O
assessment	O
and	O
the	O
histological	O
findings	O
of	O
the	O
excised	O
tumor	O
.	O
Of	O
three	O
in	O
vitro	O
culture	O
methods	O
tested	O
,	O
i.e.	O
,	O
a	O
long	O
-	O
term	O
bone	O
marrow	O
culture	O
(	O
LTBMC	O
)	O
,	O
a	O
liquid	O
culture	O
,	O
and	O
a	O
methylcellulose	O
clonal	O
cell	O
culture	O
,	O
the	O
LTBMC	O
was	O
found	O
to	O
be	O
the	O
most	O
sensitive	O
for	O
detecting	O
tumor	O
cells	O
.	O
This	O
LTBMC	O
was	O
considered	O
to	O
be	O
useful	O
for	O
not	O
only	O
achieving	O
a	O
definitive	O
neuroblastoma	B-malignancy-type
diagnosis	O
but	O
also	O
the	O
early	O
detection	O
of	O
bone	B-malignancy-type
marrow	I-malignancy-type
metastasis	I-malignancy-type
in	O
N-myc	O
gene	O
amplified	O
neuroblastomas	B-malignancy-type
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
8589359	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Childs	O
Nerv	O
Syst	O
.	O
2002	O
Apr;18	O
(	O
3-	O
4)	O
:	O
112-7.	O
Epub	O
2002	O
Feb	O
23	O
.	O
Telomerase	O
in	O
brain	B-malignancy-type
tumors	I-malignancy-type
.	O
Falchetti	O
ML	O
,	O
Larocca	O
LM	O
,	O
Pallini	O
R.	O
Institute	O
of	O
Neurobiology	O
and	O
Molecular	O
Medicine	O
,	O
CNR	O
,	O
Viale	O
Marx	O
15	O
,	O
00137	O
Rome	O
,	O
Italy	O
.	O
falchetti@in	O
.rm	O
.cnr	O
.it	O
INTRODUCTION	O
:	O
In	O
recent	O
years	O
,	O
many	O
scientists	O
involved	O
in	O
cancer	O
research	O
have	O
directed	O
their	O
attention	O
to	O
telomerase	O
,	O
an	O
enzymatic	O
complex	O
which	O
is	O
specifically	O
involved	O
in	O
duplicating	O
telomeres	O
,	O
the	O
very	O
ends	O
of	O
linear	O
chromosomes	O
.	O
The	O
discovery	O
that	O
most	O
immortal	O
cell	O
lines	O
in	O
vitro	O
and	O
human	O
tumor	O
cells	O
in	O
vivo	O
have	O
telomerase	O
activity	O
,	O
in	O
contrast	O
to	O
telomerase	O
-	O
negative	O
normal	O
somatic	O
cells	O
,	O
has	O
made	O
telomerase	O
a	O
candidate	O
for	O
use	O
as	O
a	O
molecular	O
marker	O
of	O
malignancy	O
and	O
even	O
as	O
a	O
target	O
for	O
anticancer	O
therapies	O
.	O
Thus	O
,	O
the	O
assessment	O
of	O
the	O
role	O
of	O
telomerase	O
activity	O
in	O
neoplastic	O
transformation	O
has	O
become	O
a	O
key	O
issue	O
in	O
oncology	O
,	O
as	O
stated	O
by	O
the	O
exponential	O
increase	O
of	O
papers	O
on	O
telomerase	O
in	O
the	O
last	O
5	O
years	O
.	O
OBJECT	O
:	O
In	O
this	O
paper	O
,	O
we	O
review	O
some	O
recent	O
data	O
from	O
the	O
literature	O
,	O
including	O
our	O
own	O
studies	O
,	O
on	O
the	O
regulation	O
of	O
telomerase	O
activity	O
in	O
brain	B-malignancy-type
tumors	I-malignancy-type
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
11981616	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
1995	O
Jun	O
26;211(	O
3	O
)	O
:	O
1006-14	O
.	O
Pentoxifylline	O
augments	O
but	O
does	O
not	O
antagonize	O
TNF	O
alpha	O
-	O
mediated	O
neuroblastoma	B-malignancy-type
cell	O
differentiation	O
:	O
modulation	O
of	O
calcium	O
mobilization	O
but	O
not	O
cAMP	O
.	O
Yang	O
KD	O
,	O
Chuen	O
HL	O
,	O
Shaio	O
MF.	O
Department	O
of	O
Pediatrics	O
,	O
Tri	O
-	O
service	O
General	O
Hospital	O
,	O
Taipei	O
,	O
Taiwan	O
,	O
R.O.C.	O
We	O
described	O
here	O
that	O
pentoxifylline	O
(	O
PTX	O
)	O
,	O
which	O
is	O
well	O
known	O
to	O
counteract	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
-	O
mediated	O
inflammatory	O
responses	O
,	O
augmented	O
TNF	O
alpha	O
-	O
induced	O
neuroblastoma	B-malignancy-type
cell	O
differentiation	O
in	O
conjunction	O
with	O
growth	O
inhibition	O
and	O
cell	O
-	O
cycle	O
arrest	O
in	O
G1	O
phase	O
.	O
PTX	O
also	O
enhanced	O
TNF	O
alpha	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
acetylcholine	O
-	O
mediated	O
[Ca2+]i	O
mobilization	O
in	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Furthermore	O
,	O
we	O
found	O
that	O
addition	O
of	O
cAMP	O
failed	O
to	O
induce	O
neuroblastoma	B-malignancy-type
cell	O
differentiation	O
,	O
whereas	O
blockade	O
of	O
[Ca2+]i	O
mobilization	O
by	O
8-(N,N-diethyl-amino)octyl-3,4,5-trimethoxybenzoate	O
HCl	O
(	O
TMB-8	O
,	O
10	O
microM	O
)	O
did	O
induce	O
neuroblastoma	B-malignancy-type
cell	O
differentiation	O
.	O
Taken	O
together	O
,	O
these	O
results	O
indicated	O
that	O
PTX	O
possessed	O
a	O
novel	O
signal	O
transduction	O
,	O
down	O
-	O
regulation	O
of	O
[Ca2+]i	O
mobilization	O
,	O
to	O
augment	O
but	O
not	O
counteract	O
TNF	O
alpha	O
-	O
mediated	O
functions	O
.	O
PMID	O
:	O
7598686	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neuroreport	O
.	O
1998	O
Jan	O
5;	O
9	O
(	O
1	O
)	O
:99	O
-	O
103	O
.	O
Inhibition	O
of	O
phospholipase	O
C	O
blocks	O
opioid	O
receptor	O
-	O
mediated	O
activation	O
of	O
Gi	O
proteins	O
.	O
Wu	O
YL	O
,	O
Pei	O
G	O
,	O
Fan	O
GH.	O
Shanghai	O
Institute	O
of	O
Cell	O
Biology	O
,	O
Chinese	O
Academy	O
of	O
Sciences	O
,	O
People	O
's	O
Republic	O
of	O
China	O
.	O
Activation	O
of	O
phospholipase	O
C	O
(	O
PLC	O
)	O
in	O
response	O
to	O
stimulation	O
of	O
delta	O
-	O
opioid	O
,	O
m4	O
muscarinic	O
and	O
alpha2	O
adrenergic	O
receptors	O
was	O
observed	O
in	O
NG108-15	O
cells	O
.	O
Treatment	O
with	O
PLC	O
specific	O
inhibitors	O
,	O
U73122	O
and	O
ET-18-OCH3	O
,	O
blocked	O
delta	O
-	O
opioid	O
receptor	O
-	O
mediated	O
activation	O
of	O
G	O
proteins	O
with	O
no	O
effect	O
on	O
opioid	O
binding	O
to	O
the	O
receptors	O
.	O
U73122	O
treatment	O
also	O
suppressed	O
functional	O
responses	O
of	O
m4	O
muscarinic	O
and	O
alpha2	O
adrenergic	O
receptors	O
in	O
NG108-15	O
cells	O
.	O
Furthermore	O
,	O
the	O
G	O
protein	O
activation	O
mediated	O
by	O
mu	O
-	O
and	O
delta	O
-	O
opioid	O
receptors	O
and	O
opioid	O
receptor	O
-	O
like	O
receptor	O
(	O
ORL1	O
)	O
were	O
abolished	O
by	O
U73122	O
in	O
SK-N-SH	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Inhibition	O
of	O
adenylyl	O
cyclase	O
induced	O
by	O
high	O
concentrations	O
of	O
GTP	O
was	O
blocked	O
by	O
U73122	O
,	O
suggesting	O
that	O
blockade	O
is	O
at	O
the	O
level	O
of	O
G	O
proteins	O
.	O
Our	O
results	O
thus	O
indicated	O
that	O
inhibition	O
of	O
PLC	O
leads	O
to	O
blockade	O
of	O
Gi	O
protein	O
activation	O
mediated	O
by	O
opioid	O
receptors	O
or	O
other	O
Gi	O
-	O
coupled	O
receptors	O
.	O
PMID	O
:	O
9592056	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
1988	O
Dec;8	O
5	O
(	O
23	O
)	O
:9253	O
-	O
7.	O
Human	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
is	O
a	O
growth	O
factor	O
active	O
on	O
a	O
variety	O
of	O
cell	O
types	O
of	O
nonhemopoietic	O
origin	O
.	O
Dedhar	O
S	O
,	O
Gaboury	O
L,	O
Galloway	O
P,	O
Eaves	O
C.	O
Department	O
of	O
Advanced	O
Therapeutics	O
,	O
British	O
Columbia	O
Cancer	O
Research	O
Centre	O
,	O
Vancouver	O
,	O
Canada	O
.	O
Granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM-CSF	O
)	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
glycoprotein	O
hormones	O
that	O
stimulate	O
the	O
proliferation	O
and	O
differentiation	O
of	O
hemopoietic	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
We	O
now	O
report	O
that	O
human	O
GM-CSF	O
can	O
also	O
stimulate	O
the	O
proliferation	O
of	O
two	O
osteogenic	B-malignancy-type
sarcoma	I-malignancy-type
cell	O
lines	O
,	O
a	O
breast	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
line	O
,	O
a	O
simian	O
virus	O
40	O
-	O
transformed	O
marrow	O
stromal	O
cell	O
line	O
,	O
and	O
normal	O
marrow	O
fibroblast	O
precursors	O
.	O
These	O
findings	O
suggest	O
a	O
more	O
general	O
regulatory	O
function	O
of	O
GM-CSF	O
on	O
nonhemopoietic	O
cell	O
types	O
than	O
previously	O
anticipated	O
.	O
They	O
also	O
raise	O
the	O
possibility	O
of	O
adverse	O
side	O
effects	O
of	O
GM-CSF	O
therapy	O
in	O
patients	O
whose	O
malignant	O
cells	O
may	O
be	O
directly	O
stimulated	O
by	O
this	O
molecule	O
and	O
suggest	O
a	O
previously	O
unanticipated	O
role	O
of	O
GM-CSF	O
gene	O
activation	O
in	O
the	O
evolution	O
of	O
solid	B-malignancy-type
tumors	I-malignancy-type
and	O
in	O
the	O
pathogenesis	O
of	O
myelofibrosis	O
.	O
PMID	O
:	O
3057504	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Endocrinology	O
.	O
2000	O
Nov;141(	O
11	O
)	O
:4309	O
-	O
12	O
.	O
Distinct	O
subcellular	O
localization	O
of	O
transiently	O
expressed	O
types	O
1	O
and	O
2	O
iodothyronine	O
deiodinases	O
as	O
determined	O
by	O
immunofluorescence	O
confocal	O
microscopy	O
.	O
Baqui	O
MM	O
,	O
Gereben	O
B	O
,	O
Harney	O
JW	O
,	O
Larsen	O
PR	O
,	O
Bianco	O
AC	O
.	O
Department	O
of	O
Medicine	O
,	O
Brigham	O
and	O
Women	O
's	O
Hospital	O
,	O
Harvard	O
Medical	O
School	O
,	O
Boston	O
,	O
MA	O
,	O
USA	O
.	O
We	O
compared	O
the	O
subcellular	O
localization	O
of	O
FLAG	O
-	O
epitope	O
tagged	O
Types	O
1	O
and	O
2	O
deiodinases	O
(	O
D1	O
and	O
D2	O
)	O
transiently	O
expressed	O
in	O
human	O
embryonic	O
kidney	O
(	O
HEK-293	O
)	O
and	O
mouse	O
neuroblastoma	B-malignancy-type
(	O
NB2A	O
)	O
cells	O
.	O
D2	O
is	O
an	O
integral	O
membrane	O
protein	O
based	O
on	O
resistance	O
to	O
extraction	O
at	O
pH	O
11	O
with	O
the	O
NH2	O
terminus	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
.	O
Immunofluorescence	O
confocal	O
microscopy	O
using	O
anti	O
-	O
FLAG	O
and	O
anti	O
-	O
GRP78	O
/	O
BiP	O
antibodies	O
showed	O
the	O
FLAG	O
-	O
D1	O
signal	O
was	O
found	O
in	O
the	O
periphery	O
of	O
the	O
cells	O
and	O
not	O
co	O
-	O
localized	O
with	O
the	O
ER	O
specific	O
marker	O
GRP78	O
/	O
BiP	O
.	O
On	O
the	O
other	O
hand	O
,	O
FLAG	O
-	O
D2	O
protein	O
was	O
found	O
in	O
the	O
ER	O
co	O
-	O
localized	O
with	O
the	O
GRP78	O
/	O
BiP	O
protein	O
.	O
These	O
differential	O
distribution	O
patterns	O
indicate	O
subcellular	O
sorting	O
of	O
D1	O
and	O
D2	O
is	O
determined	O
by	O
intrinsic	O
protein	O
sequence	O
and	O
can	O
explain	O
the	O
ready	O
access	O
of	O
D2	O
-	O
generated	O
T3	O
to	O
the	O
nucleus	O
.	O
PMID	O
:	O
11089566	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Pathol	O
.	O
1990	O
Sep;1	O
(	O
1	O
)	O
:	O
41-6.	O
Amplification	O
of	O
the	O
MYCN	O
oncogene	O
and	O
deletion	O
of	O
putative	O
tumour	O
suppressor	O
gene	O
in	O
human	O
neuroblastomas	B-malignancy-type
.	O
Schwab	O
M.	O
Institute	O
for	O
Experimental	O
Pathology	O
,	O
German	O
Cancer	O
Research	O
Center	O
,	O
Heidelberg	O
.	O
Human	O
neuroblastoma	B-malignancy-type
cells	O
often	O
carry	O
non	O
-	O
random	O
chromosomal	O
abnormalities	O
signalling	O
genetic	O
alterations	O
.	O
Quite	O
frequent	O
are	O
'	O
double	O
minutes	O
'	O
(	O
DMs	O
)	O
and	O
homogeneously	O
staining	O
regions	O
(	O
HSRs	O
)	O
,	O
both	O
cytogenetic	O
manifestations	O
of	O
amplified	O
DNA	O
,	O
and	O
chromosome	O
1p	O
-	O
deletions	O
indicating	O
loss	O
of	O
genetic	O
information	O
.	O
With	O
the	O
identification	O
of	O
amplified	O
MYCN	O
and	O
the	O
demonstration	O
of	O
a	O
consensus	O
deletion	O
spanning	O
the	O
chromosome	O
1p36.1-2	O
region	O
it	O
appears	O
now	O
likely	O
that	O
both	O
amplification	O
of	O
a	O
cellular	O
oncogene	O
and	O
loss	O
of	O
a	O
tumour	O
-	O
suppressor	O
gene	O
play	O
an	O
important	O
role	O
in	O
neuroblastoma	B-malignancy-type
.	O
Amplification	O
of	O
MYCN	O
is	O
an	O
indicator	O
for	O
poor	O
prognosis	O
,	O
even	O
when	O
classical	O
morphological	O
criteria	O
would	O
suggest	O
a	O
better	O
outcome	O
.	O
Consequently	O
,	O
patients	O
with	O
amplification	O
are	O
subjected	O
to	O
more	O
intensive	O
therapeutic	O
regimens	O
.	O
Amplification	O
of	O
MYCN	O
is	O
a	O
paradigm	O
for	O
the	O
clinical	O
use	O
of	O
an	O
oncogene	O
alteration	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
1669692	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1998	O
Mar	O
6;273	O
(	O
10	O
)	O
:	O
5821	O
-	O
8.	O
Glyceraldehyde-3-phosphate	O
dehydrogenase	O
,	O
the	O
putative	O
target	O
of	O
the	O
antiapoptotic	O
compounds	O
CGP	O
3466	O
and	O
R-(-)-deprenyl	O
.	O
Kragten	O
E	O
,	O
Lalande	O
I	O
,	O
Zimmermann	O
K,	O
Roggo	O
S	O
,	O
Schindler	O
P,	O
Muller	O
D	O
,	O
van	O
Oostrum	O
J,	O
Waldmeier	O
P,	O
Furst	O
P.	O
Novartis	O
Pharma	O
Research	O
,	O
Core	O
Technology	O
Area	O
,	O
CH-4002	O
Basel	O
,	O
Switzerland	O
.	O
R-(-)-Deprenyl	O
(	O
Selegiline	O
)	O
represents	O
one	O
of	O
the	O
drugs	O
currently	O
used	O
for	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
.	O
This	O
compound	O
was	O
shown	O
to	O
protect	O
neurons	O
or	O
glias	O
from	O
programmed	O
cell	O
death	O
in	O
a	O
variety	O
of	O
models	O
.	O
The	O
mechanism	O
of	O
action	O
of	O
neuroprotection	O
as	O
well	O
as	O
inhibition	O
of	O
apoptosis	O
remains	O
elusive	O
.	O
CGP	O
3466	O
is	O
a	O
structurally	O
related	O
analog	O
of	O
R-(-)-deprenyl	O
that	O
exhibits	O
virtually	O
no	O
monoamine	O
oxidase	O
type	O
B	O
inhibiting	O
activity	O
but	O
is	O
neuroprotective	O
in	O
the	O
picomolar	O
concentration	O
range	O
.	O
We	O
showed	O
specific	O
binding	O
of	O
CGP	O
3466	O
to	O
glyceraldehyde-3-phosphate	O
dehydrogenase	O
by	O
affinity	O
binding	O
,	O
by	O
affinity	O
labeling	O
,	O
and	O
by	O
means	O
of	O
BIAcore(R)	O
technology	O
.	O
Apoptosis	O
assays	O
based	O
on	O
the	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
PAJU	O
established	O
the	O
importance	O
of	O
this	O
interaction	O
for	O
mediating	O
drug	O
-	O
induced	O
inhibition	O
of	O
programmed	O
cell	O
death	O
.	O
PMID	O
:	O
9488718	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nat	O
Med	O
.	O
2000	O
May	O
;	O
6	O
(	O
5	O
)	O
:	O
529-	O
35	O
.	O
Comment	O
in	O
:	O
Nat	O
Med	O
.	O
2000	O
May	O
;	O
6	O
(	O
5	O
)	O
:	O
498-500	O
.	O
Nat	O
Med	O
.	O
2002	O
Dec;	O
8	O
(	O
12	O
)	O
:	O
1333	O
-	O
5	O
;	O
author	O
reply	O
1335	O
.	O
Caspase	O
8	O
is	O
deleted	O
or	O
silenced	O
preferentially	O
in	O
childhood	O
neuroblastomas	B-malignancy-type
with	O
amplification	O
of	O
MYCN	O
.	O
Teitz	O
T	O
,	O
Wei	O
T	O
,	O
Valentine	O
MB	O
,	O
Vanin	O
EF	O
,	O
Grenet	O
J,	O
Valentine	O
VA	O
,	O
Behm	O
FG	O
,	O
Look	O
AT	O
,	O
Lahti	O
JM	O
,	O
Kidd	O
VJ.	O
Department	O
of	O
Tumor	O
Cell	O
Biology	O
,	O
St.	O
Jude	O
Children	O
's	O
Research	O
Hospital	O
,	O
332	O
N	O
.	O
Lauderdale	O
,	O
Memphis	O
,	O
Tennessee	O
38101	O
,	O
USA	O
.	O
Caspase	O
8	O
is	O
a	O
cysteine	O
protease	O
regulated	O
in	O
both	O
a	O
death	O
-	O
receptor	O
-	O
dependent	O
and	O
-	O
independent	O
manner	O
during	O
apoptosis	O
.	O
Here	O
,	O
we	O
report	O
that	O
the	O
gene	O
for	O
caspase	O
8	O
is	O
frequently	O
inactivated	O
in	O
neuroblastoma	B-malignancy-type
,	O
a	O
childhood	O
tumor	O
of	O
the	O
peripheral	O
nervous	O
system	O
.	O
The	O
gene	O
is	O
silenced	O
through	O
DNA	O
methylation	O
as	O
well	O
as	O
through	O
gene	O
deletion	O
.	O
Complete	O
inactivation	O
of	O
CASP8	O
occurred	O
almost	O
exclusively	O
in	O
neuroblastomas	B-malignancy-type
with	O
amplification	O
of	O
the	O
oncogene	O
MYCN	O
.	O
Caspase	O
8	O
-	O
null	O
neuroblastoma	B-malignancy-type
cells	O
were	O
resistant	O
to	O
death	O
receptor	O
-	O
and	O
doxorubicin	O
-	O
mediated	O
apoptosis	O
,	O
deficits	O
that	O
were	O
corrected	O
by	O
programmed	O
expression	O
of	O
the	O
enzyme	O
.	O
Thus	O
,	O
caspase	O
8	O
acts	O
as	O
a	O
tumor	O
suppressor	O
in	O
neuroblastomas	B-malignancy-type
with	O
amplification	O
of	O
MYCN	O
.	O
PMID	O
:	O
10802708	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Breast	O
Cancer	O
Res	O
Treat	O
.	O
1999	O
Nov	O
;	O
58	O
(	O
1	O
)	O
:	O
25-9	O
.	O
p73	O
mutations	O
are	O
not	O
detected	O
in	O
sporadic	O
and	O
hereditary	O
breast	B-malignancy-type
cancer	I-malignancy-type
.	O
Schwartz	O
DI	O
,	O
Lindor	O
NM	O
,	O
Walsh	O
-	O
Vockley	O
C	O
,	O
Roche	O
PC	O
,	O
Mai	O
M	O
,	O
Smith	O
DI	O
,	O
Liu	O
W	O
,	O
Couch	O
FJ	O
.	O
Department	O
of	O
Laboratory	O
Medicine	O
and	O
Pathology	O
,	O
Mayo	O
Foundation	O
,	O
Rochester	O
,	O
MN	O
55905	O
,	O
USA	O
.	O
Recently	O
,	O
a	O
novel	O
tumor	O
suppressor	O
gene	O
,	O
p73	O
,	O
was	O
isolated	O
and	O
mapped	O
to	O
chromosome	O
1p36	O
,	O
a	O
region	O
commonly	O
associated	O
with	O
loss	O
of	O
heterozygosity	O
in	O
neuroblastoma	B-malignancy-type
and	O
other	O
human	O
malignancies	O
,	O
including	O
breast	B-malignancy-type
cancer	I-malignancy-type
.	O
The	O
p73	O
gene	O
shares	O
considerable	O
homology	O
with	O
the	O
common	O
tumor	O
suppressor	O
gene	O
p53	O
,	O
both	O
in	O
composition	O
and	O
function	O
.	O
This	O
study	O
examines	O
the	O
potential	O
participation	O
of	O
p73	O
in	O
the	O
pathogenesis	O
of	O
sporadic	O
and	O
hereditary	O
breast	B-malignancy-type
cancers	I-malignancy-type
.	O
Mutation	O
analysis	O
of	O
29	O
hereditary	O
breast	B-malignancy-type
cancer	I-malignancy-type
cases	O
revealed	O
five	O
independent	O
silent	O
mutations	O
in	O
the	O
hereditary	O
cases	O
that	O
are	O
unlikely	O
to	O
play	O
a	O
role	O
in	O
tumor	O
development	O
.	O
Mutation	O
analysis	O
of	O
48	O
sporadic	O
breast	B-malignancy-type
tumors	I-malignancy-type
did	O
not	O
identify	O
any	O
unique	O
variants	O
.	O
Eleven	O
common	O
polymorphisms	O
scattered	O
throughout	O
the	O
gene	O
were	O
also	O
detected	O
.	O
Thus	O
,	O
mutations	O
in	O
the	O
p73	O
gene	O
appear	O
to	O
play	O
little	O
if	O
any	O
role	O
in	O
hereditary	O
or	O
sporadic	O
breast	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
10634515	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Neuroreport	O
.	O
1997	O
May	O
27	O
;	O
8	O
(	O
8	O
)	O
:	O
1913-8	O
.	O
Endogenous	O
opioid	O
receptor	O
-	O
like	O
receptor	O
in	O
human	O
neuroblastoma	B-malignancy-type
SK-N-SH	O
cells	O
:	O
activation	O
of	O
inhibitory	O
G	O
protein	O
and	O
homologous	O
desensitization	O
.	O
Cheng	O
ZJ	O
,	O
Fan	O
GH	O
,	O
Zhao	O
J	O
,	O
Zhang	O
Z	O
,	O
Wu	O
YL	O
,	O
Jiang	O
LZ	O
,	O
Zhu	O
Y	O
,	O
Pei	O
G	O
,	O
Ma	O
L	O
.	O
Shanghai	O
Institute	O
of	O
Cell	O
Biology	O
,	O
Chinese	O
Academy	O
of	O
Sciences	O
,	O
People	O
's	O
Republic	O
of	O
China	O
.	O
Endogenous	O
expression	O
of	O
opioid	O
receptor	O
-	O
like	O
receptor	O
(	O
ORL1	O
)	O
,	O
in	O
human	O
neuroblastoma	B-malignancy-type
SK-N-SH	O
cells	O
was	O
demonstrated	O
by	O
binding	O
with	O
nociceptin	O
/	O
orphanin	O
FQ	O
(	O
N	O
/	O
OFQ	O
)	O
.	O
Scatchard	O
analysis	O
of	O
[3H]	O
N	O
/	O
OFQ	O
saturation	O
binding	O
data	O
gave	O
Kd	O
=	O
1.3	O
+/-	O
0.1	O
nM	O
and	O
Bmax	O
=	O
1.58	O
+/-	O
2.5	O
fmol	O
/	O
mg	O
protein	O
.	O
N	O
/	O
OFQ	O
stimulation	O
increased	O
[35S]GTP	O
gamma	O
S	O
binding	O
to	O
cell	O
membranes	O
and	O
attenuated	O
forskolin	O
-	O
induced	O
cAMP	O
accumulation	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O
The	O
effects	O
of	O
N	O
/	O
OFQ	O
were	O
eliminated	O
by	O
the	O
pretreatment	O
of	O
pertussis	O
toxin	O
(	O
PTX	O
)	O
but	O
not	O
by	O
the	O
antagonists	O
of	O
opioid	O
receptors	O
,	O
revealing	O
mediation	O
of	O
N	O
/	O
OFQ	O
signal	O
transduction	O
by	O
ORL1	O
receptor	O
and	O
PTX	O
sensitive	O
G	O
protein(s)	O
.	O
The	O
ability	O
of	O
N	O
/	O
OFQ	O
to	O
inhibit	O
cAMP	O
production	O
was	O
greatly	O
reduced	O
after	O
prechallenging	O
with	O
N	O
/	O
OFQ	O
,	O
indicating	O
that	O
ORL1	O
undergoes	O
homologous	O
desensitization	O
in	O
neuronal	O
cells	O
.	O
PMID	O
:	O
9223076	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Neuroreport	O
.	O
1997	O
Jul	O
7	O
;	O
8	O
(	O
9-10	O
)	O
:	O
2143-8	O
.	O
Long	O
-	O
term	O
morphine	O
treatment	O
increases	O
Ku	O
protein	O
DNA	O
end	O
-	O
binding	O
activity	O
.	O
Bakalkin	O
G	O
,	O
Yakovleva	O
T	O
,	O
Melzig	O
M	O
,	O
Terenius	O
L	O
.	O
Department	O
of	O
Clinical	O
Neuroscience	O
,	O
Karolinska	O
Institute	O
,	O
Stockholm	O
,	O
Sweden	O
.	O
Human	O
neuroblastoma	B-malignancy-type
SH-SY5Y	O
and	O
small	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
carcinoma	I-malignancy-type
U1690	O
cells	O
of	O
neuroendocrine	O
origin	O
were	O
exposed	O
to	O
morphine	O
for	O
1	O
h	O
,	O
3	O
h	O
or	O
5	O
days	O
.	O
These	O
treatments	O
did	O
not	O
alter	O
activities	O
of	O
AP-1	O
,	O
NF-kappa	O
B	O
and	O
YY1	O
transcription	O
factors	O
in	O
SH-SY5Y	O
cells	O
or	O
NF-kappa	O
B	O
and	O
YY1	O
in	O
U1690	O
cells	O
.	O
Five	O
-	O
day	O
morphine	O
treatment	O
,	O
however	O
,	O
caused	O
a	O
twofold	O
increase	O
in	O
the	O
activity	O
of	O
a	O
sequence	O
-	O
non	O
-	O
specific	O
,	O
spermidine	O
-	O
activated	O
DNA	O
-	O
binding	O
factor	O
in	O
U1690	O
cells	O
.	O
The	O
morphine	O
effect	O
was	O
prevented	O
by	O
the	O
antagonist	O
naloxone	O
.	O
The	O
DNA	O
-	O
binding	O
factor	O
bound	O
preferentially	O
to	O
double	O
-	O
stranded	O
DNA	O
ends	O
.	O
This	O
fact	O
and	O
data	O
on	O
subunit	O
composition	O
,	O
molecular	O
masses	O
of	O
subunits	O
,	O
and	O
supershift	O
/	O
inhibition	O
by	O
specific	O
antibodies	O
in	O
a	O
band	O
shift	O
assay	O
,	O
show	O
the	O
spermidine	O
-	O
activated	O
factor	O
to	O
be	O
identical	O
with	O
the	O
Ku	O
protein	O
,	O
the	O
DNA	O
-	O
binding	O
subunit	O
of	O
DNA	O
-	O
dependent	O
protein	O
kinase	O
.	O
The	O
effect	O
observed	O
may	O
be	O
one	O
of	O
the	O
mechanisms	O
through	O
which	O
opioids	O
influence	O
gene	O
regulation	O
.	O
PMID	O
:	O
9243600	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cell	O
.	O
2003	O
Jan	O
10	O
;	O
112	O
(	O
1	O
)	O
:	O
29-40	O
.	O
Comment	O
in	O
:	O
Cell	O
.	O
2003	O
Jan	O
10	O
;	O
112	O
(	O
1	O
)	O
:	O
1-2	O
.	O
Parc	O
:	O
a	O
cytoplasmic	O
anchor	O
for	O
p53	O
.	O
Nikolaev	O
AY	O
,	O
Li	O
M	O
,	O
Puskas	O
N	O
,	O
Qin	O
J	O
,	O
Gu	O
W	O
.	O
Institute	O
for	O
Cancer	O
Genetics	O
and	O
Department	O
of	O
Pathology	O
,	O
College	O
of	O
Physicians	O
and	O
Surgeons	O
,	O
Columbia	O
University	O
,	O
1150	O
St.	O
Nicholas	O
Avenue	O
,	O
New	O
York	O
,	O
NY	O
10032	O
,	O
USA	O
.	O
Nuclear	O
localization	O
of	O
p53	O
is	O
essential	O
for	O
its	O
tumor	O
suppressor	O
function	O
.	O
Here	O
,	O
we	O
have	O
identified	O
Parc	O
,	O
a	O
Parkin	O
-	O
like	O
ubiquitin	O
ligase	O
,	O
as	O
a	O
cytoplasmic	O
anchor	O
protein	O
in	O
p53	O
-	O
associated	O
protein	O
complexes	O
.	O
Parc	O
directly	O
interacts	O
and	O
forms	O
a	O
approximately	O
1	O
MDa	O
complex	O
with	O
p53	O
in	O
the	O
cytoplasm	O
of	O
unstressed	O
cells	O
.	O
In	O
the	O
absence	O
of	O
stress	O
,	O
inactivation	O
of	O
Parc	O
induces	O
nuclear	O
localization	O
of	O
endogenous	O
p53	O
and	O
activates	O
p53	O
-	O
dependent	O
apoptosis	O
.	O
Overexpression	O
of	O
Parc	O
promotes	O
cytoplasmic	O
sequestration	O
of	O
ectopic	O
p53	O
.	O
Furthermore	O
,	O
abnormal	O
cytoplasmic	O
localization	O
of	O
p53	O
was	O
observed	O
in	O
a	O
number	O
of	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
;	O
RNAi	O
-	O
mediated	O
reduction	O
of	O
endogenous	O
Parc	O
significantly	O
sensitizes	O
these	O
neuroblastoma	B-malignancy-type
cells	O
in	O
the	O
DNA	O
damage	O
response	O
.	O
These	O
results	O
reveal	O
that	O
Parc	O
is	O
a	O
critical	O
regulator	O
in	O
controlling	O
p53	O
subcellular	O
localization	O
and	O
subsequent	O
function	O
.	O
PMID	O
:	O
12526791	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Biol	O
Pharm	O
Bull	O
.	O
1998	O
Mar	O
;	O
21	O
(	O
3	O
)	O
:	O
210-3	O
.	O
Generation	O
of	O
immortalized	O
murine	O
forebrain	O
cell	O
lines	O
expressing	O
an	O
alpha	O
isoform	O
of	O
Ca2+	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
II	O
.	O
Fujii	O
M,	O
Nomura	O
T	O
,	O
Kumatoriya	O
K,	O
Yoshimura	O
Y	O
,	O
Yamauchi	O
T.	O
Department	O
of	O
Biochemistry	O
,	O
Faculty	O
of	O
Pharmaceutical	O
Sciences	O
,	O
University	O
of	O
Tokushima	O
,	O
Shomachi	O
,	O
Japan	O
.	O
Immortalized	O
hybrid	O
cells	O
were	O
generated	O
by	O
the	O
somatic	O
fusion	O
of	O
the	O
cells	O
from	O
the	O
forebrain	O
of	O
embryonic	O
mouse	O
with	O
N18TG2	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Three	O
monoclonal	O
hybrid	O
cell	O
lines	O
,	O
designated	O
NF26	O
,	O
NF81	O
,	O
and	O
NF83	O
(	O
neuroblastoma	B-malignancy-type
forebrain	O
hybrid	O
cells	O
)	O
,	O
expressing	O
an	O
alpha	O
isoform	O
of	O
Ca2+	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
II	O
(	O
CaM	O
kinase	O
II	O
)	O
were	O
isolated	O
,	O
and	O
their	O
expression	O
was	O
demonstrated	O
by	O
immunoblotting	O
and	O
immunocytochemistry	O
using	O
a	O
monoclonal	O
antibody	O
specific	O
to	O
the	O
a	O
isoform	O
of	O
the	O
enzyme	O
.	O
The	O
kinase	O
activity	O
of	O
the	O
hybrid	O
cells	O
was	O
2	O
-	O
to	O
3	O
-	O
fold	O
higher	O
than	O
that	O
of	O
the	O
parent	O
neuroblastoma	B-malignancy-type
line	O
N18TG2	O
cells	O
.	O
The	O
neuronal	O
origin	O
of	O
these	O
lines	O
was	O
shown	O
by	O
their	O
immunoreactivity	O
to	O
neurofilament	O
protein	O
,	O
a	O
neuron	O
specific	O
marker	O
.	O
Lines	O
NF26	O
,	O
NF81	O
,	O
and	O
NF83	O
are	O
the	O
first	O
cell	O
lines	O
to	O
express	O
the	O
gene	O
of	O
the	O
alpha	O
isoform	O
of	O
CaM	O
kinase	O
II	O
in	O
the	O
brain	O
.	O
PMID	O
:	O
9556146	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Detect	O
Prev	O
.	O
1996	O
;	O
20	O
(	O
2	O
)	O
:	O
108-13	O
.	O
Use	O
of	O
gene	O
marking	O
in	O
bone	O
marrow	O
transplantation	O
.	O
Heslop	O
HE	O
,	O
Rooney	O
CM	O
,	O
Rill	O
DR	O
,	O
Krance	O
RA	O
,	O
Brenner	O
MK	O
.	O
Division	O
of	O
Bone	O
Marrow	O
Transplantation	O
,	O
St.	O
Jude	O
Children	O
's	O
Research	O
Hospital	O
,	O
Memphis	O
,	O
TN	O
38105	O
,	O
USA	O
.	O
We	O
have	O
used	O
gene	O
marking	O
to	O
investigate	O
the	O
mechanism	O
of	O
relapse	O
and	O
biology	O
of	O
reconstitution	O
following	O
bone	O
marrow	O
transplantation	O
(	O
BMT	O
)	O
.	O
The	O
rationale	O
for	O
our	O
initial	O
protocols	O
was	O
to	O
learn	O
if	O
residual	O
malignant	O
cells	O
in	O
autologous	O
marrow	O
contribute	O
to	O
subsequent	O
relapse	O
.	O
Marked	O
malignant	O
cells	O
were	O
found	O
at	O
the	O
time	O
of	O
relapse	O
in	O
6	O
/	O
8	O
patients	O
relapsing	O
after	O
autologous	O
BMT	O
for	O
AML	B-malignancy-type
or	O
neuroblastoma	B-malignancy-type
showing	O
the	O
infused	O
marrow	O
contributed	O
to	O
disease	O
recurrence	O
.	O
Modifications	O
of	O
this	O
marker	O
approach	O
with	O
two	O
distinguishable	O
vectors	O
are	O
now	O
being	O
used	O
to	O
compare	O
the	O
efficacy	O
of	O
purging	O
techniques	O
.	O
We	O
were	O
also	O
able	O
to	O
evaluate	O
gene	O
transfer	O
to	O
normal	O
progenitors	O
and	O
demonstrated	O
that	O
the	O
marker	O
gene	O
was	O
expressed	O
for	O
up	O
to	O
36	O
months	O
.	O
Gene	O
marking	O
is	O
also	O
being	O
used	O
to	O
trace	O
the	O
fate	O
of	O
EBV	O
-	O
specific	O
CTLs	O
that	O
we	O
are	O
administering	O
to	O
recipients	O
of	O
allogeneic	O
BMT	O
and	O
has	O
provided	O
evidence	O
of	O
persistence	O
of	O
adoptively	O
transferred	O
CTL	O
for	O
up	O
to	O
10	O
months	O
.	O
PMID	O
:	O
8706035	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Neurosurg	O
Sci	O
.	O
1997	O
Mar	O
(	O
1	O
)	O
:	O
117-22	O
.	O
Surgical	O
treatment	O
of	O
anterior	B-malignancy-type
callosal	I-malignancy-type
tumors	I-malignancy-type
.	O
D'Angelo	O
V	O
,	O
Napolitano	O
M	O
,	O
Gorgoglione	O
L	O
,	O
Scarabino	O
T	O
,	O
Latino	O
R	O
,	O
Simone	O
P	O
,	O
Bisceglia	O
M	O
.	O
Department	O
of	O
Neurosurgery	O
,	O
Casa	O
Sollievo	O
della	O
Sofferenza	O
Hospital	O
IRCCS	O
,	O
S.	O
Giovanni	O
Rotondo	O
,	O
Foggia	O
,	O
Italy	O
.	O
OBJECTIVE	O
:	O
Thirteen	O
patients	O
with	O
neoplasm	O
of	O
anterior	O
corpus	O
callosum	O
have	O
undergone	O
our	O
observation	O
during	O
the	O
last	O
two	O
years	O
.	O
METHODS	O
:	O
For	O
the	O
diagnosis	O
,	O
all	O
the	O
patients	O
underwent	O
TC	O
,	O
NMR	O
and	O
stereotactic	O
biopsy	O
.	O
In	O
6	O
cases	O
with	O
glioblastomas	B-malignancy-type
,	O
a	O
radiation	O
treatment	O
was	O
adopted	O
.	O
The	O
other	O
7	O
patients	O
underwent	O
total	O
surgical	O
treatment	O
in	O
5	O
cases	O
,	O
and	O
partial	O
in	O
2	O
cases	O
,	O
as	O
documented	O
by	O
postoperative	O
contrast	O
-	O
enhanced	O
CT	O
scanning	O
.	O
Histologically	O
,	O
there	O
were	O
:	O
3	O
glioblastomas	B-malignancy-type
,	O
1	O
grade	O
III	O
astrocytoma	B-malignancy-type
,	O
1	O
neuroblastoma	B-malignancy-type
(	O
PNET	B-malignancy-type
)	O
,	O
2	O
pilocytic	B-malignancy-type
astrocytomas	I-malignancy-type
.	O
RESULTS	O
:	O
Neuropsychological	O
tests	O
carried	O
out	O
on	O
the	O
5	O
patients	O
still	O
living	O
showed	O
persistent	O
disturbances	O
of	O
verbal	O
memory	O
in	O
all	O
five	O
and	O
disturbances	O
of	O
verbal	O
phonological	O
fluency	O
in	O
3	O
cases	O
.	O
No	O
patient	O
presented	O
apraxia	O
,	O
dysgraphia	O
and	O
dyslexia	O
.	O
CONCLUSIONS	O
:	O
Thus	O
,	O
no	O
severe	O
neuropsychological	O
deficits	O
developed	O
after	O
surgical	O
treatment	O
of	O
anterior	B-malignancy-type
callosal	I-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
9273869	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Neurochem	O
Int	O
.	O
1998	O
Jan	O
;	O
32	O
(	O
1	O
)	O
:	O
93-102	O
.	O
Nitric	O
oxide	O
donor	O
-	O
induced	O
p53	O
-	O
sensitive	O
cell	O
death	O
is	O
enhanced	O
by	O
Bcl-2	O
reduction	O
in	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Kitamura	O
Y	O
,	O
Kamoshima	O
W	O
,	O
Shimohama	O
S	O
,	O
Nomura	O
Y	O
,	O
Taniguchi	O
T.	O
Department	O
of	O
Neurobiology	O
,	O
Kyoto	O
Pharmaceutical	O
University	O
,	O
Japan	O
.	O
In	O
human	O
neuroblastoma	B-malignancy-type
SH-SY5Y	O
cells	O
,	O
S-nitroso-N-acetylpenicillamine	O
(	O
SNAP	O
)	O
,	O
a	O
nitric	O
oxide	O
(	O
NO	O
)	O
-	O
donor	O
,	O
caused	O
cell	O
death	O
accompanying	O
p53	O
expression	O
,	O
nucleosomal	O
DNA	O
fragmentation	O
and	O
cell	O
death	O
.	O
In	O
addition	O
,	O
SNAP	O
-	O
induced	O
cell	O
death	O
and	O
DNA	O
fragmentation	O
were	O
enhanced	O
by	O
pretreatment	O
for	O
4	O
days	O
with	O
N6,2'-O-dibutyryl	O
cyclic	O
AMP	O
(	O
diBu-cAMP	O
)	O
or	O
staurosporine	O
,	O
while	O
those	O
were	O
not	O
changed	O
by	O
pretreatment	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O
Protein	O
level	O
of	O
Bcl-2	O
was	O
decreased	O
by	O
pretreatment	O
with	O
diBu-cAMP	O
or	O
staurosporine	O
,	O
and	O
,	O
on	O
the	O
contrary	O
,	O
the	O
level	O
was	O
increased	O
by	O
pretreatment	O
with	O
PMA	O
.	O
However	O
,	O
these	O
pretreatments	O
did	O
not	O
change	O
Bax	O
protein	O
level	O
and	O
SNAP	O
-	O
induced	O
p53	O
expression	O
.	O
However	O
,	O
SNAP	O
-	O
treatment	O
did	O
not	O
change	O
protein	O
levels	O
of	O
Bcl-2	O
and	O
Bax	O
.	O
These	O
results	O
suggest	O
that	O
SNAP	O
-	O
induced	O
p53	O
-	O
sensitive	O
apoptosis	O
is	O
enhanced	O
by	O
Bcl-2	O
reduction	O
,	O
and	O
that	O
Bcl-2	O
and	O
Bax	O
may	O
act	O
downstream	O
of	O
p53	O
in	O
SH-SY5Y	O
cells	O
.	O
PMID	O
:	O
9460707	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Metab	O
Brain	O
Dis	O
.	O
2003	O
Sep	O
;	O
18	O
(	O
3	O
)	O
:	O
221-31	O
.	O
L-cysteine	O
increases	O
glucose	O
uptake	O
in	O
mouse	O
soleus	O
muscle	O
and	O
SH-SY5Y	O
cells	O
.	O
Gazit	O
V	O
,	O
Ben	O
-	O
Abraham	O
R	O
,	O
Vofsi	O
O	O
,	O
Katz	O
Y	O
.	O
Laboratory	O
for	O
Anesthesia	O
,	O
Pain	O
and	O
Neural	O
Research	O
,	O
The	O
Bruce	O
Rappaport	O
Faculty	O
of	O
Medicine	O
,	O
Technion-	O
Israel	O
Institute	O
of	O
Technology	O
,	O
Haifa	O
,	O
Israel	O
.	O
Previous	O
investigation	O
demonstrated	O
the	O
potential	O
of	O
L-cysteine	O
(	O
L-Cys	O
)	O
at	O
high	O
concentrations	O
to	O
cause	O
hypoglycemia	O
in	O
mice	O
totally	O
deprived	O
of	O
insulin	O
.	O
For	O
further	O
elucidation	O
of	O
the	O
glucose	O
-	O
lowering	O
mechanism	O
,	O
glucose	O
uptake	O
and	O
quantity	O
of	O
glucose	O
transporters	O
(	O
GLUTs	O
3	O
and	O
4	O
)	O
in	O
mouse	O
soleus	O
muscle	O
and	O
C2C12	O
muscle	O
cells	O
,	O
as	O
well	O
as	O
in	O
human	O
SH-SY5Y	O
neuroblastoma	B-malignancy-type
cells	O
,	O
were	O
investigated	O
.	O
A	O
marked	O
enhancement	O
of	O
glucose	O
uptake	O
was	O
demonstrated	O
,	O
peaking	O
at	O
5.0	O
mM	O
L-Cys	O
in	O
soleus	O
muscle	O
(	O
P	O
<	O
0.05	O
)	O
and	O
SH-SY5Y	O
cells	O
(	O
P	O
<	O
0.001	O
)	O
,	O
respectively	O
.	O
In	O
contrast	O
,	O
glucose	O
uptake	O
was	O
not	O
affected	O
in	O
the	O
C2C12	O
muscle	O
cells	O
.	O
Kinetic	O
analysis	O
of	O
the	O
SH-SY5Y	O
glucose	O
uptake	O
showed	O
a	O
2.5	O
-	O
fold	O
increase	O
in	O
maximum	O
transport	O
velocity	O
compared	O
with	O
controls	O
(	O
P	O
<	O
0.001	O
)	O
.	O
In	O
addition	O
,	O
both	O
GLUT3	O
and	O
GLUT4	O
levels	O
were	O
increased	O
following	O
exposure	O
to	O
L-Cys	O
.	O
Our	O
findings	O
point	O
to	O
a	O
possible	O
hypoglycemic	O
effect	O
of	O
L-Cys	O
.	O
PMID	O
:	O
14567472	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
1990	O
Aug	O
16	O
;	O
170	O
(	O
3	O
)	O
:	O
1096-101	O
.	O
Covalent	O
crosslinking	O
analysis	O
of	O
angiotensin	O
receptors	O
on	O
differentiated	O
NG108-15	O
cells	O
.	O
Carrithers	O
MD	O
,	O
Koide	O
KA	O
,	O
Raman	O
VK	O
,	O
Masuda	O
S	O
,	O
Weyhenmeyer	O
JA	O
.	O
Neuroscience	O
Program	O
,	O
University	O
of	O
Illinois	O
,	O
Urbana	O
61801	O
.	O
Neuroblastoma	B-malignancy-type
x	O
glioma	B-malignancy-type
hybrid	O
cells	O
(	O
NG108-15	O
)	O
were	O
used	O
as	O
a	O
model	O
system	O
to	O
characterize	O
neuronal	O
-	O
glial	O
type	O
angiotensin	O
(	O
ANG	O
)	O
receptors	O
by	O
covalent	O
crosslinking	O
analysis	O
.	O
After	O
differentiation	O
with	O
1.5	O
%	O
DMSO	O
and	O
0.5	O
%	O
fetal	O
bovine	O
serum	O
for	O
four	O
to	O
five	O
days	O
,	O
saturation	O
analysis	O
revealed	O
a	O
single	O
high	O
affinity	O
site	O
with	O
a	O
Kd	O
=	O
1.35	O
+/-	O
0.42	O
nM	O
and	O
a	O
Bmax	O
=	O
468	O
+/-	O
106	O
fmol	O
/	O
mg	O
protein	O
.	O
Using	O
the	O
homobifunctional	O
crosslinking	O
reagent	O
bis(sulfosuccinimidyl)	O
suberate	O
(	O
BS3	O
)	O
,	O
a	O
site	O
with	O
an	O
estimated	O
Mr	O
of	O
78	O
kDa	O
was	O
specifically	O
labeled	O
with	O
125I	O
-	O
ANG	O
II	O
as	O
determined	O
by	O
SDS-polyacrylamide	O
gel	O
electrophoresis	O
.	O
Both	O
ANG	O
II	O
and	O
ANG	O
III	O
(	O
10(-6)	O
M	O
)	O
inhibited	O
specific	O
labeling	O
.	O
The	O
Ki	O
for	O
ANG	O
III	O
binding	O
was	O
similar	O
by	O
both	O
pharmacologic	O
(	O
Ki	O
=	O
3.33	O
+/-	O
0.98	O
nM	O
)	O
and	O
gel	O
densitometric	O
(	O
Ki	O
=	O
2.65	O
+/-	O
0.32	O
nM	O
)	O
analyses	O
.	O
We	O
conclude	O
that	O
the	O
78	O
kDa	O
protein	O
represents	O
a	O
high	O
affinity	O
ANG	O
binding	O
site	O
with	O
similar	O
affinities	O
for	O
both	O
ANG	O
II	O
and	O
ANG	O
III	O
.	O
PMID	O
:	O
2390077	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Mol	O
Endocrinol	O
.	O
1990	O
Feb	O
;	O
4	O
(	O
1	O
)	O
:	O
37-41	O
.	O
Procholecystokinin	O
and	O
proenkephalin	O
A	O
mRNA	O
expression	O
is	O
modulated	O
by	O
cyclic	O
AMP	O
and	O
noradrenaline	O
.	O
Monstein	O
HJ	O
,	O
Folkesson	O
R	O
,	O
Geijer	O
T	O
.	O
Department	O
of	O
Clinical	O
Chemistry	O
,	O
Laboratory	O
for	O
Molecular	O
Biology	O
,	O
Copenhagen	O
,	O
Denmark	O
.	O
Regulation	O
of	O
the	O
expression	O
of	O
procholecystokinin	O
(	O
proCCK	O
)	O
and	O
proenkephalin	O
A	O
mRNA	O
was	O
studied	O
in	O
the	O
human	O
neuroblastoma	B-malignancy-type
cell	O
line	O
SK-N-MC	O
.	O
Cells	O
were	O
treated	O
with	O
dibutyryl-3',5'-cyclic	O
AMP	O
(	O
dbcAMP	O
)	O
,	O
noradrenaline	O
or	O
isoproterenol	O
,	O
a	O
beta-adrenoceptor	O
agonist	O
.	O
Levels	O
of	O
proCCK	O
and	O
proenkephalin	O
A	O
mRNA	O
were	O
determined	O
by	O
Northern	O
blot	O
analysis	O
with	O
proCCK	O
-	O
and	O
proenkephalin	O
A	O
-	O
specific	O
cRNA	O
hybridization	O
probes	O
9	O
h	O
after	O
drug	O
treatments	O
.	O
ProCCK	O
and	O
proenkephalin	O
A	O
mRNA	O
were	O
co	O
-	O
expressed	O
in	O
SK-N-MC	O
cells	O
.	O
ProCCK	O
mRNA	O
levels	O
were	O
increased	O
1.5	O
-	O
2.5	O
times	O
by	O
dbcAMP	O
,	O
noradrenaline	O
and	O
isoproterenol	O
when	O
compared	O
with	O
controls	O
.	O
The	O
level	O
of	O
proenkephalin	O
A	O
mRNA	O
increased	O
approximately	O
two	O
to	O
three	O
times	O
under	O
the	O
same	O
drug	O
conditions	O
,	O
whereas	O
the	O
level	O
of	O
N-myc	O
mRNA	O
did	O
not	O
change	O
significantly	O
.	O
These	O
results	O
suggest	O
that	O
expression	O
of	O
proCCK	O
and	O
proenkephalin	O
A	O
mRNA	O
may	O
be	O
regulated	O
by	O
a	O
similar	O
cAMP	O
-	O
dependent	O
mechanism	O
in	O
the	O
SK-N-MC	O
cell	O
line	O
.	O
PMID	O
:	O
2157452	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
.	O
1986	O
Jun	O
1	O
;	O
57	O
(	O
11	O
)	O
:	O
2158-61	O
.	O
Double	O
minute	O
chromosomes	O
.	O
A	O
bone	O
marrow	O
indicator	O
of	O
neuroblastoma	B-malignancy-type
metastasis	O
and	O
relapse	O
:	O
two	O
case	O
reports	O
.	O
O'Malley	O
DP	O
,	O
Cousineau	O
AJ	O
,	O
Kulkarni	O
R	O
,	O
Higgins	O
JV	O
.	O
Two	O
cases	O
of	O
childhood	O
neuroblastoma	B-malignancy-type
are	O
presented	O
.	O
Case	O
1	O
was	O
diagnosed	O
as	O
Stage	O
IV	O
with	O
metastasis	O
to	O
the	O
bone	O
marrow	O
.	O
During	O
remission	O
,	O
histologic	O
studies	O
of	O
bone	O
marrow	O
aspirate	O
and	O
biopsy	O
showed	O
a	O
normocellular	O
marrow	O
with	O
no	O
evidence	O
of	O
malignant	O
cells	O
.	O
Concurrent	O
cytogenetic	O
studies	O
of	O
the	O
bone	O
marrow	O
showed	O
the	O
majority	O
of	O
the	O
cells	O
to	O
contain	O
double	O
minute	O
chromosomes	O
(	O
DM	O
)	O
.	O
The	O
chromosome	O
findings	O
indicated	O
the	O
presence	O
of	O
neuroblastoma	B-malignancy-type
cells	O
in	O
the	O
marrow	O
prior	O
to	O
histologic	O
evidence	O
of	O
relapse	O
.	O
Case	O
2	O
was	O
diagnosed	O
as	O
Stage	O
I	O
neuroblastoma	B-malignancy-type
with	O
no	O
metastasis	O
to	O
the	O
bone	O
marrow	O
.	O
Subsequent	O
cytogenetic	O
studies	O
showed	O
DM	O
present	O
in	O
a	O
small	O
number	O
of	O
cells	O
and	O
a	O
deletion	O
of	O
chromosome	O
1	O
(	O
1p	O
-	O
)	O
in	O
a	O
single	O
cell	O
.	O
The	O
chromosome	O
findings	O
indicated	O
an	O
advanced	O
stage	O
of	O
malignancy	O
which	O
was	O
not	O
evident	O
with	O
histologic	O
techniques	O
.	O
These	O
findings	O
suggest	O
that	O
cytogenetic	O
analysis	O
of	O
bone	O
marrow	O
can	O
be	O
a	O
valuable	O
aid	O
to	O
the	O
early	O
diagnosis	O
,	O
prognosis	O
,	O
and	O
treatment	O
of	O
neuroblastoma	B-malignancy-type
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
3697914	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Eur	O
J	O
Hum	O
Genet	O
.	O
2002	O
Mar	O
;	O
10	O
(	O
3	O
)	O
:	O
183-7	O
.	O
Hirschsprung	O
associated	O
GDNF	O
mutations	O
do	O
not	O
prevent	O
RET	O
activation	O
.	O
Borghini	O
S	O
,	O
Bocciardi	O
R	O
,	O
Bonardi	O
G	O
,	O
Matera	O
I	O
,	O
Santamaria	O
G	O
,	O
Ravazzolo	O
R	O
,	O
Ceccherini	O
I	O
.	O
Laboratorio	O
di	O
Genetica	O
Molecolare	O
,	O
Istituto	O
G	O
.	O
Gaslini	O
,	O
16148	O
Genova	O
,	O
Italy	O
.	O
Hirschsprung	O
disease	O
(	O
HSCR	O
)	O
is	O
a	O
complex	O
disorder	O
characterised	O
by	O
aganglia	O
of	O
distal	O
gastrointestinal	O
tracts	O
.	O
The	O
highest	O
proportion	O
of	O
both	O
familial	O
and	O
sporadic	O
cases	O
is	O
due	O
to	O
mutations	O
of	O
the	O
RET	O
proto	O
-	O
oncogene	O
.	O
Five	O
germline	O
mutations	O
in	O
the	O
glial	O
cell	O
-	O
line	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
GDNF	O
)	O
gene	O
,	O
one	O
of	O
the	O
RET	O
ligands	O
,	O
have	O
been	O
detected	O
in	O
HSCR	O
patients	O
.	O
Pedigrees	O
analysis	O
and	O
the	O
observed	O
association	O
between	O
these	O
GDNF	O
alterations	O
and	O
RET	O
variants	O
in	O
the	O
same	O
patients	O
raised	O
the	O
question	O
of	O
whether	O
the	O
GDNF	O
gene	O
plays	O
any	O
causative	O
/	O
predisposing	O
role	O
in	O
HSCR	O
pathogenesis	O
.	O
In	O
the	O
present	O
work	O
,	O
we	O
have	O
studied	O
the	O
ability	O
of	O
GDNF	O
proteins	O
,	O
each	O
bearing	O
one	O
of	O
the	O
reported	O
mutations	O
,	O
to	O
activate	O
RET	O
by	O
performing	O
a	O
functional	O
test	O
in	O
cultured	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Consistently	O
with	O
the	O
lack	O
of	O
genotype	O
/	O
phenotype	O
correlation	O
in	O
human	O
subjects	O
,	O
our	O
results	O
indicate	O
absence	O
of	O
detectable	O
alterations	O
of	O
mutant	O
GDNF	O
induced	O
RET	O
activation	O
.	O
PMID	O
:	O
11973622	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Diagn	O
Mol	O
Pathol	O
.	O
1993	O
Sep	O
;	O
2	O
(	O
3	O
)	O
:	O
158-62	O
.	O
dbl	O
oncogene	O
expression	O
in	O
childhood	O
tumors	O
and	O
tumor	O
cell	O
lines	O
.	O
Navarro	O
S	O
,	O
Pellin	O
A	O
,	O
Noguera	O
R	O
,	O
Diaz	O
MP	O
,	O
Tsokos	O
M,	O
Triche	O
TJ	O
,	O
Llombart-Bosch	O
A	O
.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Valencia	O
,	O
Spain	O
.	O
We	O
studied	O
the	O
expression	O
of	O
the	O
dbl	O
oncogene	O
in	O
the	O
total	O
RNA	O
obtained	O
from	O
a	O
wide	O
spectrum	O
of	O
childhood	O
tumors	O
,	O
including	O
Ewing	B-malignancy-type
's	I-malignancy-type
sarcomas	I-malignancy-type
,	O
peripheral	B-malignancy-type
neuroectodermal	I-malignancy-type
tumors	I-malignancy-type
(	O
PNET	B-malignancy-type
)	O
,	O
esthesioneuroblastomas	B-malignancy-type
,	O
neuroblastomas	B-malignancy-type
,	O
retinoblastomas	B-malignancy-type
,	O
rhabdomyosarcomas	B-malignancy-type
,	O
osteosarcomas	B-malignancy-type
,	O
and	O
synovial	B-malignancy-type
sarcomas	I-malignancy-type
.	O
Material	O
was	O
obtained	O
from	O
primary	O
tumors	O
,	O
nude	O
mice	O
xenografts	O
,	O
and	O
tumor	O
cell	O
lines	O
.	O
Following	O
the	O
Northern	O
blot	O
technique	O
,	O
a	O
single	O
band	O
of	O
2.8	O
kb	O
was	O
found	O
in	O
each	O
analyzed	O
case	O
.	O
Induction	O
of	O
neural	O
differentiation	O
in	O
Ewing	B-malignancy-type
's	I-malignancy-type
sarcoma	I-malignancy-type
,	O
peripheral	B-malignancy-type
PNET	I-malignancy-type
,	O
and	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
with	O
dibutyryl	O
cyclic	O
AMP	O
did	O
not	O
change	O
the	O
expression	O
of	O
the	O
dbl	O
oncogene	O
.	O
We	O
conclude	O
that	O
the	O
wide	O
expression	O
of	O
the	O
dbl	O
oncogene	O
in	O
these	O
childhood	O
tumors	O
reduces	O
its	O
value	O
as	O
a	O
molecular	O
marker	O
for	O
their	O
differential	O
diagnosis	O
;	O
on	O
the	O
other	O
hand	O
,	O
the	O
dbl	O
oncogene	O
does	O
not	O
appear	O
to	O
be	O
an	O
essential	O
molecular	O
factor	O
in	O
the	O
process	O
of	O
neuroectodermal	O
differentiation	O
of	O
small	B-malignancy-type
round	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
of	O
childhood	O
.	O
PMID	O
:	O
8287229	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

EMBO	O
J	O
.	O
1997	O
Jun	O
2	O
;	O
16	O
(	O
11	O
)	O
:	O
2985-95	O
.	O
Targeted	O
expression	O
of	O
MYCN	O
causes	O
neuroblastoma	B-malignancy-type
in	O
transgenic	O
mice	O
.	O
Weiss	O
WA	O
,	O
Aldape	O
K	O
,	O
Mohapatra	O
G	O
,	O
Feuerstein	O
BG	O
,	O
Bishop	O
JM	O
.	O
G.W.	O
Hooper	O
Foundation	O
,	O
and	O
Department	O
of	O
Neurology	O
,	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
94143-0552	O
,	O
USA	O
.	O
The	O
proto	O
-	O
oncogene	O
MYCN	O
is	O
often	O
amplified	O
in	O
human	O
neuroblastomas	B-malignancy-type
.	O
The	O
assumption	O
that	O
the	O
amplification	O
contributes	O
to	O
tumorigenesis	O
has	O
never	O
been	O
tested	O
directly	O
.	O
We	O
have	O
created	O
transgenic	O
mice	O
that	O
overexpress	O
MYCN	O
in	O
neuroectodermal	O
cells	O
and	O
develop	O
neuroblastoma	B-malignancy-type
.	O
Analysis	O
of	O
tumors	O
by	O
comparative	O
genomic	O
hybridization	O
revealed	O
gains	O
and	O
losses	O
of	O
at	O
least	O
seven	O
chromosomal	O
regions	O
,	O
all	O
of	O
which	O
are	O
syntenic	O
with	O
comparable	O
abnormalities	O
detected	O
in	O
human	O
neuroblastomas	B-malignancy-type
.	O
In	O
addition	O
,	O
we	O
have	O
shown	O
that	O
increases	O
in	O
MYCN	O
dosage	O
or	O
deficiencies	O
in	O
either	O
of	O
the	O
tumor	O
suppressor	O
genes	O
NF1	O
or	O
RB1	O
can	O
augment	O
tumorigenesis	O
by	O
the	O
transgene	O
.	O
Our	O
results	O
provide	O
direct	O
evidence	O
that	O
MYCN	O
can	O
contribute	O
to	O
the	O
genesis	O
of	O
neuroblastoma	B-malignancy-type
,	O
suggest	O
that	O
the	O
genetic	O
events	O
involved	O
in	O
the	O
genesis	O
of	O
neuroblastoma	B-malignancy-type
can	O
be	O
tumorigenic	O
in	O
more	O
than	O
one	O
chronological	O
sequence	O
,	O
and	O
offer	O
a	O
model	O
for	O
further	O
study	O
of	O
the	O
pathogenesis	O
and	O
therapy	O
of	O
neuroblastoma	B-malignancy-type
.	O
PMID	O
:	O
9214616	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Neuroscience	O
.	O
1988	O
Oct	O
;	O
27	O
(	O
1	O
)	O
:	O
309-15	O
.	O
Synapse	O
-	O
competence	O
of	O
LA-N-2	O
human	O
neuroblastoma	B-malignancy-type
cells	O
in	O
coculture	O
with	O
rat	O
striated	O
muscle	O
cells	O
.	O
Yeh	O
HH	O
,	O
Notter	O
MF	O
,	O
Kordowerr	O
JH	O
,	O
Gash	O
DM	O
.	O
Department	O
of	O
Neurobiology	O
and	O
Anatomy	O
,	O
University	O
of	O
Rochester	O
School	O
of	O
Medicine	O
and	O
Dentistry	O
,	O
NY	O
14642	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
cells	O
of	O
the	O
human	O
neuroblastoma	B-malignancy-type
line	O
,	O
LA-N-2	O
,	O
are	O
capable	O
of	O
establishing	O
functional	O
synapses	O
in	O
culture	O
.	O
We	O
used	O
a	O
coculture	O
system	O
in	O
which	O
striated	O
muscle	O
cells	O
from	O
the	O
rat	O
served	O
as	O
postsynaptic	O
targets	O
for	O
the	O
cholinergic	O
LA-N-2	O
cells	O
.	O
By	O
recording	O
postsynaptic	O
responses	O
from	O
muscle	O
cells	O
,	O
differentiated	O
LA-N-2	O
cells	O
were	O
found	O
to	O
innervate	O
muscle	O
cells	O
,	O
releasing	O
acetylcholine	O
spontaneously	O
at	O
LA-N-2	O
-	O
muscle	O
synapses	O
.	O
A	O
subpopulation	O
of	O
the	O
LA-N-2	O
cells	O
forming	O
synapses	O
with	O
the	O
muscle	O
cells	O
also	O
developed	O
the	O
ability	O
to	O
release	O
acetylcholine	O
in	O
response	O
to	O
stimulation	O
.	O
This	O
,	O
coupled	O
with	O
results	O
obtained	O
from	O
experiments	O
examining	O
the	O
time	O
course	O
of	O
synapse	O
formation	O
,	O
led	O
us	O
to	O
propose	O
that	O
the	O
extent	O
to	O
which	O
LA-N-2	O
cells	O
in	O
our	O
coculture	O
system	O
are	O
differentiated	O
may	O
vary	O
and	O
that	O
this	O
variation	O
may	O
underlie	O
the	O
degree	O
to	O
which	O
they	O
express	O
neuron	O
-	O
like	O
transmission	O
properties	O
.	O
PMID	O
:	O
2904665	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Treat	O
Res	O
.	O
1997;77	O
:187	O
-	O
216	O
.	O
Allogeneic	O
umbilical	O
cord	O
blood	O
transplantation	O
.	O
Wagner	O
JE.	O
Department	O
of	O
Pediatrics	O
,	O
University	O
of	O
Minnesota	O
School	O
of	O
Medicine	O
,	O
Minneapolis	O
55455	O
,	O
USA	O
.	O
Interest	O
in	O
umbilical	O
cord	O
blood	O
as	O
an	O
alternate	O
source	O
of	O
hematopoietic	O
stem	O
cells	O
is	O
growing	O
rapidly	O
.	O
Umbilical	O
cord	O
blood	O
offers	O
the	O
clinician	O
a	O
source	O
of	O
hematopoietic	O
stem	O
cells	O
that	O
is	O
rarely	O
contaminated	O
by	O
latent	O
viruses	O
and	O
is	O
readily	O
available	O
.	O
Moreover	O
,	O
the	O
collection	O
of	O
umbilical	O
cord	O
blood	O
poses	O
no	O
risk	O
to	O
the	O
donor	O
;	O
there	O
is	O
no	O
need	O
for	O
general	O
anesthesia	O
or	O
blood	O
replacement	O
,	O
and	O
the	O
procedure	O
causes	O
no	O
discomfort	O
.	O
Whether	O
cord	O
blood	O
lymphocytes	O
are	O
as	O
likely	O
to	O
cause	O
GVHD	O
as	O
lymphocytes	O
from	O
older	O
individuals	O
is	O
unknown	O
.	O
Current	O
clinical	O
experience	O
would	O
suggest	O
that	O
the	O
incidence	O
may	O
be	O
low	O
.	O
Few	O
of	O
the	O
patients	O
transplanted	O
with	O
umbilical	O
cord	O
blood	O
thus	O
far	O
have	O
developed	O
clinically	O
significant	O
GVHD	O
,	O
including	O
recipients	O
of	O
HLA	O
-	O
disparate	O
grafts	O
.	O
These	O
results	O
and	O
associated	O
laboratory	O
findings	O
pose	O
intriguing	O
possibilities	O
for	O
the	O
future	O
of	O
umbilical	O
cord	O
blood	O
stem	O
cells	O
in	O
the	O
setting	O
of	O
unrelated	O
transplantation	O
.	O
With	O
the	O
marked	O
incidence	O
of	O
grade	O
2	O
-	O
4	O
acute	O
GVHD	O
that	O
is	O
currently	O
observed	O
after	O
unrelated	O
bone	O
marrow	O
transplantation	O
,	O
a	O
reduction	O
in	O
incidence	O
or	O
severity	O
would	O
be	O
a	O
major	O
advancement	O
in	O
this	O
field	O
.	O
In	O
the	O
setting	O
of	O
autologous	O
trans	O
-	O
plantation	O
,	O
there	O
are	O
other	O
intriguing	O
possibilities	O
;	O
for	O
example	O
,	O
cord	O
blood	O
may	O
be	O
an	O
optimal	O
source	O
of	O
pluripotential	O
stem	O
cells	O
for	O
gene	O
therapy	O
.	O
The	O
large	O
-	O
scale	O
collection	O
and	O
storage	O
of	O
cord	O
blood	O
stem	O
cells	O
has	O
become	O
a	O
reality	O
.	O
Pilot	O
programs	O
for	O
the	O
banking	O
of	O
unrelated	O
umbilical	O
cord	O
blood	O
have	O
already	O
begun	O
in	O
the	O
United	O
States	O
and	O
Europe	O
.	O
Not	O
only	O
is	O
there	O
the	O
potential	O
for	O
reducing	O
the	O
time	O
from	O
search	O
initiation	O
to	O
the	O
time	O
of	O
donor	O
stem	O
cell	O
acquisition	O
but	O
also	O
there	O
is	O
the	O
potential	O
for	O
reducing	O
the	O
risks	O
associated	O
with	O
unrelated	O
bone	O
marrow	O
transplantation	O
.	O
There	O
is	O
also	O
the	O
hope	O
of	O
remedying	O
the	O
shortage	O
of	O
donors	O
from	O
ethnic	O
and	O
racial	O
backgrounds	O
that	O
are	O
currently	O
underrepresented	O
in	O
most	O
unrelated	O
donor	O
programs	O
.	O
Even	O
with	O
the	O
creation	O
of	O
such	O
banks	O
,	O
it	O
should	O
not	O
be	O
forgotten	O
that	O
the	O
collection	O
of	O
umbilical	O
cord	O
bloods	O
should	O
at	O
least	O
be	O
considered	O
when	O
a	O
child	O
with	O
leukemia	B-malignancy-type
,	O
lymphoma	B-malignancy-type
,	O
neuroblastoma	B-malignancy-type
,	O
marrow	O
failure	O
syndrome	O
,	O
immunodeficiency	O
state	O
,	O
or	O
inborn	O
error	O
of	O
metabolism	O
has	O
a	O
mother	O
who	O
is	O
pregnant	O
.	O
The	O
clinical	O
results	O
to	O
date	O
in	O
small	O
recipients	O
would	O
suggest	O
that	O
it	O
is	O
at	O
least	O
as	O
good	O
as	O
bone	O
marrow	O
;	O
but	O
additional	O
patients	O
and	O
more	O
time	O
will	O
be	O
needed	O
to	O
finalize	O
this	O
conclusion	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
9071504	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
2000	O
Jan	O
6;19(	O
1	O
)	O
:	O
51	O
-60	O
.	O
Erratum	O
in	O
:	O
Oncogene	O
2000	O
Aug	O
10	O
;19(	O
34	O
)	O
:	O
3958	O
.	O
p27Kip1	O
accumulation	O
is	O
associated	O
with	O
retinoic	O
-	O
induced	O
neuroblastoma	B-malignancy-type
differentiation	O
:	O
evidence	O
of	O
a	O
decreased	O
proteasome	O
-	O
dependent	O
degradation	O
.	O
Borriello	O
A	O
,	O
Pietra	O
VD	O
,	O
Criscuolo	O
M,	O
Oliva	O
A	O
,	O
Tonini	O
GP	O
,	O
Iolascon	O
A	O
,	O
Zappia	O
V	O
,	O
Ragione	O
FD.	O
Institute	O
of	O
Biochemistry	O
of	O
Macromolecules	O
,	O
Second	O
University	O
of	O
Naples	O
,	O
via	O
Constantinopoli	O
16	O
,	O
80138	O
Naples	O
,	O
Italy	O
.	O
Development	O
of	O
human	O
neuroblastoma	B-malignancy-type
is	O
due	O
to	O
an	O
arrest	O
in	O
the	O
differentiation	O
program	O
of	O
neural	O
crest	O
sympathoadrenal	O
progenitor	O
cells	O
.	O
However	O
,	O
neuroblastomas	B-malignancy-type
,	O
as	O
well	O
as	O
their	O
derived	O
cell	O
lines	O
,	O
maintain	O
the	O
potentiality	O
of	O
terminal	O
differentiation	O
.	O
We	O
investigated	O
the	O
molecular	O
mechanisms	O
by	O
which	O
retinoic	O
acid	O
,	O
a	O
molecule	O
introduced	O
in	O
clinical	O
trials	O
for	O
chemotherapy	O
,	O
induces	O
differentiation	O
in	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Our	O
findings	O
demonstrate	O
that	O
the	O
retinoic	O
acid	O
-	O
dependent	O
growth	O
arrest	O
of	O
LAN-5	O
neuroblastoma	B-malignancy-type
cell	O
line	O
is	O
associated	O
to	O
a	O
very	O
large	O
accumulation	O
(	O
>	O
tenfold	O
)	O
of	O
p27Kip1	O
protein	O
,	O
a	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
;	O
the	O
protein	O
binds	O
and	O
inhibits	O
cyclin	O
-	O
dependent	O
kinase	O
2	O
,	O
4	O
and	O
6	O
activities	O
,	O
thus	O
hampering	O
pRb	O
and	O
p107	O
phosphorylation	O
.	O
p27Kip1	O
build	O
-	O
up	O
was	O
observable	O
as	O
an	O
early	O
phenomenon	O
(	O
12	O
-	O
24	O
h	O
)	O
after	O
retinoic	O
exposure	O
and	O
resulted	O
in	O
a	O
time	O
-	O
dependent	O
accumulation	O
of	O
high	O
quantities	O
of	O
a	O
free	O
p27Kip1	O
form	O
.	O
Furthermore	O
,	O
retinoic	O
treatment	O
causes	O
an	O
increase	O
of	O
cyclin	O
-	O
dependent	O
kinase	O
5	O
level	O
and	O
activity	O
;	O
however	O
,	O
immunoprecipitation	O
studies	O
proved	O
the	O
absence	O
of	O
interaction	O
with	O
p27kip1	O
.	O
No	O
noticeable	O
variation	O
of	O
other	O
components	O
of	O
G1	O
phase	O
cell	O
cycle	O
engine	O
was	O
observed	O
.	O
Pulse	O
-	O
chase	O
experiments	O
showed	O
a	O
remarkable	O
elongation	O
of	O
p27Kip1	O
half	O
-	O
life	O
in	O
retinoic	O
-	O
treated	O
LAN-5	O
,	O
while	O
no	O
enhancement	O
of	O
p27Kip1	O
gene	O
expression	O
and	O
of	O
the	O
translational	O
efficiency	O
of	O
its	O
messenger	O
RNA	O
were	O
demonstrated	O
.	O
In	O
vivo	O
degradation	O
of	O
p27Kip1	O
was	O
sensitive	O
to	O
two	O
highly	O
specific	O
proteasome	O
inhibitors	O
,	O
LLnL	O
and	O
lactacystin	O
,	O
while	O
the	O
calpain	O
inhibitor	O
II	O
ALLM	O
and	O
the	O
cysteine	O
protease	O
inhibitor	O
E64	O
did	O
not	O
modify	O
the	O
level	O
of	O
the	O
protein	O
.	O
LLnL	O
treatment	O
caused	O
a	O
very	O
rapid	O
(	O
2	O
h	O
)	O
build	O
-	O
up	O
of	O
the	O
Cdk	O
inhibitor	O
content	O
and	O
the	O
accumulation	O
of	O
higher	O
molecular	O
weight	O
anti	O
-	O
p27Kip1	O
immunoreactive	O
bands	O
,	O
which	O
probably	O
represent	O
ubiquitinated	O
forms	O
of	O
the	O
protein	O
.	O
Finally	O
,	O
in	O
vitro	O
experiments	O
demonstrated	O
that	O
extracts	O
prepared	O
from	O
retinoic	O
-	O
treated	O
LAN-5	O
cells	O
degraded	O
recombinant	O
p27Kip1	O
at	O
a	O
rate	O
remarkably	O
slower	O
than	O
the	O
untreated	O
cells	O
.	O
Our	O
results	O
indicate	O
that	O
retinoic	O
acid	O
strongly	O
increases	O
p27Kip1	O
levels	O
by	O
down	O
-	O
regulating	O
the	O
ubiquitin	O
-	O
proteasome	O
p27Kip1	O
degrading	O
pathway	O
.	O
PMID	O
:	O
10644979	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurosci	O
Res	O
.	O
2003	O
Dec	O
1;74	O
(	O
5	O
)	O
:744	O
-53	O
.	O
Differential	O
regulation	O
of	O
polysialyltransferase	O
expression	O
during	O
hippocampus	O
development	O
:	O
Implications	O
for	O
neuronal	O
survival	O
.	O
Brocco	O
M,	O
Pollevick	O
GD	O
,	O
Frasch	O
AC	O
.	O
Instituto	O
de	O
Investigaciones	O
Biotecnologicas-	O
Instituto	O
Tecnologico	O
de	O
Chascomus	O
-Consejo	O
Nacional	O
de	O
Investigaciones	O
Cientificas	O
y	O
Tecnicas	O
,	O
Universidad	O
Nacional	O
de	O
General	O
San	O
Martin	O
,	O
San	O
Martin	O
,	O
Pcia	O
de	O
Buenos	O
Aires	O
,	O
Argentina	O
.	O
Polysialyltransferases	O
ST8SiaII	O
/	O
STX	O
and	O
ST8SiaIV	O
/	O
PST	O
add	O
polysialic	O
acid	O
(	O
PSA	O
)	O
to	O
the	O
neural	O
cell	O
adhesion	O
molecule	O
(	O
NCAM	O
)	O
.	O
Surface	O
-	O
located	O
PSA	O
is	O
involved	O
in	O
cell	O
-	O
cell	O
interactions	O
participating	O
in	O
structural	O
and	O
functional	O
plasticity	O
of	O
neuronal	O
circuits	O
.	O
This	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
polysialyltransferase	O
regulation	O
pattern	O
during	O
hippocampal	O
development	O
.	O
Polysialyltransferase	O
expression	O
levels	O
analyzed	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
indicated	O
that	O
ST8SiaII	O
/	O
STX	O
mRNA	O
is	O
markedly	O
down	O
-	O
regulated	O
in	O
vivo	O
,	O
decreasing	O
abruptly	O
at	O
about	O
the	O
first	O
week	O
of	O
postnatal	O
development	O
.	O
ST8SiaII	O
/	O
STX	O
mRNA	O
is	O
also	O
down	O
-	O
regulated	O
in	O
hippocampal	O
cells	O
in	O
culture	O
,	O
accompanying	O
the	O
morphological	O
differentiation	O
of	O
neuronal	O
interconnectivity	O
.	O
In	O
contrast	O
,	O
ST8SiaIV	O
/	O
PST	O
levels	O
remain	O
comparatively	O
low	O
during	O
hippocampus	O
ontogeny	O
.	O
Immunolabeling	O
of	O
primary	O
hippocampal	O
culture	O
assays	O
demonstrated	O
that	O
PSA	O
expression	O
parallels	O
ST8SiaII	O
/	O
STX	O
mRNA	O
levels	O
.	O
In	O
comparison	O
,	O
polysialyltransferase	O
mRNA	O
levels	O
are	O
not	O
regulated	O
in	O
neuroblastoma	B-malignancy-type
cells	O
during	O
their	O
proliferation	O
.	O
Sequence	O
analysis	O
of	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
of	O
ST8SiaII	O
/	O
STX	O
cDNA	O
indicated	O
putative	O
regulatory	O
motifs	O
.	O
This	O
information	O
and	O
the	O
observed	O
changes	O
in	O
mRNA	O
half	O
-	O
life	O
during	O
development	O
suggest	O
that	O
ST8SiaII	O
/	O
STX	O
might	O
be	O
also	O
regulated	O
at	O
the	O
posttranscriptional	O
level	O
.	O
To	O
understand	O
the	O
reasons	O
for	O
the	O
tight	O
control	O
of	O
ST8SiaII	O
/	O
STX	O
expression	O
during	O
development	O
,	O
we	O
overexpressed	O
the	O
enzyme	O
in	O
hippocampal	O
primary	O
cultures	O
by	O
transfection	O
.	O
Overexpression	O
of	O
ST8SiaII	O
/	O
STX	O
wild	O
type	O
as	O
well	O
as	O
of	O
a	O
mutant	O
lacking	O
enzymatic	O
activity	O
affected	O
neuronal	O
viability	O
,	O
leading	O
to	O
cell	O
death	O
.	O
However	O
,	O
this	O
phenomenon	O
was	O
abolished	O
by	O
a	O
double	O
mutation	O
in	O
the	O
ST8SiaII	O
/	O
STX	O
that	O
prevents	O
formation	O
of	O
its	O
three	O
-	O
dimentional	O
structure	O
.	O
Interestingly	O
,	O
the	O
overexpressed	O
polysialyltransferase	O
accumulates	O
not	O
only	O
in	O
the	O
perinuclear	O
region	O
but	O
also	O
in	O
the	O
plasma	O
membrane	O
.	O
Thus	O
,	O
overexpression	O
of	O
an	O
ST8SiaII	O
/	O
STX	O
that	O
conserves	O
its	O
structure	O
leads	O
to	O
abnormal	O
accumulation	O
of	O
the	O
protein	O
,	O
probably	O
on	O
the	O
neuronal	O
surface	O
,	O
affecting	O
cell	O
viability	O
.	O
This	O
result	O
explains	O
the	O
importance	O
of	O
an	O
accurate	O
regulation	O
of	O
polysialyltransferase	O
expression	O
during	O
development	O
.	O
Copyright	O
2003	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
14635225	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
2000	O
Feb	O
1;60	O
(	O
3	O
)	O
:	O
712-21	O
.	O
Integrins	O
alpha(v)beta3	O
and	O
alpha(v)beta5	O
are	O
expressed	O
by	O
endothelium	O
of	O
high	O
-	O
risk	O
neuroblastoma	B-malignancy-type
and	O
their	O
inhibition	O
is	O
associated	O
with	O
increased	O
endogenous	O
ceramide	O
.	O
Erdreich-Epstein	O
A	O
,	O
Shimada	O
H,	O
Groshen	O
S	O
,	O
Liu	O
M,	O
Metelitsa	O
LS	O
,	O
Kim	O
KS	O
,	O
Stins	O
MF	O
,	O
Seeger	O
RC	O
,	O
Durden	O
DL.	O
Division	O
of	O
Hematology-Oncology	O
,	O
Children	O
's	O
Hospital	O
Los	O
Angeles	O
,	O
University	O
of	O
Southern	O
California	O
School	O
of	O
Medicine	O
,	O
90027	O
,	O
USA	O
.	O
Inhibition	O
of	O
the	O
RGD	O
-	O
binding	O
integrins	O
,	O
alpha(v)beta3	O
and	O
alpha(v)beta5	O
,	O
prevents	O
endothelial	O
cell	O
anchorage	O
and	O
induces	O
endothelial	O
apoptosis	O
,	O
which	O
results	O
in	O
disruption	O
of	O
tumor	O
angiogenesis	O
and	O
inhibition	O
of	O
tumor	O
growth	O
in	O
animal	O
models	O
.	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
by	O
immunohistochemical	O
analysis	O
that	O
integrin	O
alpha(v)beta3	O
was	O
expressed	O
by	O
61	O
%	O
(	O
mean	O
)	O
of	O
microvessels	O
in	O
high	O
-	O
risk	O
neuroblastomas	B-malignancy-type
(	O
stage	O
IV	O
and	O
MYCN	O
-	O
amplified	O
stage	O
III	O
;	O
n	O
=	O
28	O
)	O
but	O
only	O
by	O
18	O
%	O
(	O
mean	O
)	O
of	O
microvessels	O
in	O
low	O
-	O
risk	O
tumors	B-malignancy-type
(	O
stages	O
I	O
and	O
II	O
and	O
non	O
-	O
MYCN	O
-	O
amplified	O
stage	O
III	O
;	O
n	O
=	O
12	O
)	O
.	O
Integrin	O
alpha(v)beta5	O
was	O
found	O
on	O
60	O
%	O
(	O
mean	O
)	O
of	O
microvessels	O
in	O
21	O
Stage	O
IV	O
tumors	B-malignancy-type
.	O
These	O
data	O
suggest	O
that	O
neuroblastomas	B-malignancy-type
may	O
be	O
targeted	O
for	O
antiangiogenic	O
treatment	O
directed	O
against	O
endothelial	O
integrins	O
alpha(v)beta3	O
and	O
alpha(v)beta5	O
.	O
In	O
cell	O
culture	O
,	O
inhibition	O
of	O
integrin	O
-	O
dependent	O
endothelial	O
cell	O
anchorage	O
to	O
vitronectin	O
by	O
RGDfV	O
,	O
an	O
RGD	O
function	O
-	O
blocking	O
cyclic	O
peptide	O
,	O
induced	O
apoptosis	O
in	O
bovine	O
brain	O
endothelial	O
cells	O
compared	O
with	O
the	O
control	O
peptide	O
,	O
RADfV	O
(	O
37.5	O
%	O
versus	O
8.7	O
%	O
,	O
respectively	O
)	O
,	O
as	O
detected	O
by	O
chromatin	O
condensation	O
and	O
nuclear	O
fragmentation	O
.	O
Treatment	O
with	O
RGDfV	O
but	O
not	O
with	O
RADfV	O
,	O
which	O
prevented	O
attachment	O
of	O
endothelial	O
cells	O
to	O
vitronectin	O
or	O
fibronectin	O
,	O
was	O
associated	O
with	O
up	O
to	O
a	O
50	O
%	O
increase	O
in	O
endogenous	O
ceramide	O
,	O
a	O
lipid	O
second	O
messenger	O
that	O
can	O
mediate	O
cell	O
death	O
.	O
Furthermore	O
,	O
exogenous	O
C2	O
-	O
ceramide	O
was	O
cytotoxic	O
to	O
bovine	O
brain	O
endothelial	O
cells	O
and	O
induced	O
activation	O
of	O
C-jun	O
N-terminal	O
kinase	O
(	O
JNK	O
)	O
,	O
a	O
MAP	O
kinase	O
that	O
can	O
be	O
activated	O
in	O
stress	O
-	O
induced	O
apoptosis	O
pathways	O
.	O
This	O
suggests	O
that	O
ceramide	O
may	O
function	O
in	O
detachment	O
-	O
induced	O
endothelial	O
cell	O
apoptosis	O
,	O
originating	O
from	O
inhibition	O
of	O
vitronectin	O
binding	O
to	O
integrins	O
such	O
as	O
alpha(v)beta3	O
and	O
alpha(v)beta5	O
.	O
This	O
is	O
the	O
first	O
report	O
to	O
demonstrate	O
expression	O
of	O
integrins	O
alpha(v)beta3	O
and	O
alpha(v)beta5	O
by	O
microvascular	O
endothelium	O
of	O
a	O
childhood	O
tumor	B-malignancy-type
and	O
association	O
of	O
their	O
expression	O
with	O
neuroblastoma	B-malignancy-type
aggressiveness	O
.	O
Furthermore	O
,	O
our	O
data	O
provide	O
the	O
first	O
suggestion	O
that	O
inhibition	O
of	O
endothelial	O
cell	O
anchorage	O
,	O
resulting	O
from	O
specific	O
blockade	O
of	O
RGD	O
-	O
binding	O
integrins	O
,	O
increases	O
endogenous	O
ceramide	O
,	O
which	O
may	O
contribute	O
to	O
endothelial	O
cell	O
death	O
.	O
PMID	O
:	O
10676658	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2000	O
Aug	O
4;275	O
(	O
31	O
)	O
:24013-	O
21	O
.	O
Cytoplasmic	O
,	O
nuclear	O
,	O
and	O
golgi	O
localization	O
of	O
RGS	O
proteins	O
.	O
Evidence	O
for	O
N-terminal	O
and	O
RGS	O
domain	O
sequences	O
as	O
intracellular	O
targeting	O
motifs	O
.	O
Chatterjee	O
TK	O
,	O
Fisher	O
RA.	O
Department	O
of	O
Pharmacology	O
,	O
University	O
of	O
Iowa	O
College	O
of	O
Medicine	O
,	O
Iowa	O
City	O
,	O
Iowa	O
52242	O
,	O
USA	O
.	O
RGS	O
proteins	O
comprise	O
a	O
family	O
of	O
proteins	O
named	O
for	O
their	O
ability	O
to	O
negatively	O
regulate	O
heterotrimeric	O
G	O
protein	O
signaling	O
.	O
Biochemical	O
studies	O
suggest	O
that	O
members	O
of	O
this	O
protein	O
family	O
act	O
as	O
GTPase	O
-	O
activating	O
proteins	O
for	O
certain	O
Galpha	O
subunits	O
,	O
thereby	O
accelerating	O
the	O
turn	O
-	O
off	O
mechanism	O
of	O
Galpha	O
and	O
terminating	O
signaling	O
by	O
both	O
Galpha	O
and	O
Gbetagamma	O
subunits	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
used	O
confocal	O
microscopy	O
to	O
examine	O
the	O
intracellular	O
distribution	O
of	O
several	O
RGS	O
proteins	O
in	O
COS-7	O
cells	O
expressing	O
RGS	O
-	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
fusion	O
proteins	O
and	O
in	O
cells	O
expressing	O
RGS	O
proteins	O
endogenously	O
.	O
RGS2	O
and	O
RGS10	O
accumulated	O
in	O
the	O
nucleus	O
of	O
COS-7	O
cells	O
transfected	O
with	O
GFP	O
constructs	O
of	O
these	O
proteins	O
.	O
In	O
contrast	O
,	O
RGS4	O
and	O
RGS16	O
accumulated	O
in	O
the	O
cytoplasm	O
of	O
COS-7	O
transfectants	O
.	O
As	O
observed	O
in	O
COS-7	O
cells	O
,	O
RGS4	O
exhibited	O
cytoplasmic	O
localization	O
in	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
,	O
and	O
RGS10	O
exhibited	O
nuclear	O
localization	O
in	O
human	O
glioma	B-malignancy-type
cells	O
.	O
Deletion	O
or	O
alanine	O
substitution	O
of	O
an	O
N-terminal	O
leucine	O
repeat	O
motif	O
present	O
in	O
both	O
RGS4	O
and	O
RGS16	O
,	O
a	O
domain	O
identified	O
as	O
a	O
nuclear	O
export	O
sequence	O
in	O
HIV	O
Rev	O
and	O
other	O
proteins	O
,	O
promoted	O
nuclear	O
localization	O
of	O
these	O
proteins	O
in	O
COS-7	O
cells	O
.	O
In	O
agreement	O
with	O
this	O
observation	O
,	O
treatment	O
of	O
mouse	O
neuroblastoma	B-malignancy-type
cells	O
with	O
leptomycin	O
B	O
to	O
inhibit	O
nuclear	O
protein	O
export	O
by	O
exportin1	O
resulted	O
in	O
accumulation	O
of	O
RGS4	O
in	O
the	O
nucleus	O
of	O
these	O
cells	O
.	O
GFP	O
fusions	O
of	O
RGS	O
domains	O
of	O
RGS	O
proteins	O
localized	O
in	O
the	O
nucleus	O
,	O
suggesting	O
that	O
nuclear	O
localization	O
of	O
RGS	O
proteins	O
results	O
from	O
nuclear	O
targeting	O
via	O
RGS	O
domain	O
sequences	O
.	O
RGSZ	O
,	O
which	O
shares	O
with	O
RGS	O
-	O
GAIP	O
a	O
cysteine	O
-	O
rich	O
string	O
in	O
its	O
N-terminal	O
region	O
,	O
localized	O
to	O
the	O
Golgi	O
complex	O
in	O
COS-7	O
cells	O
.	O
Deletion	O
of	O
the	O
N-terminal	O
domain	O
of	O
RGSZ	O
that	O
includes	O
the	O
cysteine	O
motif	O
promoted	O
nuclear	O
localization	O
of	O
RGSZ	O
.	O
None	O
of	O
the	O
RGS	O
proteins	O
examined	O
were	O
localized	O
at	O
the	O
plasma	O
membrane	O
.	O
These	O
results	O
demonstrate	O
that	O
RGS	O
proteins	O
localize	O
in	O
the	O
nucleus	O
,	O
the	O
cytoplasm	O
,	O
or	O
shuttle	O
between	O
the	O
nucleus	O
and	O
cytoplasm	O
as	O
nucleo	O
-	O
cytoplasmic	O
shuttle	O
proteins	O
.	O
RGS	O
proteins	O
localize	O
differentially	O
within	O
cells	O
as	O
a	O
result	O
of	O
structural	O
differences	O
among	O
these	O
proteins	O
that	O
do	O
not	O
appear	O
to	O
be	O
important	O
determinants	O
for	O
their	O
G	O
protein	O
-	O
regulating	O
activities	O
.	O
These	O
findings	O
suggest	O
involvement	O
of	O
RGS	O
proteins	O
in	O
more	O
complex	O
cellular	O
functions	O
than	O
currently	O
envisioned	O
.	O
PMID	O
:	O
10791963	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
.	O
1994	O
Sep;70	O
(	O
3	O
)	O
:	O
440	O
-4.	O
Differential	O
nm23	O
gene	O
expression	O
at	O
the	O
fetal	O
-	O
maternal	O
interface	O
.	O
Shi	O
Y	O
,	O
Parhar	O
RS	O
,	O
Zou	O
M,	O
al-Sedairy	O
S	O
,	O
Farid	O
NR.	O
Molecular	O
Endocrinology	O
Laboratory	O
,	O
King	O
Faisal	O
Specialist	O
Hospital	O
and	O
Research	O
Centre	O
,	O
Riyadh	O
,	O
Kingdom	O
of	O
Saudi	O
Arabia	O
.	O
The	O
product	O
of	O
the	O
nm23	O
gene	O
has	O
been	O
proposed	O
as	O
a	O
candidate	O
tumour	O
metastasis	O
suppressor	O
protein	O
.	O
A	O
strong	O
association	O
has	O
been	O
observed	O
between	O
reduced	O
expression	O
of	O
the	O
nm23	O
gene	O
and	O
acquisition	O
of	O
metastatic	O
behaviour	O
in	O
some	O
tumour	O
cells	O
,	O
including	O
breast	B-malignancy-type
cancer	I-malignancy-type
and	O
melanoma	B-malignancy-type
,	O
but	O
not	O
in	O
others	O
,	O
such	O
as	O
neuroblastoma	B-malignancy-type
and	O
colon	B-malignancy-type
,	O
cervical	B-malignancy-type
and	O
thyroid	B-malignancy-type
cancers	I-malignancy-type
.	O
During	O
the	O
early	O
gestation	O
period	O
both	O
human	O
and	O
murine	O
trophoblast	O
cells	O
exhibit	O
in	O
vitro	O
invasive	O
properties	O
similar	O
to	O
those	O
of	O
neoplastic	B-malignancy-type
cells	O
.	O
Such	O
invasive	O
properties	O
,	O
however	O
,	O
disappear	O
in	O
the	O
late	O
stage	O
of	O
gestation	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
abundance	O
of	O
nm23	O
mRNA	O
from	O
various	O
fetal	O
-	O
maternal	O
interface	O
tissues	O
(	O
uterus	O
,	O
decidua	O
,	O
placenta	O
and	O
embryo	O
)	O
during	O
early	O
(	O
day	O
8	O
)	O
,	O
mid	O
(	O
day	O
14	O
)	O
and	O
late	O
(	O
day	O
18	O
)	O
stages	O
of	O
gestation	O
in	O
CD1	O
mice	O
,	O
in	O
order	O
to	O
determine	O
whether	O
nm23	O
plays	O
any	O
anti	O
-	O
invasive	O
and/or	O
biological	O
roles	O
during	O
gestation	O
.	O
nm23	O
was	O
found	O
to	O
be	O
expressed	O
in	O
all	O
the	O
tissues	O
during	O
the	O
early	O
and	O
mid	O
stages	O
of	O
gestation	O
.	O
The	O
expression	O
levels	O
were	O
,	O
however	O
,	O
variable	O
among	O
different	O
tissues	O
and	O
development	O
stages	O
.	O
In	O
the	O
early	O
stage	O
,	O
nm23	O
mRNA	O
levels	O
were	O
the	O
highest	O
and	O
similar	O
among	O
tissues	O
from	O
the	O
uterus	O
,	O
decidua	O
,	O
placenta	O
and	O
embryo	O
.	O
In	O
the	O
mid	O
stage	O
,	O
the	O
mRNA	O
levels	O
were	O
reduced	O
significantly	O
in	O
the	O
uterus	O
,	O
decidua	O
and	O
placenta	O
,	O
but	O
not	O
in	O
the	O
embryo	O
.	O
In	O
the	O
late	O
stage	O
,	O
nm23	O
mRNA	O
was	O
further	O
reduced	O
to	O
the	O
extent	O
that	O
it	O
could	O
not	O
be	O
seen	O
in	O
the	O
decidua	O
,	O
was	O
barely	O
seen	O
in	O
the	O
uterus	O
and	O
was	O
weakly	O
present	O
in	O
the	O
placenta	O
.	O
However	O
,	O
the	O
mRNA	O
level	O
of	O
the	O
embryo	O
in	O
the	O
late	O
stage	O
was	O
still	O
high	O
and	O
similar	O
to	O
the	O
early	O
stage	O
.	O
We	O
also	O
examined	O
nm23	O
expression	O
in	O
trophoblast	O
cells	O
from	O
normal	O
human	O
term	O
placenta	O
and	O
a	O
highly	O
metastatic	O
human	O
choriocarcinoma	B-malignancy-type
cell	O
line	O
,	O
JAR	O
.	O
nm23	O
expression	O
was	O
significantly	O
higher	O
in	O
JAR	O
than	O
in	O
normal	O
placenta	O
,	O
indicating	O
that	O
nm23	O
does	O
not	O
appear	O
to	O
have	O
an	O
anti	O
-	O
metastatic	O
function	O
in	O
this	O
cell	O
line	O
.	O
Several	O
cytokines	O
--	O
interleukin	O
2	O
(	O
IL-2	O
)	O
,	O
tumour	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
and	O
interferon	O
gamma	O
(	O
IFN-gamma	O
)	O
--	O
and	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
known	O
to	O
modulate	O
tumour	O
growth	O
and	O
metastasis	O
were	O
examined	O
to	O
determine	O
whether	O
they	O
regulate	O
nm23	O
expression	O
in	O
JAR	O
in	O
vitro	O
.	O
The	O
B16F10	O
melanoma	B-malignancy-type
cell	O
line	O
was	O
used	O
as	O
control	O
.	O
No	O
effect	O
was	O
found	O
in	O
the	O
JAR	O
cell	O
line	O
,	O
whereas	O
TNF-alpha	O
,	O
IFN-gamma	O
and	O
PGE2	O
down	O
-	O
regulated	O
nm23	O
expression	O
in	O
the	O
B16F10	O
cell	O
line	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
PMID	O
:	O
8080727	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
1993	O
Oct	O
15	O
;53(	O
20	O
)	O
:	O
4978	O
-86	O
.	O
Regulation	O
of	O
Bcl-2	O
oncoprotein	O
levels	O
with	O
differentiation	O
of	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Hanada	O
M,	O
Krajewski	O
S	O
,	O
Tanaka	O
S	O
,	O
Cazals-Hatem	O
D	O
,	O
Spengler	O
BA	O
,	O
Ross	O
RA	O
,	O
Biedler	O
JL	O
,	O
Reed	O
JC	O
.	O
La	O
Jolla	O
Cancer	O
Research	O
Foundation	O
,	O
Cancer	O
Research	O
Center	O
,	O
California	O
92037	O
.	O
When	O
established	O
in	O
culture	O
,	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
typically	O
are	O
comprised	O
of	O
heterogeneous	O
cellular	O
subpopulations	O
,	O
including	O
neuroblastic	O
(	O
N-type	O
)	O
,	O
substrate	O
-	O
adherent	O
(	O
S-type	O
)	O
,	O
and	O
intermediate	O
(	O
I-type	O
)	O
cells	O
that	O
can	O
be	O
distinguished	O
by	O
their	O
characteristic	O
morphologies	O
and	O
expression	O
of	O
differentiation	O
-	O
associated	O
antigens	O
.	O
Here	O
we	O
examined	O
the	O
relative	O
levels	O
of	O
the	O
Bcl-2	O
oncoprotein	O
in	O
15	O
clones	O
derived	O
from	O
four	O
different	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
.	O
Among	O
six	O
clones	O
isolated	O
from	O
the	O
SK-N-SH	O
line	O
,	O
levels	O
of	O
p26-Bcl-2	O
correlated	O
with	O
morphology	O
and	O
differentiation	O
markers	O
with	O
the	O
hierarchy	O
of	O
bcl-2	O
expression	O
being	O
:	O
N-type	O
cells	O
>	O
N	O
/	O
I	O
-	O
type	O
>	O
I-type	O
>	O
S-type	O
.	O
Furthermore	O
,	O
stimulation	O
of	O
one	O
of	O
the	O
N-type	O
clones	O
,	O
SH-SY5Y	O
,	O
with	O
the	O
phorbol	O
ester	O
,	O
12-O-tetradecanoylphorbol-13-acetate	O
,	O
induced	O
differentiation	O
toward	O
a	O
more	O
neuronal	O
-	O
like	O
phenotype	O
and	O
resulted	O
in	O
a	O
5	O
-	O
to	O
10	O
-	O
fold	O
elevation	O
in	O
the	O
relative	O
levels	O
of	O
Bcl-2	O
protein	O
.	O
High	O
relative	O
amounts	O
of	O
p26-Bcl-2	O
protein	O
were	O
also	O
found	O
in	O
an	O
N-type	O
clone	O
derived	O
from	O
the	O
SMS-KCN	O
line	O
.	O
In	O
two	O
N-type	O
clones	O
derived	O
from	O
the	O
LA-N-1	O
line	O
,	O
however	O
,	O
levels	O
of	O
Bcl-2	O
protein	O
were	O
only	O
moderately	O
elevated	O
,	O
and	O
in	O
one	O
N-type	O
clone	O
from	O
the	O
SK-N-BE(2)	O
line	O
the	O
levels	O
of	O
Bcl-2	O
protein	O
were	O
low	O
.	O
Thus	O
,	O
high	O
relative	O
levels	O
of	O
Bcl-2	O
oncoprotein	O
are	O
not	O
a	O
universal	O
feature	O
of	O
N-type	O
cells	O
(	O
three	O
of	O
six	O
clones	O
tested	O
)	O
.	O
In	O
contrast	O
,	O
all	O
5	O
of	O
the	O
S-type	O
clones	O
evaluated	O
contained	O
relatively	O
low	O
levels	O
of	O
Bcl-2	O
protein	O
,	O
suggesting	O
that	O
these	O
cells	O
(	O
which	O
may	O
represent	O
embryonic	O
precursors	O
of	O
Schwann	O
,	O
glial	O
,	O
and	O
melanocytic	O
cells	O
)	O
do	O
not	O
typically	O
express	O
the	O
bcl-2	O
gene	O
at	O
high	O
levels	O
.	O
Consistent	O
with	O
this	O
inverse	O
correlation	O
between	O
Bcl-2	O
protein	O
levels	O
and	O
S-type	O
characteristics	O
,	O
stimulation	O
of	O
an	O
I-type	O
clone	O
derived	O
from	O
the	O
SK-N-BE(2)	O
line	O
with	O
5-bromodeoxyuridine	O
was	O
accompanied	O
by	O
an	O
accumulation	O
of	O
S-type	O
cells	O
in	O
these	O
cultures	O
,	O
decreased	O
Bcl-2	O
protein	O
,	O
diminutions	O
in	O
the	O
neuronal	O
markers	O
neurofilament-M	O
and	O
neuron	O
-	O
specific	O
enolase	O
,	O
and	O
an	O
increase	O
in	O
the	O
relative	O
levels	O
of	O
the	O
S-type	O
marker	O
proteins	O
vimentin	O
and	O
beta-2-microglobulin	O
.	O
Conversely	O
,	O
stimulation	O
of	O
this	O
I-type	O
clone	O
with	O
retinoic	O
acid	O
resulted	O
in	O
an	O
accumulation	O
of	O
N-type	O
cells	O
(	O
which	O
are	O
thought	O
to	O
represent	O
embryonic	O
precursors	O
of	O
sympathetic	O
neurons	O
)	O
,	O
decreased	O
vimentin	O
and	O
beta-2-microglobulin	O
,	O
increased	O
neurofilament-M	O
,	O
and	O
a	O
marked	O
elevation	O
in	O
p26-Bcl-2	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
PMID	O
:	O
8402688	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pediatr	O
Surg	O
.	O
2000	O
Jan;35	O
(	O
1	O
)	O
:	O
88	O
-91	O
.	O
Features	O
and	O
outcome	O
of	O
neuroblastoma	B-malignancy-type
detected	O
before	O
birth	O
.	O
Granata	O
C	O
,	O
Fagnani	O
AM	O
,	O
Gambini	O
C	O
,	O
Boglino	O
C	O
,	O
Bagnulo	O
S	O
,	O
Cecchetto	O
G	O
,	O
Federici	O
S	O
,	O
Inserra	O
A	O
,	O
Michelazzi	O
A	O
,	O
Riccipetitoni	O
G	O
,	O
Rizzo	O
A	O
,	O
Tamaro	O
P,	O
Jasonni	O
V	O
,	O
De	O
Bernardi	O
B.	O
Paediatric	O
Surgery	O
Department	O
at	O
G.	O
Gaslini	O
Hospital	O
,	O
Genova	O
,	O
Italy	O
.	O
BACKGROUND	O
/	O
PURPOSE	O
:	O
The	O
growing	O
use	O
of	O
routine	O
ultrasonography	O
during	O
pregnancy	O
is	O
leading	O
to	O
an	O
increasing	O
number	O
of	O
prenatally	O
diagnosed	O
neuroblastomas	B-malignancy-type
.	O
Optimal	O
strategy	O
has	O
not	O
yet	O
been	O
defined	O
for	O
these	O
patients	O
,	O
because	O
knowledge	O
on	O
this	O
particular	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
population	O
is	O
still	O
limited	O
.	O
However	O
,	O
definite	O
guidelines	O
are	O
needed	O
to	O
avoid	O
inadequate	O
treatment	O
.	O
The	O
authors	O
analyzed	O
the	O
cases	O
of	O
antenatally	O
detected	O
NB	B-malignancy-type
(	O
ADNB	B-malignancy-type
)	O
reported	O
in	O
the	O
Italian	O
Neuroblastoma	B-malignancy-type
Registry	O
during	O
the	O
past	O
6	O
years	O
to	O
elucidate	O
the	O
features	O
of	O
this	O
subset	O
of	O
NB	B-malignancy-type
.	O
METHODS	O
:	O
The	O
Italian	O
Neuroblastoma	B-malignancy-type
Registry	O
was	O
reviewed	O
for	O
the	O
period	O
January	O
1993	O
to	O
December	O
1998	O
to	O
collect	O
clinical	O
,	O
radiographic	O
,	O
surgical	O
,	O
and	O
histopathological	O
data	O
on	O
ADNB	B-malignancy-type
cases	O
.	O
NB	B-malignancy-type
stage	O
was	O
evaluated	O
according	O
to	O
INSS	O
criteria	O
.	O
All	O
patients	O
had	O
undergone	O
imaging	O
(	O
computed	O
tomography	O
or	O
magnetic	O
resonance	O
imaging	O
)	O
of	O
the	O
primary	O
tumor	B-malignancy-type
and	O
bone	O
marrow	O
biopsy	O
before	O
surgical	O
resection	O
.	O
RESULTS	O
:	O
Seventeen	O
patients	O
were	O
identified	O
.	O
Primary	O
tumour	B-malignancy-type
site	O
was	O
adrenal	B-malignancy-type
glands	I-malignancy-type
in	O
16	O
cases	O
and	O
retroperitoneal	B-malignancy-type
ganglia	I-malignancy-type
in	O
1	O
.	O
Stage	O
distribution	O
was	O
stage	O
I	O
,	O
13	O
cases	O
;	O
stage	O
II-A	O
,	O
1	O
case	O
;	O
stage	O
II-B	O
,	O
1	O
case	O
;	O
stage	O
IV-S	O
,	O
2	O
cases	O
.	O
All	O
cases	O
underwent	O
primary	O
tumour	B-malignancy-type
resection	O
.	O
Mean	O
age	O
at	O
surgery	O
was	O
4	O
weeks	O
.	O
Resection	O
of	O
primary	O
tumor	B-malignancy-type
was	O
radical	O
in	O
16	O
cases	O
,	O
partial	O
in	O
1	O
.	O
All	O
tumors	B-malignancy-type
were	O
characterised	O
by	O
favourable	O
histology	O
according	O
to	O
Shimada	O
classification	O
.	O
N-myc	O
gene	O
amplification	O
was	O
studied	O
in	O
14	O
patients	O
.	O
N-myc	O
amplification	O
was	O
detected	O
only	O
in	O
a	O
newborn	O
with	O
stage	O
II-A	O
NB	O
,	O
who	O
died	O
of	O
massive	O
bleeding	O
2	O
days	O
after	O
tumor	B-malignancy-type
resection	O
.	O
DNA	O
index	O
and	O
1p	O
deletion	O
were	O
studied	O
in	O
11	O
and	O
8	O
patients	O
,	O
respectively	O
.	O
Both	O
diploidy	O
and	O
deletion	O
of	O
1p	O
were	O
observed	O
in	O
a	O
newborn	O
who	O
subsequently	O
died	O
of	O
disease	O
progression	O
despite	O
surgery	O
,	O
chemotherapy	O
,	O
and	O
radiation	O
therapy	O
.	O
Fourteen	O
of	O
17	O
patients	O
currently	O
are	O
alive	O
and	O
free	O
of	O
disease	O
,	O
and	O
one	O
with	O
IV-S	O
NB	O
and	O
short	O
follow	O
-	O
up	O
is	O
alive	O
with	O
disease	O
.	O
CONCLUSIONS	O
:	O
Our	O
data	O
give	O
evidence	O
that	O
in	O
most	O
cases	O
infants	O
with	O
ADNB	B-malignancy-type
represent	O
a	O
subset	O
of	O
patients	O
with	O
excellent	O
outcome	O
.	O
Aggressive	O
treatment	O
may	O
not	O
always	O
be	O
necessary	O
.	O
Infants	O
with	O
ADNB	B-malignancy-type
with	O
unfavorable	O
features	O
should	O
undergo	O
early	O
surgical	O
excision	O
,	O
whereas	O
patients	O
with	O
favourable	O
features	O
could	O
be	O
observed	O
awaiting	O
spontaneous	O
regression	O
of	O
the	O
mass	B-malignancy-type
,	O
reserving	O
delayed	O
surgery	O
for	O
tumors	B-malignancy-type
that	O
increase	O
in	O
size	O
or	O
do	O
not	O
regress	O
.	O
PMID	O
:	O
10646781	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Natl	O
Cancer	O
Inst	O
.	O
2004	O
Jan	O
7;96	O
(	O
1	O
)	O
:46-55	O
.	O
Effect	O
of	O
imatinib	O
mesylate	O
on	O
neuroblastoma	B-malignancy-type
tumorigenesis	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
expression	O
.	O
Beppu	O
K,	O
Jaboine	O
J,	O
Merchant	O
MS	O
,	O
Mackall	O
CL	O
,	O
Thiele	O
CJ.	O
Pediatric	O
Oncology	O
Branch	O
,	O
Center	O
for	O
Cancer	O
Research	O
,	O
National	O
Cancer	O
Institute	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
MD	O
20892	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
Alternative	O
treatment	O
options	O
are	O
needed	O
for	O
advanced	O
neuroblastoma	B-malignancy-type
patients	O
because	O
their	O
prognosis	O
remains	O
poor	O
after	O
intensive	O
chemotherapy	O
.	O
Neuroblastoma	B-malignancy-type
cells	O
express	O
platelet	O
-	O
derived	O
growth	O
factor	O
(	O
PDGF	O
)	O
,	O
stem	O
cell	O
factor	O
(	O
SCF	O
)	O
,	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
their	O
respective	O
receptors	O
,	O
PDGFR	O
,	O
c-Kit	O
,	O
and	O
Flk-1	O
.	O
We	O
therefore	O
evaluated	O
the	O
effects	O
of	O
imatinib	O
mesylate	O
(	O
imatinib	O
)	O
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
tyrosine	O
kinase	O
activities	O
of	O
c-Kit	O
and	O
PDGFR	O
,	O
on	O
the	O
growth	O
of	O
neuroblastoma	B-malignancy-type
cells	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
METHODS	O
:	O
We	O
tested	O
seven	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
for	O
their	O
sensitivity	O
to	O
imatinib	O
.	O
Cell	O
viability	O
was	O
assessed	O
by	O
trypan	O
blue	O
dye	O
exclusion	O
.	O
Apoptosis	O
was	O
evaluated	O
by	O
nuclear	O
staining	O
,	O
flow	O
cytometry	O
,	O
and	O
western	O
blotting	O
.	O
Protein	O
assays	O
included	O
immunoprecipitation	O
,	O
western	O
blotting	O
,	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
,	O
and	O
immunohistochemistry	O
.	O
mRNA	O
expression	O
was	O
assessed	O
by	O
northern	O
blotting	O
.	O
We	O
used	O
a	O
xenograft	O
model	O
in	O
SCID	O
mice	O
(	O
10	O
mice	O
per	O
group	O
)	O
to	O
evaluate	O
the	O
effects	O
of	O
imatinib	O
oral	O
therapy	O
(	O
50	O
or	O
100	O
mg	O
/	O
kg	O
every	O
12	O
hours	O
for	O
14	O
days	O
)	O
on	O
neuroblastoma	B-malignancy-type
tumor	O
growth	O
.	O
All	O
statistical	O
tests	O
were	O
two	O
-	O
sided	O
.	O
RESULTS	O
:	O
All	O
seven	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
treated	O
with	O
imatinib	O
displayed	O
concentration	O
-	O
dependent	O
decreases	O
in	O
cell	O
viability	O
,	O
which	O
coincided	O
with	O
an	O
induction	O
of	O
apoptosis	O
,	O
and	O
with	O
ligand	O
-	O
stimulated	O
phosphorylation	O
of	O
c-Kit	O
and	O
PDGFR	O
.	O
The	O
imatinib	O
concentrations	O
that	O
caused	O
50	O
%	O
inhibition	O
of	O
growth	O
and	O
50	O
%	O
inhibition	O
of	O
ligand	O
-	O
induced	O
phosphorylation	O
of	O
these	O
receptors	O
were	O
9	O
-	O
13	O
micro	O
M	O
and	O
0.1	O
-	O
0.5	O
microM	O
,	O
respectively	O
.	O
Expression	O
of	O
VEGF	O
,	O
but	O
not	O
phosphorylation	O
of	O
Flk-1	O
,	O
its	O
receptor	O
,	O
was	O
reduced	O
in	O
neuroblastoma	B-malignancy-type
cells	O
treated	O
with	O
imatinib	O
at	O
10	O
microM	O
or	O
higher	O
.	O
Mice	O
treated	O
with	O
imatinib	O
at	O
50	O
mg	O
/	O
kg	O
or	O
100	O
mg	O
/	O
kg	O
had	O
statistically	O
significantly	O
smaller	O
tumors	B-malignancy-type
than	O
control	O
mice	O
treated	O
with	O
vehicle	O
(	O
mean	O
tumor	B-malignancy-type
volume	O
in	O
mice	O
treated	O
with	O
imatinib	O
at	O
50	O
mg	O
/	O
kg	O
=	O
1546	O
mm3	O
,	O
in	O
control	O
mice	O
=	O
2954	O
mm3	O
;	O
difference	O
=	O
1408	O
mm3	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
657	O
to	O
2159	O
mm3	O
;	O
P	O
<	O
.001	O
;	O
mean	O
tumor	B-malignancy-type
volume	O
in	O
mice	O
treated	O
with	O
imatinib	O
at	O
100	O
mg	O
/	O
kg	O
=	O
463	O
mm3	O
;	O
difference	O
=	O
2491	O
mm3	O
,	O
95	O
%	O
CI	O
=	O
1740	O
to	O
3242	O
mm3	O
;	O
P	O
<	O
.001	O
)	O
.	O
CONCLUSIONS	O
:	O
Imatinib	O
inhibited	O
the	O
growth	O
of	O
neuroblastoma	B-malignancy-type
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
This	O
inhibition	O
was	O
associated	O
with	O
suppression	O
of	O
PDGFR	O
and	O
c-Kit	O
phosphorylation	O
and	O
inhibition	O
of	O
VEGF	O
expression	O
.	O
PMID	O
:	O
14709738	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Verh	O
K	O
Acad	O
Geneeskd	O
Belg	O
.	O
2003	O
;6	O
5	O
(	O
1	O
)	O
:	O
5-23	O
;	O
discussion	O
23	O
-	O
8.	O
[	O
The	O
neuroblastoma	B-malignancy-type
,	O
"	O
enfant	O
terrible	O
"	O
among	O
pediatric	O
tumors	O
]	O
[	O
Article	O
in	O
Dutch	O
]	O
Laureys	O
G.	O
Afdeling	O
pediatrische	O
hematologie	O
/	O
oncologie	O
Kliniek	O
voor	O
Kinderziekten	O
C.	O
Hooft-UZ	O
RUG	O
De	O
Pintelaan	O
185	O
,	O
B	O
-	O
9000	O
Gent	O
.	O
Neuroblastoma	B-malignancy-type
belongs	O
to	O
the	O
group	O
of	O
small	B-malignancy-type
blue	I-malignancy-type
round	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
and	O
originates	O
in	O
precursor	O
cells	O
of	O
the	O
sympathetic	O
neural	O
tissue	O
.	O
This	O
tumor	O
occurs	O
at	O
the	O
pediatric	O
age	O
and	O
has	O
fascinated	O
and	O
intrigued	O
both	O
clinicians	O
and	O
researchers	O
because	O
of	O
its	O
variable	O
and	O
often	O
unpredictable	O
clinical	O
behaviour	O
.	O
Indeed	O
,	O
the	O
clinical	O
outcome	O
of	O
neuroblastoma	B-malignancy-type
patients	O
not	O
only	O
depends	O
on	O
the	O
clinical	O
extension	O
of	O
the	O
disease	O
,	O
but	O
also	O
on	O
other	O
factors	O
including	O
age	O
at	O
diagnosis	O
,	O
presence	O
or	O
absence	O
in	O
the	O
tumor	O
cells	O
of	O
molecular	O
and	O
biological	O
characteristics	O
with	O
prognostic	O
value	O
(	O
e.g.	O
amplification	O
of	O
the	O
oncogene	O
MYCN	O
,	O
frequently	O
associated	O
with	O
chromosome	O
1p	O
-	O
deletion	O
is	O
predictive	O
for	O
poor	O
survival	O
chance	O
)	O
.	O
In	O
1983	O
an	O
abdominal	B-malignancy-type
stage	I-malignancy-type
3	I-malignancy-type
neuroblastoma	I-malignancy-type
was	O
diagnosed	O
in	O
a	O
9	O
-	O
months	O
old	O
boy	O
.	O
He	O
died	O
of	O
the	O
disease	O
3	O
years	O
later	O
.	O
Karyotyping	O
studies	O
in	O
this	O
patient	O
revealed	O
a	O
constitutional	O
chromosome	O
translocation	O
t	O
(	O
1	O
;	O
17	O
)	O
with	O
a	O
breakpoint	O
involving	O
the	O
terminal	O
part	O
of	O
the	O
chromosome	O
1p	O
arm	O
.	O
We	O
hypothesized	O
that	O
this	O
patient	O
was	O
predisposed	O
to	O
the	O
development	O
of	O
neuroblastoma	B-malignancy-type
because	O
he	O
carried	O
in	O
all	O
his	O
somatic	O
cells	O
a	O
chromosomal	O
abnormality	O
involving	O
the	O
region	O
frequently	O
deleted	O
in	O
neuroblastoma	B-malignancy-type
tumor	O
cells	O
.	O
We	O
assumed	O
that	O
the	O
chromosomal	O
translocation	O
breakpoints	O
might	O
indicate	O
the	O
regions	O
harbouring	O
genes	O
involved	O
in	O
neuroblastoma	B-malignancy-type
development	O
.	O
A	O
somatic	O
cell	O
fusion	O
experiment	O
was	O
performed	O
between	O
the	O
patient	O
's	O
fibroblasts	O
(	O
the	O
only	O
remaining	O
source	O
of	O
patient	O
material	O
)	O
and	O
a	O
fast	O
growing	O
Chinese	O
hamster	O
ovary	O
cell	O
line	O
to	O
assure	O
the	O
possibilities	O
to	O
perform	O
further	O
research	O
.	O
These	O
somatic	O
cell	O
hybrids	O
indeed	O
contained	O
the	O
human	O
translocation	O
chromosomes	O
.	O
Further	O
characterization	O
of	O
the	O
translocation	O
breakpoints	O
by	O
FISH	O
(	O
fluorescent	O
in	O
situ	O
hybridisation	O
)	O
resulted	O
in	O
the	O
identification	O
of	O
NPPA	O
(	O
formerly	O
PND	O
,	O
the	O
gene	O
for	O
pronatriodilatine	O
)	O
and	O
A12M2	O
(	O
an	O
adenovirus	O
integration	O
site	O
)	O
as	O
flanking	O
markers	O
for	O
the	O
1p	O
breakpoint	O
.	O
The	O
17q	O
breakpoint	O
was	O
located	O
between	O
the	O
NF1	O
(	O
neurofibromatosis	O
1	O
)	O
gene	O
and	O
the	O
SCYA7	O
(	O
harboring	O
the	O
gene	O
encoding	O
the	O
monocyte	O
chemotactic	O
protein-3	O
)	O
.	O
Starting	O
from	O
these	O
markers	O
chromosome	O
walking	O
experiments	O
furthered	O
the	O
characterization	O
of	O
the	O
chromosomal	O
breakpoint	O
regions	O
and	O
enabled	O
to	O
identify	O
breakpoint	O
overlapping	O
cosmids	O
.	O
Sequence	O
analysis	O
of	O
these	O
markers	O
is	O
ongoing	O
and	O
will	O
reveal	O
if	O
the	O
breakpoint	O
regions	O
indeed	O
harbour	O
a	O
gene	O
involved	O
in	O
neuroblastoma	B-malignancy-type
development	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
12802894	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Physiol	O
.	O
1988	O
Mar	O
;	O
397	O
:	O
185-207	O
.	O
Inositol	O
1,4,5-trisphosphate	O
and	O
diacylglycerol	O
mimic	O
bradykinin	O
effects	O
on	O
mouse	O
neuroblastoma	B-malignancy-type
x	I-malignancy-type
rat	I-malignancy-type
glioma	I-malignancy-type
hybrid	I-malignancy-type
cells	O
.	O
Brown	O
DA	O
,	O
Higashida	O
H	O
.	O
Laboratory	O
of	O
Cell	O
Biology	O
,	O
National	O
Institute	O
of	O
Mental	O
Health	O
,	O
Bethesda	O
,	O
MD	O
20892	O
.	O
1.	O
The	O
role	O
of	O
inositol	O
1,4,5-trisphosphate	O
(	O
InsP3	O
)	O
and	O
diacylglycerol	O
(	O
DAG	O
)	O
as	O
possible	O
mediators	O
of	O
the	O
membrane	O
current	O
responses	O
of	O
NG108-15	O
neuroblastoma	B-malignancy-type
x	I-malignancy-type
glioma	I-malignancy-type
hybrid	I-malignancy-type
cells	O
to	O
bradykinin	O
(	O
BK	O
,	O
Brown	O
&	O
Higashida	O
,	O
1988	O
b	O
)	O
has	O
been	O
tested	O
using	O
intracellular	O
ionophoresis	O
of	O
InsP3	O
and	O
external	O
application	O
of	O
phorbol	O
dibutyrate	O
(	O
PDBu	O
)	O
and	O
1-oleoyl-2-acetylglycerol	O
(	O
OAG	O
)	O
.	O
2.	O
Intracellular	O
ionophoresis	O
of	O
InsP3	O
into	O
cells	O
clamped	O
at	O
-	O
30	O
to	O
-	O
50	O
mV	O
produced	O
(i)	O
a	O
transient	O
outward	O
current	O
,	O
(ii)	O
a	O
transient	O
outward	O
current	O
followed	O
by	O
an	O
inward	O
current	O
,	O
or	O
(iii)	O
an	O
inward	O
current	O
.	O
All	O
currents	O
were	O
accompanied	O
by	O
an	O
increased	O
input	O
conductance	O
.	O
3.	O
The	O
transient	O
outward	O
current	O
reversed	O
at	O
between	O
-	O
80	O
and	O
-	O
90	O
mV	O
.	O
The	O
reversal	O
potential	O
was	O
shifted	O
to	O
more	O
positive	O
potentials	O
on	O
raising	O
extracellular	O
[	O
K	O
+	O
]	O
,	O
suggesting	O
that	O
it	O
resulted	O
from	O
an	O
increased	O
K	O
+	O
conductance	O
.	O
4.	O
The	O
outward	O
current	O
was	O
inhibited	O
by	O
apamin	O
(	O
0.4	O
microM	O
)	O
or	O
d-tubocurarine	O
(	O
0.2	O
-	O
0.5	O
mM	O
)	O
;	O
these	O
drugs	O
also	O
inhibit	O
the	O
outward	O
current	O
produced	O
by	O
BK	O
or	O
by	O
intracellular	O
Ca2	O
+	O
injections	O
(	O
Brown	O
&	O
Higashida	O
,	O
1988	O
a	O
,	O
b	O
)	O
.	O
The	O
outward	O
current	O
was	O
also	O
slowly	O
reduced	O
in	O
0	O
mM	O
[	O
Ca2	O
+	O
]	O
or	O
0.5	O
mM	O
[	O
Cd2	O
+	O
]	O
plus	O
2	O
mM	O
[	O
Co2	O
+	O
]	O
solution	O
.	O
5.	O
Ionophoretic	O
injection	O
of	O
inositol	O
1,3,4-trisphosphate	O
and	O
inositol	O
1,3,4,5-tetrakisphosphate	O
,	O
guanosine	O
trisphosphate	O
or	O
inorganic	O
phosphate	O
did	O
not	O
evoke	O
an	O
outward	O
current	O
but	O
produced	O
only	O
an	O
inward	O
current	O
with	O
an	O
increased	O
conductance	O
,	O
reversing	O
at	O
between	O
-	O
10	O
and	O
-	O
20	O
mV	O
.	O
6.	O
Bath	O
application	O
of	O
PDBu	O
(	O
10	O
nM-1	O
microM	O
)	O
or	O
OAG	O
(	O
1	O
-	O
10	O
microM	O
)	O
produced	O
an	O
inward	O
current	O
with	O
a	O
fall	O
in	O
input	O
conductance	O
.	O
The	O
inward	O
current	O
was	O
voltage	O
dependent	O
and	O
was	O
accompanied	O
by	O
an	O
inhibition	O
of	O
the	O
time	O
-	O
dependent	O
current	O
relaxations	O
associated	O
with	O
activation	O
or	O
deactivation	O
of	O
the	O
voltage	O
-	O
dependent	O
K	O
+	O
current	O
,	O
IM	O
.	O
7.	O
PDBu	O
did	O
not	O
clearly	O
reduce	O
the	O
Ca2	O
+	O
current	O
or	O
the	O
Ca2	O
+	O
-	O
dependent	O
K	O
+	O
current	O
recorded	O
in	O
these	O
cells	O
.	O
During	O
superfusion	O
with	O
PDBu	O
,	O
the	O
outward	O
current	O
produced	O
by	O
intracellular	O
ionophoresis	O
of	O
InsP3	O
was	O
greatly	O
enhanced	O
.	O
8.	O
The	O
results	O
support	O
the	O
view	O
that	O
the	O
two	O
membrane	O
current	O
responses	O
to	O
BK	O
might	O
both	O
result	O
from	O
accelerated	O
membrane	O
phosphatidylinositide	O
hydrolysis	O
.	O
One	O
product	O
,	O
InsP3	O
,	O
releases	O
Ca2	O
+	O
and	O
activates	O
an	O
apamin	O
-	O
curare	O
-	O
sensitive	O
outward	O
K	O
+	O
current	O
;	O
this	O
effect	O
is	O
imitated	O
by	O
intracellular	O
InsP3	O
ionophoresis	O
.	O
The	O
second	O
product	O
,	O
DAG	O
;	O
activates	O
protein	O
kinase	O
C	O
to	O
inhibit	O
the	O
voltage	O
-	O
dependent	O
K	O
+	O
current	O
IM	O
and	O
generate	O
an	O
inward	O
current	O
;	O
this	O
effect	O
is	O
imitated	O
by	O
external	O
application	O
of	O
PDBu	O
or	O
OAG	O
.	O
PMID	O
:	O
3261793	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Res	O
.	O
1999	O
Apr	O
15	O
;	O
59	O
(	O
8	O
)	O
:	O
1852-6	O
.	O
S-adenosylmethionine	O
synthetase	O
is	O
overexpressed	O
in	O
murine	O
neuroblastoma	B-malignancy-type
cells	O
resistant	O
to	O
nucleoside	O
analogue	O
inhibitors	O
of	O
S-adenosylhomocysteine	O
hydrolase	O
:	O
a	O
novel	O
mechanism	O
of	O
drug	O
resistance	O
.	O
Dwivedi	O
RS	O
,	O
Wang	O
LJ	O
,	O
Mirkin	O
BL	O
.	O
Children's	O
Memorial	O
Institute	O
for	O
Education	O
and	O
Research	O
,	O
Children's	O
Memorial	O
Medical	O
Center	O
,	O
Department	O
of	O
Pediatrics	O
,	O
Northwestern	O
University	O
Medical	O
School	O
,	O
Chicago	O
,	O
Illinois	O
60614	O
,	O
USA	O
.	O
ramaa@nwu.edu	O
S-Adenosylmethionine	O
(	O
AdoMet	O
)	O
synthetase	O
(	O
EC	O
2.5.1.6	O
)	O
,	O
which	O
catalyzes	O
the	O
synthesis	O
of	O
AdoMet	O
from	O
methionine	O
and	O
ATP	O
,	O
is	O
the	O
major	O
methyl	O
donor	O
for	O
transmethylation	O
reactions	O
and	O
propylamino	O
donor	O
for	O
the	O
biosynthesis	O
of	O
polyamines	O
in	O
biological	O
systems	O
.	O
We	O
have	O
reported	O
previously	O
that	O
wild	O
-	O
type	O
C-1300	O
murine	O
neuroblastoma	B-malignancy-type
(	O
wMNB	B-malignancy-type
)	O
cells	O
,	O
made	O
resistant	O
to	O
the	O
nucleoside	O
analogue	O
(Z)-5'-fluoro-4',5'-didehydro-5'-deoxyadenosine	O
(	O
MDL	O
28,842	O
)	O
,	O
an	O
irreversible	O
inhibitor	O
of	O
S-adenosylhomocysteine	O
(	O
AdoHcy	O
)	O
hydrolase	O
(	O
EC	O
3.3.1.1	O
)	O
,	O
express	O
increased	O
AdoMet	O
synthetase	O
activity	O
(	O
M.	O
R.	O
Hamre	O
et	O
al.	O
,	O
Oncol.	O
Res.	O
,	O
7	O
:	O
487	O
-	O
492	O
,	O
1995	O
)	O
.	O
In	O
the	O
present	O
study	O
,	O
immunoblot	O
analyses	O
of	O
AdoMet	O
Synthetase	O
with	O
isoform	O
-	O
specific	O
(	O
MATII	O
)	O
antibodies	O
demonstrated	O
an	O
elevation	O
in	O
the	O
AdoMet	O
synthetase	O
immunoprotein	O
in	O
nucleoside	O
analogue	O
-	O
resistant	O
MNB	B-malignancy-type
cells	O
(	O
rMNB-MDL	B-malignancy-type
)	O
when	O
compared	O
to	O
wild	O
-	O
type	O
,	O
nonresistant	O
MNB	B-malignancy-type
cells	O
.	O
An	O
increase	O
of	O
2.1	O
-	O
fold	O
was	O
observed	O
in	O
the	O
alpha2	O
/	O
alpha2	O
'	O
catalytic	O
subunit	O
,	O
which	O
differed	O
significantly	O
from	O
the	O
much	O
smaller	O
increment	O
in	O
the	O
noncatalytic	O
beta-subunit	O
of	O
AdoMet	O
synthetase	O
.	O
Densitometric	O
analyses	O
revealed	O
that	O
an	O
increased	O
expression	O
of	O
AdoMet	O
synthetase	O
in	O
rMNB-MDL	B-malignancy-type
cells	O
was	O
due	O
to	O
overexpression	O
of	O
the	O
alpha2	O
(	O
Mr	O
53,000	O
;	O
2.6	O
-	O
fold	O
)	O
and	O
alpha2	O
'	O
(	O
Mr	O
51,000	O
;	O
1.8	O
-	O
fold	O
)	O
subunits	O
.	O
AdoMet	O
synthetase	O
mRNA	O
expression	O
in	O
rMNB-MDL	B-malignancy-type
cells	O
was	O
remarkably	O
greater	O
than	O
wMNB	B-malignancy-type
cells	O
,	O
as	O
determined	O
by	O
quantitative	O
competitive	O
reverse	O
transcription	O
-	O
PCR	O
(	O
QC	O
-	O
PCR	O
)	O
analysis	O
.	O
DNA	O
(	O
cytosine	O
)	O
methyl	O
transferase	O
expression	O
,	O
measured	O
by	O
reverse	O
transcription	O
-	O
PCR	O
analysis	O
,	O
was	O
also	O
elevated	O
significantly	O
in	O
rMNB-MDL	B-malignancy-type
cells	O
.	O
In	O
contrast	O
,	O
Western	O
blot	O
analyses	O
demonstrated	O
down	O
-	O
regulation	O
(	O
1.6	O
-	O
fold	O
)	O
of	O
AdoMet	O
synthetase	O
in	O
doxorubicin	O
-	O
resistant	O
human	O
leukemia	B-malignancy-type
cells	O
(	O
HL-60-R	B-malignancy-type
)	O
expressing	O
multidrug	O
resistance	O
protein	O
when	O
compared	O
with	O
wild	O
-	O
type	O
,	O
nonresistant	O
HL-60	B-malignancy-type
cells	O
.	O
The	O
resistance	O
of	O
rMNB-MDL	B-malignancy-type
cells	O
to	O
nucleoside	O
analogue	O
inhibitors	O
of	O
S-adenosylhomocysteine	O
hydrolase	O
correlates	O
directly	O
with	O
overexpression	O
of	O
the	O
alpha2	O
/	O
alpha2	O
'	O
subunits	O
of	O
AdoMet	O
synthetase	O
.	O
Cellular	O
adaptation	O
allows	O
sufficient	O
AdoMet	O
to	O
be	O
synthesized	O
,	O
so	O
that	O
viability	O
of	O
the	O
MNB	B-malignancy-type
cells	O
can	O
be	O
maintained	O
even	O
in	O
the	O
presence	O
of	O
high	O
AdoHcy	O
concentrations	O
.	O
This	O
novel	O
mechanism	O
of	O
drug	O
resistance	O
does	O
not	O
appear	O
to	O
require	O
multidrug	O
resistance	O
protein	O
(	O
P-glycoprotein	O
)	O
overexpression	O
.	O
PMID	O
:	O
10213491	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Cell	O
Biol	O
.	O
1990	O
Jun	O
;	O
110	O
(	O
6	O
)	O
:	O
2185-93	O
.	O
Isolation	O
of	O
a	O
novel	O
integrin	O
receptor	O
mediating	O
Arg	O
-	O
Gly	O
-	O
Asp	O
-	O
directed	O
cell	O
adhesion	O
to	O
fibronectin	O
and	O
type	O
I	O
collagen	O
from	O
human	O
neuroblastoma	B-malignancy-type
cells	O
.	O
Association	O
of	O
a	O
novel	O
beta	O
1	O
-	O
related	O
subunit	O
with	O
alpha	O
v	O
.	O
Dedhar	O
S	O
,	O
Gray	O
V	O
.	O
Department	O
of	O
Advanced	O
Therapeutics	O
,	O
Cancer	O
Control	O
Agency	O
of	O
British	O
Columbia	O
,	O
Vancouver	O
,	O
Canada	O
.	O
We	O
report	O
the	O
isolation	O
from	O
two	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
of	O
an	O
Arg	O
-	O
Gly	O
-	O
Asp	O
-	O
dependent	O
integrin	O
complex	O
capable	O
of	O
binding	O
to	O
vitronectin	O
,	O
fibronectin	O
,	O
and	O
type	O
I	O
collagen	O
.	O
The	O
two	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
,	O
SK-N-SH	O
and	O
IMR-32	O
,	O
exhibit	O
specific	O
attachment	O
to	O
fibronectin	O
and	O
type	O
I	O
collagen	O
.	O
SK-N-SH	O
cells	O
exhibit	O
a	O
much	O
stronger	O
attachment	O
to	O
vitronectin	O
than	O
the	O
IMR-32	O
cells	O
,	O
which	O
attach	O
poorly	O
to	O
this	O
substrate	O
.	O
Affinity	O
chromatography	O
of	O
octylglucoside	O
extracts	O
of	O
125I	O
surface	O
-	O
labeled	O
cells	O
on	O
GRGDSPK	O
-	O
Sepharose	O
columns	O
resulted	O
in	O
the	O
specific	O
binding	O
and	O
elution	O
with	O
GRGDSP	O
of	O
three	O
radiolabeled	O
polypeptides	O
with	O
relative	O
molecular	O
masses	O
of	O
135	O
,	O
115	O
,	O
and	O
90	O
kD	O
when	O
analyzed	O
by	O
SDS-PAGE	O
under	O
nonreducing	O
conditions	O
.	O
In	O
the	O
SK-N-SH	O
cells	O
the	O
135	O
-	O
and	O
90	O
-	O
kD	O
polypeptides	O
were	O
more	O
abundant	O
whereas	O
in	O
the	O
IMR-32	O
cells	O
the	O
135	O
-	O
and	O
115	O
-	O
kD	O
polypeptides	O
were	O
more	O
highly	O
expressed	O
.	O
Liposomes	O
prepared	O
from	O
fractions	O
containing	O
all	O
three	O
polypeptides	O
bound	O
to	O
vitronectin	O
,	O
fibronectin	O
,	O
and	O
type	O
I	O
collagen	O
,	O
whereas	O
liposomes	O
prepared	O
from	O
the	O
135	O
-	O
and	O
115	O
-	O
kD	O
polypeptides	O
bound	O
only	O
to	O
fibronectin	O
and	O
type	O
I	O
collagen	O
.	O
Polyclonal	O
antibodies	O
against	O
the	O
alpha	O
/	O
beta	O
complexes	O
of	O
both	O
the	O
vitronectin	O
receptor	O
and	O
the	O
fibronectin	O
receptor	O
immunoprecipitated	O
all	O
three	O
polypeptides	O
.	O
A	O
monoclonal	O
antibody	O
against	O
beta	O
1	O
immunoprecipitated	O
only	O
the	O
135	O
-	O
and	O
the	O
115	O
-	O
kD	O
polypeptides	O
,	O
whereas	O
a	O
monoclonal	O
antibody	O
against	O
beta	O
3	O
subunit	O
immunoprecipitated	O
the	O
135	O
-	O
and	O
90	O
-	O
kD	O
polypeptides	O
.	O
Although	O
,	O
the	O
115	O
-	O
kD	O
polypeptide	O
could	O
be	O
recognized	O
by	O
an	O
anti	O
-	O
beta	O
1	O
antibody	O
,	O
a	O
comparison	O
of	O
peptide	O
maps	O
generated	O
by	O
V8	O
protease	O
digestion	O
of	O
the	O
115	O
-	O
kD	O
polypeptide	O
and	O
beta	O
1	O
subunit	O
immunoprecipitated	O
from	O
GRGDSPK	O
-	O
Sepharose	O
flow	O
-	O
through	O
material	O
indicated	O
that	O
these	O
two	O
polypeptides	O
are	O
distinct	O
.	O
Depletion	O
of	O
the	O
90	O
-	O
kD	O
polypeptide	O
with	O
an	O
anti	O
-	O
beta	O
3	O
monoclonal	O
antibody	O
did	O
not	O
effect	O
the	O
ability	O
of	O
the	O
115	O
-	O
and	O
135	O
-	O
kD	O
polypeptides	O
to	O
bind	O
to	O
GRGDSPK	O
-	O
Sepharose	O
.	O
These	O
data	O
indicate	O
that	O
the	O
SK-N-SH	O
and	O
IMR-32	O
neuroblastoma	B-malignancy-type
cells	O
express	O
a	O
novel	O
"	O
beta	O
1	O
-	O
like	O
"	O
integrin	O
subunit	O
that	O
can	O
associate	O
with	O
alpha	O
v	O
and	O
can	O
bind	O
to	O
RGD	O
.	O
We	O
propose	O
to	O
name	O
this	O
beta	O
1	O
-	O
like	O
subunit	O
beta	O
n	O
.	O
The	O
data	O
reported	O
here	O
thus	O
demonstrate	O
that	O
in	O
these	O
two	O
cell	O
lines	O
alpha	O
v	O
associates	O
with	O
two	O
beta	O
subunits	O
,	O
beta	O
n	O
and	O
beta	O
3	O
,	O
forming	O
two	O
heterodimers	O
.	O
The	O
alpha	O
v	O
beta	O
n	O
complex	O
mediates	O
binding	O
to	O
fibronectin	O
and	O
type	O
I	O
collagen	O
,	O
whereas	O
the	O
alpha	O
v	O
beta	O
3	O
complex	O
mediates	O
binding	O
to	O
vitronectin	O
.	O
PMID	O
:	O
1693626	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Pediatr	O
Surg	O
.	O
2001	O
Dec;36	O
(	O
12	O
)	O
:178	O
5	O
-91	O
.	O
The	O
inhibitor	O
of	O
apoptosis	O
protein	O
survivin	O
is	O
associated	O
with	O
high	O
-	O
risk	O
behavior	O
of	O
neuroblastoma	B-malignancy-type
.	O
Azuhata	O
T	O
,	O
Scott	O
D	O
,	O
Takamizawa	O
S	O
,	O
Wen	O
J,	O
Davidoff	O
A	O
,	O
Fukuzawa	O
M,	O
Sandler	O
A	O
.	O
Department	O
of	O
Surgery	O
,	O
University	O
of	O
Iowa	O
,	O
Iowa	O
City	O
,	O
IA	O
52242	O
,	O
USA	O
.	O
BACKGROUND	O
/	O
PURPOSE	O
:	O
Apoptotic	O
factors	O
inducing	O
or	O
preventing	O
cell	O
death	O
may	O
intrinsically	O
govern	O
the	O
behavior	O
of	O
some	O
tumors	O
.	O
Survivin	O
is	O
a	O
recently	O
described	O
member	O
of	O
the	O
inhibitor	O
of	O
apoptosis	O
protein	O
(	O
IAP	O
)	O
family	O
,	O
that	O
is	O
expressed	O
in	O
a	O
cell	O
cycle	O
-	O
dependent	O
manner	O
and	O
is	O
found	O
in	O
tumors	O
of	O
unfavorable	O
histology	O
.	O
This	O
study	O
examines	O
the	O
presence	O
of	O
several	O
apoptotic	O
factors	O
,	O
including	O
survivin	O
,	O
in	O
neuroblastoma	B-malignancy-type
(	I-malignancy-type
NB	I-malignancy-type
)	I-malignancy-type
tumors	I-malignancy-type
.	O
Clues	O
to	O
survivin	O
's	O
function	O
in	O
NB	B-malignancy-type
are	O
provided	O
by	O
examining	O
its	O
association	O
with	O
behavior	O
and	O
cell	O
dynamics	O
in	O
tumors	O
and	O
cell	O
lines	O
.	O
METHODS	O
:	O
Expression	O
of	O
a	O
panel	O
of	O
apoptosis	O
factors	O
were	O
quantified	O
in	O
15	O
NB	B-malignancy-type
and	O
related	O
tumors	O
before	O
chemotherapy	O
and	O
in	O
3	O
NB	B-malignancy-type
cell	O
lines	O
(	O
NB7	O
,	O
NB10	O
,	O
and	O
NB16	O
)	O
.	O
Survivin	O
and	O
other	O
apoptotic	O
factors	O
,	O
as	O
well	O
N-myc	O
amplification	O
in	O
primary	O
tumors	O
was	O
correlated	O
with	O
recurrent	O
disease	O
and	O
outcome	O
.	O
Proliferation	O
rate	O
,	O
apoptosis	O
assays	O
,	O
cell	O
cycle	O
analysis	O
,	O
and	O
drug	O
-	O
or	O
immune	O
-	O
mediated	O
cell	O
death	O
were	O
assessed	O
in	O
cell	O
lines	O
and	O
evaluated	O
in	O
the	O
context	O
of	O
differential	O
survivin	O
and	O
apoptosis	O
gene	O
expression	O
.	O
RESULTS	O
:	O
All	O
7	O
tumors	O
that	O
went	O
on	O
to	O
recur	O
expressed	O
survivin	O
,	O
whereas	O
expression	O
was	O
absent	O
in	O
all	O
8	O
tumors	O
that	O
went	O
into	O
remission	O
.	O
N-myc	O
was	O
amplified	O
in	O
4	O
(	O
57.1	O
%	O
)	O
of	O
the	O
7	O
recurrent	O
tumors	O
.	O
Of	O
the	O
8	O
tumors	O
that	O
were	O
cured	O
,	O
Fas	O
was	O
expressed	O
in	O
3	O
(	O
38	O
%	O
)	O
,	O
TRAIL-R1	O
in	O
6	O
(	O
75	O
%	O
)	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
R1	O
in	O
8	O
(	O
100	O
%	O
)	O
,	O
whereas	O
these	O
pro	O
-	O
apoptotic	O
receptors	O
were	O
present	O
in	O
only	O
1	O
(	O
14	O
%	O
)	O
,	O
1	O
(	O
14	O
%	O
)	O
,	O
and	O
4	O
(	O
57	O
%	O
)	O
of	O
the	O
7	O
tumors	O
that	O
went	O
on	O
to	O
recur	O
,	O
respectively	O
.	O
Of	O
the	O
3	O
cell	O
lines	O
,	O
NB10	O
expressed	O
the	O
least	O
survivin	O
,	O
displayed	O
the	O
lowest	O
proliferation	O
index	O
,	O
and	O
had	O
the	O
fewest	O
number	O
of	O
cells	O
in	O
the	O
G2	O
/	O
M	O
(	O
mitotic	O
)	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O
Furthermore	O
,	O
NB10	O
also	O
was	O
most	O
sensitive	O
to	O
TNF	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
(	O
TRAIL	O
)	O
or	O
etoposide	O
-	O
induced	O
cell	O
death	O
.	O
CONCLUSIONS	O
:	O
In	O
primary	O
NB	B-malignancy-type
tumors	I-malignancy-type
,	O
survivin	O
expression	O
was	O
associated	O
with	O
tumors	O
of	O
high	O
risk	O
and	O
unfavorable	O
prognosis	O
,	O
whereas	O
pro	O
-	O
apoptotic	O
receptor	O
expression	O
was	O
more	O
abundant	O
in	O
tumors	O
of	O
favorable	O
prognosis	O
.	O
In	O
this	O
small	O
series	O
,	O
survivin	O
expression	O
appeared	O
to	O
be	O
more	O
predictive	O
of	O
recurrent	O
disease	O
than	O
N-myc	O
amplification	O
.	O
In	O
cell	O
lines	O
,	O
survivin	O
expression	O
was	O
cell	O
cycle	O
dependent	O
,	O
and	O
its	O
expression	O
was	O
associated	O
with	O
greater	O
proliferation	O
rates	O
and	O
greater	O
resistance	O
to	O
drug	O
-	O
or	O
immune	O
-	O
mediated	O
cell	O
death	O
.	O
Survivin	O
expression	O
may	O
become	O
a	O
useful	O
prognostic	O
marker	O
in	O
NB	B-malignancy-type
and	O
could	O
be	O
a	O
potential	O
target	O
for	O
the	O
treatment	O
of	O
this	O
tumor	O
.	O
J	O
Pediatr	O
Surg	O
36	O
:178	O
5-1791	O
.	O
Copyright	O
2001	O
by	O
W.B.	O
Saunders	O
Company	O
.	O
PMID	O
:	O
11733907	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Pharmacol	O
.	O
1996	O
Dec;50	O
(	O
6	O
)	O
:	O
1432-42	O
.	O
Analysis	O
of	O
the	O
alpha2C	O
-	O
adrenergic	O
receptor	O
gene	O
promoter	O
and	O
its	O
cell	O
-	O
type	O
-	O
specific	O
activity	O
.	O
Saulnier	O
-	O
Blache	O
JS	O
,	O
Yang	O
Q	O
,	O
Sherlock	O
JD	O
,	O
Lanier	O
SM	O
.	O
Department	O
of	O
Pharmacology	O
,	O
Medical	O
University	O
of	O
South	O
Carolina	O
,	O
Charleston	O
29425	O
,	O
USA	O
.	O
As	O
an	O
initial	O
approach	O
to	O
define	O
the	O
regulatory	O
elements	O
and	O
transcriptional	O
factors	O
that	O
account	O
for	O
cell	O
-	O
restricted	O
expression	O
of	O
the	O
alpha2c	O
-	O
adrenergic	O
receptor	O
(	O
AR	O
)	O
gene	O
,	O
we	O
isolated	O
and	O
characterized	O
the	O
receptor	O
gene	O
and	O
identified	O
regions	O
of	O
the	O
gene	O
conferring	O
cell	O
-	O
specific	O
expression	O
.	O
A	O
4300	O
-	O
nucleotide	O
(	O
nt	O
)	O
fragment	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
rat	O
alpha2c	O
-	O
AR	O
gene	O
was	O
isolated	O
from	O
a	O
genomic	O
library	O
.	O
The	O
genomic	O
sequence	O
contained	O
the	O
uninterrupted	O
sequence	O
of	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
of	O
a	O
previously	O
isolated	O
alpha2c	O
-	O
AR	O
cDNA	O
clone	O
indicating	O
the	O
lack	O
of	O
introns	O
in	O
the	O
5	O
'	O
gene	O
segment	O
.	O
RNase	O
protection	O
assays	O
and/or	O
RNA	O
blot	O
analysis	O
indicated	O
the	O
expression	O
of	O
alpha2c	O
-	O
AR	O
mRNA	O
in	O
rat	O
brain	O
but	O
not	O
in	O
kidney	O
or	O
liver	O
,	O
which	O
is	O
consistent	O
with	O
the	O
major	O
expression	O
of	O
this	O
gene	O
in	O
neuronal	O
tissue	O
.	O
The	O
5	O
'	O
gene	O
segment	O
was	O
used	O
to	O
identify	O
sites	O
of	O
transcriptional	O
initiation	O
and	O
promoter	O
activity	O
by	O
RNase	O
protection	O
assays	O
and	O
transient	O
transfection	O
of	O
reporter	O
gene	O
constructs	O
.	O
With	O
the	O
use	O
of	O
RNA	O
probes	O
progressively	O
upstream	O
of	O
the	O
translational	O
start	O
site	O
,	O
RNase	O
protection	O
assays	O
with	O
rat	O
brain	O
total	O
RNA	O
indicated	O
multiple	O
sites	O
of	O
transcriptional	O
initiation	O
within	O
a	O
approximately	O
70	O
-	O
nt	O
span	O
(	O
-	O
660	O
to	O
-	O
730	O
nt	O
5	O
'	O
to	O
the	O
translational	O
start	O
codon	O
)	O
.	O
The	O
zone	O
of	O
transcriptional	O
initiation	O
was	O
part	O
of	O
a	O
larger	O
GC	O
-	O
rich	O
area	O
of	O
the	O
5	O
'	O
gene	O
segment	O
that	O
is	O
a	O
characteristic	O
of	O
genes	O
initiating	O
transcripts	O
at	O
multiple	O
sites	O
.	O
The	O
promoter	O
activity	O
of	O
this	O
zone	O
of	O
transcriptional	O
initiation	O
and	O
the	O
influence	O
of	O
gene	O
segments	O
5	O
'	O
to	O
this	O
area	O
were	O
addressed	O
using	O
chloramphenicol	O
acetyl	O
transferase	O
reporter	O
gene	O
constructs	O
.	O
Transient	O
transfection	O
of	O
reporter	O
gene	O
constructs	O
indicated	O
that	O
a	O
96	O
-	O
nt	O
gene	O
fragment	O
(	O
-	O
699	O
/	O
-	O
603	O
relative	O
to	O
the	O
translational	O
start	O
codon	O
)	O
was	O
sufficient	O
to	O
direct	O
transcription	O
in	O
the	O
neuroblastoma	B-malignancy-type
X	O
glioma	B-malignancy-type
hybrid	O
cell	O
line	O
NG108-15	O
,	O
a	O
cell	O
line	O
expressing	O
the	O
endogenous	O
alpha2c	O
-	O
AR	O
.	O
Promoter	O
activity	O
was	O
not	O
observed	O
in	O
constructs	O
lacking	O
the	O
zone	O
of	O
transcriptional	O
initiation	O
.	O
The	O
promoter	O
segment	O
was	O
inactive	O
when	O
introduced	O
into	O
the	O
rat	O
glioma	B-malignancy-type
cell	O
line	O
C6B4	O
,	O
the	O
rat	O
submandibular	O
cell	O
line	O
RSMT-A5	O
,	O
and	O
the	O
rat	O
pancreatic	O
beta	O
cell	O
line	O
RIN-5AH	O
,	O
all	O
of	O
which	O
do	O
not	O
express	O
the	O
endogenous	O
alpha2c	O
-	O
AR	O
gene	O
.	O
Upon	O
incubation	O
with	O
nuclear	O
extracts	O
,	O
a	O
129	O
-	O
nt	O
fragment	O
encompassing	O
the	O
promoter	O
exhibited	O
a	O
gel	O
mobility	O
shift	O
pattern	O
that	O
was	O
specific	O
for	O
cells	O
expressing	O
the	O
receptor	O
protein	O
and	O
involved	O
a	O
nuclear	O
protein	O
that	O
recognized	O
a	O
Sp1	O
oligonucleotide	O
.	O
These	O
data	O
indicate	O
that	O
a	O
96	O
-	O
nt	O
gene	O
promoter	O
segment	O
of	O
the	O
alpha2c	O
-	O
AR	O
gene	O
functions	O
in	O
a	O
cell	O
-	O
type	O
-	O
specific	O
manner	O
.	O
PMID	O
:	O
8967963	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Intervirology	O
.	O
1996;39	O
(	O
4	O
)	O
:259	O
-69	O
.	O
Modulatory	O
effects	O
of	O
human	O
cytomegalovirus	O
infection	O
on	O
malignant	O
properties	O
of	O
cancer	O
cells	O
.	O
Cinatl	O
J	O
Jr	O
,	O
Cinatl	O
J,	O
Vogel	O
JU	O
,	O
Rabenau	O
H,	O
Kornhuber	O
B	O
,	O
Doerr	O
HW	O
.	O
Institute	O
of	O
Medical	O
Virology	O
,	O
University	O
Clinics	O
of	O
Frankfurt	O
/	O
Main	O
,	O
Germany	O
.	O
Although	O
there	O
is	O
no	O
definitive	O
evidence	O
of	O
the	O
association	O
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
infection	O
with	O
human	O
cancers	O
,	O
the	O
oncogenic	O
potential	O
of	O
HCMV	O
has	O
been	O
well	O
established	O
by	O
in	O
vitro	O
studies	O
demonstrating	O
the	O
ability	O
of	O
UV	O
-	O
irradiated	O
or	O
infectious	O
virus	O
to	O
transform	O
a	O
variety	O
of	O
cells	O
.	O
After	O
prolonged	O
passaging	O
the	O
transformed	O
cell	O
type	O
was	O
maintained	O
while	O
HCMV	O
DNA	O
sequences	O
were	O
no	O
more	O
detectable	O
.	O
Three	O
morphological	O
transforming	O
regions	O
(	O
mtr	O
)	O
of	O
HCMV	O
have	O
been	O
identified	O
.	O
The	O
effects	O
of	O
HCMV	O
on	O
cellular	O
functions	O
which	O
may	O
be	O
associated	O
with	O
the	O
malignant	O
phenotype	O
include	O
the	O
expression	O
of	O
oncogenes	O
and	O
transcriptional	O
activation	O
of	O
growth	O
factors	O
and	O
interleukin	O
synthesis	O
.	O
In	O
infected	O
cells	O
,	O
HCMV	O
induces	O
cytoskeletal	O
alterations	O
and	O
changes	O
in	O
expression	O
of	O
cell	O
surface	O
receptors	O
for	O
extracellular	O
matrix	O
proteins	O
which	O
could	O
result	O
in	O
increased	O
motility	O
and	O
dissemination	O
of	O
cancer	O
cells	O
.	O
Several	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
undergo	O
maturation	O
in	O
different	O
neural	O
crest	O
derived	O
cell	O
types	O
upon	O
treatment	O
with	O
oncogenic	O
potential	O
agents	O
,	O
i.e.	O
retinoic	O
acid	O
.	O
The	O
persistent	O
HCMV	O
infection	O
of	O
neuroblastoma	B-malignancy-type
cells	O
(	O
>	O
1	O
year	O
)	O
is	O
accompanied	O
by	O
the	O
increased	O
expression	O
of	O
oncoproteins	O
(	O
i.e.	O
N-myc	O
)	O
and	O
decreased	O
expression	O
of	O
tyrosine	O
hydroxylase	O
and	O
dopamine	O
-	O
beta-hydroxylase	O
.	O
The	O
activation	O
of	O
the	O
cellular	O
metabolism	O
is	O
due	O
to	O
HCMV	O
binding	O
to	O
cellular	O
receptors	O
(	O
prior	O
to	O
virus	O
gene	O
expression	O
)	O
and	O
to	O
the	O
activity	O
of	O
HCMV	O
immediate	O
early	O
(	O
IE	O
)	O
gene	O
products	O
.	O
IE	O
proteins	O
act	O
directly	O
as	O
transcriptional	O
activators	O
or	O
their	O
activity	O
is	O
mediated	O
by	O
a	O
variety	O
of	O
cellular	O
transcription	O
factors	O
.	O
HCMV	O
infection	O
may	O
result	O
in	O
activation	O
of	O
promoters	O
of	O
cellular	O
genes	O
coding	O
for	O
cytokines	O
,	O
replication	O
enzymes	O
,	O
proto	O
-	O
oncogenes	O
and	O
viral	O
promoters	O
.	O
Recently	O
it	O
has	O
been	O
demonstrated	O
that	O
HCMV	O
IE	O
proteins	O
block	O
apoptosis	O
probably	O
by	O
suppressing	O
the	O
ability	O
of	O
the	O
antioncogene	O
p53	O
to	O
activate	O
a	O
reporter	O
gene	O
.	O
The	O
interactions	O
of	O
HCMV	O
with	O
tumor	O
suppressor	O
proteins	O
such	O
as	O
p53	O
or	O
retinoblastoma	O
(	O
pRb	O
)	O
susceptibility	O
protein	O
are	O
reminiscent	O
of	O
those	O
mediated	O
by	O
the	O
oncoproteins	O
of	O
DNA	O
tumor	O
viruses	O
.	O
The	O
acquisition	O
of	O
a	O
fully	O
malignant	O
phenotype	O
by	O
normal	O
cells	O
is	O
thought	O
to	O
require	O
several	O
mutations	O
in	O
a	O
number	O
of	O
cellular	O
genes	O
.	O
In	O
this	O
connection	O
,	O
HCMV	O
may	O
play	O
the	O
role	O
of	O
a	O
nonobligate	O
either	O
direct	O
or	O
indirect	O
cofactor	O
for	O
tumor	O
genesis	O
,	O
e.g.	O
by	O
blocking	O
apoptosis	O
,	O
which	O
may	O
be	O
an	O
essential	O
requirement	O
for	O
tumor	O
progression	O
.	O
Due	O
to	O
the	O
stimulation	O
of	O
growth	O
factors	O
and/or	O
inhibition	O
of	O
antioncogenes	O
by	O
its	O
gene	O
products	O
,	O
HCMV	O
may	O
modulate	O
the	O
malignant	O
potential	O
for	O
tumor	O
cells	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
9078467	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
2003	O
Nov	O
1;6	O
3(	O
21	O
)	O
:7256-62	O
.	O
Induction	O
of	O
chromosomal	O
instability	O
in	O
colonic	O
cells	O
by	O
the	O
human	O
polyomavirus	O
JC	O
virus	O
.	O
Ricciardiello	O
L,	O
Baglioni	O
M,	O
Giovannini	O
C	O
,	O
Pariali	O
M,	O
Cenacchi	O
G	O
,	O
Ripalti	O
A	O
,	O
Landini	O
MP	O
,	O
Sawa	O
H,	O
Nagashima	O
K,	O
Frisque	O
RJ	O
,	O
Goel	O
A	O
,	O
Boland	O
CR	O
,	O
Tognon	O
M,	O
Roda	O
E	O
,	O
Bazzoli	O
F.	O
Department	O
of	O
Internal	O
Medicine	O
and	O
Gastroenterology	O
,	O
University	O
of	O
Bologna	O
,	O
Via	O
Massarenti	O
9	O
,	O
Pad	O
5	O
Stanza	O
28	O
,	O
40138	O
Bologna	O
,	O
Italy	O
.	O
ricciard@med	O
.unibo	O
.it	O
Most	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
display	O
chromosomal	O
instability	O
,	O
which	O
is	O
characterized	O
by	O
gross	O
chromosomal	O
rearrangements	O
,	O
loss	O
of	O
heterozygosity	O
and	O
aneuploidy	O
.	O
We	O
have	O
previously	O
demonstrated	O
a	O
link	O
between	O
JC	O
virus	O
strains	O
Mad-1	O
and	O
Delta98	O
and	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Others	O
have	O
also	O
associated	O
the	O
virus	O
to	O
the	O
induction	O
of	O
colon	B-malignancy-type
cancer	I-malignancy-type
and	O
aneuploid	O
brain	B-malignancy-type
tumors	I-malignancy-type
by	O
producing	O
a	O
highly	O
tumorigenic	O
protein	O
named	O
T	O
antigen	O
(	O
TAg	O
)	O
,	O
which	O
binds	O
to	O
beta-catenin	O
and	O
inactivates	O
key	O
proteins	O
such	O
as	O
p53	O
.	O
The	O
aim	O
is	O
to	O
demonstrate	O
that	O
JC	O
virus	O
is	O
capable	O
of	O
inducing	O
chromosomal	O
instability	O
in	O
colonic	O
cells	O
.	O
We	O
used	O
the	O
human	O
colon	B-malignancy-type
cancer	I-malignancy-type
cell	O
line	O
RKO	O
as	O
a	O
model	O
.	O
The	O
cell	O
line	O
has	O
wild-type	O
p53	O
,	O
wild-type	O
beta-catenin	O
and	O
APC	O
and	O
is	O
diploid	O
.	O
Neuroblastoma	B-malignancy-type
JCI	O
cells	O
,	O
which	O
are	O
infected	O
with	O
the	O
virus	O
,	O
VA13	O
fibroblasts	O
,	O
which	O
are	O
transformed	O
by	O
the	O
SV40	O
TAg	O
,	O
were	O
used	O
as	O
positive	O
controls	O
.	O
HCT116	O
,	O
which	O
has	O
mutated	O
beta-catenin	O
,	O
and	O
SW480	O
,	O
which	O
is	O
a	O
model	O
of	O
CIN	B-malignancy-type
,	O
were	O
also	O
used	O
as	O
controls	O
.	O
The	O
genomes	O
of	O
the	O
Mad-1	O
and	O
Delta98	O
strains	O
were	O
transfected	O
into	O
cells	O
.	O
As	O
negative	O
controls	O
we	O
used	O
pUC	O
or	O
no	O
plasmids	O
.	O
Cells	O
were	O
collected	O
at	O
0	O
,	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
after	O
transfection	O
.	O
PCR	O
was	O
used	O
for	O
the	O
detection	O
of	O
TAg	O
and	O
the	O
regulatory	O
region	O
DNA	O
sequences	O
at	O
different	O
time	O
frames	O
and	O
Southern	O
blot	O
of	O
whole	O
genomic	O
extracts	O
for	O
viral	O
DNA	O
integration	O
into	O
the	O
host	O
genome	O
.	O
Immunofluorescence	O
and	O
Western	O
blot	O
were	O
performed	O
for	O
TAg	O
,	O
viral	O
capsid	O
proteins	O
,	O
and	O
nuclear	O
beta-catenin	O
expressions	O
,	O
whereas	O
coimmunoprecipitation	O
was	O
used	O
to	O
detect	O
protein	O
interactions	O
.	O
Karyotype	O
analysis	O
and	O
electron	O
microscopy	O
were	O
performed	O
to	O
seek	O
chromosomal	O
instability	O
and	O
cell	O
abnormalities	O
,	O
respectively	O
.	O
Retention	O
of	O
viral	O
sequences	O
was	O
observed	O
for	O
Mad-1	O
-	O
and	O
Delta98	O
-	O
transfected	O
RKO	O
cells	O
at	O
all	O
time	O
frames	O
with	O
PCR	O
only	O
,	O
whereas	O
Southern	O
blot	O
analysis	O
showed	O
nonintegrated	O
sequences	O
at	O
T7	O
alone	O
.	O
TAg	O
and	O
capsid	O
protein	O
expressions	O
,	O
as	O
well	O
as	O
increased	O
p53	O
and	O
nuclear	O
beta-catenin	O
,	O
were	O
observed	O
between	O
T0	O
and	O
T7	O
for	O
Mad-1	O
and	O
Delta98	O
alone	O
.	O
Also	O
,	O
interaction	O
between	O
TAg	O
and	O
both	O
p53	O
and	O
beta-catenin	O
was	O
also	O
observed	O
between	O
T0	O
and	O
T7	O
.	O
Chromosomal	O
instability	O
,	O
characterized	O
by	O
chromosomal	O
breakage	O
,	O
dicentric	O
chromosomes	O
,	O
and	O
increasing	O
ploidy	O
,	O
was	O
observed	O
at	O
all	O
time	O
frames	O
for	O
Mad-1	O
and	O
Delta98	O
,	O
as	O
well	O
as	O
cell	O
abnormalities	O
.	O
In	O
conclusion	O
,	O
we	O
demonstrate	O
that	O
JC	O
virus	O
Mad-1	O
and	O
Delta98	O
are	O
able	O
to	O
induce	O
chromosomal	O
instability	O
in	O
colonic	O
cells	O
with	O
a	O
hit	O
and	O
run	O
mechanism	O
that	O
involves	O
an	O
early	O
interaction	O
with	O
beta-catenin	O
and	O
p53	O
.	O
PMID	O
:	O
14612521	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1996	O
Feb	O
2;271	O
(	O
5	O
)	O
:2709	O
-	O
16	O
.	O
Interaction	O
of	O
ethanol	O
with	O
inducers	O
of	O
glucose	O
-	O
regulated	O
stress	O
proteins	O
.	O
Ethanol	O
potentiates	O
inducers	O
of	O
grp78	O
transcription	O
.	O
Hsieh	O
KP	O
,	O
Wilke	O
N	O
,	O
Harris	O
A	O
,	O
Miles	O
MF.	O
Ernest	O
Gallo	O
Clinic	O
and	O
Research	O
Center	O
,	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
94110	O
,	O
USA	O
.	O
GRP78	O
,	O
a	O
molecular	O
chaperone	O
expressed	O
in	O
the	O
endoplasmic	O
reticulum	O
,	O
is	O
a	O
"	O
glucose	O
-	O
regulated	O
protein	O
"	O
induced	O
by	O
stress	O
responses	O
that	O
deplete	O
glucose	O
or	O
intracisternal	O
calcium	O
or	O
otherwise	O
disrupt	O
glycoprotein	O
trafficking	O
.	O
Previously	O
we	O
showed	O
that	O
chronic	O
ethanol	O
exposure	O
increases	O
the	O
expression	O
of	O
GRP78	O
.	O
To	O
further	O
understand	O
the	O
mechanism	O
underlying	O
ethanol	O
regulation	O
of	O
GRP78	O
expression	O
,	O
we	O
studied	O
the	O
interaction	O
between	O
ethanol	O
and	O
classical	O
modulators	O
of	O
GRP78	O
expression	O
in	O
NG108-15	O
neuroblastoma	B-malignancy-type
x	I-malignancy-type
glioma	I-malignancy-type
cells	O
.	O
We	O
found	O
that	O
,	O
in	O
addition	O
to	O
increasing	O
basal	O
levels	O
of	O
GRP78	O
mRNA	O
(	O
"	O
induction	O
"	O
)	O
,	O
ethanol	O
produced	O
greater	O
than	O
additive	O
increases	O
in	O
the	O
induction	O
of	O
GRP78	O
mRNA	O
by	O
the	O
"	O
classical	O
"	O
GRP	O
inducers	O
A23187	O
,	O
brefeldin	O
A	O
,	O
and	O
thapsigargin	O
(	O
"	O
potentiation	O
"	O
)	O
.	O
Both	O
the	O
ethanol	O
induction	O
and	O
potentiation	O
responses	O
modulated	O
grp78	O
gene	O
transcription	O
as	O
determined	O
by	O
stable	O
transfection	O
analyses	O
with	O
the	O
rat	O
grp78	O
promoter	O
.	O
Ethanol	O
potentiated	O
the	O
action	O
of	O
all	O
classical	O
inducers	O
of	O
grp78	O
transcription	O
that	O
were	O
studied	O
.	O
In	O
contrast	O
,	O
co	O
-	O
treatment	O
with	O
the	O
classical	O
GRP	O
inducers	O
thapsigargin	O
and	O
tunicamycin	O
produced	O
only	O
simple	O
additive	O
increases	O
in	O
grp78	O
promoter	O
activity	O
.	O
Transient	O
transfection	O
studies	O
with	O
deletion	O
mutants	O
of	O
the	O
rat	O
grp78	O
promoter	O
showed	O
that	O
cis	O
-	O
acting	O
promoter	O
sequences	O
required	O
for	O
ethanol	O
induction	O
differ	O
from	O
those	O
mediating	O
responses	O
to	O
classical	O
GRP	O
inducers	O
.	O
Furthermore	O
,	O
linker	O
-	O
scanning	O
mutations	O
of	O
the	O
grp78	O
promoter	O
suggested	O
that	O
the	O
ethanol	O
potentiation	O
response	O
required	O
a	O
cis	O
-	O
acting	O
promoter	O
element	O
different	O
from	O
those	O
involved	O
in	O
induction	O
by	O
ethanol	O
or	O
classical	O
inducing	O
agents	O
.	O
While	O
the	O
ethanol	O
induction	O
response	O
required	O
16	O
-	O
24	O
h	O
to	O
be	O
detectable	O
,	O
ethanol	O
potentiation	O
of	O
thapsigargin	O
occurred	O
within	O
6	O
h	O
.	O
The	O
potentiation	O
response	O
also	O
decayed	O
rapidly	O
after	O
ethanol	O
removal	O
.	O
In	O
addition	O
,	O
the	O
protein	O
kinase	O
A	O
inhibitor	O
Rp-cAMPS	O
and	O
protein	O
phosphatase	O
inhibitor	O
okadaic	O
acid	O
both	O
increased	O
ethanol	O
potentiation	O
of	O
thapsigargin	O
while	O
Sp-cAMPS	O
,	O
an	O
activator	O
of	O
protein	O
kinase	O
A	O
,	O
decreased	O
ethanol	O
potentiation	O
.	O
Taken	O
together	O
,	O
our	O
findings	O
suggest	O
two	O
mechanisms	O
by	O
which	O
ethanol	O
regulates	O
grp78	O
transcription	O
,	O
both	O
differing	O
from	O
the	O
action	O
of	O
classical	O
GRP	O
inducers	O
such	O
as	O
thapsigargin	O
.	O
One	O
mechanism	O
(	O
potentiation	O
)	O
involves	O
a	O
protein	O
phosphorylation	O
cascade	O
and	O
potentiates	O
the	O
action	O
of	O
classical	O
GRP	O
inducers	O
.	O
In	O
contrast	O
,	O
GRP78	O
induction	O
by	O
ethanol	O
involves	O
promoter	O
sequences	O
and	O
a	O
mechanistic	O
pathway	O
separate	O
from	O
that	O
of	O
the	O
ethanol	O
potentiation	O
response	O
or	O
classical	O
GRP78	O
inducers	O
.	O
These	O
studies	O
show	O
that	O
ethanol	O
produces	O
a	O
novel	O
and	O
complex	O
regulation	O
of	O
grp78	O
transcription	O
which	O
could	O
be	O
of	O
particular	O
importance	O
during	O
neuronal	O
exposure	O
to	O
GRP	O
-	O
inducing	O
stressors	O
as	O
might	O
occur	O
with	O
central	O
nervous	O
system	O
injury	O
.	O
PMID	O
:	O
8576245	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pathol	O
Res	O
Pract	O
.	O
1996	O
Jul;19	O
2	O
(	O
7	O
)	O
:768	O
-80	O
.	O
Molecular	O
mechanisms	O
of	O
multidrug	O
resistance	O
in	O
cancer	O
chemotherapy	O
.	O
Nooter	O
K,	O
Stoter	O
G.	O
Department	O
of	O
Medical	O
Oncology	O
,	O
Rotterdam	O
Cancer	O
Institute	O
,	O
The	O
Netherlands	O
.	O
The	O
occurrence	O
of	O
multidrug	O
resistance	O
(	O
MDR	O
)	O
is	O
one	O
of	O
the	O
main	O
obstacles	O
in	O
the	O
successful	O
chemotherapeutic	O
treatment	O
of	O
cancer	O
.	O
MDR	O
cell	O
lines	O
are	O
resistant	O
to	O
the	O
so	O
-	O
called	O
naturally	O
occurring	O
anti	O
-	O
cancer	O
drugs	O
,	O
such	O
as	O
anthracyclines	O
,	O
Vinca	O
alkaloids	O
and	O
epipodophyllotoxins	O
,	O
but	O
are	O
not	O
cross	O
-	O
resistant	O
to	O
alkylating	O
agents	O
,	O
antimetabolites	O
and	O
cisplatin	O
.	O
So	O
far	O
,	O
three	O
separate	O
forms	O
of	O
MDR	O
have	O
been	O
characterized	O
in	O
more	O
detail	O
:	O
classical	O
MDR	O
,	O
non	O
-	O
Pgp	O
MDR	O
and	O
atypical	O
MDR	O
.	O
Although	O
all	O
three	O
MDR	O
phenotypes	O
have	O
much	O
in	O
common	O
with	O
respect	O
to	O
cross	O
-	O
resistance	O
patterns	O
,	O
the	O
underlying	O
mechanisms	O
certainly	O
differ	O
.	O
Atypical	O
MDR	O
is	O
associated	O
with	O
quantitative	O
and	O
qualitative	O
alterations	O
in	O
topoisomerase	O
II	O
alpha	O
,	O
a	O
nuclear	O
enzyme	O
that	O
actively	O
participates	O
in	O
the	O
lethal	O
action	O
of	O
cytotoxic	O
drugs	O
.	O
Atypical	O
MDR	O
cells	O
do	O
not	O
overexpress	O
P-glycoprotein	O
,	O
and	O
are	O
unaltered	O
in	O
their	O
ability	O
to	O
accumulate	O
drugs	O
.	O
In	O
this	O
review	O
we	O
will	O
focus	O
on	O
classical	O
and	O
non	O
-	O
Pgp	O
MDR	O
.	O
The	O
molecular	O
mechanism	O
of	O
classical	O
and	O
non	O
-	O
Pgp	O
MDR	O
is	O
transcriptional	O
activation	O
of	O
membrane	O
-	O
bound	O
transport	O
proteins	O
.	O
These	O
transport	O
proteins	O
belong	O
to	O
the	O
ATP	O
-	O
binding	O
cassette	O
(	O
ABC	O
)	O
superfamily	O
of	O
transport	O
systems	O
.	O
The	O
classical	O
MDR	O
phenotype	O
is	O
characterized	O
by	O
a	O
reduced	O
ability	O
to	O
accumulate	O
drugs	O
,	O
due	O
to	O
activity	O
of	O
an	O
energy	O
-	O
dependent	O
uni	O
-	O
directional	O
,	O
membrane	O
-	O
bound	O
,	O
drug	O
-	O
efflux	O
pump	O
with	O
broad	O
substrate	O
specificity	O
.	O
The	O
classical	O
MDR	O
drug	O
pump	O
is	O
composed	O
of	O
a	O
transmembrane	O
glycoprotein	O
(	O
P-glyco-protein-Pgp	O
)	O
with	O
a	O
molecular	O
weight	O
of	O
170	O
kD	O
,	O
and	O
is	O
,	O
in	O
man	O
,	O
encoded	O
by	O
the	O
so	O
-	O
called	O
multidrug	O
resistance	O
(	O
MDR1	O
)	O
gene	O
.	O
Typically	O
,	O
non	O
-	O
Pgp	O
MDR	O
has	O
no	O
P-gly-coprotein	O
expression	O
,	O
yet	O
has	O
about	O
the	O
same	O
cross	O
-	O
resistance	O
pattern	O
as	O
classical	O
MDR	O
.	O
This	O
non	O
-	O
Pgp	O
MDR	O
phenotype	O
is	O
caused	O
by	O
overexpression	O
of	O
the	O
multidrug	O
resistance	O
-	O
associated	O
protein	O
(	O
MRP	O
)	O
gene	O
,	O
which	O
encodes	O
a	O
190	O
kD	O
membrane	O
-	O
bound	O
glycoprotein	O
(	O
MRP	O
)	O
.	O
MRP	O
probably	O
works	O
by	O
direct	O
extrusion	O
of	O
cytotoxic	O
drugs	O
from	O
the	O
cell	O
and/or	O
by	O
mediating	O
sequestration	O
of	O
the	O
drugs	O
into	O
intracellular	O
compartments	O
,	O
both	O
leading	O
to	O
a	O
reduction	O
in	O
effective	O
intracellular	O
drug	O
concentrations	O
.	O
For	O
the	O
classical	O
MDR	O
phenotype	O
,	O
evidence	O
is	O
accumulating	O
that	O
it	O
plays	O
a	O
role	O
indeed	O
,	O
in	O
clinical	O
drug	O
resistance	O
,	O
especially	O
in	O
some	O
hematological	O
malignancies	O
(	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
,	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
and	O
non	B-malignancy-type
-	I-malignancy-type
Hodgkin	I-malignancy-type
's	I-malignancy-type
lymphoma	I-malignancy-type
)	O
and	O
solid	O
tumors	O
(	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcomas	I-malignancy-type
and	O
neuroblastoma	B-malignancy-type
)	O
.	O
The	O
association	O
of	O
MRP	O
with	O
clinical	O
drug	O
resistance	O
has	O
not	O
been	O
elaborated	O
,	O
yet	O
,	O
and	O
studies	O
on	O
MRP	O
expression	O
in	O
human	O
cancer	O
have	O
just	O
begun	O
.	O
We	O
found	O
that	O
overexpression	O
of	O
MRP	O
,	O
as	O
determined	O
by	O
RNase	O
protection	O
assay	O
as	O
well	O
as	O
by	O
immunohistochemistry	O
,	O
occurs	O
in	O
several	O
human	O
cancers	O
,	O
among	O
which	O
are	O
cancer	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
,	O
esophagus	B-malignancy-type
,	O
breast	B-malignancy-type
and	O
ovary	B-malignancy-type
,	O
and	O
leukemias	B-malignancy-type
.	O
Further	O
studies	O
are	O
indicated	O
to	O
establish	O
whether	O
elevated	O
MRP	O
expression	O
at	O
diagnosis	O
is	O
an	O
unfavorable	O
prognostic	O
factor	O
for	O
clinical	O
outcome	O
of	O
chemotherapy	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
8880878	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Cancer	O
Res	O
Clin	O
Oncol	O
.	O
2000	O
Jan;126	O
(	O
1	O
)	O
:	O
12-8.	O
Evaluation	O
of	O
Epstein	O
-	O
Barr	O
virus	O
infection	O
in	O
sinonasal	B-malignancy-type
small	I-malignancy-type
round	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
.	O
Shinokuma	O
A	O
,	O
Hirakawa	O
N	O
,	O
Tamiya	O
S	O
,	O
Oda	O
Y	O
,	O
Komiyama	O
S	O
,	O
Tsuneyoshi	O
M.	O
Department	O
of	O
Anatomic	O
Pathology	O
,	O
Graduate	O
School	O
of	O
Medical	O
Sciences	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
,	O
Japan	O
.	O
Sinonasal	B-malignancy-type
undifferentiated	I-malignancy-type
carcinoma	I-malignancy-type
,	O
olfactory	B-malignancy-type
neuroblastoma	I-malignancy-type
and	O
malignant	B-malignancy-type
melanoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
sinonasal	I-malignancy-type
regions	I-malignancy-type
are	O
included	O
within	O
the	O
category	O
of	O
small	O
round	O
cell	O
tumors	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
sinonasal	I-malignancy-type
region	I-malignancy-type
.	O
It	O
is	O
difficult	O
to	O
diagnose	O
these	O
tumors	O
on	O
the	O
basis	O
of	O
light	O
-	O
microscopic	O
features	O
alone	O
,	O
but	O
,	O
in	O
some	O
instances	O
,	O
immunohistochemical	O
staining	O
evaluating	O
cytokeratin	O
and	O
S-	O
100	O
protein	O
,	O
for	O
example	O
,	O
is	O
of	O
value	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
sinonasal	O
region	O
is	O
a	O
significant	O
site	O
for	O
Epstein	O
-	O
Barr	O
-virus	O
(	O
EBV	O
)	O
-	O
related	O
tumors	O
,	O
including	O
sinonasal	B-malignancy-type
undifferentiated	I-malignancy-type
carcinoma	I-malignancy-type
or	O
malignant	B-malignancy-type
lymphoma	I-malignancy-type
.	O
Twenty-three	O
sinonasal	B-malignancy-type
small	I-malignancy-type
round	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
(	O
SSRCT	B-malignancy-type
)	O
comprising	O
5	O
sinonasal	B-malignancy-type
undifferentiated	I-malignancy-type
carcinomas	I-malignancy-type
,	O
9	O
olfactory	B-malignancy-type
neuroblastomas	I-malignancy-type
and	O
9	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
were	O
evaluated	O
for	O
the	O
presence	O
of	O
EBV	O
infection	O
by	O
in	O
situ	O
hybridization	O
for	O
EBV-encoded	O
RNA	O
,	O
combined	O
with	O
immunostaining	O
for	O
EBV	O
-	O
related	O
proteins	O
(	O
LMP-1	O
and	O
EBNA2	O
)	O
.	O
Furthermore	O
,	O
55	O
SSRCT	B-malignancy-type
comprising	O
37	O
sinonasal	B-malignancy-type
undifferentiated	I-malignancy-type
carcinomas	I-malignancy-type
,	O
9	O
olfactory	B-malignancy-type
neuroblastomas	I-malignancy-type
,	O
and	O
9	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
were	O
examined	O
for	O
the	O
presence	O
of	O
cytokeratins	O
(	O
AE1	O
/	O
AE3	O
and	O
CAM5.2	O
)	O
,	O
S-	O
100	O
protein	O
and	O
p53	O
protein	O
using	O
immunohistochemical	O
staining	O
.	O
According	O
to	O
in	O
situ	O
hybridization	O
for	O
detecting	O
EBV-encoded	O
RNA	O
1	O
(	O
EBER1	O
)	O
,	O
all	O
of	O
the	O
sinonasal	B-malignancy-type
undifferentiated	I-malignancy-type
carcinomas	I-malignancy-type
showed	O
clear	O
,	O
intense	O
hybridization	O
signals	O
localized	O
over	O
the	O
nuclei	O
of	O
the	O
tumor	O
cells	O
and	O
,	O
in	O
3	O
out	O
of	O
9	O
(	O
33.3	O
%	O
)	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
,	O
hybridization	O
signals	O
were	O
also	O
recognized	O
.	O
However	O
,	O
none	O
of	O
the	O
olfactory	B-malignancy-type
neuroblastomas	I-malignancy-type
revealed	O
hybridization	O
signals	O
.	O
Immunohistochemically	O
,	O
4	O
out	O
of	O
5	O
(	O
80	O
%	O
)	O
sinonasal	B-malignancy-type
undifferentiated	I-malignancy-type
carcinomas	I-malignancy-type
were	O
positive	O
for	O
LMP	O
-1	O
,	O
whereas	O
only	O
2	O
out	O
9	O
(	O
22.2	O
%	O
)	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
and	O
no	O
olfactory	B-malignancy-type
neuroblastomas	I-malignancy-type
were	O
positive	O
.	O
With	O
regard	O
to	O
EBNA2	O
,	O
sinonasal	B-malignancy-type
undifferentiated	I-malignancy-type
carcinomas	I-malignancy-type
,	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
and	O
olfactory	B-malignancy-type
neuroblastomas	I-malignancy-type
were	O
all	O
negative	O
.	O
Out	O
of	O
37	O
sinonasal	B-malignancy-type
undifferentiated	I-malignancy-type
carcinomas	I-malignancy-type
35	O
(	O
94.6	O
%	O
)	O
showed	O
a	O
diffuse	O
positive	O
immunoreaction	O
for	O
AE1	O
/	O
AE3	O
,	O
whereas	O
neither	O
olfactory	B-malignancy-type
neuroblastoma	I-malignancy-type
nor	O
malignant	B-malignancy-type
melanoma	I-malignancy-type
revealed	O
a	O
positive	O
reaction	O
.	O
All	O
9	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
and	O
6	O
out	O
of	O
9	O
olfactory	B-malignancy-type
neuroblastomas	I-malignancy-type
(	O
75	O
%	O
)	O
were	O
positive	O
for	O
S-	O
100	O
protein	O
,	O
whereas	O
only	O
6	O
cases	O
of	O
sinonasal	B-malignancy-type
undifferentiated	I-malignancy-type
carcinomas	I-malignancy-type
(	O
19.4	O
%	O
)	O
were	O
positive	O
.	O
As	O
for	O
p53	O
protein	O
,	O
16	O
of	O
37	O
sinonasal	B-malignancy-type
undifferentiated	I-malignancy-type
carcinomas	I-malignancy-type
(	O
43.2	O
%	O
)	O
were	O
positive	O
,	O
whereas	O
neither	O
olfactory	B-malignancy-type
neuroblastoma	I-malignancy-type
nor	O
malignant	B-malignancy-type
melanoma	I-malignancy-type
revealed	O
any	O
positive	O
reaction	O
.	O
The	O
above	O
results	O
suggest	O
that	O
EBV	O
infection	O
is	O
closely	O
associated	O
with	O
sinonasal	B-malignancy-type
undifferentiated	I-malignancy-type
carcinomas	I-malignancy-type
,	O
and	O
that	O
some	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
may	O
also	O
have	O
a	O
relationship	O
with	O
its	O
infection	O
.	O
For	O
the	O
differential	O
diagnosis	O
of	O
SSRCT	B-malignancy-type
,	O
it	O
is	O
important	O
to	O
evaluate	O
EBV	O
infection	O
along	O
with	O
immunohistochemical	O
staining	O
for	O
cytokeratins	O
and	O
S-	O
100	O
protein	O
.	O
The	O
overexpression	O
of	O
p53	O
protein	O
was	O
found	O
to	O
be	O
related	O
to	O
the	O
oncogenesis	O
of	O
sinonasal	B-malignancy-type
undifferentiated	I-malignancy-type
carcinoma	I-malignancy-type
;	O
however	O
,	O
there	O
was	O
no	O
association	O
between	O
its	O
overexpression	O
and	O
malignant	B-malignancy-type
melanoma	I-malignancy-type
or	O
olfactory	B-malignancy-type
neuroblastoma	I-malignancy-type
.	I-malignancy-type
PMID	O
:	O
10641744	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Thyroid	O
.	O
1998	O
Oct;8	O
(	O
10	O
)	O
:	O
89	O
7	O
-	O
901	O
.	O
The	O
thyrotropin	O
-	O
releasing	O
hormone	O
gene	O
1998	O
:	O
cloning	O
,	O
characterization	O
,	O
and	O
transcriptional	O
regulation	O
in	O
the	O
central	O
nervous	O
system	O
,	O
heart	O
,	O
and	O
testis	O
.	O
Wilber	O
JF	O
,	O
Xu	O
AH	O
.	O
Division	O
of	O
Endocrinology	O
,	O
University	O
of	O
Maryland	O
Medical	O
System	O
,	O
Baltimore	O
21201-1595	O
.	O
Mechanisms	O
of	O
triiodothyronine	O
(	O
T3	O
)	O
negative	O
regulation	O
of	O
the	O
human	O
thyrotropin	O
-	O
releasing	O
hormone	O
(	O
TRH	O
)	O
gene	O
were	O
investigated	O
with	O
a	O
chimeric	O
construct	O
of	O
the	O
5	O
'	O
flanking	O
region	O
fused	O
to	O
a	O
luciferase	O
reporter	O
gene	O
,	O
transfected	O
into	O
human	O
neuroblastoma	B-malignancy-type
cells	O
(	O
HTB-11	O
)	O
.	O
Maximum	O
negative	O
regulation	O
was	O
achieved	O
with	O
constructs	O
containing	O
bases	O
-	O
242	O
to	O
+	O
54	O
.	O
Four	O
sequences	O
in	O
this	O
region	O
exhibited	O
homology	O
with	O
half	O
sites	O
of	O
thyroid	O
hormone	O
response	O
elements	O
(	O
TRE	O
)	O
(	O
AGGTCA	O
)	O
.	O
The	O
most	O
important	O
site	O
was	O
a	O
sequence	O
with	O
an	O
overlapping	O
TRE	O
/	O
CRE	O
,	O
involving	O
bases	O
-	O
53	O
to	O
-	O
60	O
(	O
TGACCTCA	O
)	O
.	O
Potential	O
combinatorial	O
interactions	O
of	O
thyroid	O
hormone	O
receptors	O
and	O
CREB	O
at	O
this	O
site	O
were	O
explored	O
.	O
Modest	O
promoter	O
stimulation	O
was	O
achieved	O
with	O
dibutyryl	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
(	O
10(-3)	O
M	O
)	O
plus	O
IBMX	O
(	O
0.5	O
mM	O
)	O
.	O
Stimulation	O
was	O
greatly	O
enhanced	O
(	O
+	O
820	O
%	O
)	O
by	O
cotransfection	O
of	O
a	O
constitutively	O
activated	O
protein	O
kinase	O
A	O
(	O
pPKA	O
)	O
construct	O
.	O
Cotransfection	O
with	O
pCREB	O
increased	O
stimulation	O
further	O
to	O
1350	O
%	O
above	O
control	O
.	O
Stimulation	O
of	O
pPKA	O
and	O
pCREB	O
interfered	O
with	O
stimulation	O
by	O
unliganded	O
TRbeta1	O
,	O
and	O
co	O
-	O
transfected	O
pPKA	O
and	O
pCREB	O
blocked	O
T3	O
negative	O
inhibition	O
by	O
TRbeta1	O
-	O
T3	O
complexes	O
.	O
When	O
this	O
site	O
was	O
mutated	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
mutagenesis	O
,	O
the	O
mutant	O
construct	O
failed	O
to	O
respond	O
to	O
unliganded	O
TRbeta1	O
,	O
and	O
stimulation	O
by	O
pPKA	O
and/or	O
pCREB	O
was	O
inhibited	O
markedly	O
,	O
from	O
12.5	O
-	O
to	O
2.1	O
-	O
fold	O
,	O
p	O
<	O
0.001	O
.	O
Moreover	O
,	O
TRbeta1	O
-	O
T3	O
complexes	O
failed	O
to	O
show	O
any	O
inhibition	O
of	O
the	O
mutated	O
promoter	O
.	O
These	O
results	O
suggest	O
that	O
negative	O
regulation	O
is	O
achieved	O
by	O
inhibition	O
of	O
CREB	O
stimulation	O
of	O
the	O
TRH	O
promoter	O
at	O
this	O
overlapping	O
TRE	O
/	O
CRE	O
site	O
.	O
The	O
two	O
cosuppressors	O
,	O
NCoR	O
and	O
SMRT	O
,	O
were	O
able	O
to	O
augment	O
stimulation	O
of	O
the	O
TRH	O
promoter	O
by	O
unliganded	O
TRbeta1	O
and	O
enhance	O
the	O
magnitude	O
of	O
T3	O
inhibition	O
.	O
The	O
potential	O
role	O
of	O
the	O
TRH	O
gene	O
and	O
the	O
pathophysiology	O
of	O
thyroid	O
hormone	O
resistance	O
was	O
investigated	O
with	O
three	O
mutant	O
TRbeta1	O
constructs	O
.	O
Thyroid	O
hormone	O
resistance	O
was	O
found	O
to	O
be	O
expressed	O
at	O
the	O
level	O
of	O
TRH	O
gene	O
regulation	O
,	O
due	O
to	O
lowered	O
inhibition	O
by	O
mutant	O
TRbeta1	O
-	O
T3	O
complexes	O
and	O
by	O
their	O
dominant	O
negative	O
effects	O
on	O
wild	O
-	O
type	O
TRbeta1	O
-	O
T3	O
inhibition	O
.	O
TRH	O
gene	O
expression	O
has	O
been	O
identified	O
in	O
the	O
heart	O
.	O
Cardiac	O
TRH	O
mRNA	O
was	O
not	O
regulated	O
by	O
T3	O
,	O
in	O
contrast	O
to	O
HTB-11	O
cells	O
,	O
but	O
cardiac	O
TRH	O
mRNA	O
density	O
could	O
be	O
augmented	O
by	O
glucocorticoids	O
and	O
by	O
testosterone	O
.	O
TRH	O
receptors	O
were	O
identified	O
using	O
Scatchard	O
blots	O
that	O
showed	O
a	O
kilodalton	O
of	O
1.4	O
nM	O
and	O
a	O
bmax	O
of	O
10	O
pmol	O
/	O
mg	O
protein	O
.	O
TRH-R	O
mRNA	O
was	O
identified	O
also	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
.	O
Enhanced	O
ventricular	O
contractility	O
by	O
TRH	O
was	O
demonstrated	O
in	O
both	O
an	O
open	O
-	O
chested	O
dog	O
preparation	O
and	O
in	O
ex	O
vivo	O
ventricular	O
myocytes	O
,	O
using	O
video	O
edge	O
cinematography	O
.	O
Under	O
controlled	O
conditions	O
,	O
myocyte	O
shortening	O
was	O
13.3	O
%	O
,	O
and	O
TRH	O
(	O
10(-6)	O
M	O
)	O
caused	O
muscle	O
shortening	O
to	O
increase	O
140	O
%	O
,	O
(	O
p	O
<	O
0.005	O
)	O
.	O
TRH	O
gene	O
expression	O
was	O
demonstrated	O
exclusively	O
in	O
Leydig	O
cells	O
of	O
the	O
testis	O
.	O
High	O
affinity	O
binding	O
sites	O
were	O
identified	O
in	O
testicular	O
membranes	O
with	O
a	O
kilodalton	O
of	O
1.6	O
x	O
10(-6)	O
M	O
.	O
TRH	O
was	O
able	O
to	O
inhibit	O
LH	O
and	O
HCG	O
-	O
activated	O
testosterone	O
secretion	O
significantly	O
.	O
Thus	O
,	O
one	O
paracrine	O
role	O
of	O
TRH	O
in	O
the	O
testis	O
may	O
be	O
to	O
serve	O
as	O
inhibitory	O
modulator	O
of	O
gonadotropin	O
-	O
stimulated	O
testosterone	O
secretion	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
9827656	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Oncol	O
.	O
1997	O
Mar;15	O
(	O
3	O
)	O
:	O
1171	O
-	O
82	O
.	O
N-Myc	O
gene	O
amplification	O
is	O
a	O
major	O
prognostic	O
factor	O
in	O
localized	O
neuroblastoma	B-malignancy-type
:	O
results	O
of	O
the	O
French	O
NBL	O
90	O
study	O
.	O
Neuroblastoma	O
Study	O
Group	O
of	O
the	O
Societe	O
Francaise	O
d'Oncologie	O
Pediatrique	O
.	O
Rubie	O
H,	O
Hartmann	O
O	O
,	O
Michon	O
J,	O
Frappaz	O
D	O
,	O
Coze	O
C	O
,	O
Chastagner	O
P,	O
Baranzelli	O
MC	O
,	O
Plantaz	O
D	O
,	O
Avet-	O
Loiseau	O
H,	O
Benard	O
J,	O
Delattre	O
O	O
,	O
Favrot	O
M,	O
Peyroulet	O
MC	O
,	O
Thyss	O
A	O
,	O
Perel	O
Y	O
,	O
Bergeron	O
C	O
,	O
Courbon	O
-	O
Collet	O
B	O
,	O
Vannier	O
JP	O
,	O
Lemerle	O
J,	O
Sommelet	O
D.	O
Unite	O
d'Hemato-Oncologie	O
Pediatrique	O
,	O
Service	O
de	O
Medecine	O
Infantile	O
B	O
,	O
CHU	O
Purpan	O
,	O
Toulouse	O
,	O
France	O
.	O
PURPOSE	O
:	O
To	O
assess	O
the	O
relevance	O
of	O
N-Myc	O
gene	O
amplification	O
(	O
NMA	O
)	O
as	O
a	O
prognostic	O
factor	O
in	O
localized	O
neuroblastoma	B-malignancy-type
(	O
NB	B-malignancy-type
)	O
and	O
to	O
evaluate	O
whether	O
less	O
intensive	O
adjuvant	O
treatment	O
is	O
advisable	O
in	O
infants	O
without	O
NMA	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Assessment	O
of	O
NBs	B-malignancy-type
included	O
clinical	O
and	O
imaging	O
data	O
to	O
allow	O
tumor	O
-	O
node	O
-	O
metastasis	O
(	O
TNM	O
)	O
staging	O
,	O
biologic	O
determinations	O
(	O
N-Myc	O
gene	O
analysis	O
)	O
,	O
and	O
standard	O
histology	O
and	O
work-up	O
to	O
eliminate	O
metastatic	O
spread	O
(	O
metaiodobenzylguanidine	O
[	O
MIBG	O
]	O
scintigraphy	O
and	O
extensive	O
bone	O
marrow	O
staging	O
)	O
.	O
Resectability	O
was	O
defined	O
according	O
to	O
imaging	O
findings	O
.	O
Chemotherapy	O
was	O
indicated	O
in	O
children	O
older	O
than	O
1	O
year	O
at	O
diagnosis	O
who	O
had	O
postoperative	O
residual	O
disease	O
or	O
lymph	O
node	O
(	O
LN	O
)	O
involvement	O
,	O
in	O
infants	O
with	O
NMA	O
,	O
or	O
as	O
primary	O
treatment	O
in	O
children	O
with	O
an	O
unresectable	O
NB	B-malignancy-type
,	O
including	O
dumbbell	O
tumors	O
.	O
Radiotherapy	O
was	O
recommended	O
in	O
children	O
older	O
than	O
1	O
who	O
presented	O
with	O
persistent	O
gross	O
residual	O
disease	O
at	O
the	O
end	O
of	O
therapy	O
.	O
RESULTS	O
:	O
Between	O
1990	O
and	O
1994	O
,	O
316	O
consecutive	O
children	O
who	O
presented	O
with	O
a	O
localized	O
NB	B-malignancy-type
were	O
registered	O
in	O
the	O
NBL	O
90	O
study	O
.	O
The	O
median	O
age	O
was	O
12	O
months	O
,	O
and	O
42	O
patients	O
had	O
dumbbell	O
tumors	O
(	O
13	O
%	O
)	O
.	O
NMA	O
was	O
found	O
in	O
22	O
of	O
225	O
assessable	O
children	O
(	O
10	O
%	O
)	O
and	O
correlated	O
with	O
adverse	O
prognostic	O
indicators	O
such	O
as	O
age	O
older	O
than	O
1	O
year	O
,	O
an	O
abdominal	B-malignancy-type
primary	I-malignancy-type
tumor	I-malignancy-type
,	O
a	O
large	O
tumor	O
(	O
T3	O
)	O
,	O
and	O
unresectability	O
.	O
Among	O
186	O
children	O
who	O
had	O
primary	O
excision	O
,	O
five	O
died	O
of	O
surgery	O
-	O
related	O
complications	O
.	O
Primary	O
chemotherapy	O
was	O
given	O
to	O
130	O
patients	O
,	O
which	O
allowed	O
removal	O
of	O
the	O
tumor	O
in	O
all	O
but	O
four	O
.	O
The	O
5	O
-	O
year	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
event	O
-	O
free	O
survival	O
(	O
EFS	O
)	O
rates	O
were	O
,	O
respectively	O
,	O
91	O
%	O
and	O
84	O
%	O
with	O
a	O
median	O
follow-up	O
time	O
of	O
36	O
months	O
.	O
The	O
outcome	O
of	O
infants	O
and	O
older	O
children	O
was	O
similar	O
(	O
P	O
=	O
.2	O
)	O
.	O
EFS	O
of	O
patients	O
with	O
resectable	O
tumors	O
was	O
slightly	O
better	O
than	O
with	O
unresectable	O
primary	O
tumors	O
(	O
EFS	O
,	O
89	O
%	O
v	O
78	O
%	O
;	O
P	O
=	O
.02	O
)	O
.	O
In	O
dumbbell	O
NBs	B-malignancy-type
,	O
neurologic	O
recovery	O
was	O
achieved	O
in	O
74	O
%	O
of	O
cases	O
that	O
presented	O
with	O
symptoms	O
,	O
and	O
initial	O
laminectomy	O
was	O
avoided	O
in	O
75	O
%	O
of	O
children	O
.	O
In	O
a	O
univariate	O
analysis	O
,	O
large	O
tumors	O
,	O
high	O
neuron	O
-	O
specific	O
enolase	O
(	O
NSE	O
)	O
and	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
levels	O
,	O
positive	O
LNs	O
,	O
macroscopic	O
residue	O
,	O
and	O
NMA	O
adversely	O
influenced	O
outcome	O
.	O
In	O
the	O
multivariate	O
analysis	O
,	O
NMA	O
was	O
the	O
most	O
powerful	O
unfavorable	O
predictive	O
indicator	O
:	O
OS	O
and	O
EFS	O
rates	O
for	O
these	O
children	O
were	O
36	O
%	O
and	O
32	O
%	O
,	O
compared	O
with	O
98	O
%	O
and	O
90	O
%	O
in	O
nonamplified	O
tumors	O
(	O
P	O
<	O
.001	O
)	O
.	O
CONCLUSION	O
:	O
Our	O
data	O
confirm	O
the	O
overall	O
good	O
prognosis	O
of	O
localized	O
NBs	B-malignancy-type
,	O
even	O
when	O
unresectable	O
.	O
NMA	O
is	O
the	O
most	O
relevant	O
adverse	O
prognostic	O
factor	O
in	O
localized	O
NBs	B-malignancy-type
,	O
and	O
more	O
intensive	O
treatment	O
should	O
be	O
investigated	O
in	O
these	O
patients	O
.	O
Prospective	O
studies	O
of	O
other	O
biologic	O
factors	O
are	O
warranted	O
to	O
tailor	O
therapy	O
more	O
accurately	O
.	O
The	O
EFS	O
of	O
children	O
who	O
underwent	O
primary	O
surgery	O
was	O
excellent	O
,	O
and	O
further	O
justifies	O
elimination	O
of	O
adjuvant	O
treatment	O
provided	O
they	O
have	O
no	O
NMA	O
.	O
Despite	O
the	O
elimination	O
of	O
postoperative	O
therapy	O
,	O
infants	O
with	O
non	O
-	O
NMA	O
tumors	O
have	O
an	O
excellent	O
outcome	O
,	O
which	O
suggests	O
that	O
initial	O
chemotherapy	O
can	O
be	O
further	O
reduced	O
in	O
case	O
of	O
unresectable	O
NBs	B-malignancy-type
.	O
Publication	O
Types	O
:	O
Multicenter	O
Study	O
PMID	O
:	O
9060561	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

